Tokushima University / Educator and Researcher Directory --- Akaike, Masashi

Personal Web Page

https://researchmap.jp/read0054340 (researchmap)

Field of Study

○	Medicine

Subject of Study

○

Book / Paper

Book:

1.	Masashi Akaike : 歯科医師のための医学ハンドブック「呼吸困難・息切れ・喘息」, 医歯薬出版株式会社, May 2014.
2.	Katsuhiko Yoshimoto, Masashi Akaike, Minoru Irahara and Keiko Aota : 歯科医師のための医学ハンドブック, 医歯薬出版株式会社, Tokyo, May 2014.
3.	Masashi Akaike and Toshio Matsumoto : V 実験的研究 6．血管内皮障害―nitric oxideの観点から―, KINPODO, INC., Oct. 2010.

Academic Paper (Judged Full Paper):

1.	Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Mitsuhiro Goda, Nawa Hideki, Yuya Horinouchi, Nakamura Toshimi, Hakuno Harumasa, Shinomiya Kazuaki, Yoshito Zamami, Masahiko Azuma, Masashi Akaike and Keisuke Ishizawa : Assessing the effects of interprofessional education by hospital pharmacists on pharmaceutical students using a self-evaluation scale, Journal of Pharmaceutical Health Care and Sciences, Vol.10, No.16, 2024.
2.	Rie Fujikawa, 高開登茂子, Hiroko Kume, 三木幸代, 原田路可, Chikako Kane, Masashi Akaike, Hiroaki Yanagawa and Minoru Irahara : モンゴル国 A 病院のモンゴル人看護師のリスク感性の分析, 日本看護学会誌 18(1): 13-20, 2023, Vol.18, No.1, 13-20, 2023.
3.	青木理紗, Kazumi Takaishi, 西川美佳, Shigeki Fujiwara Joseph Luke, Masami Nagamune, Masashi Akaike, Fumiaki Kawano and Shinji Kawahito : Comparison of Four Types of Airway Management Simulator in Tracheal Intubation, The Journal of Japanese Dental Education Association, Vol.38, No.1, 63-68, 2022. (Keyword) tracheal intubation / airway management / simulator / simulation / cardiopulmonary resuscitation (Link to Publication Site) ● Publication site (DOI): 10.24744/jdea.38.1_63 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390573407641146752 ● Search Scopus @ Elsevier (DOI): 10.24744/jdea.38.1_63 (DOI: 10.24744/jdea.38.1_63, CiNii: 1390573407641146752)
4.	Y Hoshina, Keigo Yada, H Maki, T Yoshino, H Takaiso and Masashi Akaike : Medical English Education in Japan: Developing a Curriculum to Motivate Students by Providing Visualizing Opportunities Using Near-peer Teaching, The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 332-334, 2022. (Summary) Despite advancements in the pedagogy of medical education in various fields, Japan has no standardized medical English education. The U.S. Medical Licensing Examination (USMLE) Study Group of Tokushima is an extracurricular activity in which medical students and recent graduates meet every 1-2 months. The aim is to stimulate students' curiosity ; cultivate their initiative, self-efficacy, and English learning goals ; and motivate them to be self-regulated learners. Accordingly, we conducted near-peer teaching style lectures that focused on sharing medical English-related experiences, so students could have regular opportunities to visualize the benefits of learning medical English. Following the activities, we observed increased motivation and self-study among students, resulting in a high USMLE passing rate. Furthermore, five members started their training at American hospitals and pursued careers in English-speaking environments. Thus, near-peer teaching style leads to shared medical English-related experiences that help students to visualize English-related opportunities. This education style taught by similar generations aids in setting a specific goal by providing access to role models, cultivating their initiative and self-efficacy, motivating them to learn English, and producing positive outcomes.Modifying the curriculum to actively create opportunities for students to visualize themselves in an international environment can motivate them to continue learning English. J. Med. Invest. 69 : 332-334, August, 2022. (Keyword) Curriculum / Education, Medical / Humans / Japan / Learning / Students, Medical / Teaching (Tokushima University Institutional Repository) ● Metadata: 117767 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.332 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244792 ● CiNii @ National Institute of Informatics (CRID): 1390293788341785728 ● Search Scopus @ Elsevier (PMID): 36244792 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.332 (Tokushima University Institutional Repository: 117767, DOI: 10.2152/jmi.69.332, PubMed: 36244792, CiNii: 1390293788341785728)
5.	Akira Takashima, Shusuke Yagi, Koji Yamaguchi, Kiyoe Kurahashi, Yuko Kojima, Robert Zheng, Takayuki Ise, Kenya Kusunose, Sumiko Yoshida, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike and Masataka Sata : Congenital Hypogonadotropic Hypogonadism with Early-Onset Coronary Artery Disease., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 189-191, 2021. (Summary) The patient with congenital hypogonadotropic hypogonadism (HH) shows low serum levels of androgen, which is a group of sex hormones including testosterone, caused by the decreased gonadotropin release in the hypothalamus. Recent reports showed androgens exert protective effects against insulin resistance or atherosclerotic diseases, such as diabetes mellitus or coronary artery disease. However, whether the juvenile hypogonadism affects the diabetes or cardiovascular disease is unclear. We report a case of a middle-aged man with congenital HH who had severe coronary artery disease complicated with metabolic disorders. J. Med. Invest. 68 : 189-191, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 116019 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.189 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994469 ● Search Scopus @ Elsevier (PMID): 33994469 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.189 (Tokushima University Institutional Repository: 116019, DOI: 10.2152/jmi.68.189, PubMed: 33994469)
6.	Mitsuteru Yoshida, Akira Tangoku, Kousaku Higashino, Kazuya Kondo, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama and Yoshihiro Tsuruo : 【最先端医療を支える解剖学】呼吸器外科における最先端手術手技とCAL(Clinical Anatomy Laboratory), Shikoku Acta Medica, Vol.76, No.5-6, 225-234, 2020. (Summary) Recently, endoscopic surgery is the most common procedurein the field of thoracic surgery. The newestthoracic surgeryapproaches are the video-assisted thoracic surgery(VATS), the one-port video-assisted thoracic surgery, and the robotic surgery. The individual advantages and disadvantages of these procedures have been discussed. VATS covers a field of view of the surgical field from the leg to the head. The basic method in performing VATS is that the surgeon operates on the abdominal area of the patient and the assistant expands the surgical field from the patient's back. It is currently the standard surgical procedure. The advantage of one-port VATS is the one port itself and its cosmetic advantages and pain reduction. The advantage of robotic surgery is that it has a clear three-dimensional enlarged field of view and can be performed using the delicate moving robotic arm. However, a good surgical training system should be established for the familiarization of these procedures. The clinical anatomy laboratory is the most efficient surgical training in addition to dry and wet lab training. Our institution has fresh-frozen cadavers, which are rare in Japan. The participating thoracic surgeons underwent training for VATS lobectomy, subxiphoid extended thymectomy, and pleurectomy decortication. This training is beneficial for educational and clinical purposes. In the future, we must obtain consistent surgical education before and after graduation using fresh-frozen cadavers. At the same time, a good organ model for training is also necessary. The surgeon has to cooperate with anatomy doctors for the development of a good surgical organ model. For the development of future surgical medicine, surgical training programs should be implemented. (Keyword) thoracic surgery / fresh frozen cadaver / surgical training (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050020840088219904 (CiNii: 1050020840088219904)
7.	Yoshihiko Ueno, Yosuke Seki, Masashi Akaike and Masako Nomaguchi : 教育連動型AO入試の設計と実施ーー地方国立大学における研究医の養成・確保をめざしてーー, The Journal of University Admissions Research, No.30, 207-213, 2020. (Keyword) 教育連動型AO入試 / 研究医 / 四国 / アドミッション・ポリシー / 採点方法のルール (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522543655921123712 (CiNii: 1522543655921123712)
8.	Mitsuhiro Tsuboi, Mariko Aoyama, Hiromitsu Takizawa, Mitsuteru Yoshida, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama, Yoshihiro Tsuruo and Akira Tangoku : 内視鏡手術の教育システム, Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery, Vol.37, No.1, 22-26, 2020. (Link to Publication Site) ● Publication site (DOI): 10.11226/jaesjsts.37.1_22 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390848250117531136 ● Search Scopus @ Elsevier (DOI): 10.11226/jaesjsts.37.1_22 (DOI: 10.11226/jaesjsts.37.1_22, CiNii: 1390848250117531136)
9.	Shusuke Yagi, Daisuke Kondo, Takayuki Ise, Daiju Fukuda, Koji Yamaguchi, Tetsuzo Wakatsuki, Yutaka Kawabata, Hiroyuki Ito, Yoshihito Saijo, Hiromitsu Seno, Kumiko Sutou, Rie Ueno, Takafumi Todoroki, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Michio Shimabukuro, Ken-ichi Aihara, Masashi Akaike and Masataka Sata : Association of Decreased Docosahexaenoic Acid Level After Statin Therapy and Low Eicosapentaenoic Acid Level with In-Stent Restenosis in Patients with Acute Coronary Syndrome, Journal of Atherosclerosis and Thrombosis, Vol.26, No.3, 272-281, 2019. (Summary) It is speculated that statin therapy modulates the synthesis of polyunsaturated fatty acids (PUFA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). However, the data available on the effects of statin therapy on the serum levels of PUFA and the subsequent impact on in-stent restenosis (ISR) in patients with acute coronary syndrome (ACS) are limited. A total of 120 ACS patients who received emergent coronary stent implantation, follow-up coronary angiography to evaluate ISR, and new statin therapy were enrolled. We measured the serum levels of the PUFA and lipids at the onset of ACS and at the follow-up coronary angiography. The follow-up coronary angiography revealed 38 ISR cases. New statin therapy significantly reduced the serum levels of DHA and low-density lipoprotein cholesterol (LDL-C), while it did not affect EPA level. Single regression analysis revealed that a decreased serum level of LDL-C was associated with decreased DHA level. The multiple logistic regression analysis revealed that the decreased DHA level after statin therapy and low serum level of EPA on admission were determinants of prevalence of ISR. Statin therapy decreased the serum level of DHA with a parallel reduction in LDL-C level in patients with ACS. Decreased DHA level after statin therapy and low EPA level on admission are risk factors for ISR, indicating that in patients with ACS, decreased serum levels of DHA may be a residual target for the prevention of ISR. (Keyword) Acute Coronary Syndrome / Aged / Coronary Restenosis / Docosahexaenoic Acids / Eicosapentaenoic Acid / female / Follow-Up Studies / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / male / Prognosis / Retrospective Studies / Risk Factors / Stents (Tokushima University Institutional Repository) ● Metadata: 113220 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.44735 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30135329 ● Summary page in Scopus @ Elsevier: 2-s2.0-85062425735 (Tokushima University Institutional Repository: 113220, DOI: 10.5551/jat.44735, PubMed: 30135329, Elsevier: Scopus)
10.	Shusuke Yagi, Robert Zheng, Seiichi Nishiyama, Yutaka Kawabata, Takayuki Ise, Kosuke Sugiura, Haruhiko Yoshinari, Toshihiko Nishisho, Yoshimi Bando, Kumiko Kagawa, Daiju Fukuda, Tomohiro Soga, Yoshihito Saijoh, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinji Kawahito, Masashi Akaike and Masataka Sata : Osteolytic primary bone lymphoma in the multiple bones, The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 347-350, 2019. (Summary) Primary non-Hodgkin bone lymphoma (PBL) can involve solitary or multiple destructive bone lesions such as those of the femur or pelvis humerus, and some cases have osteolytic lesions. PBL is a rare disease in adults. Thus, PBL is rarely considered a differential diagnosis of the osteolytic tumor. In addition, PBL can be underdiagnosed because patients do not experience symptoms or show objective abnormalities in the early stage. Here, we reported an elderly patient with PBL in multiple bones, including the cranial and femoral bones that were fractured due to falling. J. Med. Invest. 66 : 347-350, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114167 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.347 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656303 ● Summary page in Scopus @ Elsevier: 2-s2.0-85074142443 (Tokushima University Institutional Repository: 114167, DOI: 10.2152/jmi.66.347, PubMed: 31656303, Elsevier: Scopus)
11.	Shusuke Yagi, Rie Ueno, Kumiko Sutou, Tetsuzo Wakatsuki, Koji Yamaguchi, Yoshihito Saijo, Tomoya Hara, Takayuki Ise, Kenya Kusunose, Mika Bando, Tomomi Matsuura, Takeshi Tobiume, Hirotsugu Yamada, Daiju Fukuda, Takeshi Soeki, Masashi Akaike and Masataka Sata : Lambda-like J wave due to acute myocardial infarction of the diagonal branch, The Journal of Medical Investigation : JMI, Vol.66, No.1,2, 185-187, 2019. (Summary) The culprit lesion of acute myocardial infarction could be predicted by electrocardiogram findings. However, we experienced some cases with coronary angiographic finding in the area of ST-T elevation that was different from that predicted. The lambda-like J wave could be caused by ischemia although the mechanism has not been fully elucidated. We report a case of acute myocardial infarction that showed discrepancy between ST-T elevation with lambda-like ischemic J wave in a broad area and coronary angiographical finding of diagonal branch occlusion. J. Med. Invest. 66 : 185-187, February, 2019. (Tokushima University Institutional Repository) ● Metadata: 113420 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.185 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31064936 ● Summary page in Scopus @ Elsevier: 2-s2.0-85065772885 (Tokushima University Institutional Repository: 113420, DOI: 10.2152/jmi.66.185, PubMed: 31064936, Elsevier: Scopus)
12.	K Adachi, S Hashiguchi, M Saito, S Kashiwagi, T Miyazaki, H Kawai, Hirotsugu Yamada, T Iwase, Masashi Akaike, Shoichiro Takao, M Kobayashi, M Ishizaki, T Matsumura, M Mori-Yoshimura and E Kimura : Detection and management of cardiomyopathy in female dystrophinopathy carriers, Journal of the Neurological Sciences, Vol.386, 74-80, 2018. (Summary) Regular health checkups for mothers of patients with Duchenne muscular dystrophy have been performed at National Hospital Organization Tokushima Hospital since 1994. Among 43 mothers participated in this study, 28 dystrophinopathy carriers were identified. Skeletal and cardiac muscle functions of these subjects were examined. High serum creatine kinase was found in 23 subjects (82.1%). Obvious muscle weakness was present in 5 (17.8%) and had progressed from 1994 to 2015. Cardiomyopathy was observed in 15 subjects (60.0%), including dilated cardiomyopathy-like damage that was more common in the left ventricular (LV) posterior wall. Late gadolinium enhancement on cardiac MRI was found in 5 of 6 subjects, suggesting fibrotic cardiac muscle. In speckle tracking echocardiography performed seven years later, global longitudinal strain was decreased in these subjects, indicating LV myocardial contractile abnormality. These results suggest that female dystrophinopathy carriers should receive regular checkups for detection and treatment of cardiomyopathy, even if they have no cardiac symptoms. (Keyword) Adult / Cardiomyopathies / Contrast Media / Creatine Kinase / Disease Management / Dystrophin / Electrocardiography / Female / Gadolinium / Humans / Image Processing, Computer-Assisted / Middle Aged / Muscle, Skeletal / Mutation / Natriuretic Peptide, Brain / Neuroimaging / Neurologic Examination / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 115572 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jns.2017.12.024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29358000 ● Search Scopus @ Elsevier (PMID): 29358000 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jns.2017.12.024 (Tokushima University Institutional Repository: 115572, DOI: 10.1016/j.jns.2017.12.024, PubMed: 29358000)
13.	T Miyamoto, A Akaishi, T Takagai, K Kida, Masashi Akaike and Hiroaki Yanagawa : Implementation of clinical research coordinator hospital certification course to spread understanding of clinical trials, Japanese Journal of Clinical Pharmacology and Therapeutics, Vol.49, No.1, 7-11, 2018. (Tokushima University Institutional Repository) ● Metadata: 111285 (Link to Publication Site) ● Publication site (DOI): 10.3999/jscpt.49.7 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85042626614 (Tokushima University Institutional Repository: 111285, DOI: 10.3999/jscpt.49.7, Elsevier: Scopus)
14.	Hiromu Yamazaki, Shusuke Yagi, Yuta Torii, Rie Amano, Yasuyuki Oomichi, Teruaki Sangawa, Daiju Fukuda, Muneyuki Kadota, Takayuki Ise, Rie Ueno, Tomoya Hara, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels, Journal of Cardiology, Vol.71, No.3, 305-309, 2017. (Summary) It is well known that warfarin inhibits the synthesis of vitamin K-dependent anticoagulants, including thrombin, protein C and S, and factor Xa, leading, paradoxically, to an initial hypercoagulable state. Edoxaban, a direct inhibitor of activated factor X is widely used for the treatment of acute venous thromboembolism (VTE). However, the effect of edoxaban on circulating coagulation factors, in patients with acute VTE, remains unknown. We enrolled 57 patients with acute VTE with/without pulmonary embolism treated with edoxaban (n=37) or warfarin (n=20) in a clinical setting. Before treatment and 2 weeks after treatment, we evaluated thrombotic burden using ultrasound or computed tomography angiography. We also evaluated thrombin generation, represented by prothrombin fragment F1+2; thrombus degradation, represented by D-dimer; and levels of anticoagulants, including protein C, protein S, and antithrombin III. Both edoxaban and warfarin treatment improved thrombotic burden and decreased prothrombin fragment F1+2, and D-dimer. Edoxaban treatment preserved protein C and protein S levels. In contrast, warfarin decreased protein C and protein S levels. Neither treatment affected antithrombin III. Edoxaban improves VTE while preserving protein C and protein S levels, thereby indicating that edoxaban improves thrombotic burden while maintaining levels of anticoagulants. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2017.09.009 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29100817 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032912457 (DOI: 10.1016/j.jjcc.2017.09.009, PubMed: 29100817, Elsevier: Scopus)
15.	Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-Ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Masdan Hotimah Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Munehide Matsuhisa, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus., Advances in Therapy, Vol.35, No.1, 124-134, 2017. (Summary) Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively. After excluding 27 patients whose HbA1c levels could not be evaluated 3 months after treatment, the glucose-lowering effects of SGLT2 inhibitors were assessed in 275 patients by measuring HbA1c levels before and 3 months after treatment. The predictors for changes in HbA1c levels after 3 months of treatment were evaluated. SGLT2 inhibitor treatment for 3 months decreased HbA1c levels from 7.8 ± 1.2% to 7.4 ± 1.0% (p < 0.0001). A multiple regression analysis showed that the independent determinants for SGLT2 inhibitor treatment effect included decreased HbA1c levels after 1 month of treatment, high baseline HbA1c levels, and a high estimated glomerular filtration rate (eGFR). We show that type 2 diabetes patients who received the greatest glucose-lowering effect with SGLT2 inhibitor treatment were those with preserved renal function (high baseline eGFR) and high baseline HbA1c levels. Moreover, SGLT2 inhibitor treatment efficacy could be predicted by the patients' initial response to treatment. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12325-017-0639-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29185199 ● Summary page in Scopus @ Elsevier: 2-s2.0-85035102977 (DOI: 10.1007/s12325-017-0639-z, PubMed: 29185199, Elsevier: Scopus)
16.	Shusuke Yagi, Takeshi Soeki, Ken-Ichi Aihara, Daiju Fukuda, Takayuki Ise, Muneyuki Kadota, Sachiko Bando, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Kenya Kusunose, Hirotsugu Yamada, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Low Serum Levels of Eicosapentaenoic Acid and Docosahexaenoic Acid are Risk Factors for Cardiogenic Syncope in Patients with Brugada Syndrome, International Heart Journal, Vol.58, No.5, 720-723, 2017. (Summary) The n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have antiarrhythmic effects, possibly via modulation of the cardiac ion channels. Nevertheless, it is unknown whether low serum levels of n-3 PUFAs are risk factors for ventricular fibrillation in patients with Brugada syndrome (BrS). We retrospectively reviewed data from 62 men with BrS and evaluated their serum levels of EPA and DHA, and the risk factors for sudden cardiac death, including a history of cardiogenic syncope. Nineteen patients had a history of cardiogenic syncope, and their EPA and DHA levels were significantly lower than those of the patients without syncope. Multivariate logistic regression analysis revealed that low EPA and DHA levels were associated with the incidence of syncope. The receiver-operator characteristic curve showed the area under the curves of EPA and DHA for history of syncope were 0.84 and 0.72, respectively. In conclusion, low levels of EPA and DHA are risk factors for cardiogenic syncope in patients with BrS, which suggests that n-3 PUFAs play important roles in preventing ventricular fibrillation in BrS. (Keyword) Adult / Aged / Aged, 80 and over / Biomarkers / Brugada Syndrome / Chromatography, Gas / Docosahexaenoic Acids / Eicosapentaenoic Acid / Electrocardiography / Follow-Up Studies / Humans / Incidence / Japan / Male / Middle Aged / Prevalence / ROC Curve / Retrospective Studies / Risk Assessment / Risk Factors / Syncope / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.16-278 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28966307 ● CiNii @ National Institute of Informatics (CRID): 1390282680202467328 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032215381 (DOI: 10.1536/ihj.16-278, PubMed: 28966307, CiNii: 1390282680202467328, Elsevier: Scopus)
17.	Yuriko Takagawa, Shusuke Yagi, Takayuki Ise, Ayumi Ishii, Koji Nishikawa, Daiju Fukuda, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Shinsuke Katoh, Ken-ichi Aihara, Masashi Akaike and Masataka Sata : Improved Exercise Capacity After Cardiac Rehabilitation Is Associated with Reduced Visceral Fat in Patients with Chronic Heart Failure., International Heart Journal, Vol.58, No.5, 746-751, 2017. (Summary) Participation in a comprehensive cardiac rehabilitation (CR) program has been shown to reduce mortality and improve exercise capacity and symptoms in patients with chronic heart failure (CHF). Reduced exercise capacity leads to a concomitant reduction of skeletal muscle mass and accumulation of body fat. However, it is currently unknown whether CR reduces visceral adipose tissue (VAT) and/or subcutaneous abdominal adipose tissue (SAT) in patients with CHF. In addition, the body composition associated with improved exercise capacity after CR in patients with CHF has not been previously studied. Nineteen CHF patients who were categorized as NYHA functional class II or III and had received optimal medical treatment including a CR program for 5 months were enrolled in this study. The CR program significantly increased peak VO and reduced B-type natriuretic peptide. In addition, fat and body composition analysis showed reductions in the visceral fat tissue (VAT) area, subcutaneous abdominal adipose tissue (SAT) area, body weight, and total fat weight after CR. There were no changes in total water weight and total muscle weight. Single regression analysis revealed that the amelioration of reduced exercise capacity seen after CR is associated with reduced VAT area but not with SAT area or body weight. In conclusion, CR reduces VAT and improves exercise capacity in patients with CHF. This suggests that reducing VAT is important for CR to be most effective in the treatment of CHF. (Keyword) Body Composition / Cardiac Rehabilitation / Exercise Tolerance / Female / Follow-Up Studies / heart failure / Humans / Intra-Abdominal Fat / Male / Middle Aged / obesity / oxygen consumption / Prognosis / Retrospective Studies / Weight Loss (Tokushima University Institutional Repository) ● Metadata: 110111 (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.16-454 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28966316 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032221042 (Tokushima University Institutional Repository: 110111, DOI: 10.1536/ihj.16-454, PubMed: 28966316, Elsevier: Scopus)
18.	Shusuke Yagi, Yukina Hirata, Takayuki Ise, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Salim Masdan Hotimah, G Maimaituxun, Susumu Nishio, Yuriko Takagawa, Saori Hama, Tomomi Matsuura, Koji Yamaguchi, Takeshi Tobiume, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike, Michio Shimabukuro and Masataka Sata : Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus., Diabetology & Metabolic Syndrome, Vol.9, 78, 2017. (Summary) It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327). (Tokushima University Institutional Repository) ● Metadata: 114544 (Link to Publication Site) ● Publication site (DOI): 10.1186/s13098-017-0275-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29034006 ● Summary page in Scopus @ Elsevier: 2-s2.0-85030465923 (Tokushima University Institutional Repository: 114544, DOI: 10.1186/s13098-017-0275-4, PubMed: 29034006, Elsevier: Scopus)
19.	Shusuke Yagi, Daiju Fukuda, KI Aihara, Masashi Akaike, Michio Shimabukuro and Masataka Sata : n-3 Polyunsaturated Fatty Acids: Promising Nutrients for Preventing Cardiovascular Disease., Journal of Atherosclerosis and Thrombosis, Vol.24, No.10, 999-1010, 2017. (Summary) The adoption of the Western-style diet, with decreased fish intake and lack of exercise, has increased the prevalence of cardiovascular disease (CVD) in Japan. Statin treatment has been established to reduce the risk of cardiovascular events; however, 60%-70% of these events occur despite its use. Thus, the residual risk for CVD should be identified and resolved to reduce further cardiovascular events. The serum levels of n-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid and docosahexaenoic acid, are reportedly associated with an increased incidence of cardiovascular events and mortality, whereas the addition of n-3 PUFA treatment to the statin treatment decreases cardiovascular events. Similar to statins, n-3 PUFAs have pleiotropic effects in addition to lipid-modifying effects. Pre-clinical and clinical studies have shown that n-3 PUFAs prevent cardiovascular events by ameliorating endothelial function and attenuating lipid accumulation, vascular inflammation, and macrophage recruitment, thereby causing coronary plaque development and rupture. Taken together, n-3 PUFAs are comprehensively able to attenuate the atherogenic response. Therefore, n-3 PUFA intake is recommended to prevent cardiovascular events, particularly in patients with multiple cardiovascular risk factors. (Tokushima University Institutional Repository) ● Metadata: 115484 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.RV17013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28835582 ● Summary page in Scopus @ Elsevier: 2-s2.0-85030703516 (Tokushima University Institutional Repository: 115484, DOI: 10.5551/jat.RV17013, PubMed: 28835582, Elsevier: Scopus)
20.	Shusuke Yagi, Minoru Mitsugi, Teruaki Sanagawa, Masashi Akaike and Masataka Sata : Paget-Schroetter Syndrome in a Baseball Pitcher., International Heart Journal, Vol.58, No.4, 637-640, 2017. (Summary) Paget-Schroetter syndrome (PSS) is thrombosis of the deep veins draining the upper extremity due to anatomic abnormalities of the thoracic outlet that cause subclavian compression and subsequent thrombosis, leading to thrombus formation in the subclavian vein. Vigorous arm activity in sports is a known risk factor. Here, we report a case of Paget-Schroetter syndrome in a 31-year-old male non-professional baseball pitcher. (Keyword) Adult / Baseball / Fibrinolytic Agents / Humans / Male / Thrombolytic Therapy / Tomography, X-Ray Computed / Upper Extremity Deep Vein Thrombosis (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.16-447 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28701678 ● Summary page in Scopus @ Elsevier: 2-s2.0-85026825932 (DOI: 10.1536/ihj.16-447, PubMed: 28701678, Elsevier: Scopus)
21.	Takeshi Mitsuhashi, Ryoko Uemoto, Kazue Ishikawa, Sumiko Yoshida, Yasumasa Ikeda, Shusuke Yagi, Toshio Matsumoto, Masashi Akaike and Ken-ichi Aihara : Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice., Journal of Atherosclerosis and Thrombosis, 2017. (Summary) Pitavastatin exerts eNOS-independent protective effects against atherogenesis and hind-limb ischemia in mice, which may occur via modifications on key molecules such as AMPK and diverse molecules. (Tokushima University Institutional Repository) ● Metadata: 115483 (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.37747 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28592707 ● Search Scopus @ Elsevier (PMID): 28592707 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.37747 (Tokushima University Institutional Repository: 115483, DOI: 10.5551/jat.37747, PubMed: 28592707)
22.	M Kadota, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, R Ueno, Y Kawabata, T Hara, K Ogasawara, Mika Bando, S Bando, Tomomi Matsuura, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin., International Heart Journal, Vol.57, No.4, 461-465, 2016. (Summary) The renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP) regulate body fluids. Although conventional diuretics have been used for treating heart failure, they activate RAAS and exacerbate renal function. Tolvaptan, a newly developed vasopressin-2 receptor antagonist, elicits aquaresis and improves volume overload in heart failure patients, however, the predictors of tolvaptan effectiveness and the influence on the RAAS and renal function according to tolvaptan therapy are not established. We evaluated 26 chronic heart failure patients receiving therapy with 15 mg/day tolvaptan and examined their laboratory and urinary data before and after tolvaptan therapy. A response to tolvaptan was defined as a body weight decrease by more than 2 kg in a week and a urine volume increase by 500 mL/ day compared with that before tolvaptan administration. Body weight, urine volume, and brain natriuretic peptide levels significantly improved (P < 0.05), without any worsening of renal function represented by serum creatinine, sodium, and potassium. Moreover, no significant changes were observed in the plasma renin activity and plasma aldosterone concentration (PAC). In the responder group, urine osmolality before tolvaptan administration was significantly higher (P < 0.05) but declined significantly after tolvaptan administration (P < 0.05). The AVP/PAC ratio before administration was positively correlated with the efficacy of tolvaptan. Tolvaptan treatment could prevent RAAS activation in chronic heart failure patients. Moreover, monitoring the AVP/PAC ratio may be useful in predicting the tolvaptan response. (Keyword) Adult / Aged / Aged, 80 and over / Antidiuretic Hormone Receptor Antagonists / Arginine Vasopressin / Benzazepines / Body Mass Index / Female / Heart Failure / Humans / Male / Middle Aged / Prospective Studies / Renin-Angiotensin System / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 109694 (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.15-491 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27357439 ● Summary page in Scopus @ Elsevier: 2-s2.0-84979587993 (Tokushima University Institutional Repository: 109694, DOI: 10.1536/ihj.15-491, PubMed: 27357439, Elsevier: Scopus)
23.	T Shigekiyo, E Sekimoto, H Shibata, Shuji Ozaki, T Okumura, H Fujinaga, H Shibata, Ken-ichi Aihara and Masashi Akaike : Factor VII Tokushima: the first case of factor VII Cys22Gly with the development of myocardial infarction in the proband receiving recombinant factor VIIa replacement therapy., Blood Coagulation & Fibrinolysis, Vol.26, No.8, 956-958, 2015. (Summary) An 81-year-old man was referred to our department because of suspected factor VII (FVII) deficiency. His FVII activity was under 1%, whereas the FVII activity levels of his son and granddaughter were 65 and 109%, respectively. The nucleotide at position 3886 of his FVII gene was homozygous for G. A single T to G substitution results in the replacement of wild-type Cys at residue 22 by Gly. His son was heterozygous for G and T at position 3886, whereas his granddaughter was homozygous for wild-type T. These results suggest that he was homozygous for FVII Cys22Gly. He underwent radiofrequency ablation (RFA) for hepatocellular carcinoma, receiving 20 μg/kg of recombinant FVIIa prior to RFA and 10 μg/kg of recombinant FVIIa twice after RFA. He showed no bleeding tendency; however, a myocardial infarction was diagnosed and percutaneous coronary intervention was performed. (Keyword) Aged, 80 and over / Base Sequence / Blood Coagulation Tests / Coagulants / Factor VII Deficiency / Factor VIIa / Genotype / Heterozygote / Homozygote / Humans / Male / Molecular Sequence Data / Myocardial Infarction / Pedigree / Recombinant Proteins (Link to Publication Site) ● Publication site (DOI): 10.1097/MBC.0000000000000346 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26517065 ● Summary page in Scopus @ Elsevier: 2-s2.0-84947057797 (DOI: 10.1097/MBC.0000000000000346, PubMed: 26517065, Elsevier: Scopus)
24.	Shusuke Yagi, Ken-ichi Aihara, Daiju Fukuda, Akira Takashima, Mika Bando, Tomoya Hara, Sachiko Nishimoto, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome., Nutrition Journal, Vol.14, No.1, 111, 2015. (Summary) BACKGROUND: The hospitalization rate for acute coronary syndrome (ACS) for people aged 50 has remained stable over the past decade. Increased serum levels of n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are associated with a decreased incidence of cardiovascular events and mortality in older patients; however, it is currently unknown whether reduced serum levels of n-3 PUFAs is also a risk factor for ACS in patients aged 50 years.METHODS AND RESULTS: We retrospectively reviewed 102 (male/ female 73/29) Japanese ACS patients whose serum levels of EPA/arachidonic acid (AA) and DHA/AA were evaluated on admission. The EPA/AA ratio was the lowest in patients aged 50 compared to patients aged 51-74 and 75. Pearson correlation analysis showed that early ACS onset was associated with low EPA/AA and DHA/AA ratios, and multiple regression analysis determined that decreased ratios of EPA/AA and DHA/AA, and male sex, current smoker status, increased body mass index and triglyceride levels, independently correlated with early ACS onset. Conversely, low-density and high-density lipoproteins, glycated hemoglobin, and hypertension did not correlate with early ACS onset. Subgroup analyses of male patients revealed that decreased ratios of EPA/AA and DHA/AA independently correlated with early ACS onset.CONCLUSION: Decreased EPA/AA and DHA/AA ratios may be risk factors for early onset of ACS, suggesting that reduced EPA/AA and DHA/AA may represent targets for preventing ACS in Japanese young people. (Link to Publication Site) ● Publication site (DOI): 10.1186/s12937-015-0102-4 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26514181 ● Summary page in Scopus @ Elsevier: 2-s2.0-84945959581 (DOI: 10.1186/s12937-015-0102-4, PubMed: 26514181, Elsevier: Scopus)
25.	Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Daiju Fukuda, HM Salim, Masayoshi Ishida, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Toshio Matsumoto and Masataka Sata : Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus., Diabetes & Metabolism Journal, Vol.39, No.4, 342-347, 2015. (Summary) BACKGROUND: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.METHODS: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3±35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.RESULTS: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167±63 to 151±49 mg/dL (P<0.01), and from 7.5%±1.3% to 6.9%±0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.CONCLUSION: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment. (Keyword) Coronary artery disease / diabetes mellitus / Dipeptidyl-peptidase IV inhibitors / Obese / Predictive factors (Link to Publication Site) ● Publication site (DOI): 10.4093/dmj.2015.39.4.342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26301197 ● Summary page in Scopus @ Elsevier: 2-s2.0-84939780057 (DOI: 10.4093/dmj.2015.39.4.342, PubMed: 26301197, Elsevier: Scopus)
26.	Tomoya Hara, Shusuke Yagi, Masashi Akaike and Masataka Sata : Transdermal patch of bisoprolol for the treatment of hypertension complicated with aortic dissection., International Journal of Cardiology, Vol.198, 220-221, 2015. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2015.06.112 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26173061 ● Summary page in Scopus @ Elsevier: 2-s2.0-84940416779 (DOI: 10.1016/j.ijcard.2015.06.112, PubMed: 26173061, Elsevier: Scopus)
27.	Shusuke Yagi, Ken-ichi Aihara, Daiju Fukuda, Akira Takashima, Tomoya Hara, Junko Hotsuchi, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Effects of docosahexaenoic acid on the endothelial function in patients with coronary artery disease., Journal of Atherosclerosis and Thrombosis, Vol.22, No.5, 447-454, 2015. (Summary) AIM: The consumption of n-3 polyunsaturated fatty acids (PUFA), including docosahexaenoic acid DHA), reduces the incidence of cardiovascular events, and reduced serum levels of n-3 PUFA may be associated with an increased risk of cardiovascular events. However, controversy remains regarding which components of PUFA are associated with the endothelial function in patients with coronary artery disease (CAD). We therefore examined the associations between the n-3 and n-6 PUFA levels and CAD.METHODS: We retrospectively reviewed 160 consecutive Japanese patients with CAD whose endothelial function was measured according to the percent change in flow-mediated dilation (FMD) and the serum levels of n-3 PUFA, including eicosapentaenoic acid (EPA) and DHA, and n-6 PUFA, including arachidonic acid (AA) and dihomo-gamma-linolenic acid (DHLA).RESULTS: A single regression analysis showed no relationships between the FMD and the serum levels of PUFA, including EPA, DHA, AA and DHLA. In contrast, a multiple regression analysis showed that the DHA level was a positive (P0.01) and age was a negative (P0.001) contributor to an increased FMD; however, sex, body mass index, systolic and diastolic blood pressure, current/past smoking and the levels of HbA1c, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, EPA, AA and DHLA did not significantly affect the outcome.CONCLUSIONS: The serum level of DHA is associated with the endothelial function evaluated according to the FMD in patients with CAD, thus suggesting that a low serum level of DHA may be a predictive biomarker for endothelial dysfunction. (Keyword) Flow-mediated dilation / n-3 polyunsaturated fatty acids / Docosahexaenoic acid (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.26914 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25342567 ● CiNii @ National Institute of Informatics (CRID): 1390001204431540352 ● Summary page in Scopus @ Elsevier: 2-s2.0-84929412906 (DOI: 10.5551/jat.26914, PubMed: 25342567, CiNii: 1390001204431540352, Elsevier: Scopus)
28.	S Kimura, Yuka Ueda, Takayuki Ise, Shusuke Yagi, Takashi Iwase, K Nishikawa, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinsuke Katoh, Masashi Akaike, Natsuo Yasui and Masataka Sata : Impact of supervised cardiac rehabilitation on urinary albumin excretion in patients with cardiovascular disease., International Heart Journal, Vol.56, No.1, 105-109, 2015. (Summary) Urinary albumin excretion is a predictor of cardiovascular death. Cardiac rehabilitation (CR) with exercise training (ET) has been shown to improve exercise capacity and prognosis in patients with cardiovascular disease (CVD). However, it remains unclear whether CR reduces urinary albumin excretion in CVD patients. We performed a retrospective, observational study using data obtained from 98 male CVD patients without macroalbuminuria and estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m(2) who participated in CR with ET during hospitalization. Twenty-three patients continued supervised ET for 6 months (supervised group) and 75 patients quit supervised ET (non-supervised group). The supervised ET program consisted of 60 minutes of supervised sessions 1-3 times a week and 30-60 minutes of home exercise at least twice a week. Urinary albumin/creatinine ratio (ACR) was significantly decreased in the supervised group at 6 months after enrollment (43 ± 71 mg/g to 17 ± 20 mg/g creatinine, P < 0.05) but not in the non-supervised group. eGFR was unchanged in the supervised group but was significantly decreased in the non-supervised group (72 ± 18 mL/minute/1.73 m(2) to 67 ± 17 mL/minute/1.73 m(2), P < 0.001). The results of multiple regression analysis showed that only supervised ET was an independent contributor to ACR. CR with supervised ET decreased urinary albumin excretion without deterioration of renal function. These findings suggest that continuation of a supervised ET program is associated with reduction in the development of CVD and reduction in cardiovascular morbidity and mortality in CVD patients. (Keyword) Cardiac rehabilitation / Renal function / Cardiovascular disease (Tokushima University Institutional Repository) ● Metadata: 109367 (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.14-161 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25742947 ● Search Scopus @ Elsevier (PMID): 25742947 ● Search Scopus @ Elsevier (DOI): 10.1536/ihj.14-161 (Tokushima University Institutional Repository: 109367, DOI: 10.1536/ihj.14-161, PubMed: 25742947)
29.	Shusuke Yagi, A Takashima, M Mitsugi, T Wada, Junko Hotsuchi, Ken-ichi Aihara, T Hara, Masayoshi Ishida, Daiju Fukuda, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension., Therapeutics and Clinical Risk Management, Vol.11, 83-88, 2015. (Summary) Background: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.Methods: We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.Results: The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.Conclusion: The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension. (Keyword) blood pressure / combination tablet / uric acid / low-density lipoprotein cholesterol / high-density lipoprotein cholesterol (Link to Publication Site) ● Publication site (DOI): 10.2147/TCRM.S72299 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25624765 ● Summary page in Scopus @ Elsevier: 2-s2.0-84921260560 (DOI: 10.2147/TCRM.S72299, PubMed: 25624765, Elsevier: Scopus)
30.	Shusuke Yagi, T Hara, R Ueno, Ken-ichi Aihara, Daiju Fukuda, A Takashima, Junko Hotsuchi, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Serum concentration of eicosapentaenoic acid is associated with cognitive function in patients with coronary artery disease., Nutrition Journal, Vol.13, No.1, 112, 2014. (Summary) BACKGROUND: Recent studies have shown that intake of n-3 polyunsaturated fatty acids (PUFAs) is associated with reduced risk of cognitive impairment and coronary artery disease (CAD); however, it is currently unknown whether reduced serum n-3 PUFA is associated with cognitive impairment in patients with CAD.METHODS: We retrospectively evaluated cognitive function with the mini-mental state examination (MMSE), serum levels of PUFAs (including eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], dihomogammalinolenic acid [DGLA], and arachidonic acid [AA]), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking), and parameters of cardiac function (left ventricular ejection fraction and brain natriuretic peptide levels) in 146 Japanese CAD patients. The associations between the MMSE scores and the other parameters were evaluated.RESULTS: Pearson correlation analysis showed that EPA (R =0.25, P <0.01), EPA/AA ratio (R =0.22, P =0.01), and left ventricular ejection fraction (R =0.15, P =0.04) were positively associated with MMSE score, and that age (R = -0.20, P <0.01) and brain natriuretic peptide levels (R = -0.28, P <0.01) were inversely associated with MMSE score. Multiple regression analysis showed that age (P <0.05) was negatively associated with MMSE score, while EPA (P <0.01) and EPA/AA ratio (P <0.05) were positively associated with MMSE score; however, sex; body mass index; left ventricular ejection fraction; levels of DHA, AA, and DGLA; DHA/AA ratio; brain natriuretic peptide; and presence of hypertension, dyslipidemia, diabetes mellitus, cerebrovascular disease, and history of current/previous smoking were statistically excluded.CONCLUSIONS: Serum EPA concentration is associated with cognitive function in patients with CAD, suggesting that a low serum EPA level is a risk factor for cognitive impairment independent of cardiac function, including left ventricular ejection fraction. This correlation potentially lends further support to a role of dietary n-3 PUFAs in preventing the cognitive decline in CAD patients. (Keyword) Aged / Arachidonic Acid / Cognition / Cognition Disorders / Coronary Disease / Eicosapentaenoic Acid / Fatty Acids, Omega-3 / Female / Humans / Japan / Male / Middle Aged / Retrospective Studies / Risk Factors / Stroke Volume (Link to Publication Site) ● Publication site (DOI): 10.1186/1475-2891-13-112 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25471307 ● Summary page in Scopus @ Elsevier: 2-s2.0-84926465688 (DOI: 10.1186/1475-2891-13-112, PubMed: 25471307, Elsevier: Scopus)
31.	A Takashima, Takayuki Ise, Shusuke Yagi, Takashi Iwase, S Kimura, Yuka Ueda, K Nishikawa, A Ishii, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinsuke Katoh, Masashi Akaike and Masataka Sata : Cardiac rehabilitation reduces serum levels of oxidized low-density lipoprotein., Circulation Journal, Vol.78, No.11, 2682-2687, 2014. (Summary) BACKGROUND: Oxidized low-density lipoprotein (oxLDL) levels have been found to play an important role in the progression of atherosclerosis. However, methods for effectively reducing oxLDL levels have not been established. Comprehensive cardiac rehabilitation (CR) with exercise training prevents the progression of atherosclerosis, and might reduce oxLDL levels.MethodsandResults:We measured the serum levels of malondialdehyde-modified LDL (MDA-LDL), a marker of oxLDL, in 136 patients who were enrolled in a 6-month CR program. Peak oxygen consumption (VO2) and MDA-LDL levels were analyzed, before and 6 months after enrolment. In total, 67 patients completed the CR program (CR group) and 69 patients failed to complete the program (non-CR group). Peak VO2increased significantly in the CR group (P<0.01). The levels of MDA-LDL decreased significantly in the CR group (P<0.01) but not in the non-CR group. VO2(peak VO2after CR-peak VO2before CR) was negatively associated with MDA-LDL (MDA-LDL after CR-MDA-LDL before CR) (R(2)=0.11, P=0.01). Multiple regression analysis showed that continuing CR was an independent determining factor for lowering MDA-LDL levels.CONCLUSIONS: CR decreases oxLDL levels in patients with cardiovascular diseases. Moreover, CR may prevent cardiovascular events through an antioxidative effect. (Circ J 2014; 78: 2682-2687). (Keyword) Cardiac rehabilitation / Lipoproteins / Oxidative stress (Tokushima University Institutional Repository) ● Metadata: 109368 (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-14-0532 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25241889 ● Search Scopus @ Elsevier (PMID): 25241889 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-14-0532 (Tokushima University Institutional Repository: 109368, DOI: 10.1253/circj.CJ-14-0532, PubMed: 25241889)
32.	Nhat-Tu Le, Yuichiro Takei, Yuki Izawa-Ishizawa, Kyung-Sun Heo, Hakjoo Lee, V Alan Smrcka, L Benjamin Miller, Ae Kyung Ko, Sara Ture, Craig Morrell, Keigi Fujiwara, Masashi Akaike and Jun-Ichi Abe : Identification of Activators of ERK5 Transcriptional Activity by High-Throughput Screening and the Role of Endothelial ERK5 in Vasoprotective Effects Induced by Statins and Antimalarial Agents., The Journal of Immunology, Vol.193, No.7, 3803-3815, 2014. (Summary) Because ERK5 inhibits endothelial inflammation and dysfunction, activating ERK5 might be a novel approach to protecting vascular endothelial cells (ECs) against various pathological conditions of the blood vessel. We have identified small molecules that protect ECs via ERK5 activation and determined their contribution to preventing cardiac allograft rejection. Using high-throughput screening, we identified certain statins and antimalarial agents including chloroquine, hydroxychloroquine, and quinacrine as strong ERK5 activators. Pitavastatin enhanced ERK5 transcriptional activity and Kruppel-like factor-2 expression in cultured human and bovine ECs, but these effects were abolished by the depletion of ERK5. Chloroquine and hydroxychloroquine upregulated ERK5 kinase activity and inhibited VCAM-1 expression in an ERK5-dependent but MAPK/ERK kinase 5- and Kruppel-like factor 2/4-independent manner. Leukocyte rolling and vascular reactivity were used to evaluate endothelial function in vivo, and we found that EC-specific ERK5 knockout (ERK5-EKO) mice exhibited increased leukocyte rolling and impaired vascular reactivity, which could not be corrected by pitavastatin. The role of endothelial ERK5 in acute cardiac allograft rejection was also examined by heterotopic grafting of the heart obtained from either wild-type or ERK5-EKO mice into allomismatched recipient mice. A robust increase in both inflammatory gene expression and CD45-positive cell infiltration into the graft was observed. These tissue rejection responses were inhibited by pitavastatin in wild-type but not ERK5-EKO hearts. Our study has identified statins and antimalarial drugs as strong ERK5 activators and shown that ERK5 activation is preventive of endothelial inflammation and dysfunction and acute allograft rejection. (Link to Publication Site) ● Publication site (DOI): 10.4049/jimmunol.1400571 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25187658 ● Search Scopus @ Elsevier (PMID): 25187658 ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.1400571 (DOI: 10.4049/jimmunol.1400571, PubMed: 25187658)
33.	T Hara, K Kishi-Tanaka, Takashi Iwase, Hirotsugu Yamada, Masashi Akaike and Masataka Sata : Utility of lower limb positive pressure test for diagnosis of diastolic heart failure: a case report., The Journal of Medical Investigation : JMI, Vol.61, No.3-4, 404-408, 2014. (Summary) A 70-year-old woman with dyspnea on exertion was admitted to our hospital. She had a history of apical hypertrophic cardiomyopathy (HCM) and repeated hospitalization for heart failure. Results of physical examination were normal except for leg edema. Echocardiography showed apical HCM with preserved LV systolic function (LVEF = 70%). Although dyspnea on exertion and leg edema improved rapidly with the use of diuretics, her symptoms soon worsened when daily activity was started again. In order to examine the effect of preload on hemodynamics, we performed a lower limb positive pressure test by compressing both legs using a household air leg massager. Echocardiography showed increases in mitral E velocity, E/A ratio and pulmonary venous D flow as well as decrease in stroke volume during the lower limb positive pressure test. Simultaneously-recorded pressure study also showed elevated LVEDP and increased v wave of pulmonary capillary wedge pressure. These results suggested that even a small increase in preload led to elevation of LVEDP and symptomatic worsening due to severe diastolic heart failure in the present case. The lower limb positive pressure test may be useful for assessing the effect of preload on hemodynamics in patients with diastolic heart failure. (Keyword) diastolic heart failure / lower limb positive pressure test / apical hypertrophic cardiomyopathy (Tokushima University Institutional Repository) ● Metadata: 109593 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.404 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25264062 ● CiNii @ National Institute of Informatics (CRID): 1390282679219954688 ● Summary page in Scopus @ Elsevier: 2-s2.0-84907518768 (Tokushima University Institutional Repository: 109593, DOI: 10.2152/jmi.61.404, PubMed: 25264062, CiNii: 1390282679219954688, Elsevier: Scopus)
34.	Shusuke Yagi, M Fujimura, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, M Tada, Yuka Ueda, Takayuki Ise, Koji Yamaguchi, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Increase in serum triglyceride was associated with coronary plaque vulnerability in a patient with rheumatoid arthritis., Journal of Cardiology Cases, Vol.10, No.2, 54-57, 2014. (Summary) Rates of morbidity and mortality from cardiovascular disease are high in patients with rheumatoid arthritis (RA); however, the mechanisms and biomarkers that reflect coronary plaque vulnerability have not yet been established. We present a case of acute coronary syndrome (ACS) presumably caused by exacerbation of chronic inflammation of RA, in which an abrupt increase in serum triglyceride was seen on the day of onset of ACS but not during effort angina. This case suggests that RA patients with an abrupt increase in triglyceride need intensive care including anti-platelet and statin therapy for the prevention of coronary plaque rupture.<Learning objective: Triglyceride might be a sensitive biomarker of activated macrophages and plaque vulnerability in patients with RA. RA patients with an abrupt increase in triglyceride might need intensive care including anti-platelet and statin therapy for the prevention of coronary plaque rupture.> (Keyword) Acute coronary syndrome / Triglyceride / Tumor necrosis factor- / Biomarker (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jccase.2014.04.009 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84905378195 (DOI: 10.1016/j.jccase.2014.04.009, Elsevier: Scopus)
35.	Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Itsuro Endo, Junko Hotsuchi, Takayuki Ise, Takashi Iwase, Masashi Akaike, Toshio Matsumoto and Masataka Sata : High serum parathyroid hormone and calcium are risk factors for hypertension in Japanese patients., Endocrine Journal, Vol.61, No.7, 727-733, 2014. (Summary) Excess parathyroid hormone (PTH), known as primary hyperparathyroidism (pHPT), results in hypercalcemia and bone loss. Recent studies have shown that PTH is associated with the occurrence of hypertension in Western countries; however, controversy remains regarding high serum levels of PTH and calcium as risk factors for hypertension in Japanese patients. We retrospectively enrolled 114 consecutive Japanese patients who visited our hospital for examination and treatment of hypercalcemia and/or hypertension with serum calcium levels ≥ 9.8 mg/dL. To estimate the prevalence of hypertension, the patients were categorized according to calcium levels into hypercalcemic (10.2-13.4 mg/dL) and normocalcemic (9.8-10.1 mg/dL) groups, which were further categorized into high PTH (50-440 pg/mL) and low PTH (8-49 pg/mL) groups. The prevalence of hypertension was higher in patients with hypercalcemia than in patients with normocalcemia in both the high and low PTH groups. The prevalence of hypertension was higher in patients with high serum PTH levels than in patients with low serum PTH levels in both the hypercalcemic and normocalcemic groups. Logistic multiple regression analysis determined that serum calcium (P < 0.05) and PTH (P < 0.01) levels were positive contributors to hypertension. In conclusion, high serum levels of PTH and calcium are risk factors for hypertension in Japanese patients. (Keyword) parathyroid hormone / calcium / hypertension (Link to Publication Site) ● Publication site (DOI): 10.1507/endocrj.EJ14-0004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24849536 ● CiNii @ National Institute of Informatics (CRID): 1390001206300211712 ● Summary page in Scopus @ Elsevier: 2-s2.0-84905190698 (DOI: 10.1507/endocrj.EJ14-0004, PubMed: 24849536, CiNii: 1390001206300211712, Elsevier: Scopus)
36.	Masashi Akaike, Ken-ichi Aihara, Hiroaki Yanagawa, Takashi Iwase, Sumiko Yoshida, Sato Chiho, Saijo Tomoka, Hiroaki Mikasa, Kashiwada Yoshizaki, Yoshihisa Takaishi, Koichiro Tsuchiya, Toshiaki Tamaki, Toshio Matsumoto and Masataka Sata : Efficacy and safety of Citrus sudachi peel in obese adults:A randomized, double-blind, pilot study, Functional Foods in Health and Disease, Vol.4, No.6, 276-284, 2014. (Link to Publication Site) ● Publication site (DOI): 10.31989/ffhd.v4i7.5 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85054855286 (DOI: 10.31989/ffhd.v4i7.5, Elsevier: Scopus)
37.	S Bando, Takeshi Soeki, T Matsuura, Toshiyuki Niki, Takayuki Ise, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, T Aiba, W Shimizu and Masataka Sata : Congenital long QT syndrome with compound mutations in the KCNH2 gene., Heart and Vessels, Vol.29, No.4, 554-559, 2014. (Summary) Congenital long QT syndrome is a genetic disorder encompassing a family of mutations that can lead to aberrant ventricular electrical activity. We report on two brothers with long QT syndrome caused by compound mutations in the KCNH2 gene inherited from parents who had no prolonged QT interval on electrocardiography. The proband had syncope, and his elder brother suffered from ventricular fibrillation. Genetic testing revealed that both brothers had multiple mutations in the KCNH2 gene, including a missense mutation of C1474T (exon 6) as well as a frameshift/nonsense mutation, resulting from the insertion of 25 nucleotides, which caused an altered amino acid sequence beginning at codon 302 and a premature termination codon (i.e., TAG) at codon 339 (exon 4). Family genetic screening found that their father had the same frameshift mutation, and their mother and sister had the same missense mutation, in the KCNH2 gene. However, these other family members were asymptomatic, with normal QT intervals on electrocardiography. These results suggest that compound mutations in the KCNH2 gene inherited independently from the parents made the phenotypes of their sons more severe. (Keyword) KCNH2 gene / Long QT syndrome / Compound mutation / Missense mutation / Frameshift mutation (Link to Publication Site) ● Publication site (DOI): 10.1007/s00380-013-0406-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24057343 ● Summary page in Scopus @ Elsevier: 2-s2.0-84904036858 (DOI: 10.1007/s00380-013-0406-2, PubMed: 24057343, Elsevier: Scopus)
38.	坂東智子, Masashi Akaike, 鶴尾美穂, 石本寛子, 宮内和瑞, Yoshimi Bando, 生島葉子, 宮恵子, 瀧雅, 原田和代, 角瀬裕子 and 豊崎纏 : Support System for Women Doctors by Tokushima City Medical Association, Shikoku Acta Medica, Vol.70, No.5-6, 161-166, 2014. (Summary) In recent years, an increase in the ratio of female physicians in Tokushima Prefecture, with a particularly notable rise among younger generations that has exceeded the national average, has been observed. However, these physicians continue to face severe working environments, and support measures are required for female physicians during childbirth and in the early stages of parenthood. To this end, the Tokushima City Medical Association has been involved in initiatives to support female physicians since 2008. First, we developed ``Net Joy,'' a website that provides the information necessary for female physicians to continue their clinical work through a bulletin board system that offers information on topics such as employment and childcare. Furthermore, we have administered questionnaire surveys related to working environments and support systems in clinical training hospitals and compiled a booklet entitled Support Notebook for Female Physicians that is available on the Net Joy website. Since 2011, as post-residency training in ultrasound techniques, we have held six separate practical training seminars at the Tokushima University Hospital Ultrasound Examination Center and the Tokushima City Medical Association Hall. Since 2014, we have been involved in efforts to enhance its training content and develop it into a long-term program. (Keyword) female physicians / website / practical training seminar (Tokushima University Institutional Repository) ● Metadata: 109897 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050020697877549056 (Tokushima University Institutional Repository: 109897, CiNii: 1050020697877549056)
39.	Kyung-Sun Heo, J Hannah Cushman, Masashi Akaike, Chang-Hoon Woo, Xin Wang, Xing Qiu, Keigi Fujiwara and Jun-ichi Abe : ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis., Circulation, Vol.130, No.2, 180-191, 2014. (Summary) Our results demonstrate that ERK5, which is robustly activated by statins, is a hub molecule that upregulates macrophage efferocytosis, thereby suppressing atherosclerotic plaque formation. Molecules that upregulate ERK5 and its signaling in macrophages may be good drug targets for suppressing cardiovascular diseases. (Keyword) Animals / Atherosclerosis / Cells, Cultured / Enzyme Activation / Macrophages / Mice / Mice, Inbred C57BL / Mice, Knockout / Mitogen-Activated Protein Kinase 7 / Phagocytosis (Link to Publication Site) ● Publication site (DOI): 10.1161/CIRCULATIONAHA.113.005991 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25001623 ● Search Scopus @ Elsevier (PMID): 25001623 ● Search Scopus @ Elsevier (DOI): 10.1161/CIRCULATIONAHA.113.005991 (DOI: 10.1161/CIRCULATIONAHA.113.005991, PubMed: 25001623)
40.	Takayuki Ise, Takashi Iwase, S Masuda, Shusuke Yagi, Masashi Akaike, S Nishio, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute pulmonary thromboembolism from deep vein thrombosis induced by trauma to the popliteal vein with a tennis racket., Journal of Cardiology Cases, Vol.9, No.4, 162-164, 2014. (Summary) Acute pulmonary thromboembolism (PTE) is mainly caused by deep vein thrombosis (DVT) and sometimes leads to a fatal outcome. Few cases of sport-related lower extremity DVT, involving direct external trauma, have been reported. A 58-year-old man, without any risk factors for thromboembolism suffered acute PTE from DVT after playing tennis. A detailed history revealed that he had hit his popliteal vein with each swing of his tennis racket and the site of the trauma, at popliteal fossa, was exactly the same as the site of the DVT formation. Therefore, the cause of DVT was suspected to be the repeated trauma to the popliteal vein. The repeated external trauma to the popliteal vein may have caused vascular endothelial damage, leading to DVT. (Keyword) Acute pulmonary thromboembolism / Deep vein thrombosis / Trauma (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jccase.2014.01.001 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84897413698 (DOI: 10.1016/j.jccase.2014.01.001, Elsevier: Scopus)
41.	Shusuke Yagi, Kadota Muneyuki, Ken-ichi Aihara, Nishikawa Koji, Hara Tomoya, Takayuki Ise, Yuka Ueda, Takashi Iwase, Masashi Akaike, Michio Shimabukuro, Shinsuke Katoh and Masataka Sata : Association of lower limb muscle mass and energy expenditure with visceral fat mass in healthy men, Diabetology & Metabolic Syndrome, Vol.6, No.1, 27, 2014. (Summary) A high-calorie diet and physical inactivity, an imbalance between caloric intake and energy consumption, are major causes of metabolic syndrome (MetS), which manifests as accumulation of visceral fat and insulin resistance. However, the lifestyle-related factors associated with visceral fat mass in healthy men are not fully understood. We evaluated visceral fat area (VFA), skeletal muscle mass, caloric intake, and energy expenditure in 67 healthy male participants (mean age, 36.9 ± 8.8 years; body mass index 23.4 ± 2.5 kg/m2). Multiple regression analysis showed that the total skeletal muscle mass (P < 0.001) were negatively and age (P < 0.001) were positively associated with VFA. Lower limb muscle mass (P < 0.001) was strongly associated with VFA. However, total caloric intake, total energy expenditure, and energy expenditure during exercise were not associated with VFA. Skeletal muscle mass especially lower limb muscle mass negatively contributes to visceral fat mass in healthy men. Therefore, maintaining lower limb muscular fitness through daily activity may be a useful strategy for controlling visceral obesity and metabolic syndrome. (Link to Publication Site) ● Publication site (DOI): 10.1186/1758-5996-6-27 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24571923 ● Summary page in Scopus @ Elsevier: 2-s2.0-84896075201 (DOI: 10.1186/1758-5996-6-27, PubMed: 24571923, Elsevier: Scopus)
42.	Takeshi Soeki, Toshiyuki Niki, E. Uematsu, S. Bando, T. Matsuura, Kenya Kusunose, Takayuki Ise, Yuka Ueda, N. Tomita, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Daiju Fukuda, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Michio Shimabukuro, I. Kishimoto, Kenji Kangawa and Masataka Sata : Ghrelin protects the heart against ischemia-induced arrhythmias by preserving connexin-43 protein., Heart and Vessels, Vol.28, No.6, 795-801, 2013. (Summary) Vagal nerve stimulation has been postulated to confer an antifibrillatory effect. We studied whether ghrelin administration would exert an antiarrhythmic effect via modulation of autonomic nerve activity in rats after acute myocardial ischemia (MI). Male Sprague-Dawley rats were exposed to 30 min of ischemia following ligation of the left coronary artery. Animals were then randomized to receive either ghrelin (n = 26) or saline (n = 26) during the period of coronary ligation. Power spectral analysis of heart-rate variability revealed that the administration of ghrelin increased the high-frequency (HF) power and decreased the low-frequency (LF)/HF ratio. Ventricular tachyarrhythmias were less frequent in rats after MI who received ghrelin in comparison with rats that received saline. Immunoblotting and immunohistochemistry revealed that rats given saline alone during MI exhibited a marked reduction in phosphorylated connexin-43 within the left ventricle, whereas those that received ghrelin displayed only minor reductions in comparison with sham-operated rats. These effects of ghrelin were diminished by the coadministration of atropine or the blockade of vagal afferents. These data demonstrate that the beneficial effect of ghrelin might be mediated by modulation of cardiac autonomic nerve activity. (Keyword) Animals / Anti-Arrhythmia Agents / Atropine / Connexin 43 / Disease Models, Animal / Ghrelin / Heart Rate / Heart Ventricles / Male / Muscarinic Antagonists / Myocardial Ischemia / Phosphorylation / Rats / Rats, Sprague-Dawley / Tachycardia, Ventricular / Time Factors / Vagotomy / Vagus Nerve (Link to Publication Site) ● Publication site (DOI): 10.1007/s00380-013-0333-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23494606 ● Search Scopus @ Elsevier (PMID): 23494606 ● Search Scopus @ Elsevier (DOI): 10.1007/s00380-013-0333-2 (DOI: 10.1007/s00380-013-0333-2, PubMed: 23494606)
43.	Shusuke Yagi, Masashi Akaike, Takayuki Ise, Yuka Ueda, Takashi Iwase and Masataka Sata : Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment., Hypertension Research, Vol.36, No.9, 753-758, 2013. (Summary) Because dementia is associated with both deterioration in the quality of life and poor prognosis, the prevention of cognitive impairment (CI) is a critical problem in public health promotion. Hypertension is a risk factor for the aggravation of CI, and the renin-angiotensin-aldosterone system (RAAS) is a key player in the increased incidence and development of hypertension. Therefore, the RAAS is considered to be a promoting factor for CI development. Conversely, recent studies have shown that lowering blood pressure with RAAS inhibitors decreases the incidence of CI, dementia and cardiovascular disease. Blood-brain barrier-penetrating RAAS inhibitors appear to have advantages in preventing cognitive decline because they can suppress the RAAS in the hippocampus, which has an important role in cognition. Thus, RAAS blockage is a notable strategy for preventing CI. (Keyword) Angiotensin-Converting Enzyme Inhibitors / Cognition / Cognition Disorders / Humans / Hypertension / Renin-Angiotensin System / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.1038/hr.2013.51 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23698805 ● Summary page in Scopus @ Elsevier: 2-s2.0-84883885656 (DOI: 10.1038/hr.2013.51, PubMed: 23698805, Elsevier: Scopus)
44.	Sumiko Yoshida, Ken-ichi Aihara, Yasumasa Ikeda, Yuka Sumitomo-Ueda, Ryoko Uemoto, Kazue Ishikawa, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Yasuhiro Mouri, Matomo Sakari, Takahiro Matsumoto, Ken-ichi Takeyama, Masashi Akaike, Mitsuru Matsumoto, Masataka Sata, Kenneth Walsh, Shigeaki Kato and Toshio Matsumoto : Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling., Circulation, Vol.128, No.1, 60-71, 2013. (Summary) These results document a physiological role of AR in sex-independent angiogenic potency and provide evidence of novel cross-talk between the androgen/AR signaling and VEGF/kinase insert domain protein receptor signaling pathways. (Link to Publication Site) ● Publication site (DOI): 10.1161/CIRCULATIONAHA.113.001533 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23723256 ● Search Scopus @ Elsevier (PMID): 23723256 ● Search Scopus @ Elsevier (DOI): 10.1161/CIRCULATIONAHA.113.001533 (DOI: 10.1161/CIRCULATIONAHA.113.001533, PubMed: 23723256)
45.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Daiju Fukuda, Masayoshi Ishida, Takayuki Ise, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro and Masataka Sata : Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems., Acta Cardiologica Sinica, Vol.29, No.3, 201-207, 2013. (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84878307366 (Elsevier: Scopus)
46.	Shuji Kato, Itsuro Endo, Mitsunori Fujimura, Rika Kuriwaka-Kido, Yuichi Fujinaka, Ken-ichi Aihara, Takashi Iwase, Daisuke Inoue, Masashi Akaike, Masahiro Abe and Toshio Matsumoto : Serum carboxy-terminal telopeptide of type I collagen (ICTP) as a surrogate marker for vulnerable plaques in atherosclerotic patients: A pilot study., Atherosclerosis, Vol.229, No.1, 182-185, 2013. (Summary) Evaluation of atherosclerotic plaques depends on invasive intravascular ultrasonography (IVUS). Carboxy-terminal telopeptide of type I collagen (ICTP) is produced by matrix metalloproteinase (MMP)-dependent digestion of type I collagen. Because vulnerable plaques are rich in type I collagen and MMPs from macrophages, we examined the association between serum ICTP and coronary plaques in patients with coronary disease. We recruited 46 men and 17 women without renal failure or bone diseases affecting serum ICTP, who underwent coronary IVUS. Serum ICTP levels were higher in patients with coronary plaques containing more than 10% necrotic core area than in patients with less than 10% necrotic core area. A positive correlation was found between serum ICTP and necrotic core area. Only serum ICTP was positively correlated with necrotic core area by multivariate analysis (p < 0.05). These results suggest that serum ICTP can be used as a non-invasive marker of vulnerable plaques in atherosclerotic patients. (Tokushima University Institutional Repository) ● Metadata: 105936 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2013.03.030 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23639859 ● Search Scopus @ Elsevier (PMID): 23639859 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2013.03.030 (Tokushima University Institutional Repository: 105936, DOI: 10.1016/j.atherosclerosis.2013.03.030, PubMed: 23639859)
47.	Takayuki Ise, K Fujioka, Takashi Iwase, J. Hotchi, Masashi Akaike and Masataka Sata : Ulcer-like projection caused by a penetrating branch to the bronchial artery., Journal of the American College of Cardiology, Vol.61, No.8, e147-147, 2013. (Keyword) Aged / Aorta, Thoracic / Back Pain / Bronchial Arteries / Female / Hematoma / Humans / Remission, Spontaneous / Rupture, Spontaneous / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jacc.2012.10.047 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23428223 ● Summary page in Scopus @ Elsevier: 2-s2.0-84874522803 (DOI: 10.1016/j.jacc.2012.10.047, PubMed: 23428223, Elsevier: Scopus)
48.	高島啓, Takayuki Ise, Yuka Ueda, Takashi Iwase, Shusuke Yagi, 前田香代子, 西川幸治, 小笠原梢, Mika Bando, 坂東左知子, 冨田紀子, Toshiyuki Niki, 發知淳子, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinsuke Katoh, Masashi Akaike, Natsuo Yasui and Masataka Sata : Cardiac rehabilitation reduces level of oxidized LDL, 心臓リハビリテーション, Vol.18, No.1, 130-133, 2013. (Keyword) 酸化LDL / 心臓リハビリテーション / 心肺運動負荷試験 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520010381154583040 (CiNii: 1520010381154583040)
49.	Yasumasa Ikeda, Ken-ichi Aihara, Sumiko Yoshida, Takashi Iwase, Soichiro Tajima, Yuki Izawa-Ishizawa, Yoshitaka Kihira, Keisuke Ishizawa, Shuhei Tomita, Koichiro Tsuchiya, Masataka Sata, Masashi Akaike, Shigeaki Kato, Toshio Matsumoto and Toshiaki Tamaki : Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway, The Journal of Biological Chemistry, Vol.287, No.41, 34256-34263, 2012. (Summary) We previously clarified that heparin cofactor II (HCII), a serine proteinase inhibitor, exerts various protective actions on cardiovascular diseases in both experimental and clinical studies. In the present study, we aimed to clarify whether HCII participates in the regulation of angiogenesis. Male heterozygous HCII-deficient (HCII(+/-)) mice and male littermate wild-type (HCII(+/+)) mice at the age of 12-16 weeks were subjected to unilateral hindlimb ligation surgery. Laser speckle blood flow analysis showed that blood flow recovery in response to hindlimb ischemia was delayed in HCII(+/-) mice compared with that in HCII(+/+) mice. Capillary number, arteriole number, and endothelial nitric-oxide synthase (eNOS), AMP-activated protein kinase (AMPK), and liver kinase B1 (LKB1) phosphorylation in ischemic muscles were decreased in HCII(+/-) mice. Human purified HCII (h-HCII) administration almost restored blood flow recovery, capillary density, and arteriole number as well as phosphorylation levels of eNOS, AMPK, and LKB1 in ischemic muscles of HCII(+/-) mice. Although treatment with h-HCII increased phosphorylation levels of eNOS, AMPK, and LKB1 in human aortic endothelial cells (HAECs), the h-HCII-induced eNOS phosphorylation was abolished by compound C, an AMPK inhibitor, and by AMPK siRNA. In a similar fashion, tube formation, proliferation, and migration of HAECs were also promoted by h-HCII treatment and were abrogated by pretreatment with compound C. HCII potentiates the activation of vascular endothelial cells and the promotion of angiogenesis in response to hindlimb ischemia via an AMPK-eNOS signaling pathway. These findings suggest that HCII is a novel therapeutic target for treatment of patients with peripheral circulation insufficiency. (Keyword) Heparin cofactor II (HCII) / vascular endothelial cells / angiogenesis (Link to Publication Site) ● Publication site (DOI): 10.1074/jbc.M112.353532 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22904320 ● Search Scopus @ Elsevier (PMID): 22904320 ● Search Scopus @ Elsevier (DOI): 10.1074/jbc.M112.353532 (DOI: 10.1074/jbc.M112.353532, PubMed: 22904320)
50.	久岡白陽花, Yuka Ueda, 前田香代子, 西川幸治, 坂東左知子, 林修司, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 冨田紀子, Takashi Iwase, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinjiro Takata, Masashi Akaike, Natsuo Yasui and Masataka Sata : (若手優秀演題セッション)尿中アルブミン排泄量に及ぼす心臓リハビリテーションの効果, 心臓リハビリテーション, Vol.17, No.1, 159-161, 2012.
51.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Takayuki Ise, Yasumasa Ikeda, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : ロスバスタチンによる脂質低下作用非依存的な形態的および機能的頸動脈硬化改善作用, Progress in Medicine, Vol.32, No.2, 315-320, 2012.
52.	Hirotsugu Kurobe, Ken-ichi Aihara, Higashida Mayuko, Hirata Yoichiro, Nishiya Masako, Matsuoka Yuki, Tamotsu Kanbara, Nakayama Taisuke, Hajime Kinoshita, Mikio Sugano, Eiki Fujimoto, Kurobe Ayako, Sugawara Noriko, Takashi Kitaichi, Masashi Akaike, Masataka Sata, Toshio Matsumoto and Tetsuya Kitagawa : Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress., Journal of Atherosclerosis and Thrombosis, Vol.18, No.12, 1080-1089, 2011. (Summary) Ezetimibe, an inhibitor of cholesterol intestinal absorption, is a lipid lowering agent. However, anti-atherogenic effects of ezetimibe have not been fully elucidated. Therefore, the objective in this study was to clarify the vascular protective effects of ezetimibe in patients with hypercholesterolemia. Ezetimibe was administered to 20 patients with hypercholesterolemia (group E), and 20 age- and sex-matched patients with hypercholesterolemia were followed as controls (group C). Difference in metabolic profiles and cardiovascular surrogate markers before ezetimibe treatment and after 12 weeks of ezetimibe treatment were statistically evaluated. Ezetimibe treatment significantly reduced serum levels of low-density lipoprotein cholesterol (LDL-C) and malondialdehyde-modified low-density lipoprotein (MDA-LDL). In addition, the values of body mass index, body weight, waist circumference, plasma HbA1c and urinary albumin were significantly decreased in group E compared to those in group C. On the other hand, high-density lipoprotein cholesterol (HDL-C) and adiponectin levels were significantly increased in group E compared to those in group C. The values of brachial-ankle pulse wave velocity (ba-PWV), mean arterial blood pressure (m-ABP), and % of flow-mediated dilation (FMD) were significantly improved in group E. Furthermore, ultrasonic studies demonstrated amelioration of the vascular stiffness of common carotid arteries in group E but not in group C. These vascular protective effects of ezetimibe were statistically correlated with the decreased values of MDA-LDL and MDA-LDL-to-LDL-C ratio but not with those of LDL-C. Ezetimibe has a lipid lowering-independent vascular protective effect in patients with hypercholesterolemia through decreasing oxidative stress. (Keyword) Aged / Azetidines / Case-Control Studies / Endothelium, Vascular / Humans / Hypercholesterolemia / Lipids / Male / Middle Aged / oxidative stress (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.9548 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22027560 ● Search Scopus @ Elsevier (PMID): 22027560 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.9548 (DOI: 10.5551/jat.9548, PubMed: 22027560)
53.	Koji Yamaguchi, Tetsuzo Wakatsuki, Toshiyuki Niki, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local persistent hypercoagulability after sirolimus-eluting stent implantation in patients with stable angina., International Journal of Cardiology, Vol.153, No.3, 272-276, 2011. (Summary) Late stent thrombosis (LST) after sirolimus-eluting stent (SES) implantation has been demonstrated previously. Although incomplete neointimal coverage after SES implantation has been reported, local long-term hypercoagulability remains unknown. We evaluated the local persistent coagulative response in eighty-three consecutive patients with stable angina, treated with either SES (n=51) or BMS (n=32) implantation for isolated de novo left anterior descending (LAD) stenosis. We measured prothrombin fragment F1+2 (frF1+2) and D-dimer levels sampled in the coronary sinus (CS) and sinus of Valsalva (V). The transcardiac gradient (Δ) was defined as the CS level minus V level. The ΔfrF1 + 2 and ΔD-dimer were significantly greater in the SES group than in the BMS group (0.50 ± 0.35 vs -0.14 ± 0.15 nmol/l, p=0.009 and 0.24 ± 0.21 vs -0.05 ± 0.16 μg/ml, p=0.041, respectively). We selected the hypocoagulative [ΔfrF1 + 2<0.15 (mean value-SD) nmol/l, n=21] and hypercoagulative [ΔfrF1 + 2>0.85 (mean value+SD) nmol/l, n=14] groups out of the SES patients. Multivariate analysis was performed to identify independent predictors of local hypercoagulability. Total SES length was the only independent predictor of local hypercoagulability. There was a significant positive correlation between the ΔfrF1 + 2 and total stent length in the SES group (r=0.57, p<0.05). An increased local coagulative response was observed in the convalescent phase after SES implantation as compared to BMS. Careful long-term follow-up of patients after longer SES implantation is recommended in order to avoid LST. (Keyword) Aged / Angina, Stable / Cohort Studies / Coronary Thrombosis / Drug-Eluting Stents / Female / Humans / Male / Middle Aged / Sirolimus / Thrombophilia / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2010.08.014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20826025 ● Search Scopus @ Elsevier (PMID): 20826025 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2010.08.014 (DOI: 10.1016/j.ijcard.2010.08.014, PubMed: 20826025)
54.	Takeshi Soeki, Toshiyuki Niki, Kenya Kusunose, Sachiko Bando, Yoichiro Hirata, Noriko Tomita, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability., Journal of Cardiology, Vol.58, No.2, 151-157, 2011. (Summary) Inflammation is a critical contributing factor to the development and progression of atherosclerosis. Pentraxin 3 (PTX3) is produced abundantly in atherosclerotic lesions while C-reactive protein (CRP) is mainly produced in the liver. In this study, we investigated whether plasma levels of PTX3 might be a sensitive marker both for the severity of coronary artery disease and vulnerable plaques. Next, we determined whether assays for inflammatory molecules can be used to monitor the therapeutic effects of telmisartan on stabilization of vulnerable atherosclerotic plaques. We measured PTX3 concentrations in the peripheral and coronary sinus plasma of 40 patients with angina pectoris (AP) and 20 control subjects. Next, in 28 patients with AP, we determined the correlation between levels of inflammatory molecules and the computed tomography (CT) density of plaques as a quantitative index of plaque vulnerability. There was no significant difference in peripheral plasma PTX3 concentrations between patients with AP and control subjects, while coronary sinus plasma PTX3 concentrations were significantly higher in AP patients than control subjects. The concentrations of PTX3 in coronary sinus and peripheral plasma correlated with Gensini scores as an index of severity of coronary atherosclerosis. Interestingly, there was a significantly negative correlation between plasma PTX3 concentrations and CT density (r=-0.67, p<0.01). On the other hand, CT density did not correlate with the peripheral plasma concentrations of monocyte chemoattractant protein-1 (MCP-1) or high-sensitivity CRP (hsCRP). Furthermore, telmisartan treatment for 6 months decreased plasma concentrations of PTX3 but not those of MCP-1 or hsCRP in 12 patients with essential hypertension. Multivariate regression analysis revealed that changes in PTX3 levels were independent of blood pressure changes. PTX3 is likely more specific than hsCRP as an indicator of coronary plaque vulnerability that could lead to plaque rupture. (Keyword) Aged / Angina Pectoris / Angiotensin II Type 1 Receptor Blockers / Benzimidazoles / Benzoates / Biological Markers / C-Reactive Protein / Coronary Artery Disease / Coronary Sinus / Disease Progression / Drug Monitoring / Female / Humans / Inflammation Mediators / Male / Middle Aged / Plaque, Atherosclerotic / Serum Amyloid P-Component / Severity of Illness Index / Tomography, Spiral Computed (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2011.04.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21676590 ● Search Scopus @ Elsevier (PMID): 21676590 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jjcc.2011.04.005 (DOI: 10.1016/j.jjcc.2011.04.005, PubMed: 21676590)
55.	Yoichiro Hirata, Minoru Tabata, Hirotsugu Kurobe, Tatsuo Motoki, Masashi Akaike, Chika Nishio, Mayuko Higashida, Hiroaki Mikasa, Yutaka Nakaya, Shuichiro Takanashi, Takashi Igarashi, Tetsuya Kitagawa and Masataka Sata : Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue., Journal of the American College of Cardiology, Vol.58, No.3, 248-255, 2011. (Summary) The purpose of this report was to assess the link between macrophage polarization in epicardial adipose tissue and atherosclerosis in patients with coronary artery disease (CAD). (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jacc.2011.01.048 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21737014 ● Search Scopus @ Elsevier (PMID): 21737014 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jacc.2011.01.048 (DOI: 10.1016/j.jacc.2011.01.048, PubMed: 21737014)
56.	Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Comparison of chronic-stage histopathological findings among 3 coronary stents implanted in the same patient., International Journal of Cardiology, Vol.150, No.1, e25-e27, 2011. (Summary) A 73-year-old woman suffering from anterior thoracic pain on exertion presented to our hospital. We performed coronary angiography and noted three stenotic legions in each coronary artery. For each angiographic finding, we implanted a bare metal stent (BMS), sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) into the right coronary artery, left anterior descending and left circumflex coronary arteries, respectively. Nine months later, she died of lung disease, and we could compare the histopathological findings among the three coronary stents. In the drug-eluting stents, very thin intima, infiltration of inflammatory cells, and fibrin deposition were observed, while thick intima and no inflammatory findings were observed in the BMS. Fibrin deposition was more marked in the PES than in the SES. This report shows marked differences in the subsequent pathological course among three stents in the same patient. (Keyword) Aged / Coronary Stenosis / Drug-Eluting Stents / Female / Humans / Paclitaxel / Sirolimus / Stents (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2009.08.032 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19735952 ● Search Scopus @ Elsevier (PMID): 19735952 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2009.08.032 (DOI: 10.1016/j.ijcard.2009.08.032, PubMed: 19735952)
57.	M Bando, Takeshi Soeki, Toshiyuki Niki, Kenya Kusunose, N Tomita, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Ventricular tachycardia in cardiac sarcoidosis controlled by radiofrequency catheter ablation., Internal Medicine, Vol.50, No.11, 1201-1206, 2011. (Summary) We report a case of a 78-year-old woman with cardiac sarcoidosis with a history of syncope and palpitation. Further assessment with echocardiography, gadolinium-enhanced cardiovascular magnetic resonance (CMR) and histology led to a diagnosis of cardiac sarcoidosis. As the patient suffered from ventricular tachycardia (VT) despite active corticosteroid therapy, an implantable cardioverter-defibrillator (ICD) was positioned. She was also administered a beta blocker, but an electrical storm appeared every several days requiring ICD therapy. The drug-refractory VT was finally controlled with a catheter ablation session, during which we could detect the VT focus in the right ventricular outflow tract next to the aneurysm by using an electroanatomic mapping system (CARTO). Referring to echocardiographic and CMR images proved very useful in detecting the aneurysm using the CARTO system. (Keyword) Adrenergic beta-Antagonists / Aged / Catheter Ablation / Comorbidity / Defibrillators, Implantable / Female / Humans / Magnetic Resonance Imaging / Sarcoidosis / Tachycardia, Ventricular / Treatment Failure / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.50.4580 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21628935 ● Search Scopus @ Elsevier (PMID): 21628935 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.50.4580 (DOI: 10.2169/internalmedicine.50.4580, PubMed: 21628935)
58.	Kenya Kusunose, Hirotsugu Yamada, Noriko Tomita, Susumu Nishio, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Serial imaging changes during treatment of Takayasu arteritis with pulmonary artery stenosis., International Journal of Cardiology, Vol.148, No.3, 47-50, 2011. (Summary) Most cases of chronic stenosis or occlusive lesions of the pulmonary arteries are attributed to thromboembolism, and pulmonary arteritis is extremely rare as the primary cause of these entities. We report a case of pulmonary stenosis and occlusion caused by Takayasu arteritis. The patient was a 54-year-old woman who presented with dyspnea. Total occlusion of the left pulmonary artery and significant stenosis of the right pulmonary artery caused by Takayasu arteritis were confirmed by various imaging modalities including pulmonary angiography, (18)fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging and real-time three-dimensional transesophageal echocardiography. After 6 weeks of steroid therapy, follow-up imaging studies showed that the stenotic lesion had resolved. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2009.02.036 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19299026 ● Search Scopus @ Elsevier (PMID): 19299026 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2009.02.036 (DOI: 10.1016/j.ijcard.2009.02.036, PubMed: 19299026)
59.	Shusuke Yagi, Masashi Akaike, Takashi Iwase, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute hemodynamic effects of adaptive servo ventilation in patients with pulmonary hypertension., International Journal of Cardiology, Vol.148, No.1, 125-127, 2011. (Keyword) Aged / Aged, 80 and over / Female / Hemodynamics / Humans / Hypertension, Pulmonary / Intermittent Positive-Pressure Ventilation / Male / Middle Aged / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2011.01.074 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21334081 ● Search Scopus @ Elsevier (PMID): 21334081 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2011.01.074 (DOI: 10.1016/j.ijcard.2011.01.074, PubMed: 21334081)
60.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Kazue Ishikawa, Sumiko Yoshida, Yuka Sumitomo-Ueda, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia., The American Journal of Cardiology, Vol.107, No.11, 1644-1649, 2011. (Summary) The aim of the present study was to evaluate the factors that modulate the protective action of statins on cardiorenal function, regardless of the lipid-lowering effect. To treat abnormal serum lipid profiles, low-dose pitavastatin (1.0 mg/day) was administered to 65 hyperlipidemic patients. The exclusion criteria included left ventricular ejection fraction <40% and apparent renal disease. Age- and gender-matched patients with hyperlipidemia (n = 40) served as the controls. After 12 to 16 weeks of pitavastatin treatment, pitavastatin had decreased low-density lipoprotein cholesterol (from 143.5 ± 31.4 to 98.2 ± 19.4 mg/dl, p <0.01), triglycerides (from 157.7 ± 57.2 to 140.5 ± 60.7 mg/dl, p <0.01), E/e' (from 10.8 ± 6.2 to 9.0 ± 4.5, p <0.05), a parameter of left ventricular diastolic function, and albuminuria (from 47.6 ± 55.9 to 28.5 ± 40.0 mg/g creatinine, p <0.01). Furthermore, pitavastatin decreased serum transforming growth factor-1 (from 709 ± 242 to 550 ± 299 pg/ml, p <0.01), urinary 8-hydroxy-2'-deoxyguanosine (from 6.6 ± 4.1 to 5.0 ± 3.1 g/g creatinine, p <0.01), an oxidative stress marker, and increased urinary nitrate and nitrite (from 22.5 ± 14.6 to 29.4 ± 27.6 nmol/g creatinine, p <0.05). No such changes were observed in the controls. Multiple regression analysis in the pitavastatin group revealed the effect of pitavastatin on cardiorenal function was associated with suppression of oxidative stress, but not on low-density lipoprotein cholesterol reduction. In conclusion, pitavastatin decreases E/e' and albuminuria, which is associated with suppression of oxidative stress. (Keyword) Aged / Albuminuria / Case-Control Studies / Cholesterol, LDL / Diastole / Female / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hyperlipidemias / Male / Middle Aged / Quinolines / Treatment Outcome / Triglycerides / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1016/j.amjcard.2011.01.054 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21458773 ● Search Scopus @ Elsevier (PMID): 21458773 ● Search Scopus @ Elsevier (DOI): 10.1016/j.amjcard.2011.01.054 (DOI: 10.1016/j.amjcard.2011.01.054, PubMed: 21458773)
61.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Yuka Sumitomo-Ueda, Sumiko Yoshida, Toshio Matsumoto and Masataka Sata : Bosentan improves systemic sclerosis-related peripheral circulation insufficiency., International Journal of Cardiology, Vol.147, No.3, 472-475, 2011. (Keyword) Adult / Aged / Blood Circulation / Female / Humans / Middle Aged / Pain Measurement / Raynaud Disease / Scleroderma, Systemic / Sulfonamides (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2011.01.025 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21296436 ● Search Scopus @ Elsevier (PMID): 21296436 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2011.01.025 (DOI: 10.1016/j.ijcard.2011.01.025, PubMed: 21296436)
62.	Yoichiro Hirata, Hirotsugu Kurobe, Masashi Akaike, Fumio Chikugo, Takaki Hori, Yoshimi Bando, Chika Nishio, Mayuko Higashida, Yutaka Nakaya, Tetsuya Kitagawa and Masataka Sata : Enhanced inflammation in epicardial fat in patients with coronary artery disease., International Heart Journal, Vol.52, No.3, 139-142, 2011. (Summary) It has been hypothesized that epicardial fat, a local visceral fat depot with close proximity to coronary arteries, may serve as a source of inflammatory cytokines and cells in coronary atherosclerotic lesions. Here, we characterized infiltration of inflammatory cells and expression of adipocytokines in epicardial adipose tissue in patients with and without coronary artery disease (CAD). Pare samples were obtained from epicardial and subcutaneous adipose tissue during elective cardiac surgery (CAD, n = 8; non-CAD, n = 9). Inflammatory cell infiltration was investigated by immunohistochemical staining using antibodies against CD3, CD4, CD8 and CD68. Expression of adipocytokines was evaluated by real-time quantitative reverse transcription-polymerase chain reaction. Infiltration of macrophages and CD8-positive T cells in the epicardial adipose tissue in the CAD group was greater than that in the non-CAD group. In contrast, there was no significant difference between the two groups in the number of inflammatory cells in subcutaneous adipose tissue. No statistical difference could be found between the CAD group and the non-CAD group in the expression levels of adiponectin and inflammatory cytokines in epicardial adipose tissue. Our findings suggest that inflammatory cell infiltration is enhanced in epicardial adipose tissue, but not in subcutaneous fat, in patients with coronary artery disease. Chronic inflammation in epicardial fat may influence the pathogenesis of coronary atherosclerosis. (Keyword) Adipokines / Adipose Tissue / Aged / CD8-Positive T-Lymphocytes / Coronary Artery Disease / Female / Humans / Inflammation / Macrophages / Male / Middle Aged / Pericardium / Subcutaneous Tissue (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.52.139 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21646734 ● Search Scopus @ Elsevier (PMID): 21646734 ● Search Scopus @ Elsevier (DOI): 10.1536/ihj.52.139 (DOI: 10.1536/ihj.52.139, PubMed: 21646734)
63.	Shunji Hashizume, Masashi Akaike, Hiroyuki Azuma, Kazue Ishikawa, Sumiko Yoshida, Yuka Ueda, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Ken-ichi Aihara, Masahiro Abe, Masataka Sata and Toshio Matsumoto : Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets., Journal of Atherosclerosis and Thrombosis, Vol.18, No.2, 138-147, 2011. (Summary) Platelet-derived growth factor (PDGF)-BB plays a crucial role in atherosclerosis and vascular remodeling by promoting the migration and proliferation of vascular smooth muscle cells. The objective of this study was to clarify the pleiotropic effect of peroxisome proliferator-activated receptor α (PPARα) activators on PDGF-BB expression in megakaryocytes and platelets. The expression of PPARα in a human erythroleukemia (HEL) cells was clearly detected by reverse transcriptase-PCR and immunofluorescence microscopy. The expression level of PPARα in HEL cells was unchanged regardless of differentiation into megakaryocytic cells by treatment with phorbol 12-myristate 13 acetate (TPA). The TPA-induced expression of PDGF-B mRNA and PDGF-BB protein levels in culture media was significantly decreased by treatment with PPARα activators, Wy14643 and fenofibric acid, in a dose-dependent manner. PDGF-BB expression induced by inflammatory cytokines, including interleukin-1β or interleukin-6, was also significantly suppressed by treatment with PPARα activators. Immunohistochemistry of human bone marrow showed the expression of PPARα in both the nucleus and cytoplasm of megakaryocytes. In addition, PDGF-BB levels in platelets were significantly decreased from 1,800±870 to 1,470±840 pg/10(5) platelets (mean±SD, p<0.05) by treatment with 300 mg fenofibrate once daily for 4 weeks in 13 patients with dyslipidemia. Activation of PPARα in megakaryocytes reduces PDGF-BB expression in platelets. PPARα activators may exert vasculo-protective action through suppression of PDGF-BB production in a megakaryocyte/platelet pathway. (Keyword) Adult / Blood Platelets / cell differentiation / Cell Line, Tumor / Dyslipidemias / Female / Fenofibrate / gene expression / Humans / immunohistochemistry / Lipids / Male / Megakaryocytes / Middle Aged / PPAR alpha / Platelet-Derived Growth Factor / Pyrimidines / RNA, Messenger / Tetradecanoylphorbol Acetate (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.5868 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21060209 ● Search Scopus @ Elsevier (PMID): 21060209 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.5868 (DOI: 10.5551/jat.5868, PubMed: 21060209)
64.	Kenya Kusunose, Hirotsugu Yamada, Susumu Nishio, Yukio Mizuguchi, Masahito Choraku, Yasuhiro Maeda, Shinobu Hosokawa, Nobuo Yamazaki, Noriko Tomita, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Validation of longitudinal peak systolic strain by speckle tracking echocardiography with visual assessment and myocardial perfusion SPECT in patients with regional asynergy., Circulation Journal, Vol.75, No.1, 141-147, 2011. (Summary) Automated function imaging (AFI) is a recently developed method of calculating the longitudinal peak systolic strains (LS) of the regional left ventricular (LV) wall using speckle tracking echocardiography and displaying them on a single bull's-eye map. The feasibility of AFI in patients with regional LV wall motion abnormalities caused by myocardial infarction (MI) was evaluated by comparison with visual assessment and myocardial perfusion single-photon emission computed tomography (SPECT). Segmental LS was measured by AFI in 60 patients with MI (67 ± 11 years) and 58 controls (71 ± 9 years). Wall thickening (WT) was measured by SPECT in 20 patients with MI. There was a strong positive linear relationship between the wall motion score index by expert visual assessment and global LS. The receiver-operating characteristic analysis revealed the best cutoff value of 11% < LS to identify hypokinetic segments. The overall accuracy of wall motion scoring by LS in the 2,006 segments was 96.8% (κ = 0.90) compared with visual assessment. The correlation coefficient between LS and WT was R² = 0.65 in the 340 segments. Assessment of LV regional asynergy by AFI showed good agreement with visual and SPECT assessments. AFI is clinically useful for quantitative assessment of LV regional wall motion abnormalities. (Keyword) Aged / Aged, 80 and over / Algorithms / Case-Control Studies / Echocardiography, Doppler / Feasibility Studies / Humans / Image Interpretation, Computer-Assisted / Japan / Middle Aged / Myocardial Contraction / Myocardial Infarction / Myocardial Perfusion Imaging / Observer Variation / Predictive Value of Tests / Reproducibility of Results / Tomography, Emission-Computed, Single-Photon / Ventricular Dysfunction, Left / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-10-0551 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21099120 ● Search Scopus @ Elsevier (PMID): 21099120 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-10-0551 (DOI: 10.1253/circj.CJ-10-0551, PubMed: 21099120)
65.	門田宗之, Yoshio Taketani, Tetsuzo Wakatsuki, Koji Yamaguchi, Kenya Kusunose, Toshiyuki Niki, 坂東左知子, 久岡白陽花, Yuka Ueda, 冨田紀子, 竹内秀和, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike, Masataka Sata, Kojiro Nagai and Toshio Doi : 繰り返す心不全と維持透析導入から離脱しえた腎動脈狭窄症の一例, Shikoku Acta Medica, Vol.66, No.5, 6, 175-180, 2010. (Tokushima University Institutional Repository) ● Metadata: 110339 (Tokushima University Institutional Repository: 110339)
66.	Takayuki Ise, Ken-ichi Aihara, Yuka Ueda, Sumiko Yoshida, Yasumasa Ikeda, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors., Hypertension Research, Vol.34, No.2, 225-231, 2010. (Summary) Thrombin has a crucial role in cardiac remodeling through protease-activated receptor-1 activation in cardiac fibroblasts and cardiomyocytes. As heparin cofactor II (HCII) inhibits the action of tissue thrombin in the cardiovascular system, it is possible that HCII counteracts the development of cardiac remodeling. We investigated the relationships between plasma HCII activity and surrogate markers of cardiac geometry, including left atrial volume index (LAVI), relative wall thickness (RWT) and left ventricular mass index, and deceleration time (DcT) and the ratio of peak E velocity to early diastolic mitral annulus velocity (E/e' ratio) as surrogate markers of left ventricular diastolic dysfunction measured using echocardiography in 304 Japanese elderly individuals without systolic heart failure (169 men and 135 women; mean age: 65.4 ± 11.8 years). Mean plasma HCII activity in all participants was 95.8 ± 17.0% and there was no difference between the mean plasma HCII activities in males and females. Multiple regression analysis revealed that there were significant inverse relationships between plasma HCII activity and LAVI (coefficient: -0.2302, P<0.001), between HCII activity and RWT (coefficient: -0.0007, P<0.05), between HCII activity and DcT (coefficient: -0.5189, P<0.05) and between HCII activity and E/e' ratio (coefficient: -0.0558, P<0.01). Plasma HCII activity was independently and inversely associated with the development of cardiac remodeling, including cardiac concentric change, left atrial enlargement and left ventricular diastolic dysfunction. These findings suggest that cardiac tissue thrombin inactivation by HCII is a novel therapeutic target for cardiac remodeling and atherosclerosis. (Keyword) Aged / Cross-Sectional Studies / Female / Heparin Cofactor II / Humans / Male / Middle Aged / Risk Factors / Ventricular Dysfunction / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1038/hr.2010.211 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21107326 ● Search Scopus @ Elsevier (PMID): 21107326 ● Search Scopus @ Elsevier (DOI): 10.1038/hr.2010.211 (DOI: 10.1038/hr.2010.211, PubMed: 21107326)
67.	Shusuke Yagi, Masashi Akaike, Takashi Iwase, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Sumiko Yoshida, Yuka Sumitomo-Ueda, Ken-ichi Aihara, Yoichiro Hirata, Munkhbaatar Dagvasumberel, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis., Internal Medicine, Vol.49, No.21, 2309-2312, 2010. (Summary) Pulmonary arterial hypertension (PAH) is a frequent complication in patients with systemic sclerosis. Bosentan is used in patients with symptomatic PAH; however, it has not been established whether or not bosentan ameliorates the progression of PAH in patients with no PAH-related symptoms. We present a case of systemic sclerosis with no PAH-related symptoms in which bosentan ameliorated exercise-induced PAH evaluated by 6-minute walk stress echocardiography, brachial flow-mediated dilation, and skin temperature of hands and feet. The results suggest that administration of bosentan in patients with early-stage PAH ameliorates pulmonary arterial vasodilatation through improvement of endothelial function. (Keyword) Exercise / Exercise Test / Female / Humans / Hypertension, Pulmonary / Middle Aged / Scleroderma, Systemic / Sulfonamides (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.49.3812 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21048365 ● CiNii @ National Institute of Informatics (CRID): 1390282679847104768 ● Search Scopus @ Elsevier (PMID): 21048365 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.49.3812 (DOI: 10.2169/internalmedicine.49.3812, PubMed: 21048365, CiNii: 1390282679847104768)
68.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Sumiko Yoshida, Yuka Ueda, Yasumasa Ikeda, Kazue Ishikawa, Toshio Matsumoto and Masataka Sata : High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension., Hypertension Research, Vol.34, No.1, 74-78, 2010. (Summary) Cognitive impairment leading to dementia is associated with high prevalence of hypertension, decreased quality of life and poor prognosis. Aldosterone is known as a risk factor for cardiovascular and cerebrovascular diseases. In addition, mineral corticoid receptors are abundantly expressed in the hippocampus, which plays a pivotal role in cognitive function; however, it has not been determined whether plasma aldosterone level is associated with cognitive impairment in patients with hypertension. We enrolled 68 patients with essential hypertension and assessed their cardiovascular risk factors, including blood pressure, hyperlipidemia, diabetes mellitus, obesity, smoking, history of cerebral infarction, renal function, parameters of inflammation, oxidative stress and nitric oxide bioavailability, a parameter of cerebral blood flow and carotid plaque by ultrasound examination, plasma renin activity and plasma aldosterone concentration (PAC). The mini-mental state examination (MMSE) was used to evaluate cognitive function. The relevance of cardiovascular risk factors and MMSE score was statistically evaluated. Multiple regression analysis showed that age (P<0.01), PAC (P<0.01) and history of cerebral infarction (P<0.05) were inversely and independently associated with MMSE score. Mineral corticoid receptor antagonists, including spironolactone and eplerenone, increased MMSE score in seven patients with hypertension, but not in the controls. In conclusion, increased PAC is associated with impaired cognitive function and mineral corticoid receptor blockade may protect against not only cardiovascular mortality, but also cognitive impairment in patients with hypertension.Hypertension Research advance online publication, 23 September 2010; doi:10.1038/hr.2010.179. (Link to Publication Site) ● Publication site (DOI): 10.1038/hr.2010.179 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20861841 ● Search Scopus @ Elsevier (PMID): 20861841 ● Search Scopus @ Elsevier (DOI): 10.1038/hr.2010.179 (DOI: 10.1038/hr.2010.179, PubMed: 20861841)
69.	Yuka Sumitomo-Ueda, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Yasumasa Ikeda, Ryoko Uemoto, Shusuke Yagi, Takashi Iwase, Kazue Ishikawa, Yoichiro Hirata, Masashi Akaike, Masataka Sata, Shigeaki Kato and Toshio Matsumoto : Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice., Hypertension, Vol.56, No.3, 430-436, 2010. (Summary) Heparin cofactor II (HCII), a serine protease inhibitor, inhibits tissue thrombin action after binding with dermatan sulfate proteoglycans in the extracellular matrix of the vascular system. We previously reported that heterozygous HCII-deficient (HCII(+/-)) humans and mice demonstrate acceleration of vascular remodeling, including atherosclerosis. However, the action of HCII on cardiac remodeling never has been determined. HCII(+/+) and HCII(+/-) mice at age 25 weeks were infused with angiotensin II (Ang II; 2.0 mg/kg/d) for 2 weeks by an osmotic mini-pump. Echocardiography revealed acceleration of cardiac concentric remodeling in HCII(+/-) mice and larger left atrial volume in HCII(+/-) mice than in HCII(+/+) mice. Histopathologic studies showed more prominent interstitial fibrosis in both the left atrium and left ventricle in HCII(+/-) mice than in HCII(+/+) mice. Daily urinary excretion of 8-hydroxy-2'-deoxyguanosine, a parameter of oxidative stress, and dihydroethidium-positive spots, indicating superoxide production in the myocardium, were markedly increased in Ang II-treated HCII(+/-) mice compared to those in HCII(+/+) mice. Cardiac gene expression levels of atrial natriuretic peptides and brain natriuretic peptides, members of the natriuretic peptide family, Nox 4, Rac-1, and p67(phox) as components of NAD(P)H oxidase, and transforming growth factor-beta1 and procollagen III were more augmented in HCII(+/-) mice than in HCII(+/+) mice. However, administration of human HCII protein attenuated all of those abnormalities in Ang II-treated HCII(+/-) mice. Moreover, human HCII protein supplementation almost abolished cardiac fibrosis in Ang II-treated HCII(+/+) mice. The results indicate that HCII has a protective role against Ang II-induced cardiac remodeling through suppression of the NAD(P)H oxidase-transforming growth factor-beta1 pathway. (Keyword) Analysis of Variance / Angiotensin II / Animals / Atrial Natriuretic Factor / Cardiomegaly / Echocardiography / Fibrosis / Heart Atria / Heparin Cofactor II / Mice / Mice, Transgenic / Myocardium / Natriuretic Peptide, Brain / Oxidative Stress / Transforming Growth Factor beta1 / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1161/HYPERTENSIONAHA.110.152207 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20660821 ● Search Scopus @ Elsevier (PMID): 20660821 ● Search Scopus @ Elsevier (DOI): 10.1161/HYPERTENSIONAHA.110.152207 (DOI: 10.1161/HYPERTENSIONAHA.110.152207, PubMed: 20660821)
70.	Hiroaki Yanagawa, Masatoshi Kishuku, Masashi Akaike, Hiroyuki Azuma and Minoru Irahara : View of physicians on and barriers to patient enrollment in a multicenter clinical trial: experience in a Japanese rural area, International Archives of Medicine, Vol.3, No.1, 7, 2010. (Summary) Clinical trials in the general practice setting are important for providing evidence on the effectiveness and safety of different agents under various conditions. In conducting these trials, the participation of physicians and patient recruitment are important issues. Various investigations in the literature have reported views and attitudes of physicians on various types of clinical trials. Nevertheless, there is still little information concerning physicians participating in a clinical trial and among them, those who could not recruit any patients (unsuccessful physician recruiters). In 2003, we collaborated in a large-scale multicenter study of Japanese hypertensive patients (COPE Trial). In Tokushima University Hospital and 18 other medical institutions, we investigated the views and attitudes of unsuccessful physician recruiters in comparison with successful physician recruiters, using a questionnaire. The questionnaire was provided by mail to 47 physicians and 27 (57%) responded. The response rate was 79% for successful physician recruiters compared to 43% (P = 0.014) for unsuccessful physician recruiters. More successful physician recruiters (73%) than unsuccessful physician recruiters (42%) stated they had participated and enrolled patients in previous multicenter clinical trials. A significantly higher number of successful physician recruiters than unsuccessful physician recruiters (42%; P = 0.040) considered the presence of a support system with clinical research coordinators (CRC) as the reason for participation (80%). A large number of unsuccessful physician recruiters experienced difficulty in obtaining informed consent (67%), whereas a significantly smaller number of successful physician recruiters experienced such difficulty (20%; P = 0.014). The difficulties experienced by unsuccessful physician recruiters in the trial were as follows: inability to find possible participants (100%), difficulty in obtaining informed consent (58%), cumbersome procedures (58%), difficulty in long-term follow up (33%), and insufficient tools for explanation and obtaining informed consent (8%). This survey showed that successful physician recruiters consider a support system with CRC of value, and that they are skillful in obtaining informed consent. These views and attitudes may have originated from past experience involving clinical trials. In this regard, we need to develop an infrastructure to enlighten physicians on this support system for the promotion of clinical trials. (Link to Publication Site) ● Publication site (DOI): 10.1186/1755-7682-3-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20525325 ● Search Scopus @ Elsevier (PMID): 20525325 ● Search Scopus @ Elsevier (DOI): 10.1186/1755-7682-3-7 (DOI: 10.1186/1755-7682-3-7, PubMed: 20525325)
71.	Sumiko Yoshida, Ken-ichi Aihara, Hiroyuki Azuma, Ryoko Uemoto, Yuka Sumitomo-Ueda, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Susumu Nishio, Hiromi Kawano, Junko Miki, Hirotsugu Yamada, Yoichiro Hirata, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function., Atherosclerosis, Vol.212, No.1, 310-315, 2010. (Summary) BACKGROUND: Dehydroepiandrosterone sulfate (DHEAS) is thought to be associated with life expectancy and anti-aging. However, its biological significance in atherosclerosis remains controversial. Therefore, the aim of this study was to determine whether DHEAS is associated with development of carotid atherosclerosis in subjects with cardiovascular risk factors. SUBJECTS AND METHODS: A total of 419 Japanese individuals (208 males and 211 females) were recruited from Tokushima University Hospital, Japan. In all subjects, maximum intima-media thickness (max-IMT) in all carotid arteries, and mean-IMT and mean blood flow volume (BFV) in the common carotid arteries (CCA) were measured by ultrasonography; endothelial function was assessed by flow-mediated vasodilation of the brachial artery (%FMD). Serum DHEAS and classical cardiovascular risk factors were also evaluated. Statistical significance was determined by multiple regression analysis to elucidate independent determinants of max-IMT, mean-IMT, mean CCA-BFV, and %FMD. RESULTS: Serum DHEAS levels were higher in males than in females. Multiple regression analysis revealed that DHEAS was an independent negative factor for both max-IMT and mean-IMT in males but not in females. In contrast, DHEAS was the sole positive factor for mean CCA-BFV in females but not in males. In addition, there was no significant relationship between %FMD and DHEAS regardless of sex and other confounding factors. CONCLUSION: Although DHEAS is not involved in endothelial function, DHEAS is inversely associated with sex-dependent diverse carotid atherosclerosis such as increased max-IMT and mean-IMT in males and decreased CCA-BFV in females. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2010.05.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20627295 ● Search Scopus @ Elsevier (PMID): 20627295 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2010.05.011 (DOI: 10.1016/j.atherosclerosis.2010.05.011, PubMed: 20627295)
72.	Yasumasa Ikeda, Ken-ichi Aihara, Masashi Akaike, Takashi Sato, Kazue Ishikawa, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Yuka Ueda, Sumiko Yoshida, Hiroyuki Azuma, Kenneth Walsh, Toshiaki Tamaki, Shigeaki Kato and Toshio Matsumoto : Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice., Molecular Endocrinology, Vol.24, No.7, 1338-1348, 2010. (Summary) Doxorubicin (Dox) has been used as a potent anticancer agent, but serious cardiotoxicity precludes its use in a wide range of patients. We have reported that the androgen-androgen receptor (AR) system plays important roles in cardiac growth and protection from angiotensin II-induced cardiac remodeling. The present study was undertaken to clarify whether the androgen-AR system exerts a cardioprotective effect against Dox-induced cardiotoxicity. Male AR knockout (ARKO) and age-matched littermate male wild-type (WT) mice at 25 wk of age were given ip injections of Dox (20 mg/kg) or a vehicle. The survival rate and left ventricular function in Dox-treated male ARKO mice were reduced compared with those in Dox-treated male WT mice. Electron microscopic study showed prominent vacuole formation of myocardial mitochondria in Dox-treated male ARKO mice. Cardiac oxidative stress and apoptosis of cardiomyocytes were increased more prominently by Dox treatment in male ARKO mice than in male WT mice. In addition, Dox-induced reduction in the expression of cardiac mitochondria transcription factor A (Tfam) and phosphorylation of serine-threonine kinase (Akt) was more pronounced in male ARKO mice than in male WT mice. In cardiac myoblast cells, testosterone up-regulated Akt phosphorylation and Tfam expression and exerted an antiapoptotic effect against Dox-induced cardiotoxicity. Collectively, the results demonstrate that Dox-induced cardiotoxicity is aggravated in male ARKO mice via exacerbation of mitochondrial damage and superoxide generation, leading to enhanced apoptosis of cardiomyocytes. Thus, the androgen-AR system is thought to counteract Dox-induced cardiotoxicity partly through activation of the Akt pathway and up-regulation of Tfam to protect cardiomyocytes from mitochondrial damage and apoptosis. (Keyword) Androgens / Animals / Antineoplastic Agents / Apoptosis / Blotting, Western / Cell Line / Cell Survival / DNA-Binding Proteins / Doxorubicin / Echocardiography / High Mobility Group Proteins / Immunoprecipitation / In Situ Nick-End Labeling / Male / Mice / Mice, Knockout / Microscopy, Electron / Myocardium / Myocytes, Cardiac / Oxidative Stress / Phosphorylation / Protein-Serine-Threonine Kinases / Rats / Receptors, Androgen / Superoxides / Testosterone / Thiobarbituric Acid Reactive Substances / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1210/me.2009-0402 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20501642 ● Search Scopus @ Elsevier (PMID): 20501642 ● Search Scopus @ Elsevier (DOI): 10.1210/me.2009-0402 (DOI: 10.1210/me.2009-0402, PubMed: 20501642)
73.	Kenya Kusunose, Hirotsugu Yamada, Takashi Iwase, Susumu Nishio, Noriko Tomita, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shoichiro Takao, Masafumi Harada, Noriko Kagawa, Eiji Kudo and Masataka Sata : Images in cardiovascular medicine. Cardiac magnetic resonance imaging and 2-dimensional speckle tracking echocardiography in secondary cardiac amyloidosis., Circulation Journal, Vol.74, No.7, 1494-1496, 2010. (Keyword) Aged / Amyloidosis / Echocardiography / Heart Diseases / Humans / magnetic resonance imaging / Male / Mitral Valve / Regional Blood Flow (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-10-0141 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20501956 ● Search Scopus @ Elsevier (PMID): 20501956 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-10-0141 (DOI: 10.1253/circj.CJ-10-0141, PubMed: 20501956)
74.	Shusuke Yagi, Masashi Akaike, Mitsunori Fujimura, Takehiko Kimura, Takeshi Nishiuchi, Takashi Iwase, Ken-ichi Aihara, Sumiko Yoshida, Yuka Sumitomo-Ueda, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoichiro Hirata, Munkhbaatar Dagvasumberel, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Congenital ventricular aneurysm as an unexpected complication of monomorphic premature ventricular contractions., Internal Medicine, Vol.49, No.10, 907-912, 2010. (Summary) Congenital ventricular diverticulum (CVD) in adults is a rare cardiac malformation, which includes fibrous type congenital ventricular aneurysm (CVA). CVA is often clinically asymptomatic and shows no abnormality in the electrocardiogram or chest X-ray. However, some cases of sudden death resulting from ventricular tachycardia, cardiac embolism or ventricular rupture have been reported. Therefore, physicians should perform further cardiac imaging studies to detect a CVA if ventricular arrhythmia originating from the left ventricle is observed. Here, we report two successfully followed cases of CVA which were diagnosed from premature ventricular contractions. (Keyword) congenital ventricular aneurysm / congenital ventricular diverticulum / ventricular arrythmia (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.49.3008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20467175 ● CiNii @ National Institute of Informatics (CRID): 1390001204871212928 ● Search Scopus @ Elsevier (PMID): 20467175 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.49.3008 (DOI: 10.2169/internalmedicine.49.3008, PubMed: 20467175, CiNii: 1390001204871212928)
75.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Kazue Ishikawa, Takashi Iwase, Yasumasa Ikeda, Takeshi Soeki, Sumiko Yoshida, Yuka Sumitomo-Ueda, Toshio Matsumoto and Masataka Sata : Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury., Hypertension, Vol.55, No.4, 918-923, 2010. (Summary) Activation of the renin-angiotensin system exacerbates atrial remodeling, leading to atrial fibrillation and thrombosis, especially in a condition with decreased NO bioavailability. Recently, it has been reported that statins reduce the incidence of atrial fibrillation through attenuation of atrial remodeling; however, the mechanisms have not been completely elucidated. Therefore, we aimed to clarify the beneficial effect of statin on atrial remodeling in condition with reduced NO bioavailability. Endothelial NO synthase(-/-) mice were sham operated or infused with angiotensin II (Ang II) via an osmotic minipump for 2 weeks, and Ang II-infused mice were divided into 3 treatment groups: pitavastatin, Tempol (a free radical scavenger), or vehicle. Echocardiography and electrocardiography showed that Ang II infusion caused left atrial enlargement and a high incidence of atrial fibrillation, whereas pitavastatin and Tempol prevented these abnormalities. In histological analysis, Ang II-induced atrial interstitial fibrosis, perivascular fibrosis, and cardiomyocyte hypertrophy were all attenuated by pitavastatin and Tempol. Immunohistochemical staining showed that Ang II downregulated thrombomodulin and tissue factor pathway inhibitor and upregulated tissue factor and plasminogen activator inhibitor 1 in the left atrium and that pitavastatin and Tempol corrected the thrombogenic condition. Moreover, pitavastatin and Tempol reduced Ang II-induced atrial superoxide production and atrial transforming growth factor-beta1 expression and Smad 2/3 phosphorylation. Atrial rac1-GTPase activity, known to activate NADPH oxidase, was attenuated by pitavastatin but not by Tempol. In conclusion, pitavastatin exerts endothelial NO synthase-independent protective actions against Ang II-induced atrial remodeling and atrial fibrillation with enhanced thrombogenicity through suppression of oxidant injury. (Keyword) Analysis of Variance / Angiotensin II / Animals / Antioxidants / Atrial Fibrillation / Blood Pressure / Blotting, Western / Cardiomegaly / Cyclic N-Oxides / Echocardiography / Fibrosis / Heart Atria / Heart Rate / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Male / Mice / Mice, Knockout / Myocytes, Cardiac / Nitric Oxide Synthase Type III / Oxidative Stress / Quinolines / Renin-Angiotensin System / Reverse Transcriptase Polymerase Chain Reaction / Signal Transduction / Smad2 Protein / Smad3 Protein / Spin Labels / Transforming Growth Factor beta1 (Link to Publication Site) ● Publication site (DOI): 10.1161/HYPERTENSIONAHA.109.146076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20194307 ● Search Scopus @ Elsevier (PMID): 20194307 ● Search Scopus @ Elsevier (DOI): 10.1161/HYPERTENSIONAHA.109.146076 (DOI: 10.1161/HYPERTENSIONAHA.109.146076, PubMed: 20194307)
76.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, Takashi Iwase, Kazue Ishikawa, Sumiko Yoshida, Yuka Sumitomo-Ueda, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoichiro Hirata, Munkhbaatar Dagvasumberel, Yoshio Taketani, Noriko Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia., Journal of Atherosclerosis and Thrombosis, Vol.17, No.2, 173-180, 2010. (Summary) AIM: Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, has been shown to reduce the intestinal absorption of cholesterol. We investigated whether it also has beneficial effects on metabolic disorder and/or renal insufficiency in patients with hypercholesterolemia. METHODS: Ezetimibe was administered to 38 Japanese patients with hypercholesterolemia to obtain appropriate low-density lipoprotein cholesterol (LDL-chol) levels. Age- and sex-matched patients with hypercholesterolemia (n=38) were the controls. We evaluated the effects of ezetimibe before and 4 to 8 weeks after ezetimibe treatment. RESULTS: Ezetimibe significantly decreased LDL-chol levels and metabolic syndrome-related factors, including body weight, waist circumference, blood pressure; homeostasis model assessment insulin resistance (HOMA-IR), and urinary albumin excretion, were significantly reduced. In addition, it decreased the level of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-alpha, the urinary excretion of 8-hydroxy-2'-deoxyguanosine, a parameter of oxidative stress, and increased the urinary excretion of nitrate and nitrite (NOx). In the controls we observed no such changes. Excepting the decrease in the serum TNF-alpha level, the effects of ezetimibe were not correlated with decreased LDL-chol levels. CONCLUSION: Ezetimibe ameliorated the status of metabolic syndrome and microalbuminuria, reduced inflammation and oxidative stress, and increased nitric oxide bioavailability in a LDL-chol reduction-dependent and -independent manner. (Keyword) Aged / Albuminuria / Anticholesteremic Agents / Azetidines / C-Reactive Protein / Case-Control Studies / Cholesterol, LDL / Deoxyguanosine / Female / Humans / Hypercholesterolemia / Male / Metabolic Diseases / Metabolic Syndrome X / Middle Aged / Nitrates / Nitrites / Oxidative Stress / Tumor Necrosis Factor-alpha (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.2378 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20150722 ● Search Scopus @ Elsevier (PMID): 20150722 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.2378 (DOI: 10.5551/jat.2378, PubMed: 20150722)
77.	Hirotsugu Kurobe, Masahisa Urata, Masaki Ueno, Masaaki Ueki, Shiro Ono, Yuki Izawa-Ishizawa, Yayoi Fukuhara, Yu Lei, Adiratna Mat Ripen, Tamotsu Kanbara, Ken-ichi Aihara, Keisuke Ishizawa, Masashi Akaike, Frank J. Gonzalez, Toshiaki Tamaki, Yousuke Takahama, Masanori Yoshizumi, Tetsuya Kitagawa and Shuhei Tomita : Role of Hypoxia-Inducible Factor 1α in T Cells as a Negative Regulator in Development of Vascular Remodeling, Arteriosclerosis, Thrombosis, and Vascular Biology, Vol.30, No.2, 210-217, 2010. (Summary) Recent studies have shown that the cellular immune response in the development of vascular remodeling modulates the resulting pathological alterations. We show that hypoxia-inducible factor 1 (Hif-1) (specifically expressed in T cells) is involved in the immune response to vascular remodeling that accompanies arteriosclerosis. To study the role of T cells in the development of vascular remodeling, femoral arterial injury induced by an external vascular polyethylene cuff was examined in mice lacking Hif-1 (specifically in T cells). We found that cuff placement caused prominent neointimal hyperplasia of the femoral artery in Hif-1- (T-cell)-deficient mice compared with that in control mice and that infiltration of inflammatory cells at the adventitia was markedly increased in the mutant mice. Studies to clarify the mechanism of augmented vascular remodeling in the mutant mice showed enhanced production of cytokines by activated T cells and augmented antibody production in response to a T-dependent antigen in the mutant mice. The results of this study revealed that Hif-1alpha in T cells plays a crucial role in vascular inflammation and remodeling in response to cuff injury as a negative regulator of T cell-mediated immune response. Potential new therapeutic strategies that target Hif-1alpha are described. (Keyword) Animals / Antibody Formation / Arteriosclerosis / Cell Hypoxia / Cell Proliferation / Chemokine CXCL12 / Chemotaxis, Leukocyte / cytokinesis / Disease Models, Animal / Femoral Artery / Hyperplasia / Hypoxia-Inducible Factor 1, alpha Subunit / Immunity, Cellular / immunohistochemistry / Lymphocyte Activation / male / Mice / knockout mice / Nitroimidazoles / Receptors, Antigen, T-Cell / T lymphocytes / Thymus Gland / Time Factors / Tunica Intima (Link to Publication Site) ● Publication site (DOI): 10.1161/ATVBAHA.109.192666 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20007912 ● Search Scopus @ Elsevier (PMID): 20007912 ● Search Scopus @ Elsevier (DOI): 10.1161/ATVBAHA.109.192666 (DOI: 10.1161/ATVBAHA.109.192666, PubMed: 20007912)
78.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, K Adachi, Y Sumitomo-Ueda, Shusuke Yagi, T Niki, Kenya Kusunose, N Tomita, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, KI Aihara, Masafumi Harada, H Nishitani and Masataka Sata : Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy., Heart Asia, Vol.2, 52-55, 2010. (Link to Publication Site) ● Publication site (DOI): 10.1136/ha.2010.002006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27325943 ● Search Scopus @ Elsevier (PMID): 27325943 ● Search Scopus @ Elsevier (DOI): 10.1136/ha.2010.002006 (DOI: 10.1136/ha.2010.002006, PubMed: 27325943)
79.	Masatomo Mihara, Ken-ichi Aihara, Yasumasa Ikeda, Sumiko Yoshida, Mizuho Kinouchi, Kiyoe Kurahashi, Yuichi Fujinaka, Masashi Akaike and Toshio Matsumoto : Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice., Endocrinology, Vol.151, No.2, 513-519, 2009. (Summary) The binding of thrombin to its receptor stimulates inflammatory cytokines including IL-6 and monocyte chemoattractant protein-1 (MCP-1); both are associated with the development of insulin resistance. Because increased adiposity enhanced the expression of coagulation factor VII that stimulates the coagulation pathway in adipose tissue, we tested whether the inhibition of thrombin action ameliorates insulin resistance in obese diabetic (Lpr(-/-):db/db) mice. The 4-wk administration of argatroban, a selective thrombin inhibitor, reduced fasting plasma glucose and ameliorated insulin resistance in these mice. It also reduced adipocyte size and macrophage infiltration into adipose tissue. The aberrant gene expression of MCP-1, IL-6, adiponectin, and factor VII and suppressed insulin receptor substrate-1-Akt signaling in adipose tissue of db/db mice were reversed by argatroban treatment. These results demonstrate that increased adiposity enhances the production of thrombin in adipose tissue by stimulating factor VII expression and suggest that increased thrombin activity in adipose tissue plays an important role in the development of insulin resistance via enhancing MCP-1 production, leading to macrophage infiltration and insulin receptor substrate-1-Akt pathway inactivation. (Link to Publication Site) ● Publication site (DOI): 10.1210/en.2009-0661 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19966184 ● Search Scopus @ Elsevier (PMID): 19966184 ● Search Scopus @ Elsevier (DOI): 10.1210/en.2009-0661 (DOI: 10.1210/en.2009-0661, PubMed: 19966184)
80.	Y Hirata, Takeshi Soeki, Masashi Akaike, Y Sakai, T Igarashi and Masataka Sata : Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters., Biomedicine & Pharmacotherapy, Vol.63, No.10, 781-786, 2009. (Summary) Impairment of cardiac function in cardiomyopathy has been postulated to be related to decreased blood flow and increased collagen synthesis. Administration of growth factors was reported to attenuate left ventricular (LV) remodeling and dysfunction in animal models of dilated cardiomyopathy. We previously reported that ONO-1301, a synthetic prostacyclin agonist with thromboxane-synthase inhibitory activity, promotes production of hepatocyte growth factor and vascular endothelial growth factor from various cell types and ameliorate ischemia-induced LV dysfunction in mice and pigs. We evaluated therapeutic efficacy of ONO-1301 in the Syrian hamster (TO-2), a model of genetically determined dilated cardiomyopathy. Either vehicle or a slow releasing form of ONO-1301 (ONO-1301-PLGA, 10mg/kg/3 weeks) was administered subcutaneously every 3 weeks to TO-2 hamsters from 24 to 32 weeks of age (n=12 for each group). Age-matched F1B hamsters were used as a control. Plasma concentration of HGF was elevated in ONO-1301-PLGA group (p<0.05). Echocardiographic study demonstrated that LV fractional shortening was significantly improved in the ONO-1301-PLGA group (25+/-4%, p<0.01) compared with that in the vehicle group (19+/-2%). Cardiac fibrosis was significantly reduced by ONO-1301-PLGA (p<0.05) as determined by Azan-Mallory staining. Capillary density of left ventricle was markedly reduced in TO-2 hamsters. ONO-1301-PLGA significantly increased capillary density in TO-2 group (p<0.05). ONO-1301 improved LV dysfunction and reduced cardiac fibrosis in the hamster model of dilated cardiomyopathy. ONO-1301 might hold a therapeutic potential in the treatment of dilated cardiomyopathy. (Keyword) Animals / Cardiomyopathy, Dilated / Cricetinae / Delayed-Action Preparations / Disease Models, Animal / Drug Carriers / Enzyme Inhibitors / Fibrosis / Lactic Acid / Male / Myocardium / Polyglycolic Acid / Pyridines / Thromboxane-A Synthase / Ventricular Dysfunction, Left (Link to Publication Site) ● Publication site (DOI): 10.1016/j.biopha.2009.09.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19906506 ● Search Scopus @ Elsevier (PMID): 19906506 ● Search Scopus @ Elsevier (DOI): 10.1016/j.biopha.2009.09.003 (DOI: 10.1016/j.biopha.2009.09.003, PubMed: 19906506)
81.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, K Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Y Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Clinical Utility of Single Beat E/e' Obtained by Simultaneous Recording of Flow and Tissue Doppler Velocities in Atrial Fibrillation with Preserved Systolic Function., JACC. Cardiovascular Imaging, Vol.2, No.10, 1147-1156, 2009. (Summary) We evaluated the usefulness of the ratio of the early diastolic transmitral flow velocity (E) to the mitral annular velocity (e') calculated from simultaneously recorded E and e' in atrial fibrillation (AF). The ratio of the E to the e' (E/e') has been reported as a useful index even in AF patients. However, E and e' were measured during different beats in the previous studies. Fifty-six AF patients with preserved systolic function (mean age 66 +/- 11 years) underwent routine echocardiographic study. The E/e' was calculated from the E and e' simultaneously recorded by the dual Doppler echocardiography. A single-beat E/e' was calculated from simultaneously recorded E and e' when the preceding RR interval/pre-preceding RR interval = 1. Brain natriuretic peptide (BNP) levels were also examined. Twenty-one patients underwent simultaneous pulmonary artery catheterization. The single-beat lateral E/e' correlated with pulmonary capillary wedge pressure (PCWP) (r = 0.74, p < 0.001). The single-beat lateral E/e' of >or=11 could predict elevated PCWP (>or=15 mm Hg) with a sensitivity of 90% and a specificity of 90%. The single-beat lateral E/e' also correlated well with the log BNP concentration. The single-beat lateral E/e' of >or=9.2 predicted a plasma BNP level of >or=200 pg/ml with 88% sensitivity and 84% specificity. The single-beat lateral E/e' correlated with plasma BNP level and PCWP in AF patients with preserved systolic function. In addition, the single-beat lateral E/e' (>or=11) was a good predictor of elevated PCWP (>or=15 mm Hg). Dual Doppler echocardiography offers an advantage of providing the single-beat lateral E/e' correctly even in AF patients, for the evaluation of left ventricular diastolic function. (Keyword) Adult / Aged / Aged, 80 and over / Atrial Fibrillation / Biological Markers / Catheterization, Swan-Ganz / Coronary Circulation / Diastole / Echocardiography, Doppler, Color / Echocardiography, Doppler, Pulsed / Female / Heart Rate / Humans / Linear Models / Male / Middle Aged / Mitral Valve / Natriuretic Peptide, Brain / Predictive Value of Tests / Pulmonary Wedge Pressure / Sensitivity and Specificity / Systole / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcmg.2009.05.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19833302 ● Search Scopus @ Elsevier (PMID): 19833302 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcmg.2009.05.013 (DOI: 10.1016/j.jcmg.2009.05.013, PubMed: 19833302)
82.	H Iwata, K Nakamura, M Sumi, M Ninomiya, Y Sakai, Y Hirata, Masashi Akaike, T Igarasi, S Takamoto, R Nagai and Masataka Sata : Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model., Life Sciences, Vol.85, No.5-6, 255-261, 2009. (Summary) It was reported that administration of angiogenic growth factors can augment collateral growth in ischemic tissues. It is assumed that angiogenic effects of cell transplantation may be mainly mediated by secretion of angiogenic cytokines. We tested feasibility of clinical use of ONO-1301, a synthetic small molecule that stimulates secretion of growth factors from various cell types, to treat patients with chronic myocardial ischemia. Effects of ONO-1301 on fibroblasts and endothelial cells were evaluated in vitro. We examined the efficacy of local delivery of ONO-1301 in models of rat hindlimb ischemia and swine chronic ischemic myocardium. ONO-1301 stimulated hepatocyte growth factor secretion from human fibroblasts. ONO-1301 promoted vascular-like tube formation by endothelial cells in vitro. Direct injection of a slow-release form of ONO-1301 (SR-ONO) to rat hindlimb ischemic muscle enhanced perfusion recovery. In a swine cardiac ischemia model, direct injection of SR-ONO into the ischemic myocardium significantly augmented collateral formation (SR-ONO vs. control; 1.7+/-0.2 vs. 1.0+/-0.2 Rentrop score), with improved local ventricular wall motion, reduced enlargement of left ventricular diastolic volume (49.5+/-1.9 mL vs. 59.7+/-4.2 mL) and increased cardiac index (4.2+/-0.1 vs. 3.4+/-0.2 L/min/m(2)). Histological analysis revealed that SR-ONO suppressed fibrosis in ischemic tissue (collagen volume fraction; 7.5+/-1.1% vs. 12.8+/-2.2%) and enhanced neovascularization (capillary density, 275.6 vs. 159.3/mm(2); arterioles 36.6 vs. 25.5 /mm(2)). Local delivery of SR-ONO might be effective for therapeutic angiogenesis and propose that local administration of slow-release of synthetic small molecules represents new strategy for therapeutic angiogenesis. (Keyword) Animals / Cells, Cultured / Collateral Circulation / Delayed-Action Preparations / Disease Models, Animal / Endothelium, Vascular / Fibroblasts / Hepatocyte Growth Factor / Hindlimb / Laser-Doppler Flowmetry / Male / Microcirculation / Myocardial Ischemia / Neovascularization, Pathologic / Prostaglandins I / Pyridines / Rats / Rats, Sprague-Dawley / Swine (Link to Publication Site) ● Publication site (DOI): 10.1016/j.lfs.2009.06.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19527738 ● Search Scopus @ Elsevier (PMID): 19527738 ● Search Scopus @ Elsevier (DOI): 10.1016/j.lfs.2009.06.002 (DOI: 10.1016/j.lfs.2009.06.002, PubMed: 19527738)
83.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, Nobuyuki Takamori, Yasumasa Ikeda, Yuka Sumitomo, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Kazue Ishikawa, Masataka Sata, Tetsuya Kitagawa and Toshio Matsumoto : Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors., Journal of Atherosclerosis and Thrombosis, Vol.16, No.2, 127-134, 2009. (Summary) AIM: Heparin cofactor II (HCII) specifically inactivates thrombin action at the injured vascular wall. We have reported that HCII is a protective factor against coronary in-stent restenosis and carotid atherosclerosis; however, it is unclear whether there is any correlation between plasma HCII levels and the development of peripheral arterial disease (PAD). METHODS: Plasma HCII activity and the ankle brachial pressure index (ABI) were determined in 494 elderly subjects with cardiovascular risk factors. PAD was diagnosed by ABI below 0.9, and 62 subjects were diagnosed with PAD. The relationship between factors that affect cardiovascular events and the prevalence of PAD was statistically evaluated. RESULTS: Mean HCII activity in PAD subjects was significantly lower than in non-PAD subjects (87.5+/-19.7% v.s. 94.6+/-17.8%, p=0.009). Multivariate logistic regression analysis showed that age (odds ratio [OR]: 1.062, p=0.0016), current smoking (OR 3.028, p=0.002) and diabetes mellitus (OR 2.656, p=0.008) were independent and progressive determinants of PAD. In contrast, HCII was an independent inhibitory factor of PAD (OR: 0.982, p=0.048). CONCLUSIONS: Plasma HCII activity is inversely related to the prevalence of PAD. HCII may function as the sole protective factor against PAD in elderly people with cardiovascular risk factors. (Keyword) Aged / Aged, 80 and over / Cardiovascular Diseases / Female / Heparin Cofactor II / Humans / Male / Middle Aged / Peripheral Vascular Diseases / Prevalence / Protective Agents / Risk Factors (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.E695 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19403987 ● Search Scopus @ Elsevier (PMID): 19403987 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.E695 (DOI: 10.5551/jat.E695, PubMed: 19403987)
84.	Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Yuka Ueda, Sumiko Yoshida, Takayuki Ise, Shusuke Yagi, Takashi Iwase, 近藤彰, 田村克也 and Toshio Matsumoto : アンジオテンシンII受容体拮抗薬バルサルタンのNO bioavailability改善効果に関する臨床的検討, Progress in Medicine, Vol.29, No.7, 1777-1782, 2009. (Summary) バルサルタンの降圧作用，動脈硬化抑制作用および糖代謝改善作用に一酸化窒素(NO)のバイオアベイラビリティの改善効果が関与しているか検討した．高血圧治療目的で通院加療中の42例を対象とした．バルサルタン投与にて，BMIやリポプロテイン(a)を含む脂質プロファイルに有意な変化は認めなかったが，収縮期血圧，脈圧，baPWVおよびHbA1cは有意に低下した．投与3ヵ月後には投与前と比較して，NOのバイオアベイラビリティのマーカーである血清硝酸/亜硝酸イオン(NOx)は約1.5倍に増加した．血清NOxの増加が，他の測定因子にどのように影響を与えているか，単変量および多変量解析を用いて解析し，血清NOxの増加量は収縮期血圧の低下と脈圧の減少との間においてそれぞれ有意な相関がみられた．また，HbA1cはバルサルタン投与3ヵ月後に有意に低下していたが，その変化はNOxの増加量と有意な相関がみられた． (Keyword) Nitrogen Oxides(血液) Glycosylated Hemoglobin A 降圧剤(治療的利用,薬理学) 高血圧(薬物療法) 生物学的利用率動脈硬化症-アテローム性(予防,診断) 経口投与一酸化窒素 Valsartan(治療的利用,薬理学) Angiotensin II Type 1 Receptor Blockers(治療的利用,薬理学) 脈波伝播速度ヒト中年(45~64) 高齢者(65~79) 男女
85.	Kenya Kusunose, Hirotsugu Yamada, Takashi Todoroki, Susumu Nishio, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Tetsuya Kitagawa and Masataka Sata : Platypnea-orthodeoxia syndrome associated with patent foramen ovale and aortic ectasia., Echocardiography, Vol.26, No.1, 114-117, 2008. (Summary) A 59-year-old man was admitted for dyspnea on exertion and edema. The patient did not have any pulmonary diseases that could cause dyspnea. Transesophageal echocardiography on the tilting bed with contrast infusion revealed a right-to-left shunt through the patent foramen ovale. Therefore, he was diagosed as platypnea-orthodeoxia syndrome due to the patent foramen ovale. Surgical closure was done and all of his symptoms had improved. (Keyword) Aortic Diseases / Dyspnea / transesophageal echocardiography / Edema, Cardiac / Foramen Ovale, Patent / Humans / Male / Middle Aged / syndrome / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1540-8175.2008.00780.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19017323 ● Search Scopus @ Elsevier (PMID): 19017323 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1540-8175.2008.00780.x (DOI: 10.1111/j.1540-8175.2008.00780.x, PubMed: 19017323)
86.	K Yamaguchi, Tetsuzo Wakatsuki, Kenya Kusunose, T Niki, K Koshiba, Hirotsugu Yamada, Takeshi Soeki and Masashi Akaike : A case of neurogenic myocardial stunning presenting transient left ventricular mid-portion ballooning simulating atypical takotsubo cardiomyopathy., Journal of Cardiology, Vol.52, No.1, 53-58, 2008. (Summary) A 57-year-old female patient, who was initially suspected to have subarachnoid hemorrhage, was admitted to our hospital. She experienced severe dyspnea and chest pain owing to pneumonia on the fourth admission day. Electrocardiography showed ST-segment elevation in leads V(2) through V(5), and echocardiography revealed hypokinetic left ventricular wall motion. No stenosis was found in the coronary arteries by urgent coronary angiography. However, left ventriculography revealed that the basal and apical areas were hyperkinetic and the mid portion was akinetic. After a month, left ventricular wall motion was improved and coronary artery spasm provocation tests were negative. Although the clinical course of this patient was similar to that of neurogenic myocardial stunning, the shape of her left ventricle was not typical. (Keyword) Coronary Angiography / Diagnosis, Differential / Echocardiography / Electrocardiography / Female / Humans / Middle Aged / Myocardial Stunning / Takotsubo Cardiomyopathy / Ventricular Dysfunction, Left (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jjcc.2008.03.004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18639778 ● Search Scopus @ Elsevier (PMID): 18639778 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jjcc.2008.03.004 (DOI: 10.1016/j.jjcc.2008.03.004, PubMed: 18639778)
87.	Masashi Akaike, 小原卓爾, 日浅光春, 藤村光則, 加藤みどり, 横井健治, 小島章裕, 岡崎誠司, 井内貴彦, 井上利彦, 住友由佳, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Ken-ichi Aihara and Hiroyuki Azuma : 高コレステロール血症患者に対するピタバスタチンの有効性総合的脂質プロファイルに関する検討, Progress in Medicine, Vol.28, No.11, 2745-2751, 2008. (Summary) 高コレステロール血症患者を対象にピタバスタチンを投与し，総合的脂質プロファイルへの影響について検討した．高コレステロール血症と診断され，ピタバスタチンを投与した87例を対象とした．ピタバスタチン投与によりTC，LDL-Cは有意に低下した．HDL-Cは有意な上昇，TGは有意な低下を認めた．ピタバスタチンを新規に投与した症例で，TC，LDL-Cは有意かつ良好な低下作用を認めた．また，HDL-Cは有意な上昇，TGは有意な低下作用を示した．Non HDL-Cは有意に低下し，LDL-C/HDL-C比は有意に減少した．動脈硬化指数は，いずれも有意に改善した．投与前後でLp(a)を測定した76例で，有意な変化は認めなかった．投与前後におけるALT，ASTの平均変化量に，有意な変化は認めなかった．CKも有意な変化は認めなかった．治療上，問題となる副作用は認めなかった． (Keyword) Cholesterol(血液) HDL Cholesterol(血液) LDL Cholesterol(血液) Triglycerides(血液) 高コレステロール血症(薬物療法) Lipoprotein(a)(血液) 治療成績 Pitavastatin(治療的利用) ヒト中年(45~64) 高齢者(65~79) 男女
88.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, Masataka Sata, Nobuyuki Takamori, Shusuke Yagi, Takashi Iwase, Yuka Sumitomo, Hirotaka Kawano, Takashi Yamada, Toru Fukuda, Takahiro Matsumoto, Keisuke Sekine, Takashi Sato, Yuko Nakamichi, Yoko Yamamoto, Kimihiro Yoshimura, Tomoyuki Watanabe, Takashi Nakamura, Akimasa Oomizu, Minoru Tsukada, Hideki Hayashi, Toshiki Sudo, Shigeaki Kato and Toshio Matsumoto : Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice, The Journal of Clinical Investigation, Vol.117, No.6, 1514-1526, 2007. (Summary) Heparin cofactor II (HCII) specifically inhibits thrombin action at sites of injured arterial wall, and patients with HCII deficiency exhibit advanced atherosclerosis. However, the in vivo effects and the molecular mechanism underlying the action of HCII during vascular remodeling remain elusive. To clarify the role of HCII in vascular remodeling, we generated HCII-deficient mice by gene targeting. In contrast to a previous report, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, prominent intimal hyperplasia with increased cellular proliferation was observed after tube cuff and wire vascular injury. The number of protease-activated receptor-1-positive (PAR-1-positive) cells was increased in the thickened vascular wall of HCII(+/-) mice, suggesting enhanced thrombin action in this region. Cuff injury also increased the expression levels of inflammatory cytokines and chemokines in the vascular wall of HCII(+/-) mice. The intimal hyperplasia in HCII(+/-) mice with vascular injury was abrogated by human HCII supplementation. Furthermore, HCII deficiency caused acceleration of aortic plaque formation with increased PAR-1 expression and oxidative stress in apoE-KO mice. These results demonstrate that HCII protects against thrombin-induced remodeling of an injured vascular wall by inhibiting thrombin action and suggest that HCII is potentially therapeutic against atherosclerosis without causing coagulatory disturbance. (Keyword) Animals / Base Sequence / Blood Vessels / DNA Primers / Embryo Loss / Female / Gene Targeting / Genes, Lethal / Genotype / Heparin Cofactor II / Heterozygote / Homozygote / Male / Mice / Mice, Inbred C57BL / knockout mice / Pregnancy (Link to Publication Site) ● Publication site (DOI): 10.1172/JCI27095 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17549254 ● Search Scopus @ Elsevier (PMID): 17549254 ● Search Scopus @ Elsevier (DOI): 10.1172/JCI27095 (DOI: 10.1172/JCI27095, PubMed: 17549254)
89.	Yasumasa Ikeda, Shusuke Yagi, Hiroshi Yamaguchi, Mitsunori Fujimura, Shunji Hashizume, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : Intra-vascular ultrasound findings of diffuse coronary atherosclerotic change in systemic lupus erythematosus with secondary antiphospholipid syndrome, Circulation Journal, Vol.70, No.8, 1082-1085, 2006. (Summary) Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are autoimmune inflammatory diseases associated with juvenile atherosclerosis and thrombosis, respectively. A 44-year-old woman who had SLE with secondary APS had been treated with corticosteroid therapy, however, her inflammatory marker had never been within a normal range in her clinical course, and finally acute myocardial infarction was developed. Intra-vascular ultrasound also revealed diffuse coronary atherosclerosis progression for her age, which might result from SLE and APS, including vascular inflammation. (Keyword) Adrenal Cortex Hormones / Adult / Antiphospholipid Syndrome / Coronary Artery Disease / Coronary Vessels / Female / Humans / Lupus Erythematosus, Systemic / Myocardial Infarction / Ultrasonography, Interventional (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.70.1082 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16864946 ● Search Scopus @ Elsevier (PMID): 16864946 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.70.1082 (DOI: 10.1253/circj.70.1082, PubMed: 16864946)
90.	Y. Kuroda, Takao Mitsui, M. Kunishige, Masayuki Shono, Masashi Akaike, H. Azuma and Toshio Matsumoto : Parkin enhances mitochondrial biogenesis in proliferating cells., Human Molecular Genetics, Vol.15, No.6, 883-895, 2006. (Summary) We describe a novel function of parkin, a RING protein, which is elaborately involved in mitochondrial biogenesis. Parkin was located within the mitochondrial organelle of proliferating cells. Anti-proliferative treatments released parkin from mitochondria to cytosol. Results of pharmacological treatments indicate that parkin was released from mitochondria when permeability transition pore was opened. The extra-mitochondrial localization was also observed in differentiated cells. In proliferating cells, transcription and replication of mitochondrial DNA was enhanced by parkin overexpression and attenuated by parkin suppression with siRNA. Parkin was associated with mitochondrial transcription factor A (TFAM) and enhanced TFAM-mediated mitochondrial transcription. These results indicate that parkin is involved in the regulation of mitochondrial transcription/replication other than the ubiquitin-mediated protein degradation system in proliferating cells. (Keyword) Parkin / mitochondria (Link to Publication Site) ● Publication site (DOI): 10.1093/hmg/ddl006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16449237 ● Search Scopus @ Elsevier (PMID): 16449237 ● Search Scopus @ Elsevier (DOI): 10.1093/hmg/ddl006 (DOI: 10.1093/hmg/ddl006, PubMed: 16449237)
91.	Yasumasa Ikeda, Ken-ichi Aihara, Takashi Sato, Masashi Akaike, Masanori Yoshizumi, Yuki Suzaki, Yuki Izawa-Ishizawa, Mitsunori Fujimura, Shunji Hashizume, Midori Kato, Shusuke Yagi, Toshiaki Tamaki, Hirotaka Kawano, Takahiro Matsumoto, Hiroyuki Azuma, Shigeaki Kato and Toshio Matsumoto : Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis., The Journal of Biological Chemistry, Vol.280, No.33, 29661-29666, 2005. (Summary) Androgen has anabolic effects on cardiac myocytes and has been shown to enhance left ventricular enlargement and function. However, the physiological and patho-physiological roles of androgen in cardiac growth and cardiac stress-induced remodeling remains unclear. We aimed to clarify whether the androgen-nuclear androgen receptor (AR) system contributes to the cardiac growth and angiotensin II (Ang II)-stimulated cardiac remodeling by using systemic AR-null male mice. AR knock-out (ARKO) male mice, at 25 weeks of age, and age-matched wild-type (WT) male mice were treated with or without Ang II stimulation (2.0 mg/kg/day) for 2 weeks. ARKO mice with or without Ang II stimulation showed a significant reduction in the heart-to-body weight ratio compared with those of WT mice. In addition, echocardiographic analysis demonstrated impairments of both the concentric hypertrophic response and left ventricular function in Ang II-stimulated ARKO mice. Western blot analysis of the myocardium revealed that activation of extracellular signal-regulated kinases (ERK) 1/2 and ERK5 by Ang II stimulation were lower in ARKO mice than those of WT mice. Ang II stimulation caused more prominent cardiac fibrosis in ARKO mice than in WT mice with enhanced expression of types I and III collagen and transforming growth factor-beta1 genes and with increased Smad2 activation. These results suggest that, in male mice, the androgen-AR system participates in normal cardiac growth and modulates cardiac adaptive hypertrophy and fibrosis during the process of cardiac remodeling under hypertrophic stress. (Keyword) Angiotensin II / Animals / blood pressure / Cardiomegaly / DNA-Binding Proteins / pulmonary fibrosis / Heart Rate / Male / Mice / Mice, Inbred C57BL / Mice, Inbred CBA / knockout mice / Mitogen-Activated Protein Kinase 1 / Mitogen-Activated Protein Kinase 3 / Mitogen-Activated Protein Kinase 7 / myocardium / RNA, Messenger / Receptors, Androgen / Smad2 Protein / Trans-Activators / Transforming Growth Factor beta / Transforming Growth Factor beta1 / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1074/jbc.M411694200 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15961403 ● Search Scopus @ Elsevier (PMID): 15961403 ● Search Scopus @ Elsevier (DOI): 10.1074/jbc.M411694200 (DOI: 10.1074/jbc.M411694200, PubMed: 15961403)
92.	Midori Kato, Hiroyuki Azuma, Masashi Akaike, Takahiko Iuchi, Ken-ichi Aihara, Yasumasa Ikeda, Mitsunori Fujimura, Tomonori Yoshida, Hiroshi Yamaguchi, Shunji Hashizume and Toshio Matsumoto : Aspirin inhibits thrombin action on endothelial cells via up-regulation of aminopeptidase N/CD13 expression., Atherosclerosis, Vol.183, No.1, 49-55, 2005. (Summary) OBJECTIVE: We hypothesized that aspirin may exhibit its anti-atherosclerotic effects via mechanisms other than cyclooxygenase inhibition in platelets. METHODS AND RESULTS: Using enhanced subtraction hybridization analysis, we found in human umbilical vein endothelial cells (HUVECs) that aspirin up-regulates the expression of aminopeptidase N (APN/CD13) mRNA and its surface protein levels in a dose-dependent manner. Enzymatic activity of APN/CD13 on HUVECs was increased approximately 1.5-fold by 1 mmol L(-1) of aspirin, and treatment with bestatin, an inhibitor for APN/CD13 metalloprotease activity, attenuated the enhanced activities of APN/CD13. Since activated thrombin receptor is reported to be inactivated by APN/CD13 in vitro, protective actions of aspirin on HUVECs by thrombin stimulation were examined, resulting in the suppression of endothelin-1 and reactive oxygen species productions in HUVECs. These inhibitory actions of aspirin were partially abrogated by bestatin. CONCLUSIONS: Aspirin may exert its anti-atherothrombotic effects in part via the inhibition of thrombin action by up-regulating APN/CD13 on endothelial cells. (Keyword) Antigens, CD13 / Aspirin / Cells, Cultured / Endothelial Cells / Endothelin-1 / Endothelium, Vascular / Enzyme Induction / Fibrinolytic Agents / Genes, Reporter / Humans / Leucine / Protease Inhibitors / RNA, Messenger / reactive oxygen species / Subtraction Technique / Thrombin / Transcription, Genetic / Transfection / Umbilical Veins (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2005.03.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 16216591 ● Search Scopus @ Elsevier (PMID): 16216591 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2005.03.003 (DOI: 10.1016/j.atherosclerosis.2005.03.003, PubMed: 16216591)
93.	Tomonori Yoshida, Hiroyuki Azuma, Ken-ichi Aihara, Mitsunori Fujimura, Masashi Akaike, Takao Mitsui and Toshio Matsumoto : Vascular smooth muscle cell proliferation is dependent upon upregulation of mitochondrial transcription factor A (mtTFA) expression in injured rat carotid artery, Atherosclerosis, Vol.178, No.1, 39-47, 2005. (Summary) Consistent with the physiological response to increased energy demand in proliferating cells, the number of mitochondria is upregulated in synthetic states of vascular smooth muscle cells (VSMC) in atherosclerotic lesion. We hypothesized that mitochondrial transcription factor A (mtTFA), a prerequisite factor for the transcription and replication of mtDNA, may be upregulated in VSMC of injured rat carotid artery, and that inhibition of its expression can attenuate the intimal thickening. Changes of intimal thickening and mtTFA expression by a treatment with antisense oligodeoxynucleotides (ODN) for mtTFA were investigated in balloon-injured rat carotid artery model. The expression of mtTFA was upregulated as early as 3 h up to 7 days after balloon injury. Delivery of ansisense ODN for mtTFA from adventitia side to injured arterial wall caused a significant decrease in intima-to-media (I/M) ratio. Furthermore, the increase in immunoreactivity and mRNA expression of mtTFA in injured artery as well as the number of mitochondria in intimal VSMC was abrogated by antisense ODN treatment. These data demonstrate that expression of mtTFA is upregulated in intimal VSMC of injured rat carotid artery, and that suppression of mtTFA expression by antisense ODN can attenuate intimal thickening after balloon injury. (Keyword) Antisense oligodeoxynucleotide / Arterial injury / Intimal thickening / Dedifferentiation / Restenosis (Link to Publication Site) ● Publication site (DOI): 10.1016/j.atherosclerosis.2004.08.029 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15585199 ● Search Scopus @ Elsevier (PMID): 15585199 ● Search Scopus @ Elsevier (DOI): 10.1016/j.atherosclerosis.2004.08.029 (DOI: 10.1016/j.atherosclerosis.2004.08.029, PubMed: 15585199)
94.	山口普史, Yasumasa Ikeda, 藤村光則, 森岡将臣, 橋詰俊二, 加藤みどり, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma, Toshio Matsumoto, 稲山真美 and Masaki Hanibuchi : アミオダロン肺合併症との鑑別を要したマイコプラズマ肺炎合併拡張型心筋症の1例, Progress in Medicine, Vol.25, No.Suppl.1, 1552-1556, 2005. (Summary) 52歳男.47歳時に拡張型心筋症と診断され,持続性心室頻拍でアミオダロン150mg/日を開始した.その後,心室頻拍が頻回となり,心臓電気生理学的検査で心室細動が誘発されたため除細動器植込み術を受け,アミオダロンは増量して継続していた.今回,乾性咳が出現し,胸部X線で左右下肺野にスリガラス状陰影を指摘された.検査所見では高度の炎症所見を認めたが,KL-6は正常範囲で,C型肝炎ウイルスとヒトT細胞性白血病ウイルスI型のキャリアであった.胸部CTでは両側下肺野を中心として壁の肥厚を伴う気管支拡張や小葉中心性の粒状・樹枝状の陰影が多発しており,周囲の肺野に淡い濃度上昇を認めた.アミオダロンの副作用か感染症かは判断できなかったが,アミオダロンは中止し,アンピシリンナトリウム・スルバクタムナトリウム合剤を開始すると共にサイトメガロウイルス高力価免疫グロブリン投与を行った.入院10日目にマイコプラズマ抗体異常高値が判明し,マイコプラズマ肺炎と診断しミノサイクリン100mg/日を開始した.その結果,炎症所見,画像所見は徐々に軽快し,アミオダロンも再開して退院となった (Keyword) Amiodarone(治療的利用,毒性・副作用) Minocycline(治療的利用) 胸部X線診断心筋症-拡張型(合併症) 鑑別診断 X線CT 肺炎-マイコプラズマ性(合併症,X線診断) 頻拍-心室性(薬物療法) 肺炎-細菌性(合併症,X線診断,薬物療法) 肺炎-間質性(化学的誘発,X線診断) 胸部CT ヒト中年(45~64) 男
95.	Masashi Akaike, Wenyi Che, Nicole-Lerner Marmarosh, Shinsuke Ohta, Masaki Osawa, Bo Ding, Bradford C. Berk, Chen Yan and Jun-ichi Abe : The Hinge-Helix 1 Region of Peroxisome Proliferator-Activated Receptor γ1 (PPARγ1) Mediates Interaction with Extracellular Signal-Regulated Kinase 5 and PPARγ1 Transcriptional Activation, --- Involvement in Flow-Induced PPARγ Activation in Endothelial Cells ---, Molecular and Cellular Biology, Vol.24, No.19, 8691-8704, 2004. (Summary) Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors that form a subfamily of the nuclear receptor gene family. Since both flow and PPARgamma have atheroprotective effects and extracellular signal-regulated kinase 5 (ERK5) kinase activity is significantly increased by flow, we investigated whether ERK5 kinase regulates PPARgamma activity. We found that activation of ERK5 induced PPARgamma1 activation in endothelial cells (ECs). However, we could not detect PPARgamma phosphorylation by incubation with activated ERK5 in vitro, in contrast to ERK1/2 and JNK, suggesting a role for ERK5 as a scaffold. Endogenous PPARgamma1 was coimmunoprecipitated with endogenous ERK5 in ECs. By mammalian two-hybrid analysis, we found that PPARgamma1 associated with ERK5a at the hinge-helix 1 region of PPARgamma1. Expressing a hinge-helix 1 region PPARgamma1 fragment disrupted the ERK5a-PPARgamma1 interaction, suggesting a critical role for hinge-helix 1 region of PPARgamma in the ERK5-PPARgamma interaction. Flow increased ERK5 and PPARgamma1 activation, and the hinge-helix 1 region of the PPARgamma1 fragment and dominant negative MEK5beta significantly reduced flow-induced PPARgamma activation. The dominant negative MEK5beta also prevented flow-mediated inhibition of tumor necrosis factor alpha-mediated NF-kappaB activation and adhesion molecule expression, including vascular cellular adhesion molecule 1 and E-selectin, indicating a physiological role for ERK5 and PPARgamma activation in flow-mediated antiinflammatory effects. We also found that ERK5 kinase activation was required, likely by inducing a conformational change in the NH(2)-terminal region of ERK5 that prevented association of ERK5 and PPARgamma1. Furthermore, association of ERK5a and PPARgamma1 disrupted the interaction of SMRT and PPARgamma1, thereby inducing PPARgamma activation. These data suggest that ERK5 mediates flow- and ligand-induced PPARgamma activation via the interaction of ERK5 with the hinge-helix 1 region of PPARgamma. (Keyword) Endothelial Cells / Gene Expression Regulation / Humans / MAP Kinase Kinase Kinases / Mitogen-Activated Protein Kinase 7 / Mitogen-Activated Protein Kinases / NF-kappa B / Phosphorylation / Protein Structure, Tertiary / Receptors, Cytoplasmic and Nuclear / Thiazolidinediones / Transcription Factors / Tumor Necrosis Factor-alpha / Vascular Cell Adhesion Molecule-1 (Link to Publication Site) ● Publication site (DOI): 10.1128/MCB.24.19.8691-8704.2004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15367687 ● Search Scopus @ Elsevier (PMID): 15367687 ● Search Scopus @ Elsevier (DOI): 10.1128/MCB.24.19.8691-8704.2004 (DOI: 10.1128/MCB.24.19.8691-8704.2004, PubMed: 15367687)
96.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, Michiko Yamashita, Toshiki Sudo, Hideki Hayashi, Yoshihisa Yamada, Fuminari Endoh, Mitsunori Fujimura, Tomonori Yoshida, Hiroshi Yamaguchi, Shunji Hashizume, Midori Kato, Kimihiro Yoshimura, Yoko Yamamoto, Shigeaki Kato and Toshio Matsumoto : Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice, The Journal of Biological Chemistry, Vol.279, No.34, 35798-35802, 2004. (Summary) Vitamin D metabolites influence the expression of various genes involved in calcium homeostasis, cell differentiation, and regulation of the immune system. Expression of these genes is mediated by the activation of the nuclear vitamin D receptor (VDR). Previous studies have shown that a hormonally active form of vitamin D, 1alpha,25-dihydroxyvitamin D3, exerts anticoagulant effects in cultured monocytic cells. To clarify whether activation of VDR plays any antithrombotic actions in vivo, hemostatic/thrombogenic systems were examined in normocalcemic VDR knock-out (KO) mice on a high calcium diet and compared with wild type and hypocalcemic VDRKO mice that were fed a regular diet. Platelet aggregation was enhanced significantly in normocalcemic VDRKO mice compared with wild type and hypocalcemic VDRKO mice. Aortic endothelial nitric-oxide (NO) synthase expression and urinary NOx excretions were reduced in hypocalcemic VDRKO mice, but not in normocalcemic VDRKO mice. Northern blot and RT-PCR analyses revealed that the gene expression of antithrombin in the liver as well as that of thrombomodulin in the aorta, liver and kidney was down-regulated in hypo- and normocalcemic VDRKO mice. Whereas tissue factor mRNA expression in the liver and kidney was up-regulated in VDRKO mice regardless of plasma calcium level. Furthermore, VDRKO mice manifested an exacerbated multi-organ thrombus formation after exogenous lipopolysaccharide injection regardless of the calcemic conditions. These results demonstrate that activation of nuclear VDR elicits antithrombotic effects in vivo, and suggest that the VDR system may play a physiological role in the maintenance of antithrombotic homeostasis. (Keyword) FILTRATION PRESSURE METHOD / TISSUE-FACTOR / 1,25-DIHYDROXYVITAMIN D-3 / ANTITHROMBIN DEFICIENCY / WHOLE-BLOOD / EXPRESSION / cells / AGGREGATION / inhibition / ALOPECIA (Link to Publication Site) ● Publication site (DOI): 10.1074/jbc.M404865200 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15205460 ● CiNii @ National Institute of Informatics (CRID): 1362262945661168512 ● Summary page in Scopus @ Elsevier: 2-s2.0-4143096123 (DOI: 10.1074/jbc.M404865200, PubMed: 15205460, CiNii: 1362262945661168512, Elsevier: Scopus)
97.	Ken-ichi Aihara, Hiroyuki Azuma, Nobuyuki Takamori, Yasuhiko Kanagawa, Masashi Akaike, Mitsunori Fujimura, Tomonori Yoshida, Shunji Hashizume, Midori Kato, Hiroshi Yamaguchi, Shuji Kato, Yasumasa Ikeda, Tomoko Arase, Akira Kondo and Toshio Matsumoto : Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals., Circulation, Vol.109, No.22, 2761-2765, 2004. (Summary) Thrombin plays a crucial role in atherothrombotic changes. Because heparin cofactor II (HCII) inhibits thrombin actions after binding to dermatan sulfate at injured arterial walls, HCII may negatively regulate thrombin actions in vascular walls. We hypothesized that plasma HCII activity is a preventive factor against atherosclerotic changes, especially in elderly individuals who already have atherosclerotic vascular injuries. Maximum plaque thickness (MPT) in the carotid artery was measured by ultrasonography in 306 Japanese elderly individuals (154 men and 152 women; age, 40 to 91 years; 68.9+/-11.1 years, mean+/-SD). The relevance of cardiovascular risk factors including plasma HCII activity to the severity of MPT was statistically evaluated. Plasma HCII activity decreased with age. Simple linear regression analysis after adjustments for age and sex showed that lipoprotein(a), glycosylated hemoglobin A1c, and presence of diabetes mellitus significantly contributed to an increase in MPT values (r=0.119, P<0.05; r=0.196, P<0.001; and r=0.227, P<0.0001, respectively). In contrast, high-density lipoprotein (HDL) cholesterol and HCII activity were negatively correlated with MPT values (r=-0.117, P<0.05, and r=-0.202, P<0.0005, respectively). Multiple regression analysis revealed that plasma HCII activity and HDL cholesterol independently contributed to the suppression of MPT values and that the antiatherogenic contribution of HCII activity was stronger than that of HDL cholesterol (P<0.001 and P<0.05, respectively). These results suggest that HCII can be a novel and independent antiatherogenic factor. Moreover, HCII is a stronger predictive factor than HDL cholesterol against carotid atherosclerosis in elderly individuals. (Keyword) Adult / Aged / Aged, 80 and over / aging / Antithrombins / Cardiovascular Diseases / Carotid Artery Diseases / Female / Heparin Cofactor II / Humans / Male / Middle Aged / Regression Analysis / Risk Factors / Severity of Illness Index (Link to Publication Site) ● Publication site (DOI): 10.1161/01.CIR.0000129968.46095.F3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 15148272 ● Search Scopus @ Elsevier (PMID): 15148272 ● Search Scopus @ Elsevier (DOI): 10.1161/01.CIR.0000129968.46095.F3 (DOI: 10.1161/01.CIR.0000129968.46095.F3, PubMed: 15148272)
98.	Masashi Akaike, Hiroyuki Azuma, 石川雅康, 井上利彦, 遠藤武徳, 岡崎誠司, 小島章裕, 佐藤幸一, 田村克也, 田村隆一, 長楽雅仁, 中平晴仁, 林郁郎, 日浅光春, 藤村光則, 松本直也, 宮恵子, 山口普史, 吉田健三, 渡部滋夫 and Toshio Matsumoto : 日本動脈硬化学会による診療ガイドラインからみた高コレステロール血症治療の動向とその問題点, Progress in Medicine, Vol.24, No.3, 767-772, 2004.
99.	Nobuyuki Takamori, Hiroyuki Azuma, Midori Kato, Shunji Hashizume, Ken-ichi Aihara, Masashi Akaike, Katsuya Tamura and Toshio Matsumoto : High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention, Circulation, Vol.109, No.4, 481-486, 2004. (Summary) Thrombin plays an important role in the development of atherosclerosis and restenosis after percutaneous coronary intervention. Because heparin cofactor II (HCII) inhibits thrombin action in the presence of dermatan sulfate, which is abundantly present in arterial wall, HCII may affect vascular remodeling by modulating thrombin action. We hypothesized that patients with high plasma HCII activity may show a reduced incidence of in-stent restenosis (ISR). Sequential coronary arteries (n=166) with NIR stent (Boston Scientific Corp) implantation in 134 patients were evaluated before, immediately after, and at 6 months after percutaneous coronary intervention. Patients were divided into the following groups: high HCII (> or =110%, 45 lesions in 36 patients), normal HCII (> or =80% and <110%, 81 lesions in 66 patients), and low HCII (<80%, 40 lesions in 32 patients). Percent diameter stenosis at follow-up in the high-HCII group (18.7%) was significantly lower (P=0.046) than that in the normal-HCII group (30.3%) or the low-HCII group (29.0%). The ISR rate in the high-HCII group (6.7%) was significantly lower than that in the low-HCII group (30.0%) (P=0.0039). Furthermore, multivariate analysis demonstrated that high plasma HCII activity is an independent factor in reducing the incidence of angiographic restenosis (odds ratio, 0.953/1% increase of HCII; 95% CI, 0.911 to 0.998). The results demonstrate that HCII may have a hitherto unrecognized effect in inhibiting ISR. The effect of HCII may be mediated by inactivating thrombin in injured arteries, thereby inhibiting vascular smooth muscle cell migration and proliferation. (Keyword) cardiovascular diseases / angioplasty / atherosclerosis / thrombin / dermatan sulfate (Link to Publication Site) ● Publication site (DOI): 10.1161/01.CIR.0000109695.39671.37 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14744972 ● Search Scopus @ Elsevier (PMID): 14744972 ● Search Scopus @ Elsevier (DOI): 10.1161/01.CIR.0000109695.39671.37 (DOI: 10.1161/01.CIR.0000109695.39671.37, PubMed: 14744972)
100.	Itsuro Endo, Daisuke Inoue, Takao Mitsui, Yoshifumi Umaki, Masashi Akaike, Tatsuya Yoshizawa, Shigeaki Kato and Toshio Matsumoto : Deletion of Vitamin D Receptor Gene in Mice Results in Abnormal Skeletal Muscle Development with Deregulated Expression of Myoregulatory Transcription Factors, Endocrinology, Vol.144, No.12, 5138-5144, 2003. (Keyword) D RESPONSE SEQUENCE / PARATHYROID-HORMONE / 1,25-DIHYDROXYVITAMIN-D3 RECEPTORS / metabolism / RICKETS / FALLS / RAT / identification / OSTEOMALACIA / MECHANISMS (Link to Publication Site) ● Publication site (DOI): 10.1210/en.2003-0502 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12959989 ● Search Scopus @ Elsevier (PMID): 12959989 ● Search Scopus @ Elsevier (DOI): 10.1210/en.2003-0502 (DOI: 10.1210/en.2003-0502, PubMed: 12959989)
101.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, 藤村光則, 吉田智則, 橋詰俊二, 加藤みどり, 山口普史, Yasumasa Ikeda, 加藤茂明 and Toshio Matsumoto : ビタミンD-ビタミンD受容体システムは生体における血液凝固調節因子である, 第25回日本血栓止血学会学術集会, Vol.14, No.5, 420, 2003. (Keyword) *Vitamin D(薬理学) 遺伝子発現血液凝固 Calcitriol Receptors Thrombomodulin マウス動物
102.	Takao Mitsui, Yoshifumi Umaki, Masakazu Nagasawa, Masashi Akaike, Satoshi Ohtsuka, Masaaki Odomi, Kenji Aki and Toshio Matsumoto : Motor neuron involvement in a patient with long-term corticosteroid administration, Internal Medicine, Vol.42, No.9, 862-866, 2003. (Summary) An asthmatic patient with corticosteroid treatment for 45 years presented with slowly progressive limb muscle atrophy. His muscle symptoms were involved in four limbs and tongue, and deep tendon reflexes were exaggerated. Biopsied muscle pathology indicated the presence of neurogenic muscular atrophy in combination with corticosteroid myopathy. Furthermore, 8-hydroxy-deoxyguanosine (8-OH-dG) was prominently increased in mitochondrial and nuclear DNA. An aerobic exercise test demonstrated remarkable serum lactate elevation, which was attenuated by the administration of coenzyme Q10. These findings are consistent with the assumption that long-term corticosteroid administration potentially induces not only myopathy but also motor neuron involvement as in mitochondrial diseases. (Keyword) asthma / corticosteroid myopathy / denervation / neurogenic muscular atrophy / mitochondria (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.42.862 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14518677 ● CiNii @ National Institute of Informatics (CRID): 1390282679843291136 ● Search Scopus @ Elsevier (PMID): 14518677 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.42.862 (DOI: 10.2169/internalmedicine.42.862, PubMed: 14518677, CiNii: 1390282679843291136)
103.	Nicole Lerner-Marmarosh, Masanori Yoshizumi, Wenyi Che, James Surapisitchat, Masashi Akaike, Bo Ding, Qunhua Huang, Chen Yan, Bradford C. Berk and Jun-ichi Abe : Inhibition of Tumor Necrosis Factor- Induced SHP-2 Phosphatase Activity by Shear Stress, Arteriosclerosis, Thrombosis, and Vascular Biology, Vol.23, No.10, 1775-1781, 2003. (Summary) Atherosclerosis preferentially occurs in areas of turbulent flow, whereas laminar flow is atheroprotective. Inflammatory cytokines have been shown to stimulate adhesion molecule expression in endothelial cells that may promote atherosclerosis, in part, by stimulating c-Jun N-terminal kinase (JNK) and nuclear factor (NF)-kappaB transcriptional activity. Because Src kinase family and Src homology region 2-domain phosphatase-2 (SHP-2) may regulate JNK activation, we studied the effect of shear stress on endothelial inflammation and JNK. Human umbilical vein endothelial cells preexposed to flow showed decreased tumor necrosis factor (TNF)-alpha-induced c-Jun and NF-kappaB transcriptional activation. TNF-alpha-mediated JNK, c-Jun, and NF-kappaB activation required Src and SHP-2 activity. Shear stress significantly inhibited SHP-2 phosphatase activity without affecting TNF-alpha-induced Src family kinase activation. Because MEKK3 and Gab1 are critical for TNF-alpha-induced c-Jun and NF-kappaB activation, we determined the role of SHP-2 phosphatase activity in MEKK3 signaling. A catalytically inactive form of SHP-2 increased MEKK3/Gab1 interaction and inhibited MEKK3 (but not MEKK1)-mediated c-Jun and NF-kappaB activation. These results suggest that SHP-2 is a key mediator for the inhibitory effects of shear stress on TNF-alpha signaling in part via regulating MEKK3/Gab1 interaction, MEKK3 signaling, and subsequent adhesion molecule expression. (Keyword) pathophysiology / cell signaling / endothelium / mechanism of atherosclerosis (Link to Publication Site) ● Publication site (DOI): 10.1161/01.ATV.0000094432.98445.36 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12947019 ● Search Scopus @ Elsevier (PMID): 12947019 ● Search Scopus @ Elsevier (DOI): 10.1161/01.ATV.0000094432.98445.36 (DOI: 10.1161/01.ATV.0000094432.98445.36, PubMed: 12947019)
104.	Makoto Kunishige, Takao Mitsui, Masashi Akaike, Masakazu Kawajiri, Masayuki Shono, Hisaomi Kawai and Toshio Matsumoto : Overexpressions of myoglobin and antioxidant enzymes in ragged-red fibers of skeletal muscle from patients with mitochondrial encephalomyopathy, Muscle & Nerve, Vol.28, No.4, 484-492, 2003. (Summary) To determine the relationship between myoglobin (Mb) and the defense system against reactive oxygen species in various myopathies, we performed immunohistochemical analyses of Mb and various antioxidant enzymes, including manganese superoxide dismutase (Mn-SOD), copper zinc SOD (CuZn-SOD), catalase (CAT), and glutathione peroxidase (GSH-Px). Biopsied muscle specimens were obtained from patients with chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS), Duchenne muscular dystrophy (DMD), and polymyositis (PM). In patients with CPEO/KSS, stainings of Mb, SOD, CAT, and GSH-Px in nonatrophic ragged-red fibers (RRFs) were more intense than those in non-RRFs. These pronounced stainings corresponded to ragged-red lesions. The staining intensities of these antioxidant enzymes were significantly correlated with that of Mb (P < 0.001). Atrophic RRFs in specimens from patients with CPEO/KSS showed intense stainings of these antioxidant enzymes but not intense staining of Mb. In specimens from patients with DMD/PM, the antioxidant enzymes but not Mb were overexpressed in degenerative fibers. These results suggest that oxidative stress is associated with Mb expression specifically in mitochondrial diseases. The antioxidant enzymes seem to be upregulated to protect against muscle damage in nonatrophic RRFs. However, the Mb-mediated oxidative damage may become more extensive and result in further mitochondrial dysfunction and progressive atrophy of RRF with impaired upregulation of Mb. (Keyword) catalase / glutathione peroxidase / oxgen radical / ragged-red fibers / superoxide dismutase (Link to Publication Site) ● Publication site (DOI): 10.1002/mus.10466 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 14506721 ● Search Scopus @ Elsevier (PMID): 14506721 ● Search Scopus @ Elsevier (DOI): 10.1002/mus.10466 (DOI: 10.1002/mus.10466, PubMed: 14506721)
105.	Mitsunori Fujimura, Masashi Akaike, Midori Kato, Nobuyuki Takamori, Masahiro Abe, Takeshi Nishiuchi, Hiroyuki Azuma and Toshio Matsumoto : Aggressive antiplatelet therapy before coronary stent implantation in acute coronary syndrome with essential thrombocythemia--a case report, Angiology, Vol.54, No.4, 485-490, 2003. (Summary) A 52-year-old man was admitted to the hospital because of unstable angina pectoris. Coronary angiography revealed severe stenosis at a proximal site of the left anterior descending artery. Essential thrombocythemia (ET) was diagnosed on the basis of findings of marked thrombocytosis (106 x 10(4)/microL) and an increased number of immature megakaryocytes in the bone marrow. Because hyperaggregability of platelets was demonstrated by an ex vivo platelet aggregation assay and by elevated plasma levels of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4), antiplatelet therapy with aspirin and ticlopidine and cytoreduction therapy with hydroxyurea were started. This combination treatment resulted in a decrease in the platelet count to less than 60 x 10(4)/microL and decreases in plasma levels of both beta-TG and PF4 to almost normal values. Percutaneous coronary angioplasty and stenting were then performed successfully without thrombotic complications. These findings suggest that combination therapy with antiplatelet and cytoreduction agents before catheter intervention is useful for the prevention of thrombotic complications in patients with acute coronary syndrome associated with essential thrombocythemia. (Keyword) Acute Disease / Angina, Unstable / Aspirin / Combined Modality Therapy / Coronary Stenosis / Humans / Hydroxyurea / Male / Middle Aged / Platelet Aggregation Inhibitors / Stents / Thrombocythemia, Essential / Ticlopidine (Link to Publication Site) ● Publication site (DOI): 10.1177/000331970305400414 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12934770 ● Search Scopus @ Elsevier (PMID): 12934770 ● Search Scopus @ Elsevier (DOI): 10.1177/000331970305400414 (DOI: 10.1177/000331970305400414, PubMed: 12934770)
106.	Scott J. Cameron, Sundeep Malik, Masashi Akaike, Nicole Lerner-Marmarosh, Chen Yan, Jiing-Dwan Lee, Jun-ichi Abe and Jay Yang : Regulation of Epidermal Growth Factor-induced Connexin 43 Gap Junction Communication by Big Mitogen-activated Protein Kinase 1/ERK5 but Not ERK1/2 Kinase Activation, The Journal of Biological Chemistry, Vol.278, No.20, 18682-18688, 2003. (Summary) The gap junction protein, Cx43, plays a pivotal role in coupling cells electrically and metabolically, and the putative phosphorylation sites that modulate its function are reflected as changes in gap junction communication. Growth factor stimulation has been correlated with a decrease in gap junction communication and a parallel activation of ERK1/2; the inhibition of epidermal growth factor (EGF)-induced Cx43 gap junction uncoupling was observed by using the MEK1/2 inhibitor, PD98059. Because 1) BMK1/ERK5, another MAPK family member also activated by growth factors, possesses a phosphorylation motif similar to ERK1/2, and 2) it has been reported that PD98059 can inhibit not only MEK1/2-ERK1/2 but also MEK5-BMK1 activation, we investigated whether BMK1 can regulate EGF-induced Cx43 gap junction uncoupling and phosphorylation, comparing this to the role of ERK1/2 on Cx43 function and phosphorylation induced by EGF. Selective activation or inactivation of ERK1/2 by using a constitutively active form or a dominant negative form of MEK1 did not regulate Cx43 gap junction coupling. In contrast, we found that BMK1, selectively activated by constitutively active MEK5alpha, induced gap junction uncoupling, and the inhibition of BMK1 activation by transfection of dominant negative BMK1 prevented EGF-induced gap junction uncoupling. Activated BMK1 selectively phosphorylates Cx43 on Ser-255 in vitro and in vivo, but not on S279/S282, which are reported as the consensus phosphorylation sites for MAPK. Furthermore, by co-immunoprecipitation, we found that BMK1 directly associates with Cx43 in vivo. These data indicate that BMK1 is more important than ERK1/2 in EGF-mediated Cx43 gap junction uncoupling by association and Cx43 Ser- 255 phosphorylation. (Keyword) Blotting, Western / Cell Line / Connexin 43 / Enzyme Activation / Enzyme Inhibitors / Epidermal Growth Factor / Flavonoids / Gap Junctions / Genes, Dominant / Humans / Immunoblotting / MAP Kinase Kinase 1 / MAP Kinase Signaling System / Microscopy, Fluorescence / Mitogen-Activated Protein Kinase 1 / Mitogen-Activated Protein Kinase 3 / Mitogen-Activated Protein Kinase 7 / Mitogen-Activated Protein Kinase Kinases / Mitogen-Activated Protein Kinases / Phosphorylation / Precipitin Tests / Protein Structure, Tertiary / Protein-Serine-Threonine Kinases / Serine / Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Transfection (Link to Publication Site) ● Publication site (DOI): 10.1074/jbc.M213283200 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12637502 ● Search Scopus @ Elsevier (PMID): 12637502 ● Search Scopus @ Elsevier (DOI): 10.1074/jbc.M213283200 (DOI: 10.1074/jbc.M213283200, PubMed: 12637502)
107.	Takahiko Iuchi, Masashi Akaike, Takao Mitsui, Yasushi Ohshima, Yasumi Shintani, Hiroyuki Azuma and Toshio Matsumoto : Glucocorticoid Excess Induces Superoxide Production in Vascular Endothelial Cells and Elicits Vascular Endothelial Dysfunction, Circulation Research, Vol.92, No.1, 81-87, 2003. (Summary) Glucocorticoid (GC) excess often elicits serious adverse effects on the vascular system, such as hypertension and atherosclerosis, and effective prophylaxis for these complications is limited. We sought to reveal the mechanism underlying GC-induced vascular complications. Responses in forearm blood flow to reactive hyperemia in 20 GC-treated patients were significantly decreased to 43+/-8.9% (mean+/-SEM) from the values obtained before GC therapy (130+/-14%). An administration of vitamin C almost normalized blood flow responses. In human umbilical vein endothelial cells (HUVECs), production of hydrogen peroxide was increased up to 166.5+/-3.3% of control values by 10(-7) mol/L dexamethasone (DEX) treatment (P<0.01). Concomitant with DEX-induced hydrogen peroxide production, intracellular amounts of peroxynitrite significantly increased and those of nitric oxide (NO) decreased, respectively (P<0.01). Immunoblotting analysis using anti-nitrotyrosine antibody showed that peroxynitrite formation was increased in DEX-treated HUVECs. Using inhibitors against metabolic pathways for generation of reactive oxygen species (ROS), we identified that the major production sources of ROS by DEX treatment were mitochondrial electron transport chain, NAD(P)H oxidase, and xanthine oxidase. These findings suggest that GC excess causes overproduction of ROS and thereby perturbs NO availability in the vascular endothelium, leading to vascular complications in patients with GC excess. (Keyword) Glucocorticoid / reactive oxygen species / nitric oxide / vascular endothelial function (Link to Publication Site) ● Publication site (DOI): 10.1161/01.RES.0000050588.35034.3C (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12522124 ● Search Scopus @ Elsevier (PMID): 12522124 ● Search Scopus @ Elsevier (DOI): 10.1161/01.RES.0000050588.35034.3C (DOI: 10.1161/01.RES.0000050588.35034.3C, PubMed: 12522124)
108.	Masashi Akaike, Hiroyuki Azuma, Ayako Kagawa, Kazuya Matsumoto, Ikuro Hayashi, Katsuya Tamura, Takeshi Nishiuchi, Takahiko Iuchi, Nobuyuki Takamori, Ken-ichi Aihara, Tomonori Yoshida, Yasuhiko Kanagawa and Toshio Matsumoto : Effect of Aspirin Treatment on Serum Concentrations of Lipoprotein(a) in Patients with Atherosclerotic Diseases, Clinical Chemistry, Vol.48, No.9, 1454-1459, 2002. (Summary) Increased serum lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerosis. We previously reported that aspirin reduced Lp(a) production by cultured hepatocytes via the reduction of apolipoprotein(a) [apo(a)] gene transcription. We evaluated both the effect of aspirin treatment (81 mg/day) on serum Lp(a) concentrations and the correlation between the degree of reduction in serum Lp(a) and the type of apo(a) isoform in 70 patients with coronary artery disease or cerebral infarction. Aspirin lowered serum Lp(a) concentrations to approximately 80% of the baseline values in patients with high Lp(a) concentrations (>300 mg/L). The percentage of decrease in serum Lp(a) was larger in patients with high Lp(a) than in patients with low Lp(a) (<300 mg/L), irrespective of apo(a) isoform size. The decreases in serum Lp(a) in high Lp(a) patients with both the high-molecular-weight and the low-molecular-weight isoforms were positively correlated with the baseline Lp(a) concentrations. Because the secretory efficiencies of apo(a) in the same isoform are likely to be similar, the difference in serum Lp(a) concentrations in patients having the same apo(a) isoform depends on the transcriptional activity of the apo(a) gene. These findings suggest that aspirin decreases serum Lp(a) concentrations via a decrease in apo(a) gene transcription more effectively in patients with high transcriptional activity of this gene. (Keyword) Arteriosclerosis / Aspirin / Cerebral Infarction / Coronary Disease / Female / Humans / Hypolipidemic Agents / Lipoprotein(a) / Male / Middle Aged / Protein Isoforms (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12194922 ● Search Scopus @ Elsevier (PMID): 12194922 (PubMed: 12194922)
109.	Takao Mitsui, Yoshifumi Umaki, Masakazu Nagasawa, Masashi Akaike, Kenji Aki, Hiroyuki Azuma, Shuji Ozaki, Masaaki Odomi and Toshio Matsumoto : Mitochondrial damage in patients with long-term corticosteroid therapy: development of oculoskeletal symptoms similar to mitochondrial disease, Acta Neuropathologica, Vol.104, No.3, 260-266, 2002. (Summary) Two patients with long-term corticosteroid administration sporadically developed limb muscle wasting followed by ophthalmoplegia, and the skeletal muscle pathology revealed ragged-red fibers (RRFs) with abnormal mitochondria, in addition to the findings of corticosteroid myopathy. The oculoskeletal symptoms of the present cases resemble those of chronic progressive external ophthalmoplegia, a type of mitochondrial disease. The ocular muscles have more RRFs than limb muscles, and large multiple deletions of mitochondrial DNA was detected in ocular and limb muscles of the two patients by PCR but not by Southern blotting. Immunohistochemistry demonstrated that 8-hydroxy-deoxyguanosine (8-OH-dG) and 4-hydroxy-2-nonenal were intensely stained in skeletal muscles of these patients particularly in RRFs. High-performance liquid chromatography with electrochemical detection analysis revealed an increase in 8-OH-dG from mitochondrial DNA. These findings may suggest that long-term corticosteroid administration potentially induces oxidative stress-mediated mitochondrial damage, resulting in the development of the oculoskeletal symptoms in some patients. (Keyword) Aldehydes / Anti-Inflammatory Agents / Deoxyguanosine / Diagnosis, Differential / Exercise Test / Female / Gene Deletion / Humans / Lactic Acid / Male / Middle Aged / Mitochondria, Muscle / Oculomotor Muscles / Ophthalmoplegia, Chronic Progressive External / Prednisolone / Superoxide Dismutase / Time Factors (Link to Publication Site) ● Publication site (DOI): 10.1007/s00401-002-0553-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12172911 ● Search Scopus @ Elsevier (PMID): 12172911 ● Search Scopus @ Elsevier (DOI): 10.1007/s00401-002-0553-5 (DOI: 10.1007/s00401-002-0553-5, PubMed: 12172911)
110.	Takao Mitsui, Hiroyuki Azuma, Masakazu Nagasawa, Takahiko Iuchi, Masashi Akaike, Masaaki Odomi and Toshio Matsumoto : Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle, Journal of Neurology, Vol.249, No.8, 1004-1009, 2002. (Summary) Corticosteroid myopathy is a major clinical problem in patients undergoing chronic corticosteroid treatment and shows insidious and progressive muscle atrophy in proximal limbs. Although several mechanisms underlying the pathophysiology of muscle injury have been postulated, precise pathogenesis is still not clear. We evaluated the mitochondrial functions in patients receiving corticosteroids compared with those in healthy controls or patients not receiving corticosteroids. The serum levels and total production of lactate were investigated by an aerobic exercise test using a bicycle ergometer. Mitochondrial respiratory activities and oxidative damage in biopsied skeletal muscles were also studied. The results of aerobic exercise tests revealed a significant overproduction of lactate in patients treated with corticosteroids ( p < 0.005), which was positively correlated with total corticosteroid doses administered ( p < 0.0001). In these patients, mitochondrial enzyme activity in complex I was significantly decreased ( p < 0.05) and oxidative damage of biopsied skeletal muscle was remarkable both in mitochondrial and nuclear DNAs ( p < 0.001). The results suggest that chronic corticosteroid administration induces mitochondrial dysfunction and oxidative damage in skeletal muscles, which may be the pathogenesis, at least in part, of corticosteroid-induced myopathy. (Keyword) Corticosteroid myopathy / Mitochondrial respiratory activity / oxidative damage / aerobic exercise / biopsied skeletal muscle (Link to Publication Site) ● Publication site (DOI): 10.1007/s00415-002-0774-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 12195445 ● Search Scopus @ Elsevier (PMID): 12195445 ● Search Scopus @ Elsevier (DOI): 10.1007/s00415-002-0774-5 (DOI: 10.1007/s00415-002-0774-5, PubMed: 12195445)
111.	Yoshifumi Umaki, Takao Mitsui, Itsuro Endo, Masashi Akaike and Toshio Matsumoto : Apoptosis-related changes in skeletal muscle of patients with mitochondreal disease., Acta Neuropathologica, Vol.103, No.2, 163-170, 2002. (Summary) Much interest has recently been shown in apoptosis-mediated roles in the pathophysiology of mitochondrial diseases, because mitochondrial defects are implicated in a wide variety of degenerative diseases. We investigated whether apoptotic events occurred in skeletal muscles of patients with mitochondrial diseases, including chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayer syndrome (KSS), and mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). In a immunohistochemical study, stainings for 8-hydroxy-deoxyguanosine (8-OH-dG), 4-hydroxy-nonenal (4-HNE), Mn-SOD, Bcl-2, cytochrome c, DNase I and Bcl-x L showed a pronounced granular distribution in the cytochrome c oxidase (COX)-negative ragged-red fibers (RRFs). On the other hand, the signals for Bax, p53, Fas and caspase 3 were not obviously increased in RRFs. In situ labeling of DNA breaks demonstrated preferential signals not only in myonuclei but also in subsarcolemmal regions of RRFs, indicating that mitochondrial as well as myonuclear DNA is fragmented in RRFs. An immunoblotting study demonstrated that cytochrome c was increased in the cytosol of diseased muscles and that DNase I was increased in mitochondria, compared to that of normal muscles. No difference was observed between protein bands at 20 kDa corresponding to caspase 3 in diseased and normal muscles. These findings demonstrate that these mitochondrial diseases harbor unique apoptosis-related changes that differ from caspase 3-dependent apoptosis. It is thought that these changes are induced by superoxide overproduction and cytochrome c release resulting from an inherent mitochondrial defect and that the events are associated with DNase I activation. (Keyword) mitochondrial diseases / skeletal muscles (Link to Publication Site) ● Publication site (DOI): 10.1007/s004010100446 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11810183 ● Search Scopus @ Elsevier (PMID): 11810183 ● Search Scopus @ Elsevier (DOI): 10.1007/s004010100446 (DOI: 10.1007/s004010100446, PubMed: 11810183)
112.	Y Kuroda, Takao Mitsui, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism, Journal of Neurology, Neurosurgery, and Psychiatry, Vol.71, No.2, 231-234, 2001. (Summary) Autosomal recessive juvenile parkinsonism (AR-JP) is characterised by homogenous clinical features and selective degeneration of nigral neurons. Recent progress in molecular genetic analyses of AR-JP has led to the identification of a novel ubiquitin-like protein, parkin, whose precise function still remains to be elucidated. Two unrelated Japanese families had levodopa unresponsive parkinsonism complicated with cerebellar and pyramidal tract dysfunction. Genetic analysis of the parkin gene and mRNA in both families disclosed identical mutations with large deletions extending from exons 3 to 4. These results suggest that the parkin protein possesses an important function not only in the substantia nigra but also in extranigral neurons of the CNS and that the phenotype of multiple system dysfunction can also be a complication in patients with AR-JP due to variations in sites of or changes in functions by parkin mutation. (Keyword) AR-JP / parkin / multiple system degeneration / deletion mutation (Link to Publication Site) ● Publication site (DOI): 10.1136/jnnp.71.2.231 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11459900 ● Search Scopus @ Elsevier (PMID): 11459900 ● Search Scopus @ Elsevier (DOI): 10.1136/jnnp.71.2.231 (DOI: 10.1136/jnnp.71.2.231, PubMed: 11459900)
113.	Ken-ichi Aihara, Hiroyuki Azuma, Yasumasa Ikeda, Masashi Akaike, Masahiro Abe, Takashi Sugihara and Toshio Matsumoto : Successful combination therapy--flunarizine,pentoxifylline, and cholestyramine--for spur cell anemia, International Journal of Hematology, Vol.73, No.3, 351-355, 2001. (Summary) Spur cell anemia, a hemolytic anemia observed in patients with alcoholic cirrhosis, is characterized by unusual erythrocyte morphology and an increased ratio of free cholesterol to phospholipid in the erythrocyte membrane. The prognosis of spur cell anemia is usually extremely poor, however, we describe here a patient with spur cell anemia who was successfully treated with combination therapy consisting of flunarizine, pentoxifylline, and cholestyramine. Initial therapy with flunarizine alone for 6 weeks did not significantly decrease the number of spur cells on peripheral blood smears. So pentoxifylline was added to the regimen. The patient recovered from the anemia, showed remarkable improvement with regard to the hyperbilirubinemia, and the changes were accompanied by a significant decrease in the number of spur cells in peripheral blood smears. To correct the hypercholesterolemia, cholestyramine was added to the regimen, which resulted in a reduction in the serum level of free cholesterol and an increase in the molar ratio of free cholesterol to phospholipid in erythrocyte membrane. However, 6 months later a skin eruption developed that was considered an adverse reaction to the drugs, so the flunarizine and pentoxifylline were discontinued. With cholestyramine therapy alone, the remission of spur cell anemia was maintained for more than 11 months. These observations suggest that non-invasive combination therapy with flunarizine, pentoxifylline, and cholestyramine is effective and valuable in the treatment of patients with spur cell anemia. (Keyword) Spur cell anemia / Free cholesterol / Hepatosplenomegaly / Pentoxifylline / Cholestyramine (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11345202 ● Search Scopus @ Elsevier (PMID): 11345202 (PubMed: 11345202)
114.	Yasuhiko Kanagawa, Toshio Shigekiyo, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima, Thrombosis and Haemostasis, Vol.85, No.1, 101-107, 2001. (Summary) We found a 66-year-old Japanese patient with type I congenital heparin cofactor (HC) II deficiency manifesting multiple atherosclerotic lesions. To investigate the molecular pathogenesis of our patient, we performed sequencing analysis and expressed recombinant human wild-type and mutant HC II molecules in COS-1 and CHO-K1 cells. Sequencing analysis following amplification of each of all 5 exons and its flanking region showed a single C to T transition at nucleotide position 12,854 in exon 5, which changed a Pro443 codon (CCG) to Leu codon (CTG). Because this mutation generates a new Bhv I site, the Bbv I digestion pattern of the PCR-amplified exon 5 fragments from each family member was analyzed. In all cases, the patterns were consistent with the activities and antigen levels of plasma HC I1 in those members. Transient transfection, metabolic labeling and pulse-chase experiments followed by immunoprecipitation analysis showed that the recombinant mutant HC II molecules were secreted from COS-1 cells in reduced amounts compared with the wild-type, and that an enhanced intracellular association of the mutant molecules with a chaperone, GRP78/BiP, was observed in CHO-K1 cells. Northern blot analysis indicated that the mutant HC I1 mRNA was transcribed at a similar level as that of wild-type. Immunohistochemical staining of the transfected cells revealed that COS-1 cells expressing the mutant HC II molecules were stained mainly in the perinuclear area. We conclude that the impaired secretion of the mutant HC II molecules, due to intracellular degradation, is the molecular pathogenesis of type I congenital HC II deficiency caused by a Pro443 to Leu mutation at reactive P2 site. (Keyword) heparin cofactor II / thrombosis / thrombin / transfection / chaperone (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 11204559 ● Summary page in Scopus @ Elsevier: 2-s2.0-0035171975 (PubMed: 11204559, Elsevier: Scopus)
115.	Masashi Akaike, 井内貴彦, 加藤みどり, 吉田智則, 橋詰俊二, 高森信行, 藤村光則, 金川泰彦, Hiroyuki Azuma and Toshio Matsumoto : 冠動脈疾患の予防ならびに治療の観点からみた高コレステロール血症治療の現状とその問題点, 診断と治療, Vol.89, No.3, 527-532, 2001. (Keyword) 冠動脈疾患 / 高コレステロール血症 / 一次予防 / 二次予防 / 高脂血症診療ガイドライン
116.	Katsuhito Adachi, Chiyomi Kimura, Miho Saito, Yuriko Ueda, Toshio Inui, Makoto Kunishige, Yoshifumi Umaki, Masashi Akaike and Hisaomi kawai : Sarcoglycan Gene Mutations,Clinical Features and Pathology of Autopsied Heart in Patients with Malignant Limb-Girdle Muscular Dystorphy(Miyoshi), Japanese Journal of National Medical Services, Vol.54, No.9, 419-423, 2000. (Keyword) サルコグリカノパチー / 遺伝子異常 / 悪性肢帯型筋ジストロフィー / 心所見 (Link to Publication Site) ● Publication site (DOI): 10.11261/iryo1946.54.419 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.11261/iryo1946.54.419 (DOI: 10.11261/iryo1946.54.419)
117.	Takao Mitsui, Masakazu Kawajiri, Makoto Kunishige, Takenori Endo, Masashi Akaike, Kenji Aki and Toshio Matsumoto : Functional association between nicotinic acetylcholine receptor and sarcomeric proteins via actin and desmin filaments, Journal of Cellular Biochemistry, Vol.77, No.4, 584-595, 2000. (Keyword) acetylcholine receptor / sarcomeric protein / actin / desmin / ATPase
118.	Ayako Kagawa, Hiroyuki Azuma, Masashi Akaike, Yasuhiko Kanagawa and Toshio Matsumoto : Aspirin Reduces Apolipoprotein(a) (Apo(a)) Production in Human Hepatocytes by Suppression of Apo(a) Gene Transcription, The Journal of Biological Chemistry, Vol.274, No.48, 34111-34115, 1999. (Summary) High serum lipoprotein(a) (Lp(a)) is a risk factor for vascular disorders. Our preliminary observations suggest that, in some patients with coronary heart disease with high serum Lp(a) levels, administration of aspirin reduced Lp(a) levels. Therefore, we aimed to analyze the effects of aspirin on the production of apo(a), the expression of apolipoprotein(a) (apo(a)) mRNA and the transcriptional activity of apo(a) gene promoter. Aspirin (5 mM) reduced the apo(a) levels in culture medium of human hepatocytes and suppressed apo(a) mRNA expression to 73% and 85% of the controls, respectively. Aspirin also reduced the transcriptional activity of apo(a) gene transfected into HepG2 hepatoma cells in a dose-dependent manner, with a maximal effect at 5 mM (44.3 +/- 1.5% of the control). Sodium salicylate (5 mM) also reduced apo(a) gene transcription, whereas indomethacin (10 microM) had no effect. Deletion analysis of apo(a) gene promoter showed that promoter region extending from -30 to +138 is critical for the effect of aspirin. Furthermore, enhanced production, mRNA expression, and gene transcription of apo(a) by interleukin-6 were also inhibited by aspirin. These results demonstrate that aspirin reduces apo(a) production from hepatocytes via reduction of the transcriptional activity of apo(a) gene with suppression of apo(a) mRNA expression. The suppression of apo(a) production by aspirin may at least in part play a role in the anti-atherogenic effect of aspirin in vascular disorders. (Keyword) Apolipoproteins A / Aspirin / Gene Expression Regulation / Humans / Indomethacin / Interleukin-6 / Liver / Luciferases / Promoter Regions, Genetic / RNA, Messenger / Recombinant Fusion Proteins / Sodium Salicylate / Transcription, Genetic / Tumor Cells, Cultured (Link to Publication Site) ● Publication site (DOI): 10.1074/jbc.274.48.34111 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 10567380 ● Summary page in Scopus @ Elsevier: 2-s2.0-0033607536 (DOI: 10.1074/jbc.274.48.34111, PubMed: 10567380, Elsevier: Scopus)
119.	Masashi Akaike, Hiroyuki Azuma, Ayako Kagawa, Yasuhiko Kanegawa, Ken-ichi Aihara, Madoka Matsuyama, Takahiko Iuchi, Nobuyuki Takamori, Tomonori Yoshida, Toshio Matsumoto, 松本和也, Ikuro Hayashi, Katsuya Tamura and Takeshi Nishiuchi : Effect of Aspirin Treatment on Serum Levels of Lipoprotein(a), --- Analysis From the Apolipoprotein(a)Isoforms ---, Shikoku Acta Medica, Vol.55, No.3, 109-114, 1999. (Keyword) Lipoprotein(a) / Apolipoprotein(a) / Aspirin / Apo(a)Isoform / Lp(a) Phenotype (Tokushima University Institutional Repository) ● Metadata: 112143 (Tokushima University Institutional Repository: 112143)
120.	Hisaomi Kawai, Masashi Akaike, Makoto Kunishige, Toshio Inui, Katsuhito Adachi, Chiyomi Kimura, Masakazu Kawajiri, Yoshihiko Nishida, Itsuro Endo, Setsuko Kashiwagi, Hiroshi Nishino, Tsutomu Fujiwara, Shiro Okuno, Carinne Roudaut, Isabelle Richard, Jacques S. Beckmann, Kazuo Miyoshi and Toshio Matsumoto : Clinical, pathological, and genetic features of limb-girdle muscular dystrophy type 2A with new calpain 3 gene mutations in seven patients from three Japanese families, Muscle & Nerve, Vol.21, No.11, 1493-1501, 1998. (Summary) We report on the clinical, pathological, and genetic features of 7 patients with limb-girdle muscular dystrophy type 2A (LGMD2A) from three Japanese families. The mean age of onset was 9.7+/-3.1 years (mean+/-SD), and loss of ambulance occurred at 38.5+/-2.1 years. Muscle atrophy was predominant in the pelvic and shoulder girdles, and proximal limb muscles. Muscle pathology revealed dystrophic changes. In two families, an identical G to C mutation at position 1080 the in calpain 3 gene was identified, and a frameshift mutation (1796insA) was found in the third family. The former mutation results in a W360R substitution in the proteolytic site of calpain 3, and the latter in a deletion of the Ca2+-binding domain. (Keyword) limb-girdle muscular dystrophy type 2A / calpain 3 gene / mutation / protease / clinical feature / pathology (Link to Publication Site) ● Publication site (DOI): 10.1002/(SICI)1097-4598(199811)21:11<1493::AID-MUS19>3.0.CO;2-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9771675 ● Search Scopus @ Elsevier (PMID): 9771675 ● Search Scopus @ Elsevier (DOI): 10.1002/(SICI)1097-4598(199811)21:11<1493::AID-MUS19>3.0.CO;2-1 (DOI: 10.1002/(SICI)1097-4598(199811)21:11<1493::AID-MUS19>3.0.CO;2-1, PubMed: 9771675)
121.	K Fukuhara, Y Urano, Masashi Akaike, K Ahsan and S Arase : Psoriatic arthritis associated with dilated cardiomyopathy and Takayasu's arteritis, The British Journal of Dermatology, Vol.138, No.2, 329-333, 1998. (Summary) A 40-year-old Japanese man with psoriatic arthritis (PA) involving the spine, sacroiliac and peripheral joints presented with dyspnoea and ankle oedema. Blood pressure was 180/110 and 114/80 mmHg in the right and left upper arms, respectively. Examinations showed left ventricular dilatation and diffuse hypokinesis of the left ventricle, with no involvement of the coronary arteries. Aortography detected total occlusion of the left subclavian artery and stenosis of the origin at the right renal artery. Dilated cardiomyopathy and Takayasu's arteritis associated with PA was diagnosed. A few cases of PA have been reported in association with cardiovascular diseases, but the association of these three diseases has not been documented in the literature to date. Dermatologists need to be aware of cardiovascular manifestations in patients with PA, because cardiovascular diseases are not rare in other seronegative spondyloarthropathies. (Keyword) Adult / Aortography / Arthritis, Psoriatic / Cardiomyopathy, Dilated / Echocardiography / Humans / Male / Takayasu Arteritis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9602885 ● Search Scopus @ Elsevier (PMID): 9602885 (PubMed: 9602885)
122.	Ktsuhito Adachi, Hisaomi Kawai, Miho Saito, Takako Naruo, Chiyomi Kimura, Hideki Mine, Toshio Inui, Setsuko Kashiwagi and Masashi Akaike : Plasma levels of brain natriuretic peptide as an index for evaluation of cardiac function in female gene carriers of Duchenne muscular dystrophy, Internal Medicine, Vol.36, No.7, 497-500, 1997. (Keyword) Duchenne muscular dystrophy(DMD) / female gene carrier / brain natriuretic peptide(BNP) / Atrial Natriuretic Peptide(ANP) / cardiac failure
123.	Masashi Akaike, Hisaomi Kawai, Kenji Yokoi, Makoto Kunishige, Hideki Mine, Yoshihiko Nishida and Shiro Saito : Cardiac dysfunction in patients with chronic progressive external ophthalmoplegia, Clinical Cardiology, Vol.20, No.3, 239-243, 1997. (Keyword) chronic progressive external ophthalmoplegia / mitochondrial myopathy / Cardiac dysfunction
124.	峯秀樹, 川井尚臣, Masashi Akaike, 国重誠, 柏木節子, 馬木良文, 仁木伸二, 川井恵子 and 齋藤史郎 : 多腺性自己免疫症候群3型に強皮症を合併したHTLV-1キャリアの1例, ホルモンと臨床, Vol.45, 93-97, 1997.
125.	足立克仁, 川井尚臣, 齋藤美穂, 柏木節子 and Masashi Akaike : Duchenne型筋ジストロフィー女性保因者における不顕性の心障害, 神経内科, Vol.46, 253-258, 1997. (Keyword) Duchenne Muscular Dystrophy / Female Gene Carrier / Brain Natriuretic Peptide / Cardiac Dysfunction
126.	N Matsumoto, Masashi Akaike, Takeshi Nishiuchi, Hisaomi Kawai and Shiro Saito : Different secretion profiles of atrial and brain natriuretic peptides after acute volume loading in patients with ischemic heart disease, Acta Cardiologica, Vol.52, No.3, 261-272, 1997. (Summary) In order to clarify the different secretion profiles of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in response to acute hemodynamic change by volume expansion, we measured plasma ANP and BNP levels after intravenous isotonic saline infusion for 3 min at a rate of 3 ml/kg body weight/min in 15 patients with ischemic heart disease. Plasma ANP and BNP levels before the volume loading were 30.7 +/- 16.7 and 19.4 +/- 24.6 pg/ml, respectively. Five and 10 minutes after infusion, plasma ANP levels rose significantly to 43.5 +/- 20.7 and to 46.0 +/- 22.5 pg/ml, respectively (p < 0.01), and plasma BNP levels rose significantly to 27.3 +/- 30.8 and 24.8 +/- 23.2 pg/ ml, respectively (p < 0.01). The BNP/ANP ratio was not affected by volume loading. The maximum increments of plasma ANP level correlated significantly with those of the mean pulmonary capillary wedge pressure (mPCWP, r = 0.78, p < 0.01) or left ventricular end-diastolic pressure (LVEDP, r = 0.86, p < 0.01). However, there were no significant correlations between the maximum increments of plasma BNP levels and those of mPCWP or LVEDP. Plasma ANP level can be a useful parameter for atrial pressure even if the hemodynamic state change rapidly. However, in an early phase of ventricular overload BNP secretion is not increased sufficiently despite the raised LVEDP, and plasma BNP level may not always reflect ventricular hemodynamics. (Keyword) Atrial Natriuretic Factor / Hemodynamics / Humans / Male / Middle Aged / Myocardial Ischemia / Natriuretic Peptide, Brain / Nerve Tissue Proteins / Sodium Chloride (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 9217917 ● Search Scopus @ Elsevier (PMID): 9217917 (PubMed: 9217917)
127.	Kazue Yamabe, Masashi Akaike, Michihisa Kato, Fumihiko Tada, Hirotsugu Yamada, Tomoko Arase and Arifumi Kohyama : The efficacy of inhaled nitic oxide in a patient with acute massive pulmonary thromboembolism., Journal of the Japanese Society of Intensive Care Medicine, Vol.3, No.4, 283-287, 1996.
128.	Miho Saito, Hisaomi Kawai, Masashi Akaike, Katsuhito Adachi, Yoshihiko Nishida and Shiro Saito : Cardiac Dysfunction with Becker Muscular Dystrophy, American Heart Journal, Vol.132, No.3, 642-647, 1996.
129.	Hideki Mine, Hisaomi Kawai, Kenji Yokoi, Masashi Akaike and Shiro Saito : High frequencies of human T-lymphotropic virus type I (HTLV-I) infection and presence of HTLV-II proviral DNA in blood donors with anti-thyroid antibodies, Journal of Molecular Medicine, Vol.74, No.8, 471-477, 1996. (Summary) To investigate the relationship between human T-lymphotropic virus (HTLV) types I and II and the pathogenesis of autoimmune thyroid diseases, we examined serum anti-thyroid antibodies in 1019 blood donors with or without serum anti-HTLV-I antibody as well as proviral DNA for HTLV-II in leukocyte DNA by the polymerase chain reaction in 395 blood donors with or without anti-thyroid antibodies. The frequency of donors with anti-HTLV-I antibody who also showed anti-thyroid antibodies (7.9%) tended to be higher than that (6.3%) among donors who did not have the anti-HTLV-I antibody. The frequency of anti-thyroid antibodies in 125 young male donors aged 16-39 years with anti-HTLV-I antibody (4.8%) was significantly higher (P < 0.05) than that (0.6%) in 164 control donors without the antibody. In blood donors with anti-thyroid antibody, 25.0% of those with anti-HTLV-I antibody and 14.3% of those without the antibody had HTLV-II proviral DNA. In contrast, in donors without anti-thyroid antibody HTLV-II proviral DNA was detected in 2.3% of those with anti-HTLV-I antibody and in 0.6% of those without the antibody. Thus the detection rates in donors with anti-thyroid antibody were significantly higher (P < 0.001) than those in donors without the antibody, regardless of HTLV-I infection. These results suggest that HTLV-I infection and the presence of HTLV-II proviral DNA may be independently related to the pathogenesis of autoimmune thyroid diseases. (Keyword) Human T-lymphotropic virus type I / Human T-lymphotropic virus type II / Retrovirus / Autoimmune thyroid diseases (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 8872861 ● Summary page in Scopus @ Elsevier: 2-s2.0-0029764409 (PubMed: 8872861, Elsevier: Scopus)
130.	川井尚臣, 横井健治, 峯秀樹, 川尻真和, 西田善彦, 斎藤史郎 and Masashi Akaike : 自己免疫性甲状腺疾患の発病とHTL-2との関係について, Japan Medical Journal, Vol.3768, 37-42, 1996.
131.	Takao Mitsui, Hisaomi Kawai, Masakazu Nagasawa, Makoto Kunishige, Masashi Akaike, Yuzo Kimura and Shiro Saito : Oxidative damage to skeletal muscle DNA from patients with mitochondrial encephalomyopathies, Journal of the Neurological Sciences, Vol.139, No.1, 111-116, 1996.
132.	Hisaomi Kawai, Takao Mitsui, Kenji Yokoi, Masashi Akaike, K Hirose, K Hizawa and S Saito : Evidence of HTLV-I in thyroid tissue in an HTLV-I carrier with Hashimoto's thyroiditis, Journal of molecular medicine, Vol.74, No.5, 275-278, 1996. (Keyword) Human T-lymphotropic virus type l / Hashimoto's thyroiditis / envelope protein / messenger RNA / in situ hybridization
133.	遠藤武徳, Masashi Akaike, 川井尚臣, 松村喜一郎 and 齋藤史郎 : 悪性肢帯型筋ジストロフィーにみられたadhalin遺伝子の異常とadhalin欠損筋ジストロフィーにおける臨床像の特徴, 臨床神経学, Vol.36, No.3, 415-422, 1996. (Keyword) 悪性肢帯型筋ジストロフィー / 常染色体劣性遺伝 / adhalin欠損症 / adhalin遺伝子異常
134.	M. Kunishige, Takao Mitsui, Masashi Akaike, Masayuki Shono, H. Kawai and Shiro Saito : Localization and amount of myoglobin and myoglobin mRNA in ragged-red fiber of patients with mitochondrial encephalomyopathy., Muscle-Nerve., Vol.19, No.2, 79-86, 1996. (Keyword) myoglobin / mitochondria
135.	Makoto Kunishige, Takao Mitsui, Masashi Akaike, Masayuki Shono, Hisaomi Kawai and Shiro Saito : Localization and amount of myoglobin and myoglobin mRNA in ragged-red fiber of patients with mitochondrial encephalomyopathy, Muscle & nerve, Vol.19, No.2, 175-182, 1996. (Keyword) myoglobin / myoglobin mRNA / in situ hybridization / ragged-red fiber / mitochondrial encephalomyopathy
136.	柏木節子, Masashi Akaike, 川井尚臣, 足立克仁 and 斎藤史郎 : Duchenne型筋ジストロフィーにおける心機能の血漿脳性ナトリウム利尿ペプチド濃度による評価, 臨床神経学, Vol.36, No.1, 7-11, 1996. (Keyword) Duchenne型筋ジストロフィー / 脳性ナトリウム利尿ペプチド(BNP) / 血漿BNP濃度 / cardiac failure
137.	Yukiko Kuroda, Takao Mitsui, Makoto Kunishige, M Shono, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : Parkin enhances mitochondrial biogenesis in proliferating cells, Hum Mol Genet, Vol.15, No.6, 883-895, 1996.
138.	山部一恵, Masashi Akaike, 加藤道久, Fumihiko Tada, Hirotsugu Yamada, 荒瀬友子 and 神山有史 : 一酸化窒素吸入療法が有効であった急性広汎型血栓塞栓症の1例, 日本集中治療学会雑誌, Vol.3(4), 283-288, 1996.
139.	市原寿江, 美馬伸章, Masashi Akaike, Hiroyuki Azuma, 重清俊雄 and 斎藤史郎 : 播種性血管内血液凝固症候群を合併した孤立性腸骨動脈瘤の1例, Japanese Journal of Geriatrics, Vol.32, No.12, 822-824, 1995.
140.	Hisaomi Kawai, Masashi Akaike, Takenori Endo, Katsuhito Abachi, Takao Mitsui, Setsuko Kashiwagi, Ysutomu Fujiwara, Shiro Okuno, Sadahito Shin, Kazuo Miyoshi, Kevin P Campbell, Hiroki Yamada, Shimizu Teruo, Kiichiro Matsumura and Shiro Saito : Adhalin Gene Mutations in Patients with Autosomal Recessive Childhood Onset Muscular Dystrophy with Adhalin Deficiency, The Journal of Clinical Investigation, Vol.96, No.3, 1202-1207, 1995. (Summary) Homozygous adhalin gene mutations were found in three patients from two consanguineous families with autosomal recessive childhood onset muscular dystrophy. Muscle biopsies from patients in each family showed complete absence of adhalin. Sequencing of adhalin cDNA prepared from skeletal muscle by reverse transcription PCR demonstrated a cytosine to thymidine substitution at nt 229 in the patient in family 1 and an adenine to guanine substitution at nt 410 and a 15-base insertion between nt 408 and 409 in the two patients in family 2. Sequencing of genomic DNA prepared from peripheral blood leukocytes by PCR confirmed these mutations. The parents in each family were found to be heterozygous for the respective mutations. These adhalin gene mutations are presumed to be responsible for the absence of adhalin in the skeletal muscle. Adhalin deficiency likely causes disruption of the muscle cell membrane, resulting in dystrophic changes in the skeletal muscle similar to dystrophin deficiency in Duchenne muscular dystrophy. (Keyword) Adult / Age of Onset / Amino Acid Sequence / Base Sequence / Biopsy / Child / Consanguinity / Cytoskeletal Proteins / DNA Primers / DNA Transposable Elements / DNA, Complementary / Female / Genes, Recessive / Homozygote / Humans / Immunohistochemistry / Male / Membrane Glycoproteins / Middle Aged / Molecular Sequence Data / Muscle, Skeletal / Muscular Dystrophies / Mutation / Pedigree / Polymerase Chain Reaction / Reference Values / Sarcoglycans (Link to Publication Site) ● Publication site (DOI): 10.1172/JCI118152 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 7657792 ● Search Scopus @ Elsevier (PMID): 7657792 ● Search Scopus @ Elsevier (DOI): 10.1172/JCI118152 (DOI: 10.1172/JCI118152, PubMed: 7657792)
141.	横井健治, Masashi Akaike and 重清俊雄 : Two Elderly Patiencs with Multiple Cerebral Infarctions Who Had Antiphospholipid Antibodies, 内科専門医会誌, Vol.7, No.3, 236-239, 1995. (Keyword) 多発性脳梗塞 / 脳血管障害 / 抗リン脂質抗体 / 抗カルジオリピン抗体 / ループスアンチコアグラント
142.	川井尚臣, 峯秀樹, 横井健治, Takao Mitsui, 土橋孝之, 柏木節子, 斎藤史郎 and Masashi Akaike : HTLV-1 感染に関連した自己免疫性甲状腺疾患の存在, Japan Medical Journal, Vol.3716, 1995.
143.	Hisaomi Kawai, Masashi Akaike, Kenji Yokoi, Yoshihiko Nishida, Makoto Kunishige, Hideki Mine and Shiro Saito : Mitochondrial encephalomyopathy with autosomal dominant inheritance, --- a clinical and genetic entity of mitochondrial diseases ---, Muscle & nerve, Vol.18, No.7, 753-760, 1995. (Keyword) Mitochondrial encephalomyopathy / autosomal dominant inheritance / mitochondrial DNA / Multiple Deletion / Non-D-Loop Region
144.	Kenji Yokoi, Hisaomi Kawai, Masashi Akaike, Hideki Mine and Shiro Saito : Presence of human T-lymphotropic virus type II-related genes in DNA of peripheral leukocytes from patients with autoimmune thyroid diseases, Journal of Medical Virology, Vol.45, No.4, 392-398, 1995. (Keyword) Graves' Diseases / Hashimoto's Thyroiditis / Human T-lymphotropic virus type 1 / Retrovirus
145.	Masashi Akaike, 川井尚臣, 国重誠 and 斎藤史郎 : 無症状の母親に筋ミトコンドリア異常が認められたKearns-Sayre症候群の1例, 臨床神経学, Vol.35, No.2, 190-194, 1995. (Keyword) ミトコンドリア脳筋症 / Kearns-Sayre症候群 / 慢性進行性外眼筋麻痺 / 遺伝性 / ミトコンドリアDNA
146.	Hisaomi Kawai, Kenji Yokoi, Masashi Akaike, Makoto Kunishige, Masahiro Abe, Y Tanouchi, Hideki Mine, Y Mimura and Shiro Saito : Graves' disease in HTLV-I carriers, Journal of molecular medicine, Vol.73, No.2, 85-88, 1995. (Keyword) human T-lymphotropic virus type I / ATL adult T-cell leukemia / HAM HTLV-I associated myelopathy / TSP tropical spastic paraparesis
147.	安藤公, Masashi Akaike, 加藤道久, 荒瀬友子 and 田村雅人 : 低分子ヘパリンによる抗凝固治療法を併用し救命し得た急性抗汎型肺血栓塞栓症の1例, ICUとCCU, Vol.19, No.7, 641-646, 1995.
148.	川井恵子, Masashi Akaike, 井出眞, 新谷保実, 板東浩 and 斎藤史郎 : 慢性甲状腺炎の経過中にインスリン依存性糖尿病を発生した多腺性自己免疫症候群3型の1例, ホルモンと臨床, Vol.43, 217-221, 1995.
149.	Masashi Akaike, 瀬戸山操, 田村隆一, 中尾克之, 西内健, 林郁郎, 松本直也, 横井健治 and 斎藤史郎 : 冠動脈疾患を合併した高脂血症に対するSimvastatinの有用性, 基礎と臨床, Vol.28, No.13, 4289-4295, 1994.
150.	日野明子, 中平晴仁, 小原卓爾, 久保克之, 原田武彦, Masashi Akaike and 中村宗夫 : 心房浸潤による心房細動を初発症状とした悪性リンパ腫の1剖検例, Respiration & Circulation, Vol.42, No.11, 1119-1123, 1994. (Keyword) 悪性リンパ腫 / 心房細動 / 心浸潤
151.	Miho Saito, Hisaomi Kawai, Katsuhito Adachi and Masashi Akaike : Clinical Feature and Mechanism of Cardiac Failure in Patients with Becker Muscular Dystrophy, Clin Neurol, Vol.34, No.2, 134-140, 1994. (Keyword) Becker Muscular Dystrophy / cardiac failure / Dilatation of the Mitral Annulus / Mitral Regurgitation
152.	Masashi Akaike, Takeshi Nishiuchi, Naoya Mtsumoto, Hisaomi Kawai and Shiro Saito : Enhanced Secretion and Impaired Natriuretic Natriuretic Action of Atrial Natriuretic Peptide in Response to Hypertonic saline Infusion in Patients with Essential Hypertension, Journal of Human Hypertension, Vol.8, No.1, 15-18, 1994. (Keyword) Atrial Natriuretic Peptide / Saline Infusion / Essential Hypertension
153.	横井健治, Masashi Akaike, 重清俊雄 and 斎藤史郎 : 抗リン脂質抗体陽性の高齢者大動脈炎症候群の1例, Japanese Journal of Geriatrics, Vol.31, No.9, 716-719, 1994. (Keyword) 大動脈炎症候群 / ループスアンチコアグラント / 抗カルジオリピン抗体 / MRアンギオグラフィー / 閉塞性血管病変
154.	横井健治, 川井尚臣, 峯秀樹, Masashi Akaike, Masahiro Abe, 国重誠, Takao Mitsui and 斎藤史郎 : バセドウ病を発症したHTLV-Iキャリアの2家系3症例, ホルモンと臨床, Vol.42, 94-97, 1994.
155.	日野明子, Masashi Akaike, 横越浩, 西田善彦, 斎藤史郎, 上田博巳, 曽我哲朗, 関貫聖二, 松本圭蔵 and Toshiaki Sano : 中枢性尿崩症を合併したリンパ球性下垂体炎の1例, ホルモンと臨床, Vol.42, No.10, 71(971)-75(975), 1994.
156.	Masashi Akaike, 西内健, 小原聡彦, 岡内泰弘, 川井尚臣 and 斎藤史郎 : 術前診断しえたUnroofed Coronary Sinusの1例, Respiration & Circulation, Vol.41, No.9, 905-909, 1993. (Keyword) 冠静脈洞左房交通症 / 心超音波断層法 / 経食道心エコー法
157.	Masashi Akaike, 横井健治, 和田美智子, 瀬部俊彦, 重清俊雄, 川井尚臣 and 斎藤史郎 : 腹部真性大動脈瘤に汎播種性血管内凝固を合併した2症例と凝固線溶系の活性化, Respiration & Circulation, Vol.41, No.3, 267-270, 1993. (Keyword) 腹部大動脈瘤 / 汎播種性血管内凝固 / 消費性凝固障害
158.	川井尚臣, Masashi Akaike, 横井健治, 玉木康民 and 斎藤史郎 : 常染色体優性の遺伝型を示すミトコンドリアミオパチー, 臨床神経学, Vol.33, No.2, 162, 1993. (Keyword) ミトコンドリアミオパチー / 常染色体優性遺伝 / ミトコンドリア DNA / 欠失 / Non-D-Loop領域
159.	川井尚臣, 横井健治, Masashi Akaike, 土橋孝之, 近藤彰, 仁木伸二, 有井敬治, 玉木康民, 斎藤美穂 and 斎藤史郎 : 橋本病患者の白血球DNAに見出されたHTLV-2プロウイルスDNA, Journal of Clinical and Experimental Medicine, Vol.164, No.2, 151-152, 1993.
160.	日野明子, Masashi Akaike, 岡川和人, 小阪昌明 and 斎藤史郎 : rhG-CSFが著効を示した塩酸チクロピジンによる再生不良貧血の1例, Biotherapy, Vol.6, No.11, 1713-1717, 1992. (Keyword) 塩酸チクロピジン / 無顆粒球症 / 遺伝子組み換え型ヒト顆粒球コロニー形成刺激因子 / リンパ球幼若化試験
161.	Osamu Miki, Tetsuya Kitagawa, Masanori Yoshizumi, Yutaka Masuda, Itsuo Katoh, Yoshiyasu Egawa, Toshihiko Sebe and Masashi Akaike : 播種性血管内凝固症候群(DIC)と腎不全を合併した高齢者腹部大動脈瘤の1手術治験例, Shikoku Acta Medica, Vol.48, No.1-3, 45-50, 1992.
162.	Masashi Akaike, Fuminobu Ishikura, Seiki Nagata, Kohji Kimura and Kunio Miyatake : Direct secretion from left atrium and pulmonary extraction of human atrial natriuretic peptide, American Heart Journal, Vol.123, No.4 Pt1, 984-989, 1992. (Link to Publication Site) ● Publication site (DOI): 10.1016/0002-8703(92)90707-3 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/0002-8703(92)90707-3 (DOI: 10.1016/0002-8703(92)90707-3)
163.	Kenji Yokoi, Masashi Akaike, Takeshi Nishiuchi, Hisaomi Kawai and Shiro Saito : Scar Formation in the Cardiac Conduction System of a Patient, Cardiology, Vol.81, 378-383, 1992. (Keyword) Complete Atrioventricular Block / Takaysu's Arteritis / Autoimmune Disease
164.	Jun Tamai, Seiki Nagata, Fuminobu Ishikura, Masashi Akaike and Kunio Miyatake : Alterations in Atrial Filling Fraction in Patients with Mitral Stenosis After Percutaneous Transvenous Mitral Commissurotomv, The American Journal of Cardiology, Vol.6, 247-251, 1992. (Keyword) Atrial Transport / Sinus Rhythm / Continuous-Wave Doppler
165.	Takayuki Tsuchihashi, Hisaomi Kawai, Masashi Akaike, Hideo Takahashi and Shiro Saito : Determination of Calcitonin Gene-Related Peptid(CGRP) in Plasma and Cerebrospinal spinal Fluid in patients with Various Diseases, Biomedical Research (India), Vol.13, No.Supplement 2, 305-307, 1992.
166.	Seiki Nagata, Fuminobu Ishikura, Takashi Yamabe, Masashi Akaike, Kohji Kimura and Kunio Miyatake : Balloon diameter of the Inoue balloon catheter during percutaneous transvenous mitral commissurotomy: clinical and experimental study, Catheterization and cardiovascular diagnosis, Vol.23, No.1, 14-19, 1991.
167.	Fuminobu Ishikura, Seiki Nagata, Masashi Akaike, Jun Tamai and Kunio Miyatake : Effects of percutaneous transvenous mitral commissurotomy on levels of plasma atrial natriuretic peptide during exercise, The American Journal of Cardiology, Vol.67, No.1, 74-78, 1991.
168.	Jun Tamai, Seiki Nagata, Masashi Akaike, Fuminobu Ishikura, Koji Kimura, Makoto Takamiya, Kunio Miyatake and Yasuharu Nimura : Improvement in mitral flow dynamics during exercise after percutaneous transvenous mitral commissurotomy. Noninvasive evaluation using continuous wave Doppler technique, Circulation, Vol.81, No.1, 46-51, 1990.
169.	Masashi Akaike, 星島康男, 秋山靖人, 吉田恭典 and 松本勲 : 月経時喀血を呈した肺子宮内膜症の1例, Internal Medicine, Vol.61, No.5, 945-947, 1988.
170.	Masashi Akaike, 竹田勝則, 宮崎修一, 井石安比古, 小阪昌明 and 斎藤史郎 : 胃病変を主とした成人T細胞性リンパ腫の1症例, 日本内科学会雑誌, Vol.76, No.1, 144-145, 1987.

Academic Paper (Unrefereed Paper):

1.	Masashi Akaike, Takuji Kawano, Masanori Miyata, Hiroshi Yoshida, Kazuya Kawase, Yuka Kubota and Maiko Kamioka : An annual report 2015 on campus wide Faculty Development programs at The University of Tokushima, Journal of University Education Research, No.13, 94-118, 2016. (Tokushima University Institutional Repository) ● Metadata: 110937 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050865122807334528 (Tokushima University Institutional Repository: 110937, CiNii: 1050865122807334528)
2.	Masashi Akaike, Takuji Kawano, Masanori Miyata, Hiroshi Yoshida, Kazuya Kawase and Maiko Kamioka : An annual report 2014 on campus wide Faculty Development programs at The University of Tokushima, Journal of University Education Research, No.12, 90-111, 2015. (Keyword) 新任教員研修 / カリキュラムマップ / 授業コンサルテーション / 大学教育カンファレンス (Tokushima University Institutional Repository) ● Metadata: 110965 (Tokushima University Institutional Repository: 110965)
3.	Tetsuzo Wakatsuki, K Yamaguchi, T Niki, Kenya Kusunose, K Koshiba, Hirotsugu Yamada, Takeshi Soeki, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : Long-term endothelial dysfunction after coronary artery stenting with drug-eluting stent associated with local inflammatory response., Circulation, Vol.118, S_749, 2008.
4.	K Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, K Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local hypercoagulability and endothelial dysfunction after sirolimus-eluting stent implantation: implication for late stent thrombosis., Circulation, Vol.118, S_651, 2008.
5.	Tetsuzo Wakatsuki, K Yamaguchi, Kenya Kusunose, T Niki, K Koshiba, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-term local inflammatory response after coronary artery stenting with drug-eluting stent., Eur Heart J, Vol.29, 505-732, 2008.
6.	S Nishio, Hirotsugu Yamada, H Motonari, H Okada, Kenya Kusunose, Y Tadatsu, M Sato, H Hiraoka, H Kawano, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Assessment of Left Atrial Ejection Force in Patients with Hypertensive Heart Disease., Journal of the American Society of Echocardiography, Vol.21, 552, 2008.
7.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, M Sato, H Hiraoka, H Kawano, Y Tadatsu, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Importance of Left Atrial Function in Cardiac Response to Increment of Preload in Patients with Old Myocardial Infarction: Assessment by Automated Left Atrial Volume Tracking Method., Journal of the American Society of Echocardiography, Vol.21, 552, 2008.
8.	S Nishio, Hirotsugu Yamada, H Motonari, Kenya Kusunose, Y Tadatsu, M Sato, H Hiraoka, H Kawano, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Beat-To-Beat Variation of Mitral Annular Velocities in Atrial Fibrillation., Journal of the American Society of Echocardiography, Vol.21, 550, 2008.
9.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, Y Tadatsu, M Sato, H Hiraoka, H Kawano, T Niki, K Yamaguchi, K Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : The Mitral L-Wave Predicts the Cardiac Response to Preload Increment in Atrial Fibrillation., Journal of the American Society of Echocardiography, Vol.21, 545, 2008.
10.	S Nishio, Hirotsugu Yamada, H Motonari, Kenya Kusunose, Y Tadatsu, M Sato, H Hiraoka, H Kawano, T Niki, K Yamaguchi, K Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Usefulness of Tei Index in Atrial Fibrillation: Assessment by Dual Doppler Echocardiography., Journal of the American Society of Echocardiography, Vol.21, 543, 2008.
11.	Kenya Kusunose, K Takechi, Hirotsugu Yamada, S Nishio, Y Tadatsu, T Niki, K Yamaguchi, K Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, M Choraku and Y Maeda : Multicenter Trial for the Validation of Automated Function Imaging in Patients with Local Left Ventricular Asynergy (VANILLA Study)., Journal of the American Society of Echocardiography, Vol.21, 538, 2008.
12.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, T Niki, K Yamaguchi, K Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Role of Left Atrial Function for Pseudonormalization of Transmitral Flow Velocity Pattern in Patients with Hypertrophic Cardiomyopathy., Journal of the American Society of Echocardiography, Vol.21, 524, 2008.
13.	Takashi Iwase, Hirotsugu Kurobe, Shusuke Yagi, 原朋子, 長楽雅仁, 藤村光則, Shuji Ozaki, Masashi Akaike, 安部正博, Yutaka Masuda, Hiroyuki Azuma, Toshio Matsumoto and Tetsuya Kitagawa : 末梢単核球細胞を用いた抹消動脈閉塞症に対する新たな血管新生治療の試み, Shikoku Acta Medica, Vol.62, No.3,4, 137-141, 2006. (Tokushima University Institutional Repository) ● Metadata: 49311 (Tokushima University Institutional Repository: 49311)

Academic Letter:

1.	Kenya Kusunose, Hirotsugu Yamada, Rino Suzukawa, Yukina Hirata, Masami Yamao, Takayuki Ise, Shusuke Yagi, Masashi Akaike and Masataka Sata : Effects of Transthoracic Echocardiographic Simulator Training on Performance and Satisfaction in Medical Students., Journal of the American Society of Echocardiography, Vol.29, No.4, 375-377, 2016. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.echo.2015.12.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26743736 ● Summary page in Scopus @ Elsevier: 2-s2.0-84960912424 (DOI: 10.1016/j.echo.2015.12.002, PubMed: 26743736, Elsevier: Scopus)

Review, Commentary:

1.	Masashi Akaike : 多職種連携教育で推進する医療教育学, 日本栄養学教育学会雑誌, Vol.3, No.1, 10-14, 2018. (Tokushima University Institutional Repository) ● Metadata: 119104 (Tokushima University Institutional Repository: 119104)
2.	Masashi Akaike : 医学部における教育評価の特殊性 ―臨床医学の面から―, 医学教育, Vol.47, No.2, 63-68, Apr. 2016. (Tokushima University Institutional Repository) ● Metadata: 119084 (Tokushima University Institutional Repository: 119084)
3.	石井亜由美, 西川幸治, Takayuki Ise, 門田宗之, Shusuke Yagi, Takashi Iwase, Hajime Kinoshita, Miho Sakata, Yasunobu Hayabuchi, Tetsuya Kitagawa, Masashi Akaike, Shinsuke Katoh and Masataka Sata : 単心室症患児の開心術後にフェイススケールを用いて心臓リハビリテーションを試みた1症例, Heart, Vol.48, No.2, 181-186, Feb. 2016. (Keyword) 心臓リハビリテーション / infant / フェイススケール
4.	Masashi Akaike : これからの医学教育∼総合診療への期待∼, 日本プライマリ・ケア連合学会四国支部論文集, Vol.8, 2-5, Jun. 2015.
5.	Masashi Akaike : クリニカル・クラークシップの現状と展望∼求められる指導医像とは∼, 徳島市民病院医学雑誌, Vol.29, 1-4, 2015.
6.	今田久美子, Shusuke Yagi, Koji Yamaguchi, Tetsuzo Wakatsuki, Takayuki Ise, 太田理絵, 門田宗之, 高島啓, 松浦朋美, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Efficacy of percutaneous transluminal renal angioplasty for renovascular hypertension complicated with heart failure, Shikoku Acta Medica, Vol.70, No.3, 4, 87-92, Aug. 2014. (Summary) 【Background】 Percutaneous transluminal renal angioplasty (PTRA) is recommended for patients with heart failure due to renovascular hypertension ; however, the clinical characteristics of the patients and the effects of PTRA on heart failure and cardiorenal function have not been elucidated. 【Methods】 We retrospectively analyzed data for 4 PTRA-treated patients (male/female, 1/3 ; mean age, 70.0±10 years ; mean left ventricular ejection fraction, 51.5±15.2%) with heart failure due to renovascular hypertension and evaluated the effects of PTRA on heart failure and cardiorenal function 6 months after treatment. 【Results】 All patients had pro-arteriosclerotic diseases including diabetes mellitus, essential thrombocythemia, heparin cofactor II deficency, metabolic syndrome, and familial hypercholesterolemia, and 3 patients had ischemic heart disease. No abdominal bruit was heard and mean plasma renin activity was 4.5±3.6 ng/ml/hr, which was not elevated, contrary to expectation. All contralateral kidneys of PTRA were nonfunctioning, suggesting bilateral kidneys were disturbed in all patients. In all patients, PTRA was successfully performed and resolved heart failure. PTRA resulted in decreases in systolic blood pressure from 157±18 to 124±8.6 mmHg, mean serum creatinine from 3.2±2.6 to 2.7±2.2 mg/dl, and mean BNP from 919±998 to 243±291 pg/ml at 6 months after treatment. PTRA did not change left ventricular ejection fraction, a parameter of systolic fraction evaluated by an echocardiogram ; however, PTRA improved E/e', a parameter of left ventricular diastolic fraction, from 16.1±5.2 to 9.7±3.7. None of the patients were hospitalized due to heart failure during the 6-month period after PTRA. 【Conclusions】 Patients with heart failure with cardiovascular risk factors should be screened for renovascular hypertension regardless of abdominal bruit or plasma renin activity. PTRA is effective for resolving heart failure and for improving renal and cardiac diastolic functions in patients with renovascular hypertension complicated with heart failure. (Keyword) heart failure / cardiac disturbance syndrome / percutaneous transluminal renal angioplasty (Tokushima University Institutional Repository) ● Metadata: 109759 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1010000782245831073 (Tokushima University Institutional Repository: 109759, CiNii: 1010000782245831073)
7.	Masashi Akaike : Pentraxin-3, --- A potential novel biomarker detecting vulnerable plaque and predicting prognosis in acute myocardial infarction ---, Circulation Journal, Vol.78, No.1, 65-66, 2014. (Keyword) C-Reactive Protein / Coronary Artery Disease / Female / Humans / Male / Myocardial Infarction / Percutaneous Coronary Intervention / Plaque, Atherosclerotic / Serum Amyloid P-Component (Link to Publication Site) ● Publication site (DOI): 10.1253/circj.CJ-13-1424 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24284958 ● Search Scopus @ Elsevier (PMID): 24284958 ● Search Scopus @ Elsevier (DOI): 10.1253/circj.CJ-13-1424 (DOI: 10.1253/circj.CJ-13-1424, PubMed: 24284958)
8.	足立克仁, Takashi Iwase, Masashi Akaike, 斎藤美穂, 柏木節子, 橋口修二, Masataka Sata, Shoichiro Takao, Masafumi Harada and 川井尚臣 : Late Gadolinium Enhancement of Cardiac Magnetic Resonance and Computed Tomography of Skeletal Muscle at Lower Legs in Female Carriers of Duchenne Muscular Dystrophy, Japanese Journal of National Medical Services, Vol.67, No.2, 63-69, Feb. 2013. (Keyword) Duchenne型筋ジストロフィー / 保因者 / 心臓MRI / ガドリニウム遅延造影 / 心機能障害 / CT (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522262181098698368 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876390340 (CiNii: 1522262181098698368, Elsevier: Scopus)
9.	Shusuke Yagi, Ken-ichi Aihara, Yasumasa Ikeda, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Effects of Statins on Cardiorenal Syndrome., International Journal of Vascular Medicine, Vol.2012, 162545, Jun. 2012. (Summary) Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS. (Link to Publication Site) ● Publication site (DOI): 10.1155/2012/162545 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22792467 ● Search Scopus @ Elsevier (PMID): 22792467 ● Search Scopus @ Elsevier (DOI): 10.1155/2012/162545 (DOI: 10.1155/2012/162545, PubMed: 22792467)
10.	Yasumasa Ikeda, Ken-ichi Aihara, Sumiko Yoshida, Masashi Akaike and Toshio Matsumoto : Effects of androgens on cardiovascular remodeling., The Journal of Endocrinology, Apr. 2012. (Summary) Androgens, the male sex hormones, exert various biological effects on many target organs through the transcriptional effects of the nuclear androgen receptor (AR). ARs are expressed not only in classical target organs, such as the brain, genital organs, bone, and skeletal muscles, but also in the cardiovascular system. Because the female sex hormones estrogens are well known to protect against cardiovascular disease, sex has been considered to have a significant clinical impact on cardiovascular mortality. However, the influence of androgens on the cardiovascular system has not been fully elucidated. To clarify this issue, we analyzed the effects of administration of angiotensin II and doxorubicin, an anticancer agent, in a loading model in male wild-type and AR-deficient mice. In this review, we focus on the actions of androgens as potential targets for the prevention of cardiovascular diseases in males. (Link to Publication Site) ● Publication site (DOI): 10.1530/JOE-12-0126 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22493003 ● Search Scopus @ Elsevier (PMID): 22493003 ● Search Scopus @ Elsevier (DOI): 10.1530/JOE-12-0126 (DOI: 10.1530/JOE-12-0126, PubMed: 22493003)
11.	Masashi Akaike : Education of Physicians in Specialties, The Journal of Japan Society for Clinical Anesthesia, Vol.31, No.7, 916, Nov. 2011. (Keyword) Clinical training / Residency program / Medical specialist / Career development / Medical education (Link to Publication Site) ● Publication site (DOI): 10.2199/jjsca.31.916 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571417125709135232 ● Search Scopus @ Elsevier (DOI): 10.2199/jjsca.31.916 (DOI: 10.2199/jjsca.31.916, CiNii: 1571417125709135232)
12.	Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, Masashi Akaike and Toshio Matsumoto : Transforming Growth Factor-1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome., Cardiology Research and Practice, Vol.2011, 175381, Dec. 2010. (Summary) Transforming growth factor-1 (TGF-1) is a polypeptide member of the transforming growth factor superfamily of cytokines. It is a secreted protein that performs many cellular functions including control of cell growth, cell proliferation, cell differentiation and apoptosis. In the cardiovascular system, TGF-1 plays pivotal roles in the pathogenesis of hypertension, restenosis after percutaneous coronary intervention, atherosclerosis, cardiac hypertrophy and heart failure. In addition, TGF-1 has been shown to be increased in adipose tissue of obese subjects with insulin resistance. Furthermore, TGF-1 is a potent initiator of proliferation of renal mesangial cells leading to chronic kidney disease. Some currently available agents can manipulate TGF-1 expression leading to amelioration of cardiovascular diseases. Thus, an understanding of interactions between chronic kidney disease and metabolic syndrome and the development of cardiovascular diseases is an important issue, and attention should be given to TGF-1 as a crucial factor for regulation and modulation of those pathological conditions. (Link to Publication Site) ● Publication site (DOI): 10.4061/2011/175381 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21234356 ● Search Scopus @ Elsevier (PMID): 21234356 ● Search Scopus @ Elsevier (DOI): 10.4061/2011/175381 (DOI: 10.4061/2011/175381, PubMed: 21234356)
13.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Heparin Cofactor II as a Novel Vascular Protective Factor Against Atherosclerosis., Journal of Atherosclerosis and Thrombosis, Vol.16, No.5, 523-531, Sep. 2009. (Summary) Heparin cofactor II (HCII) specifically inhibits thrombin action at the site of vascular wall injury. We encountered a congenital HCII deficiency patient with advanced multiple atherosclerotic lesions. This patient led us to conduct clinical studies to examine the role of HCII against atherosclerosis. We found that the incidence of in-stent restenosis after percutaneous coronary intervention, severity of carotid atherosclerosis and prevalence of peripheral arterial disease are inversely associated with plasma HCII activity. In order to clarify the vascular protective action of HCII, we generated HCII- deficient mice by gene targeting. In contrast to a previous study, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, accelerated intimal hyperplasia and frequent thrombosis were observed after cuff or wire injury of femoral arteries. The number of protease-activated receptor-1 (PAR-1) -positive cells and the gene expression levels of inflammatory cytokines and chemokines were increased in the thickened vascular walls of HCII(+/-) mice. The accelerated intimal hyperplasia in HCII+/- mice with vascular injury was attenuated by human HCII administration. Furthermore, HCII deficiency exaggerated aortic plaque formation with increased oxidative stress in apolipoprotein E(-/-) mice. These results demonstrate that HCII protects against thrombin-induced vascular remodeling in both humans and mice and suggest that HCII is a predictive biomarker and therapeutic target for atherosclerosis. (Keyword) Animals / atherosclerosis / Female / Heparin Cofactor II / Humans / knockout mice / knockout mice / Recombinant Proteins (Link to Publication Site) ● Publication site (DOI): 10.5551/jat.1552 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19729870 ● Search Scopus @ Elsevier (PMID): 19729870 ● Search Scopus @ Elsevier (DOI): 10.5551/jat.1552 (DOI: 10.5551/jat.1552, PubMed: 19729870)
14.	Masashi Akaike : 徳島大学の医学教育を考えるー臨床医学教育―, Shikoku Acta Medica, Vol.63, No.1,2, 5-10, Apr. 2007. (Tokushima University Institutional Repository) ● Metadata: 84163 (Tokushima University Institutional Repository: 84163)
15.	Masashi Akaike and Toshio Matsumoto : NO bioavailability, CLINICAL CALCIUM, Vol.17, No.6, 864-870, 2007.
16.	Masashi Akaike and Toshio Matsumoto : 血管内皮細胞に対するステロイドの影響と大腿骨頭壊死, 整形外科, Vol.48, 25-29, 2005.
17.	Ken-ichi Aihara, Masashi Akaike, Daisuke Inoue, Hiroyuki Azuma and Toshio Matsumoto : 副甲状腺機能亢進症, ホルモンと臨床, Vol.52, No.5, 93(483)-96(486), May 2004.
18.	Toshio Matsumoto, Masashi Akaike and Daisuke Inoue : 内分泌疾患, Internal Medicine, Vol.86, No.6, 1119-1127, Dec. 2000.
19.	Toshio Matsumoto and Masashi Akaike : 骨と脈管系との関わり, 骨と骨代謝, Vol.12, No.4, 319-323, 1999.
20.	Masashi Akaike and Hisaomi Kawai : Gene Analysis in Patients with Muscular Dystrophy, --- α-Sarcoglycan(Adhalin) Gene Mutations in Patients with Malignant Limb-girdle Muscular Dystrophy ---, The Official Journal of Japanese Society of Laboratory Medicine, Vol.45, No.2, 136-140, Feb. 1997. (Keyword) Malignant Limb-girdle Muscular Dystrophy / Severe Childhood Autosomal Recessive Muscular Dystrophy / α-Sarcoglycan / Adharin / Gene Analysis
21.	川井尚臣 and Masashi Akaike : Adhalin欠損悪性肢帯型筋ジストロフィーにおけるadhalin遺伝子の異常, Annual Review 神経 1996, 261-266, Feb. 1996.
22.	川井尚臣 and Masashi Akaike : 悪性肢帯型筋ジストロフィーにおけるadhalin遺伝子の異常, 神経内科, Vol.44, No.1, 24-30, 1996. (Keyword) Malignant Limb-Girdle Muscular Dystrophy / Adhalin Deficiency / adhalin Gene Mutation
23.	川井尚臣 and Masashi Akaike : 筋疾患, Monthly Book Orthopaedics, Vol.9, No.3, 53-62, 1996. (Keyword) Classification of Muscle Diseases / Polymyositis / Myopathy with Metabolic Abnormality / Hereditary Myopathy / Gene Anomaly
24.	川井尚臣 and Masashi Akaike : 症例研究ミトコンドリア脳筋症, Medical Student, Vol.6, No.7, 47-51, 1993.
25.	H Yokoi, Hisaomi Kawai, Masashi Akaike, Takao Mitsui, Y Tamaki, Setsuko Kashiwagi and Shiro Saito : Involvements of HTLV-1 and HTLV-2 in the Pathogenesis Hashimoto Thyroiditis, 80 years of Hashimoto Disease, 115-120, Dec. 1992.
26.	永田正毅 and Masashi Akaike : ドプラーエコー X,心筋症, Internal Medicine, Vol.64, No.5, 911-916, Nov. 1989.

Proceeding of International Conference:

1.	Takashi Iwata, Masashi Akaike, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Mitsuo Shimada : Usefulness of the rubric evaluation as the qualitative evaluation of the laparoscopic training., SAGES, Seattle, Apr. 2018.
2.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Development of the simulator for laparoscopic eye hand coordination training for teaching oneself training, American Gastrointestinal Endoscopic Surgeons, Apr. 2017.
3.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Daichi Ishikawa and Mitsuo Shimada : Development of the simulator for laparoscopic eye hand coordination training for teaching oneself training., SAGES, Houston, Mar. 2017.
4.	Shusuke Yagi, Takayuki Ise, Masashi Akaike and Masataka Sata : Adaptive Servo-ventilation Supported Exercise Increases Exercise Capacity in Patients With Severe Heart Failure, AHA Scientific Sessions 2016, New Orleans, Nov. 2016.
5.	Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida, Yasumasa Ikeda, Shusuke Yagi and Masahiro Abe : Pleiotropic Effects of Pitavastatin against Vascular Stress in eNOS-deficient Mice, The 10th Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases, Tokyo, Jul. 2016.
6.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Mitsuo Shimada : Trial of the filipped classroom for open suturing and simulated laparoscopic cholecystectomy for medical., Society American Gastrointestinal Endoscopic Surgeons (SAGES 2016), Boston, Mar. 2016.
7.	Takashi Iwata, Masashi Akaike, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu, 江藤祥平 and Mitsuo Shimada : Investigation of training for students who is weak in maneuver of laparoscopic surgery Laborer of the off-the-job training, Surgical Education Week, Seattle, Apr. 2015.
8.	Nhat-Tu Le, Yuichiro Takei, Yuki Izawa-Ishizawa, Kyung-Sun Heo, Hakjoo Lee, Alan V. Smrcka, Benjamin Miller, Kyung Ae Ko, Craig Morrell, Keigi Fujiwara, Masashi Akaike and Jun-ichi Abe : A HMG-CoA Reductase Inhibitor (statin) Directly Activates Endothelial Erk5 And Prevents Endothelial Dysfunction And Acute Cardiac Allograft Rejection, AHA scientific sessions 2013, Nov. 2013.
9.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, Takayuki Ise, Shusuke Yagi, Koji Yamaguchi, Hirotsugu Yamada, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata : Differentiation of left ventricular systolic dysfunction related to cardiac sarcoidosis and other heart diseases using contrast-enhanced cardiovascular magnetic resonance., ESC Congress 2013, Amsterdam, Aug. 2013.
10.	K Nishikawa, Shusuke Yagi, Takayuki Ise, Yuka Ueda, Takashi Iwase, Masashi Akaike, Michio Shimabukuro, Shinsuke Katoh and Masataka Sata : Visceral fat mass is associated with daily physical activity, leg skeletal muscle mass and fiber intake in healthy men., ESC Congress 2013, Amsterdam, Aug. 2013.
11.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Androgen Receptor is Required for Cellular Survival and Angiogenesis in Response to Ischemia via Activation of VEGF Receptor Signaling Pathway Regardless of Sex, American Heart Association Scientific Session 2012, Nov. 2012.
12.	Yasumasa Ikeda, Ken-ichi Aihara, Sumiko Yoshida, Masataka Sata, Masashi Akaike, Toshio Matsumoto and Toshiaki Tamaki : Heparin Cofactor II Promotes Angiogenesis in Response to Ischemic Hindlimb via an AMPK-eNOS-dependent Manner, American Heart Association Scientific Sessions 2012, Nov. 2012.
13.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Eicosapentaenoic acid administration ameliorates cardiac remodeling in humans and protects against Ang II-induced cardiovascular remodeling via attenuation of oxidative stress in mice., American Heart Association Scientific Sessions 2012, ロサンゼルス, Nov. 2012.
14.	Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, M Kadota, T Hara, S Bando, Toshiyuki Niki, J Hotchi, N Tomita, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Acute Hemodynamic Effects of Adaptive Servo-Ventilation in Patients with Chronic Left Heart Failure., AHA Scientific Sessions 2012, ロサンゼルス, Nov. 2012.
15.	A. Takashima, Takayuki Ise, Masashi Akaike, Yuka Ueda, Takashi Iwase, T. Hara, M. Kadota, R. Ohta, K. Ogasawara, Toshiyuki Niki, J. Hotchi, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Cardiac Rehabilitation Reduces Levels of Oxidized LDL., AHA Scientific Sessions 2012, ロサンゼルス, Nov. 2012.
16.	S. Kimura, Yuka Ueda, Takayuki Ise, Takashi Iwase, K. Maeda, K. Nishikawa, K. Ogasawara, Mika Bando, S. Bando, Toshiyuki Niki, J. Hotchi, Koji Yamaguchi, N. Tomita, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Effect of Cardiac Rehabilitation with Supervised Exercise Training on Urinary Albumin Excretion in Patients with Cardiovascular Disease., AHA Scientific Sessions 2012, ロサンゼルス, Nov. 2012.
17.	Masashi Akaike : Current Advances of Medical Education in University of Tokushima, Current advances in medical education, International conference dedicated to the 70th anniversry of Health Sciences University of Mongolia, ウランバートル, Oct. 2012.
18.	Ken-ichi Aihara, Sumiko Yoshida, Yasumasa Ikeda, Masashi Akaike and Toshio Matsumoto : Heparin cofactor II, a serine protease inhibitor, is a novel regulating factor for glucose metabolism and albuminuria, Keystone Symposia: Complications of Diabetes: Mechanisms of Injury and Failure of Repair, Mar. 2012.
19.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, Takayuki Ise, Toshiyuki Niki, Kenya Kusunose, Yuka Ueda, N. Tomita, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Ken-ichi Aihara, Tetsuzo Wakatsuki, Masafumi Harada and Masataka Sata : Detection of Cardiac Involvement in Patients with Sarcoidosis Using Cardiac Magnetic Resonance., AHA Scientific Sessions 2011, Orlando, Nov. 2011.
20.	Yasumasa Ikeda, Ken-ichi Aihara, Sumiko Yoshida, Yoshitaka Kihira, Keisuke Ishizawa, Yuki Izawa-Ishizawa, Shuhei Tomita, Masataka Sata, Masashi Akaike, Shigeki Kato, Toshio Matsumoto and Toshiaki Tamaki : Heparin Cofactor Promotes Angiogenesis via an AMPK-eNOS Signaling Pathway, High Blood Pressure Research Scientific Sessions 2011 Scientific Sessions, Orlando, Sep. 2011.
21.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 林修司, 玉井利奈, 坂東左知子, 久岡白陽花, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : ストレインイメージング法を用いた心房細動例の左室心筋機能評価―左室圧曲線との同時記録による検討―, 第98回日本循環器学会中国・四国合同地方会, Tokushima, May 2011.
22.	S Nishio, Hirotsugu Yamada, R Tamai, K Endo, S Hayashi, Kenya Kusunose, N Tomita, J Miki, S Bando, S Hisaoka, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Relationship Between Carotid Artery Stiffness Parameter β and Brachial Artery Flow-mediated Dilation in coronary Artery Disease., American College of Cardiology 2011, New Orleans, Apr. 2011.
23.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Androgen receptor is essential for cell survival and neovascularization after ischemia., American Heart Association Scientific Sessions 2010, Chicago, Nov. 2010.
24.	Koji Yamaguchi, Tetsuzo Wakatsuki, Toshiyuki Niki, Yoshio Taketani, S. Bando, S. Hisaoka, Kenya Kusunose, Yuka Ueda, H. Takeuchi, Takashi Iwase, N. Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Time-dependent Changes Of Local Coagulative Response Up To Five Years After Sirolimus-eluting Stent Implantation., American Heart Association 2010, Chicago, Nov. 2010.
25.	Tetsuzo Wakatsuki, Koji Yamaguchi, Toshiyuki Niki, Kenya Kusunose, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory and Coagulative Responses after Coronary Artery Stenting with Drug-Eluting Stent., American Heart Association 2010, Chicago, Nov. 2010.
26.	Kenya Kusunose, Hirotsugu Yamada, S. Nishio, N. Tomita, S. Hayashi, S. Bando, S. Hisaoka, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Left Ventricular Dyssynchrony during Lower Leg Positive Pressure Assessed by Real-time 3-dimensional Echocardiography., American Heart Association 2010, Chicago, Nov. 2010.
27.	Takeshi Soeki, Toshiyuki Niki, S. Bando, S. Hisaoka, H. Takeuchi, Kenya Kusunose, Koji Yamaguchi, Y. Hirata, N. Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, K. Kangawa and Masataka Sata : Ghrelin Protects Heart Against Ischemia-Induced Arrhythmias by Preserving Connexin43 Protein., American Heart Association 2010, Chicago, Nov. 2010.
28.	Y. Hirata, T. Motoki, Hirotsugu Kurobe, Masashi Akaike, M. Tabata, S. Takanashi, T. Igarashi, Tetsuya Kitagawa and Masataka Sata : Macrophage Polarization in Epicardial Adipose Tissue is Correlated with Severity of Human Coronary Artery Disease., American Heart Association 2010, Chicago, Nov. 2010.
29.	S. Yoshida, Ken-ichi Aihara, Yasumasa Ikeda, T. Ise, Yuka Ueda, Takashi Iwase, Masashi Akaike, Masataka Sata and T. Matsumoto : Androgen Receptor is Essential for Cell Survival and Neovascularization after Ischemia., American Heart Association 2010, Chicago, Nov. 2010.
30.	Kenya Kusunose, Hirotsugu Yamada, S. Nishio, N. Tomita, S. Hayashi, S. Bando, S. Hisaoka, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Time Difference between Onset of Mitral Inflow and Onset of Early Diastolic Mitral Annulus Velocity Predicts Left Ventricular End-diastolic Pressure: Assessment by Dual Doppler Echocardiography., American Heart Association 2010, Chicago, Nov. 2010.
31.	Takeshi Soeki, Toshiyuki Niki, S. Bando, S. Hisaoka, H. Takeuchi, Kenya Kusunose, Koji Yamaguchi, Y. Hirata, N. Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, K. Kangawa and Masataka Sata : Ghrelin Attenuates Myocardial Ischemia/Reperfusion Injury via the Extracellular Signal-Regulated Kinase 1/2 and Phosphatidylinositol 3-Kinase/Akt Pathway., American Heart Association 2010, Chicago, Nov. 2010.
32.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Androgen receptor participants in ischemia-induced tissue damage and angiogenesis in male mice, 23rd Scientific Meeting of the International Society of Hypertension Vancouver, Vancouver, Sep. 2010.
33.	Takashi Iwase, S. Takao, Masashi Akaike, K. Adachi, Yuka Ueda, M. Harada, H. Nishitani and Masataka Sata : Detection of Myocardial Damage in Female Carriers of Duchenne Muscular Dystrophy Using Cardiac Magnetic Resonance., ESC CONGRESS 2010, Stockholm, Aug. 2010.
34.	Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Kenya Kusunose, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Impact of Statin Theraphy on Local Coagulative Response after sirolimus-eluting Stent Implantation in late chronic Phase., ESC CONGRESS 2010, Stockholm, Aug. 2010.
35.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, K Endo, H Takashima, C Mimura, M Yamanaka, J Miki, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Effect of Preload on Left Ventricular Dyssynchrony in Patients with Dilated Cardiomyopathy: Assessment with Real-Time Three-Dimensional Echocardiography., American Society of Echocardiography 2010 21st Annual Scientific Sessions, San Diego, Jun. 2010.
36.	H Takashima, Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, C Mimura, K Endo, M Yamanaka, J Miki, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Association of Carotid Artery Atherosclerosis with Aortic Valve Sclerosis., American Society of Echocardiography 2010 21st Annual Scientific Sessions, San Diego, Jun. 2010.
37.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, J Miki, N Tomita, H Takashima, C Mimura, M Yamanaka, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Identification of Pseudonormal / Restrictive Transmitral Flow Velocity Pattern Using its Response to Nitroglycerin Spray Oral Administration., American Society of Echocardiography 2010 21st Annual Scientific Sessions, San Diego, Jun. 2010.
38.	Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Sumiko Yoshida, Yasumasa Ikeda, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Plasma heparin cofactor II activity is an independent determinant for cardiac remodeling in subjects with cardiovascular risk factors, 20th International Society for Heart Research(ISHR), Kyoto, May 2010.
39.	Ken-ichi Aihara, Yuka Ueda, Takayuki Ise, Sumiko Yoshida, Yasumasa Ikeda, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Heparin cofactor II is a novel anticardiac remodeling factor against angiotensin II excess, 20th International Society for Heart Research(ISHR), Kyoto, May 2010.
40.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Exacerbation of cell survival and impaired neovascularization after hindlimb ischemia in male androgen receptor null mice, 20th International Society for Heart Research(ISHR), Kyoto, May 2010.
41.	S. Yoshida, K. Aihara, Yuka Ueda, Yasumasa Ikeda, T. Iwase, Masashi Akaike, Masataka Sata and T. Matsumoto : Exacerbation of Cell Survival and Impaired Neovascularization after Hindlimb Ischemia in Male Androgen Receptor Null Mice., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
42.	Y. Hirata, Hirotsugu Kurobe, Masashi Akaike, F. Chikugo, Takaki Hori, Tetsuya Kitagawa and Masataka Sata : CD-8 Positive T-lymphocyte Infiltration in Epicardial Adipose Tissue in Patients with Coronary Artery Disease., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
43.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, K. Ishikawa, S. Yoshida, Yuka Ueda, Shusuke Yagi, Takashi Iwase, T. Matsumoto and Masataka Sata : Glucocorticoid causes vascular endothelial dysfunction through activation of mineralocorticoid receptor., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
44.	Ken-ichi Aihara, T. Ise, Yuka Ueda, S. Yoshida, Yasumasa Ikeda, R. Uemoto, Shusuke Yagi, Takashi Iwase, Y. Hirata, Masashi Akaike, Masataka Sata and T. Matsumoto : Plasma heparin cofactor II activity is an independent determinant for cardiac remodeling in subjects with cardiovascular risk factors., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
45.	Y. Hirata, Masashi Akaike, S. Nagahiro and Masataka Sata : Increased expression of HMGB1 in human and murine atherosclerotic lesions., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
46.	Yuka Ueda, Ken-ichi Aihara, T. Ise, S. Yoshida, Yasumasa Ikeda, R. Uemoto, Shusuke Yagi, Takashi Iwase, Y. Hirata, Masashi Akaike, Masataka Sata and T. Matsumoto : Heparin cofactor II is a novel anticardiac remodeling factoragainst angiotensin II excess., XXth World Congress of the International Society for Heart Research 2010, Kyoto, May 2010.
47.	Ken-ichi Aihara, Yuichi Fujinaka, Mizuho Kinouchi, Sumiko Yoshida, Yuka Ueda, Kurahashi Kiyoe, Itsuro Endo, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Suzuki Reiko, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Albuminuria is an independent aggravating factor for visceral fat obesity regardless of diabetes mellitus: a study using abdominal CT scan imaging, 14th International Congress of Endocrinology, Kyoto, Mar. 2010.
48.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, J Miki, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Identification of Pseudonormal Transmitral Flow Velocity Pattern using its Change by Nitroglycerin Spray Oral Administration., American College of Cardiology 2010, Mar. 2010.
49.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, J Miki, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Doppler Echocardiographic Estimation of Left Ventricular End-diastolic Pressure in Challenging, 第74回日本循環器学会総会・学術集会, Mar. 2010.
50.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, N Tomita, J Miki, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Evaluation of Secondary Pulmonary Hypertension by Tricuspid Annular Velocity Profile Using Pulsed Tissue Doppler Imaging., 第74回日本循環器学会総会・学術集会, Mar. 2010.
51.	N Tomita, Hirotsugu Yamada, Kenya Kusunose, S Nishio, K Endo, H Takashima, C Mimura, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Detection of Patent Foramen Ovale by Contrast Realtime 3-dimensional Transesophageal Echocardiography., 第74回日本循環器学会総会・学術集会, Mar. 2010.
52.	K Endo, Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, J Miki, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Ken Saito and Masataka Sata : N-3 Fatty Acids, IMT and CKD as Risk Factors in Coronary Artery Disease., 第74回日本循環器学会総会・学術集会, Mar. 2010.
53.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, N Tomita, J Miki, K Endo, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Clinical Evaluation of Stiffness Parameter beta of Common Carotid Artery Obtained by Echo-tracking Method in Coronary Heart Disease., 第74回日本循環器学会総会・学術集会, Mar. 2010.
54.	T Niki, Takeshi Soeki, Kunihiko Koshiba, Kenya Kusunose, Koji Yamaguchi, Y Hirata, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Role of Circulating High-Mobility Group Box-1 (HMGB1) in Patients with Coronary Artery Disease., 第74回日本循環器学会総会・学術集会, Mar. 2010.
55.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, K Adachi, Y Sumitomo, Shusuke Yagi, T Niki, Kenya Kusunose, N Tomita, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masafumi Harada, Hiromu Nishitani and Masataka Sata : Utility of Cardiac Magnetic Resonance for Detection of Cardiac Involvement in Female Carriers of Duchenne Muscular Dystrophy., 第74回日本循環器学会総会・学術集会, Mar. 2010.
56.	Tetsuzo Wakatsuki, Koji Yamaguchi, T Niki, Kenya Kusunose, Kunihiko Koshiba, Takashi Iwase, Yoshio Taketani, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory and Coagulative Responses after Coronary Artery Stenting with Drug-Eluting Stent., 第74回日本循環器学会総会・学術集会, Mar. 2010.
57.	Takeshi Soeki, Kunihiko Koshiba, T Niki, Kenya Kusunose, Koji Yamaguchi, Y Hirata, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Kenji Kangawa and Masataka Sata : Ghrelin Protects Heart against Ischemia-Induced Arrhythmias by Preserving Connexin43 Protein., 第74回日本循環器学会総会・学術集会, Mar. 2010.
58.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, J Miki, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Detection of Myocardial Amyloid Involvement Using 2-Dimentional Speckle Tracking Echocardiography: Utilization of Inner and Outer Myocardial Strain and Strain Rate., 第74回日本循環器学会総会・学術集会, Mar. 2010.
59.	Koji Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Time-Dependent Changes of Local Coagulative Response up to Five Years after Sirolimus-Eluting Stent Implantation., 第74回日本循環器学会総会・学術集会, Mar. 2010.
60.	C Mimura, Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, J Miki, H Takashima, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Predictive Value of Subepicardial Fat Thickness in Coronary Artery Sclerosis in Comparison with Intima-media Thickness, 第74回日本循環器学会総会・学術集会, Mar. 2010.
61.	Ken-ichi Aihara, Yuichi Fujinaka, Mizuho Kinouchi, Sumiko Yoshida, Takashi Iwase, Masashi Akaike, Yuka Ueda, Kurahashi Kiyoe, Itsuro Endo, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Hirata Yoichiro, Suzuki Reiko, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Albuminuria is an independent aggravating factor for visceral fat obesity regardless of diabetes mellitus: a study using abdominal CT scan imaging, 14th International Congress of Endocrinology, Kyoto, Japan, Mar. 2010.
62.	Ken-ichi Aihara, Sumiko Yoshida, Yuka Ueda, Uemoto Ryoko, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Rosuvastatin attenuates left ventricular mass even in subjects without cardiac hypertrophy, 14th International Congress of Endocrinology, Kyoto, Japan, Mar. 2010.
63.	Yuka Ueda, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Exacerbation of Angiotensin ll-induced Cardiac Remodeling through Enhancement of NADPH oxidase-TGF- 1 Pathway in Heparin Cofactor ll-Deficient Mice, Scientific Sessions 2009, American Heart Association, Florida, Nov. 2009.
64.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Shusuke Yagi, Yasumasa Ikeda, Takashi Iwase, Kurahashi Kiyoe, Itsuro Endo, Yuichi Fujinaka, Nishio Susumu, Hirotsugu Yamada, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Dehydroepiandrosterone sulfate is an endothelial function-independent protective factor against carotid atherosclerosis., Scientific Sessions 2009, American Heart Association, Florida, Nov. 2009.
65.	Ken-ichi Aihara, Mizuho Kinouchi, Yuichi Fujinaka, Sumiko Yoshida, Yuka Ueda, Kurahashi Kiyoe, Itsuro Endo, Uemoto Ryoko, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Albuminuria is an independent aggravating factor for visceral fat obesity regardless of diabetes mellitus: a study using abdominal CT scan imaging, Scientific Sessions 2009, American Heart Association, Florida, Nov. 2009.
66.	Koji Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Predictors of Local Persistent Hypercoagulability After Sirolimus-eluting Stent Implantation: Implication for Correlates of Late Stent Thrombosis., American Heart Association 2009, Nov. 2009.
67.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, K Endo, H Takashima, C Mimura, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Prognostic Value of Changes in Transmitral Flow Velocity Pattern During Leg Positive Pressure in Mild Heart Failure: A Clinical Application of "Preload Stress Echocardiography", American Heart Association 2009, Nov. 2009.
68.	Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory Response After Coronary Artery Stenting. Bare Metal vs Sirolimus-Eluting vs Paclitaxel-Eluting Stent., American Heart Association 2009, Nov. 2009.
69.	Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory Response After Coronary Artery Stenting with Drug-Eluting Stent., American Heart Association 2009, Nov. 2009.
70.	Kunihiko Koshiba, Takeshi Soeki, T Niki, Kenya Kusunose, Y Hirata, Koji Yamaguchi, Shusuke Yagi, N Tomita, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Kenji Kangawa and Masataka Sata : C-type Natriuretic Peptide Ameliorates the Progression of Experimental Autoimmune Myocarditis., American Heart Association 2009, Nov. 2009.
71.	Tatsuya Okada, Tomiaki Morikawa, Yuu Tamaki, Masato Tagi, Hiroki Moriguchi, Yoshiyasu Terashima, Hiroaki Mikasa, Masashi Akaike and Yoneo Yano : Scenario making support in PBL, E-Learn 2009, Vancouver, Oct. 2009.
72.	Tetsuzo Wakatsuki, Koji Yamaguchi, T Niki, Kenya Kusunose, Kunihiko Koshiba, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-term local inflammatory response after coronary artery stenting -BMS vs SES vs PES-., ESC Congress 2009, Aug. 2009.
73.	Takeshi Soeki, T Niki, Kunihiko Koshiba, Kenya Kusunose, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Plasma concentration of pentraxin 3 is a useful marker for monitoring the anti-plaque effect of telmisartan., ESC Congress 2009, Aug. 2009.
74.	Koji Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Kunihiko Koshiba, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local persistent hypercoagulability after drug-eluting stent implantation: siroliumus-eluting stent vs. paclitaxel-eluting stent., ESC Congress 2009, Aug. 2009.
75.	Y Fukuda, Takeshi Soeki, N Fukuda, S Morishita, K Sakabe, H Shinohara, Y Tamura, Masashi Akaike, Tetsuzo Wakatsuki, Hirotsugu Yamada, Takashi Iwase, Shusuke Yagi, Kunihiko Koshiba, Koji Yamaguchi, Kenya Kusunose, T Niki and Masataka Sata : Pentraxin 3, a Novel Inflammatory Marker, Predicts Left Ventricular Remodeling in Patients with Acute Myocardial Infarction., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
76.	Shusuke Yagi, Masashi Akaike, Takashi Iwase, Kenya Kusunose, T Niki, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, S Yoshida, Y Sumitomo, Ken-ichi Aihara, Toshio Matsumoto and Masataka Sata : Bosentan, an Endothelin Receptor Antagonist, Exerts Protective Actions against Systemic Sclerosis-related Peripheral Circulation Insufficiency., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
77.	Y Hirata, H Iwata, K Nakamura, Y Sakai, N Tomita, T Niki, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Synthetic Prostacycline Agonist, ONO-1301, Ameliorates Left Ventricular Dysfunction and Cardiac Fibrosis in Cardiomyopathic Hamsters., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
78.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Prediction of Cardiac Response to Preload Augmentation by Dual Doppler Echocardiography and Left Arial Volume Auto Tracking System., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
79.	M Yamanaka, Hirotsugu Yamada, Kenya Kusunose, N Tomita, S Nishio, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinji Nagahiro and Masataka Sata : Utilization of Echocardiography in Stroke Care Unit of Tokushima University Hospital., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
80.	Takeshi Soeki, T Niki, Kunihiko Koshiba, Y Hirata, N Tomita, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, H Satoh and Masataka Sata : Plasma Concentration of Pentraxin 3 is a Useful Marker for Monitoring the Anti-plaque Effect of Telmisartan., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
81.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, S Yoshida, Y Sumitomo, Kenya Kusunose, T Niki, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Takashi Iwase, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Pitavastatin Exerts LDL Cholesterol Reduction-independent Protective Action for Cardiac and Renal Function in Patients with Dyslipidemia., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
82.	Shusuke Yagi, Masashi Akaike, Ken-ichi Aihara, S Yoshida, Y Sumitomo, Kenya Kusunose, T Niki, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Takashi Iwase, N Tomita, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Toshio Matsumoto and Masataka Sata : Plasma Aldosterone Concentration is Associated with Cognitive Impairement in Patients with Hypertension., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
83.	Koji Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, Kunihiko Koshiba, N Tomita, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local Persistent Hypercoagulability after Drug-Eluting Stent Implantation: Sirolimus-Eluting Stent vs. Paclitaxel-Eluting Stent., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
84.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, K Adachi, Y Sumitomo, Shusuke Yagi, T Niki, Kenya Kusunose, N Sakamoto, Y Hirata, Koji Yamaguchi, Kunihiko Koshiba, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masafumi Harada, Hiromu Nishitani and Masataka Sata : Early Detection of Myocardial Damage in Female Carriers of Duchenne Muscular Dystrophy - the Utility of Cardiac Magnetic Resonance., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
85.	Hirotsugu Yamada, Kenya Kusunose, N Tomita, S Nishio, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Angiotensin-II Receptor Blocker Prevents the Deterioration of Left Ventricular Geometry and Diastolic Function in Hypertrophic Cardiomyopathy., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
86.	Takeshi Soeki, Kunihiko Koshiba, T Niki, Y Hirata, N Tomita, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Effect of Ghrelin on Autonomic Activity in Healthy Volunteers., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
87.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Elevation of Left Ventricular End-diastolic Pressure Enhances Mismatch between Mitral Inflow and Annular Motion., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
88.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Clinical utility of B-Flowimaging on ultrasound examination of carotid artery., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
89.	M Yamanaka, Kenya Kusunose, Hirotsugu Yamada, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Postsystolic Shortening is Superior to Peak Systolic Strain on the Prediction of Ischemia in Normal Wall Motion Segments., 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
90.	Tetsuzo Wakatsuki, Koji Yamaguchi, T Niki, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-Term Local Inflammatory Response after Coronary Artery Stenting -BMS vs. SES vs. PES-, 73th Annual scientific meeting of the Japanese circulation society, Mar. 2009.
91.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : The Mitral L-wave Predicts Adverse Response to Volume Overloading in Patients with Atrial Fibrillation., 58th American College of Cardiology, Mar. 2009.
92.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, N Tomita, T Niki, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Tricuspid Annular Velocity Profile by Pulsed Tissue Doppler Imaging for the Assessment of Serial Change of Pulmonary Artery Pressure in Secondary Pulmonary Hypertension., 58th American College of Cardiology, Mar. 2009.
93.	Ken-ichi Aihara, Sumiko Yoshida, Takayuki Ise, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Kurahashi Kiyoe, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Increased serum triglyceride but not LDL cholesterol is associated with left ventricular diastolic dysfunction., Scientific Sessions 2008, American Heart Association, New Orleans, Nov. 2008.
94.	Takayuki Ise, Ken-ichi Aihara, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Ishikawa Kazue, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Plasma Heparin Cofactor II Activity Is Inversely Associated with Left Atrial Volume and Left Ventricular Diastolic Dysfunction., Scientific Sessions 2008, American Heart Association, New Orleans, Nov. 2008.
95.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Kurahashi Kiyoe, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Dehydroepiandrosterone sulfate is an antivascular remodeling factor in elderly individuals., Scientific Sessions 2008, American Heart Association, New Orleans, Nov. 2008.
96.	Takashi Iwase, Hirotsugu Kurobe, Masashi Akaike, Shunji Nakano, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Ken-ichi Aihara, Shuji Ozaki, Masahiro Abe, Natsuo Yasui, Toshio Matsumoto, Tetsuya Kitagawa and Masataka Sata : Erythropoietin administration with autologous blood donation - a novel strategy to enhance mobilization of circulating progenitor cells, American Heart Association Sessions 2008, New Orleans, Nov. 2008.
97.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, Ishikawa Kazue, Sumitomo Yuka, Sumiko Yoshida, Takashi Iwase, Toshio Matsumoto and Masataka Sata : Pitavastatin, an HMG-CoA Reductase Inhibitor, Prevents Glucocorticoid-induced Hypertension through Ameliorating Imbalance of Oxidative Stress and Nitric Oxide Production, American Heart Association Sessions 2008, New Orleans, Nov. 2008.
98.	Tetsuzo Wakatsuki, K Yamaguchi, T Niki, Kenya Kusunose, K Koshiba, Hirotsugu Yamada, Takeshi Soeki, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : Long-term endothelial dysfunction after coronary artery stenting with drug-eluting stent associated with local inflammatory response., American Heart Association 2008, New Orleans, Nov. 2008.
99.	K Yamaguchi, Tetsuzo Wakatsuki, T Niki, Kenya Kusunose, K Koshiba, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local hypercoagulability and endothelial dysfunction after sirolimus-eluting stent implantation: implication for late stent thrombosis., American Heart Association 2008, New Orleans, Nov. 2008.
100.	Tetsuzo Wakatsuki, K Yamaguchi, Kenya Kusunose, T Niki, K Koshiba, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Long-term local inflammatory response after coronary artery stenting with drug-eluting stent., ESC Congress 2008, Munich, Aug. 2008.
101.	Masashi Akaike, Ken-ichi Aihara, Shusuke Yagi, Yasumasa Ikeda, Ishikawa Kazue, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Takashi Iwase and Toshio Matsumoto : Pitavastatin, an HMG-CoA Reductase Inhibitor, Prevents Glucocorticoid-induced Hypertension through Increased Nitric Oxide Production as a Pleiotropic Effect on Vascular Endothelial Cells, Hypertension 2008 18th Scientific Meeting of the European Society of Hypertension 22nd Scientific Meeting of the International Society of Hypertension, Berlin, Jun. 2008.
102.	Takashi Iwase, Masashi Akaike, Shunji Nakano, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Ken-ichi Aihara, Natsuo Yasui and Toshio Matsumoto : Single erythropoietin administration with autologous blood donation - a novel strategy to enhance mobilization of endothelial progenitor cells, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
103.	Sumitomo Yuka, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Acceleration of angiotensin II-induced cardiac remodeling through enhancement of oxidative stress in heparin cofactor II knockout mice, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
104.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Dehydroepiandrosterone sulfate regulates carotid blood flow in elderly individuals, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
105.	Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Serum Lipid Disorder is Associated with Left Ventricular Diastolic Dysfunction in Elderly Individuals, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
106.	Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : The active form of vitamin D, 1,25(OH)2D3, prevents vascular remodeling and glucose intolerance in elderly individuals, 22nd Scientific Meeting of the International Society of Hypertension 2008, Berlin, Germany, Berlin, Jun. 2008.
107.	S Nishio, Hirotsugu Yamada, H Motonari, H Okada, Kenya Kusunose, Y Tadatsu, M Sato, H Hiraoka, H Kawano, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Assessment of Left Atrial Ejection Force in Patients with Hypertensive Heart Disease., 18th Annual Scientific Sessions of the American Society of Echocardiography, Toronto, Jun. 2008.
108.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, M Sato, H Hiraoka, H Kawano, Y Tadatsu, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Importance of Left Atrial Function in Cardiac Response to Increment of Preload in Patients with Old Myocardial Infarction: Assessment by Automated Left Atrial Volume Tracking Method., 18th Annual Scientific Sessions of the American Society of Echocardiography, Toronto, Jun. 2008.
109.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, Y Tadatsu, M Sato, H Hiraoka, H Kawano, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Beat-To-Beat Variation of Mitral Annular Velocities in Atrial Fibrillation., 18th Annual Scientific Sessions of the American Society of Echocardiography, Toronto, Jun. 2008.
110.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, Y Tadatsu, M Sato, H Hiraoka, H Kawano, T Niki, K Yamaguchi, K Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : The Mitral L-Wave Predicts the Cardiac Response to Preload Increment in Atrial Fibrillation., 18th Annual Scientific Sessions of the American Society of Echocardiography, Toronto, Jun. 2008.
111.	S Nishio, Hirotsugu Yamada, Kenya Kusunose, Y Tadatsu, M Sato, H Hiraoka, H Kawano, T Niki, K Yamaguchi, K Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Usefulness of Tei Index in Atrial Fibrillation: Assessment by Dual Doppler Echocardiography., 18th Annual Scientific Sessions of the American Society of Echocardiography, Toronto, Jun. 2008.
112.	Kenya Kusunose, K Takechi, S Nishio, Y Tadatsu, T Niki, K Yamaguchi, K Koshiba, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, M Choraku, Y Maeda and Hirotsugu Yamada : Multicenter Trial for the Validation of Automated Function Imaging in Patients with Local Left Ventricular Asynergy (VANILLA Study), 18th Annual Scientific Sessions of the American Society of Echocardiography, Toronto, Jun. 2008.
113.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, T Niki, K Yamaguchi, K Koshiba, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Role of Left Atrial Function for Pseudonormalization of Transmitral Flow Velocity Pattern in Patients with Hypertrophic Cardiomyopathy., 18th Annual Scientific Sessions of the American Society of Echocardiography, Toronto, Jun. 2008.
114.	Kenya Kusunose, Hirotsugu Yamada, S Nishio, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : Effect of Preload Increment on Early Diastolic Transmitral and Mitral Annular Velocities in Patients with Old Myocardial Infarction., The 16th Congress of the international Cardiac Doppler Society, Kobe, Apr. 2008.
115.	Hirotsugu Yamada, Kenya Kusunose, S Nishio, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki and Masashi Akaike : The Mitral L-wave Predicts the Cardiac Response to an Increase of Preload in Atrial Fibrillation., The 16th Congress of the international Cardiac Doppler Society, Kobe, Apr. 2008.
116.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, Shusuke Yagi, Takashi Iwase, Sumitomo Yuka, Masataka Sata, Kato Shigeaki and Toshio Matsumoto : Heparin Cofactor II Deficiency Causes Accelerated Thrombosis and Atherosclerosis in Mice, American Heart Association Scientific Sessions 2006, Chicago, USA, Nov. 2006.
117.	Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Fujimura Mitsunori, Hashizume Shunji, Takashi Iwase, Shusuke Yagi, Kondo Akira, Hiroyuki Azuma and Toshio Matsumoto : Valsartan Enhances Nitric Oxide Bioavailability and Reduces Arterial Stiffness in Patients with Essential Hypertension, The 21st Scientific Meeting of the International Society of Hypertension, 2006, Fukuoka, Japan, Oct. 2006.
118.	Hirotsugu Kurobe, Yuki Izawa, Y Fukuhara, Tamotsu Kanbara, A Kurushima, Ken-ichi Aihara, Masashi Akaike, Masashi Kano, Takashi Kitaichi, Yutaka Masuda, Hiroyuki Azuma, Toshiaki Tamaki, Toshio Matsumoto, Tetsuya Kitagawa, Shuhei Tomita and Masanori Yoshizumi : HIF-ARNT transcriptional system in Tcells has a pivotal role in vascular inflammation and remodeling, XIL International Symposium on Atherosclerosis, Italy, Jun. 2006.
119.	Yutaka Masuda, H Kurobe, Takashi Kitaichi, Masashi Kano, A Kurushima, Tetsuya Kitagawa, T Iwase, Masashi Akaike, M Abe and Toshio Matsumoto : Erythropoietin induced peripheral stem cell transplantation for severe ischemic limbs, The 14th Annual Meeting of the Asian Society for Cardiovascular Surgery, Osaka, Jun. 2006.
120.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, Fujimura Mitsunori, Shusuke Yagi, Hashizume Shunji, Yasumasa Ikeda, Takashi Iwase, Takamori Nobuyuki, Tetsuya Kitagawa and Toshio Matsumoto : Plasma Heparin Cofactor II Activity is a Predictor for Incidence of Peripheral Arterial Disease in Patients with Cardiovascular Risk Factors, XIV International Symposium on Atherosclerosis, 2006 Rome, Italy, Jun. 2006.
121.	Ken-ichi Aihara, Mihara Masatomo, Hiroyuki Azuma, Masashi Akaike, Takaya Matsushita, Yasumasa Ikeda, Shusuke Yagi, Takashi Iwase, Hashizume Shunji, Fujimura Mitsunori and Toshio Matsumoto : Argatroban, a synthetic thrombin antagonist, can reduce insulin resistance though thrombin inactivation in the db/db mouse model of type 2 diabetes mellitus, XIV International Symposium on Atherosclerosis, 2006 Rome, Italy, Jun. 2006.
122.	Hirotsugu Kurobe, Yuki Izawa, Yayoi Fukuhara, Tamotsu Kanbara, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma, Tetsuya Kitagawa, Toshiaki Tamaki, Toshio Matsumoto, Masaki Ueno, Shuhei Tomita and Masanori Yoshizumi : T Cell-specific HIF-1α-deficient Mice, but Not ARNT-deficient Mice, Exhibit Exacerbated Inflammation and Vascular Remodeling in Response to Cuff Injury, American Heart Association 2005 Scientifc Sessions, Dallas, Nov. 2005.
123.	Takamori Nobuyuki, Masashi Akaike, Ken-ichi Aihara, Hirono Akira, Yamaguchi Hiroshi, Hiroyuki Azuma, Tamura Katsuya and Toshio Matsumoto : Plasma Heparin Cofactor II Activities Predict Cardiovascular Risk in Patients with Coronary Heart Disease, American Heart Associations Scientific Sessions 2005, Dallas, USA, Nov. 2005.
124.	Ken-ichi Aihara, Takamori Nobuyuki, Yasuhiko Kanagawa, Masashi Akaike, Fujimura Mitsunori, Yoshida Tomonori, Hashizume Shunji, Kato Midori, Yasumasa Ikeda, Hiroyuki Azuma and Toshio Matsumoto : Heparin cofactor II is inversely related to the severity of carotid atherosclerosis, American Heart Association, Scientific Sessions 2003 Orland Florida USA, Nov. 2003.

Proceeding of Domestic Conference:

1.	Shusuke Yagi, BANDO Ryo, Koji Yamaguchi, Takeshi Soeki, Masashi Akaike, Tetsuzo Wakatsuki and Masataka Sata : 腎血管性高血圧を合併した左室駆出率の保たれた心不全の1例, 第130回日本内科学会四国地方会, Jun. 2024.
2.	Shusuke Yagi, Takeshi Soeki, Masashi Akaike and Masataka Sata : 高血圧患者における塩分摂取量の特徴の検討, 第130回日本内科学会四国地方会, Jun. 2024.
3.	Koichi Tomita, Teruyoshi Hirayama, Hiroki Umeshima, Koichi Tsuneyama, Akiyoshi Nishimura, Hideyuki Nushida, Masashi Akaike, Hiromitsu Takizawa, Mitsuo Shimada, Yasushi Takagi, Ichiro Hashimoto and Takashi Iwata : 徳島大学医学部の系統解剖実習における画像診断技術・病理診断技術・外科的手術手技を取り入れた垂直連携教育の実践, 第129回日本解剖学会全国学術集会, Mar. 2024.
4.	Masashi Akaike : 徳島大学・モンゴル医科大学協定校契約とJICA プログラム, 第59回日本医学放射線学会秋季臨床大会, Sep. 2023.
5.	Kensei Nishida, Koichi Tsuneyama and Masashi Akaike : 医学科1年次における垂直統合型の早期体験実習の試み, 第55回日本医学教育学会大会, Jul. 2023.
6.	Hiro-omi Kanayama, Masashi Akaike, Koichi Tomita, Yoshihiro Tsuruo, Akiyoshi Nishimura, Koichi Sairyo and Keizo Wada : 徳島大学病院クリニカルアナトミー教育・研究センターの現状と展望, 第128回日本解剖学会総会・全国学術集会, Mar. 2023.
7.	Ryo Bando, Tetsuzo Wakatsuki, Koji Yamaguchi, Yutaka Kawabata, Ryota Miyamoto, Zengu Robahto, TOMONORI Takahashi, Yoshihito Saijyo, Rie Ueno, Muneyuki Kadota, Tomoya Hara, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Two-year Outcomes of Drug-coated Balloon-only Strategy for De Novo Lesions in Large Coronary Vessels, 第87回日本循環器学会学術集会, Mar. 2023.
8.	Rie Fujikawa, 高開登茂子, Hiroko Kume, 三木幸代, 原田路可, Chikako Kane, Masashi Akaike, Hiroaki Yanagawa and Minoru Irahara : モンゴル国 A 病院のモンゴル人看護師のリスク感性の分析, 第53回日本看護学会学術集会, Nov. 2022.
9.	Masami Nagamune, Masahiko Azuma, Takashi Iwata and Masashi Akaike : 医療系専門職連携教育におけるオンラインワークショップの試み, 第17回大学教育カンファレンスin徳島, Jan. 2022.
10.	青木理紗, 髙田真里菜, 篠島理, 西川美佳, 大塚拓, Shigeki Fujiwara Joseph Luke, Satoru Eguchi, Masami Nagamune, Masashi Akaike, Kazumi Takaishi and Hiroshi Kitahata : 気管挿管手技における気道管理シミュレータ4種類の比較, 第49回日本歯科麻酔学会総会・学術集会, Oct. 2021.
11.	Kensei Nishida, Mayuko Shimizu, Masahiko Azuma, Koichi Tsuneyama and Masashi Akaike : オンラインPBLチュートリアルの実施から見えてきた課題, 第53回日本医学教育学会大会, Jul. 2021.
12.	Kensei Nishida, Mayuko Shimizu, Koichi Tsuneyama and Masashi Akaike : オンラインPBLチュートリアルの実施報告ならびにその効果と課題, 大学教育カンファレンスin徳島, Jan. 2021.
13.	Shusuke Yagi, Ken-ichi Aihara, Sumiko Yoshida, Yasumasa Ikeda, Masashi Akaike and Masataka Sata : 心血管病における性機能障害と男性ホルモンの心血管保護作用, 日本性機能学会第30回学術集会,シンポジウム, Sep. 2019.
14.	Masahiko Azuma, Masami Nagamune, Takashi Iwata, Yasuhiko Nishioka and Masashi Akaike : 電子聴診器を用いた呼吸音聴診教育についての取り組み, 第51回日本医学教育学会大会, Jul. 2019.
15.	Takashi Iwata, Mitsuo Shimada, Masahiko Azuma, Masami Nagamune and Masashi Akaike : VR+AR実習は学生の腹腔鏡模擬手術実習における局所解剖理解に有用である, 第51回日本医学教育学会大会, Jul. 2019.
16.	Mitsuteru Yoshida, Takashi Iwata, Masashi Akaike, 鈴木恵美, Ryo Yamada, Mika Takashima, Daisuke Matsumoto, Naoya Kawakita, Toru Sawada, Mitsuhiro Tsuboi, Hiroaki Toba, Yukikiyo Kawakami, Hiromitsu Takizawa, Kazuya Kondo, Akira Tangoku and Yoshihiro Tsuruo : 《ワークショップ》外科手術教育の当院における取り組み, 第42回日本呼吸器内視鏡学会学術集会, Jul. 2019.
17.	谷彰浩, Kenya Kusunose, 松本和久, Tomomi Matsuura, Takayuki Ise, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Daiju Fukuda, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 拡張期僧帽弁逆流の治療適応判断に心房心室同時ペーシングが有効であった1例, 第114回日本循環器学会中国・四国合同地方会, Jun. 2019.
18.	Yoshihiko Ueno, Yosuke Seki, Masashi Akaike and Masako Nomaguchi : 教育連動型AO入試の設計と実施ー地方国立大学における研究医の養成・確保をめざしてー, 令和元年度全国大学入学者選抜研究連絡協議会大会(第14回) 招待研究会, May 2019.
19.	Masashi Akaike : 四国での専門医研修について語る, 第113回日本循環器学会四国地方会ダイバーシティシンポジウム, Dec. 2018.
20.	Takashi Iwata, Masami Nagamune, Masahiko Azuma, Mitsuo Shimada and Masashi Akaike : クリニカル・クラークシップでの手技実習の質的評価としてのルーブリック評価の有用性の検討, 第50回日本医学教育学会大会, Aug. 2018.
21.	Hiroaki Mikasa, Masashi Akaike and Akiyoshi Nishimura : 医療系学部におけるアクティブラーニングの実施状況と満足度および自学自修時間との関係, 第50回日本医学教育学会大会, Aug. 2018.
22.	Yamada Yoshiko, Yada Keigo, Hiroyuki Nodera, Koichi Sairyo, Masashi Akaike and Akiyoshi Nishimura : Effectiveness of the medical English course taught by an all-Japanese clinician team, 第21回日本医学英語教育学会, Jul. 2018.
23.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masashi Akaike : 腹腔鏡トレーニングの質的評価としてのルーブリック評価の有用性の検討, 第118回日本外科学会定期学術集会, Apr. 2018.
24.	Shusuke Yagi, Takayuki Ise, Yutaka Kawabata, Hiroyuki Ito, Kenya Kusunose, Koji Yamaguchi, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 経カテーテル大動脈弁植込み術を施した超高齢大動脈弁狭窄症の1例, 日本老年医学会四国地方会, Feb. 2018.
25.	Takafumi Todoroki, Shusuke Yagi, Kenya Kusunose, Takayuki Ise, Yoshihito Saijoh, Seno Hiromitsu, Akira Hirono, Tomomi Matsuura, Daiju Fukuda, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 膠原病患者での肺動脈楔入圧と左室拡張期末期圧の関係, 第65回日本心臓病学会学術集会, Sep. 2017.
26.	Masashi Akaike : 多職種連携教育で推進する医療教育学, 第6回日本栄養学教育学会学術総会, Sep. 2017.
27.	Masahiko Azuma, Masami Nagamune, Takashi Iwata, Kazuyoshi Kawazoe, Keisuke Ishizawa, Yutaka Taketani, Yasuhiko Nishioka and Masashi Akaike : 徳島大学における担当患者を用いた多職種連携教育の取り組み, 第49回日本医学教育学会大会, Aug. 2017.
28.	Hiroaki Mikasa, Masashi Akaike and Akiyoshi Nishimura : 学生の視点に基づいた授業改善の実践とその成果, 第49回日本医学教育学会大会, Aug. 2017.
29.	Takashi Iwata, Mitsuo Shimada, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa, Masami Nagamune and Masashi Akaike : 腹腔鏡下ペグタッチトレーニングの自学実習を目指したシミュレータの開発, 第49回日本医学教育学会大会, Aug. 2017.
30.	Mitsuteru Yoshida, Hiromitsu Takizawa, Toru Sawada, Naoya Kawakita, Mitsuhiro Tsuboi, Koichiro Kajiura, Hiroaki Toba, Yukikiyo Kawakami, Kazuya Kondo, Akira Tangoku, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama, Kousaku Higashino and Yoshihiro Tsuruo : 鏡視下手術時代の教育の開発未固定遺体を用いた胸腔鏡手術トレーニングの経験, 第42回日本外科系連合学会学術集会, Jun. 2017.
31.	Mitsuteru Yoshida, Hiromitsu Takizawa, Takahiro Yoshida, Mitsuhiro Tsuboi, Naoya Kawakita, Toru Sawada, Koichiro Kajiura, Hiroaki Toba, Yukikiyo Kawakami, Kazuya Kondo, Akira Tangoku, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama, 東野耕作 and Yoshihiro Tsuruo : 《考える外科学》未固定遺体とのシミュレーションを用いた新たな実践型内視鏡下低侵襲手術トレーニングプログラムの構築, 第117回日本外科学会定期学術集会, Apr. 2017.
32.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Daichi Ishikawa and Masashi Akaike : 腹腔鏡下eye hand coordinationトレーニングの自学実習を目指したシミュレータの開発, 第117回日本外科学会定期学術集会, Apr. 2017.
33.	轟貴史, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takayuki Ise, Tomomi Matsuura, Takeshi Tobiume, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Serum Level of Lipoprotein (a) is a Risk Factor for Aortic Valve Sclerosis in Women, 第81回日本循環器学会学術集会, Mar. 2017.
34.	山本清成, 轟貴史, 大櫛祐一郎, 上野理恵, Takayuki Ise, 瀬野弘光, 西條良仁, 高木恵理, 原知也, 川端豊, 斎藤友子, 伊藤浩敬, Tomomi Matsuura, Takeshi Tobiume, Kenya Kusunose, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, 門田友里, Masato Nishimura and Minoru Irahara : PET/CTにて診断できた心サルコイドーシスの1例, 第254回徳島医学会学術集会, Feb. 2017.
35.	Shusuke Yagi, Takayuki Ise, 西川幸治, 石井亜由美, Kenya Kusunose, Koji Yamaguchi, Tomomi Matsuura, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心不全患者に対するAdaptive servo-ventilation装着下6分間歩行における運動耐容能改善効果, 第64回日本心臓病学会学術集会, Sep. 2016.
36.	Takashi Iwata, Masashi Akaike, Masahiko Azuma and Masami Nagamune : 医療系学部中・高学年に対する他職種連携PBLチュートリアル授業の試み, 第48回日本医学教育学会大会, Jul. 2016.
37.	Masashi Akaike, Hiroaki Mikasa and Akiyoshi Nishimura : 診療参加型臨床実習における学生の満足度と学修到達度の規定因子, 第48回日本医学教育学会大会, Jul. 2016.
38.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Chie Takasu and Masashi Akaike : 若手外科医育成のための卒然教育からの工夫∼移植シンポの早期体験と反転授業を応用した実習の試み∼., 第71回日本消化器外科学会総会, Jul. 2016.
39.	松浦一義, Hirotsugu Yamada, Kenya Kusunose, 鈴川理乃, 平田有紀奈, 山尾雅美, 西尾進, Masashi Akaike and Masataka Sata : 医学生の心エコー実習におけるシミュレーター教育の効果, 日本超音波医学会第89回学術集会, May 2016.
40.	Shusuke Yagi, 西條良仁, 高川由利子, Masashi Akaike, Masataka Sata, Takeshi Kondo, Sumiko Yoshida, Itsuro Endo and Ken-ichi Aihara : 左副腎に腫瘤を認めた両側性特発性アルドステロン症の1例, 日本内科学会第114回四国地方会, May 2016.
41.	Masashi Akaike : Current Status and Issues of Clinical Clerkship in Undergraduate Medical Education in Japan - Analysis of Students Satisfaction -, 第80回日本循環器学会学術集会会長特別企画 10「日米の医学教育を考える」, Mar. 2016.
42.	Shusuke Yagi, Ken-ichi Aihara, Daiju Fukuda, A Takashima, Mika Bando, T Hara, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : Reduced Ratio of Eicosapentaenoic Acid and Docosahexaenoic Acid to Arachidonic Acid is Associated with Early Onset of Acute Coronary Syndrome., 第80回日本循環器学会学術集会, Mar. 2016.
43.	Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, T Hara, Takayuki Ise, Daiju Fukuda, Michio Shimabukuro and Masataka Sata : Modulation of Tissue Thrombin Action is a Novel Therapeutic Approach for Prevention of Polyvascular Disease., 第80回日本循環器学会学術集会, Mar. 2016.
44.	近藤大祐, Shusuke Yagi, Takayuki Ise, Koji Yamaguchi, Tetsuzo Wakatsuki, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Daiju Fukuda, Masashi Akaike, Michio Shimabukuro and Masataka Sata : 急性冠症候群発症時のイコサペント酸とドコサヘキサエン酸の血中濃度低下は慢性期冠動脈ステント内再狭窄の予測因子である, 第45回日本心脈管作動物質学会, Feb. 2016.
45.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 臨床実習での技能トレーニングにおける反転授業の効果, 大学教育カンファレンスin徳島, Jan. 2016.
46.	Hiroaki Mikasa, Masashi Akaike and Akiyoshi Nishimura : 共通教育課程における留年のリスクファクターに関する研究, 大学教育カンファレンスin徳島, Jan. 2016.
47.	Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida and Toshio Matsumoto : グルココルコイド過剰誘導酸化ストレスの臨床的評価とeNOSの有無におけるピタバスタチンの虚血臓器保護効果機構の差異, 平成27年度第1回班会議, Dec. 2015.
48.	白川光雄, 本田壮一, 松田啓次, 折野真哉, Hiroyashu Bando and Masashi Akaike : 徳島県海部郡医療方言用語集作成の試み, 第15回日本プライマリ・ケア連合学会四国支部学術集会, Nov. 2015.
49.	Masashi Akaike : 医療教育の充実と看護教育への期待, 日本看護学教育学会第25回学術集会教育講演Ⅱ, Aug. 2015.
50.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 鏡視下手技が苦手な学生に対するoff-the-jobトレーニングの工夫, 第251回徳島医学会学術集会, Aug. 2015.
51.	Hiroaki Mikasa, Masashi Akaike and Akiyoshi Nishimura : 講義の反転授業化により学生の自学自習は促進されるか, 第47回日本医学教育学会大会, Jul. 2015.
52.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : クリニカルクラークシップ学生対象の反転授業応用縫合実習の試み, 第47回日本医学教育学会大会, Jul. 2015.
53.	Akira Nishi, Misaki Murayama and Masashi Akaike : ぬいぐるみ病院活動が参加学生に及ぼす教育的効果に関する検討, 第47回日本医学教育学会大会, Jul. 2015.
54.	山田佳子, Bukasa Kalubi, Masashi Akaike and Akiyoshi Nishimura : Improving doctor-patient communication in extracurricular activities, 第18回日本医学英語教育学会, Jul. 2015.
55.	Shusuke Yagi, Takayuki Ise, 西川幸治, 石井亜由美, 高川由利子, Takashi Iwase, Masashi Akaike, Shinsuke Katoh and Masataka Sata : 重症心不全患者におけるAdaptive servo-ventilation装着による運動耐容能改善効果, 第21回日本心臓リハビリテーション学会, Jul. 2015.
56.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Chie Takasu, 江藤祥平 and Masashi Akaike : 内視鏡手術時代における卒前教育からのoff-the-jobと反転授業を応用した実習の試み, 第70回日本消化器外科学会総会, Jul. 2015.
57.	Masashi Akaike : 確かな学力による，確かな実力―能動的学習について―, 第63回中国・四国地区大学教育研究会, Jun. 2015.
58.	Yasumasa Ikeda, Ken-ichi Aihara, Sumiko Yoshida, Masashi Akaike, Toshiaki Tamaki and Toshio Matsumoto : 心血管疾患における男性ホルモンの意義, 第15回日本抗加齢医学会総会シンポジウム「知って得するテストステロンアップデート」, May 2015.
59.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Toshihiro Nakao, Masaaki Nishi, Takuya Tokunaga, Chie Takasu and Masashi Akaike : 鏡視下手技が苦手な学生をどうトレーニングするか?―off-the-job トレーニングの工夫―, 第115回日本外科学会定期学術集会, Apr. 2015.
60.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 反転授業を応用したクリニカルクラークシップ学生対象の縫合実習の試み, 第250回徳島医学会学術集会, Feb. 2015.
61.	本田壮一, Kenji Tani, 白川光雄, 橋本崇代, 小原聡彦, Masashi Akaike and Katsuhiko Yoshimoto : 医学生実習を受け入れて(第2報), 第250回徳島医学会学術集会, Feb. 2015.
62.	Hiroaki Mikasa, Masashi Akaike and Akiyoshi Nishimura : 授業のアクティブラーニング化は学生の自学自習を促進するかー反転授業の場合―, 大学教育カンファレンスin徳島大学, Dec. 2014.
63.	Masami Nagamune, Takashi Iwata, 辻暁子, 石田加寿子, 東瞳 and Masashi Akaike : 医療系学科1年生合同ワークショップの効果的実践∼8年間の振り返りより, 大学教育カンファレンスin徳島大学, Dec. 2014.
64.	今田久美子, Takayuki Ise, Shusuke Yagi, 高木恵理, 松本和久, 高川由利子, 原知也, 高島啓, 齋藤友子, Mika Bando, 山﨑宙, 坂東左知子, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 慢性血栓塞栓性肺高血圧症にリオシグアトを使用した1症例, 第105回日本循環器学会四国地方会, Dec. 2014.
65.	石井亜由美, 西川幸治, Takayuki Ise, 高川由利子, Shusuke Yagi, Takashi Iwase, Hajime Kinoshita, Miho Sakata, Yasunobu Hayabuchi, Masashi Akaike, Shinsuke Katoh, Tetsuya Kitagawa and Masataka Sata : 単心室症患児の開心術後に心臓リハビリテーションを有効に施行し得た一例, 第105回日本循環器学会四国地方会, Dec. 2014.
66.	Shusuke Yagi, 鳥居祐太, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : 突然の片側性下肢腫脹を呈した変形性関節症の2例, 第105回日本循環器学会四国地方会, Dec. 2014.
67.	稲垣太造, Shusuke Yagi, Takayuki Ise, Koji Yamaguchi, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike and Masataka Sata : 治療抵抗性本態性高血圧に対する利尿剤の効果-インダパミドが効果的であった2例の検討-, 第105回日本循環器学会四国地方会, Dec. 2014.
68.	Masashi Akaike : これからの医学教育∼総合診療への期待∼, 第14回日本PC連合学会四国ブロック支部/第21回四国地域医学研究会学術集会・合同集会ミニレクチャー, Nov. 2014.
69.	Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Takeshi Soeki and Masataka Sata : High Serum Parathyroid Hormone Is Associated with Incidence of Hypertension, 第37回日本高血圧学会総会, Oct. 2014.
70.	Takashi Iwata, Mitsuo Shimada, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Takuya Tokunaga, Chie Takasu, 江藤祥平, Toshihiro Nakao and Masashi Akaike : 内視鏡外科手術におけるOff-the-jobトレーニングを科学する, 第27回日本内視鏡外科学会総会, Oct. 2014. (Keyword) 国内学会
71.	Yosuke Sakai, Bukasa Kalubi, Masashi Akaike and A. Nishimura : Enhancing English communication skills through a students-run English-only extracurricular activity, Journal of Medical English Education, Vol.13, No.2, 38, Jul. 2014.
72.	Bukasa Kalubi, Omar Maningo Rodis, Masashi Akaike and Kiyoshi Fukui : Communication Know-how course: A practical approach to improving professional communication skills in graduate and post-graduate education, 17th JASMEE Academic Meeting, Jul. 2014.
73.	西川幸治, 石井亜由美, 後藤強, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Shinsuke Katoh and Masataka Sata : 運動習慣の有無が運動耐用能および動脈機能の関係に及ぼす影響について, 第20回日本心臓リハビリテーション学会学術集会, Jul. 2014.
74.	石井亜由美, Shusuke Yagi, 西川幸治, 後藤強, Takayuki Ise, Takashi Iwase, Masashi Akaike, Shinsuke Katoh and Masataka Sata : 心臓リハビリテーション実施期間中の体重増加が運動耐容能におよぼす影響, 第20回日本心臓リハビリテーション学会学術集会, Jul. 2014.
75.	Masami Nagamune, Takashi Iwata, 福富美紀 and Masashi Akaike : 医学生に必要な医療コミュニケーション能力―臨床実習前教育とクリニカルクラークシップとのギャップー, 第46回日本医学教育学会大会, Jul. 2014.
76.	今田久美子, Takayuki Ise, 原知也, Shusuke Yagi, Takashi Iwase, 西條良仁, 小笠原梢, 高島啓, Mika Bando, 坂東左知子, Tomomi Matsuura, Junko Hotsuchi, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心不全を合併した頻脈性心房細動にランジオロールを有効に使用することができた2症例, 第104回日本循環器学会中国・四国合同地方会, Jul. 2014.
77.	Ken-ichi Aihara, Sumiko Yoshida, Yasumasa Ikeda, 上元良子, 石川カズ江, Masashi Akaike and Toshio Matsumoto : 動脈硬化および虚血に対するeNOS非依存的なピタバスタチンの臓器保護効果の検討, 第46回日本動脈硬化学会総会・学術集会, Jul. 2014.
78.	本田壮一, 小原聡彦, Kenji Tani, 白川光雄, Masashi Akaike and Katsuhiko Yoshimoto : 医学生実習を受け入れて-5年間の経験よりー, 第110回日本内科学会四国地区支部主催四国地方会徳島, Jun. 2014.
79.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Masaaki Nishi, Motoya Chikakiyo, Chie Takasu, Hideya Kashihara, 松本規子 and Masashi Akaike : 大学と関連病院が連携した若手医師の研修プログラム構築―地方からの提言―, 第114回日本外科学会定期学術集会, Apr. 2014. (Keyword) 国内学会
80.	Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, A Takashima, Mika Bando, S Bando, T Matsuura, Junko Hotsuchi, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Impact of cardiac rehabilitation on oxidized stress in patients with heart failure., 第78回日本循環器学会学術集会, Mar. 2014.
81.	Yuki Izawa-Ishizawa, Le Nhat-Tu, 竹井雄一郎, Heo Kyung-Sun, Lee Hakjoo, Smrcka Alan, Miller Benjamin, Ko Kyung-Ae, Ture Sara, Morrell Craig, 藤原敬己, Masashi Akaike, Toshiaki Tamaki and 阿部純一 : Anti-inflammatory effects of statins and anti-malarial agents via endothelial ERK5 activation, 第87回日本薬理学会年会, Mar. 2014.
82.	Masami Nagamune, Takashi Iwata, 福富美紀 and Masashi Akaike : 臨床実習における医学生のコミュニケーションの現状, 第248回徳島医学会学術集会, Feb. 2014.
83.	宮本登志子, 明石晃代, Hiroaki Yanagawa, Masashi Akaike, 他, 木田菊枝 and 近藤佐地子 : CRCの人材育成の試み-院内キャリア形成支援センター・看護部との連携モデル-, 第248回徳島医学会学術集会, Feb. 2014.
84.	今田久美子, Shusuke Yagi, Koji Yamaguchi, Tetsuzo Wakatsuki, Takayuki Ise, 太田理絵, 門田宗之, 高島啓, 松浦朋美, Takeshi Tobiume, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : 心不全を合併した腎血管性高血圧に対する経皮的腎動脈形成術の有効性, 第248回徳島医学会学術集会, Feb. 2014.
85.	Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Sachiko Matsumoto, Daiju Fukuda, 松浦朋美, Takayuki Ise, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Toshio Matsumoto and Masataka Sata : DPP-4阻害薬の血糖降下作用に対する有効性予測因子, 第248回徳島医学会学術集会, Feb. 2014.
86.	Takashi Iwata, Masashi Akaike, Masami Nagamune, 福富美紀 and Mitsuo Shimada : 海外交流体験実習を利用したスキルスラボでのグローバルスキルトレーニング, 第248回徳島医学会学術集会(平成25年度冬期), Feb. 2014.
87.	Masashi Akaike : 学生教育環境における病院情報システム機能と運用, 大学病院情報マネジメント部門連絡会議, Feb. 2014.
88.	Takashi Iwata, Masashi Akaike, Masami Nagamune and Mitsuo Shimada : 反転授業を応用したクリニカルクラークシップ学生対象の縫合実習の試み, 第250回徳島医学会学術集会, Feb. 2014. (Keyword) 国内学会
89.	Masami Nagamune, Takashi Iwata, 福富美紀 and Masashi Akaike : 医療系学生は医療コミュニケーションをどこで学んでいるか, 大学教育カンファレンスin徳島, Dec. 2013.
90.	Takashi Iwata, 福富美紀, Masami Nagamune and Masashi Akaike : スキルス・ラボにおける海外交流トレーニング, 大学教育カンファレンスin徳島, Dec. 2013.
91.	發知淳子, Hirotsugu Yamada, 原知也, 太田理絵, 高島啓, Mika Bando, 小笠原梢, 坂東左知子, 松浦朋美, Takayuki Ise, 木村恵理子, Takeshi Tobiume, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 下肢陽圧負荷の効果があった薬剤抵抗性起立性低血圧の2症例, 第103回日本循環器学会四国地方会, Dec. 2013.
92.	石井亜由美, 西川幸治, Takayuki Ise, Shusuke Yagi, Takashi Iwase, 門田宗之, 西條良仁, 高島啓, 松浦朋美, 發知淳子, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, 中山泰介, Masashi Akaike, Shinsuke Katoh, Tetsuya Kitagawa and Masataka Sata : 人工呼吸管理中の心不全症例に心臓リハビリテーションが有効に施行しえた症例, 第103回日本循環器学会四国地方会, Dec. 2013.
93.	Takayuki Ise, Shusuke Yagi, Takashi Iwase, 西條良仁, 高木恵理, 太田理絵, 門田宗之, 原知也, 小笠原梢, 高島啓, Mika Bando, 坂東左知子, 松浦朋美, 發知淳子, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 当院でのAdaptive-Servo Ventilationが有効であった拡張障害心不全の症例検討, 第103回日本循環器学会四国地方会, Dec. 2013.
94.	宮本登志子, 明石晃代, 田島壮一郎, 天羽亜美, 大和志保, 吉丸倫子, 小杉千里, Hiroaki Yanagawa, Masashi Akaike, 木田菊枝 and 近藤佐地子 : CRCの人材育成の試み-院内キャリア形成支援センター・看護部との連携モデル-, 第34回日本臨床薬理学会年会, Dec. 2013.
95.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Motoya Chikakiyo, 柏原秀也, 松本規子, Takuya Tokunaga and Masashi Akaike : 腹腔鏡下手術トレーニングボックスを用いた鏡視下手術手技理解促進のための基礎的検討, 第26回日本内視鏡外科学会総会, Nov. 2013.
96.	Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, Shusuke Yagi, Takeshi Tobiume, Koji Yamaguchi, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Progression of a Case of Myocardial Damage Caused by Beckers Muscular Dystrophy., 第17回日本心不全学会学術集会, Nov. 2013.
97.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Kouzou Yoshikawa, Jun Higashijima, Masaaki Nishi, Motoya Chikakiyo, Takuya Tokunaga, 松本規子 and Masashi Akaike : 開腹手術は内視鏡下手術トレーニングに必要である∼鏡視下手術理解促進のための基礎的検討∼, 第75回日本臨床外科学会総会, Nov. 2013.
98.	門田宗之, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, 原知也, 太田理絵, Mika Bando, 高島啓, 坂東左知子, 松浦朋美, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 慢性心不全患者に対するトルバプタン投与における薬物血中濃度と利尿効果の検討, 第61回日本心臓病学会学術集会, Sep. 2013.
99.	Takayuki Ise, Takashi Iwase, Masashi Akaike, 西尾進, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Intramural Hematoma症例のUlcer Like Projection形成と拡大における穿通枝の重要性, 第61回日本心臓病学会学術集会, Sep. 2013.
100.	Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, Mika Bando, 西尾進, Koji Yamaguchi, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Becker型筋ジストロフィーによる心筋障害の経過を観察し得た1例, 第61回日本心臓病学会学術集会, Sep. 2013.
101.	Takashi Iwase, Shoichiro Takao, 太田理絵, Koji Yamaguchi, Masashi Akaike, Takayuki Ise, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masafumi Harada and Masataka Sata : 3ステラ非造影心臓MRI検査が左室内壁在血栓の検出ならびに治療方針決定に有用であった無症候性心筋虚血の1例, 第61回日本心臓病学会学術集会, Sep. 2013.
102.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, Takayuki Ise, Shusuke Yagi, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata : 左室収縮不全を伴う心サルコイドーシスと他の心疾患鑑別におけるガドリニウム遅延造影定量評価の有用性, 第61回日本心臓病学会学術集会, Sep. 2013.
103.	Takashi Iwata, Masashi Akaike, Masami Nagamune, 福富美紀 and Mitsuo Shimada : 腹腔鏡下手術トレーニングボックスを用いた鏡視下手術手技理解促進のための基礎的検討, 第247回徳島医学会学術集会(平成25年度夏期), Aug. 2013.
104.	門田宗之, Takayuki Ise, Shusuke Yagi, Takashi Iwase, 太田理絵, 原知也, 高島啓, Mika Bando, 坂東左知子, 松浦朋美, 發知淳子, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata and Masashi Akaike : 慢性心不全における新規利尿薬tolvaptanの効果予測因子, 第247回徳島医学会学術集会, Aug. 2013.
105.	石井亜由美, 西川幸治, Shinsuke Katoh, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Yuka Ueda, 門田宗之, 高島啓, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, 中川泰介, Tetsuya Kitagawa and Masashi Akaike : 人工呼吸管理中に心臓リハビリを有効に施行しえた開心術後の心不全症例, 第247回徳島医学会学術集会, Aug. 2013.
106.	Takashi Iwata, Mitsuo Shimada, Masami Nagamune, 福富美紀 and Masashi Akaike : システム，支援，フィードバックに着眼した腹腔鏡下手術トレーニング, 第45回日本医学教育学会大会, Jul. 2013.
107.	Masashi Akaike, Hiroaki Mikasa and Akiyoshi Nishimura : 臨床医学の教育業績評価, 第45回日本医学教育学会大会, Jul. 2013.
108.	Hiroaki Mikasa, Masashi Akaike and Akiyoshi Nishimura : ルーブリック評価を活用した項目特性分析による記述式試験問題の評価, 第45回日本医学教育学会大会, Jul. 2013.
109.	Masami Nagamune, Takashi Iwata, 福富美紀, 石田加寿子 and Masashi Akaike : OSCEにおける模擬患者演技の均一化を目標としたトレーニングの方策, 第45回日本医学教育学会大会, Jul. 2013.
110.	福富美紀, Takashi Iwata, Masami Nagamune and Masashi Akaike : スキルスラボを活用した高校生医学体験実習の卒後進路に及ぼす影響, 第45回日本医学教育学会大会, Jul. 2013.
111.	Takashi Iwata, Masashi Akaike, Masami Nagamune, 福富美紀 and Mitsuo Shimada : 腹腔鏡下手術トレーニングボックスを用いた鏡視下手術手技理解促進のための基礎的検討, 第1回日本シミュレーション医療教育学会大会, Jul. 2013.
112.	平田有紀奈, 西尾進, 友藤達陽, Mika Bando, 林修司, Junko Hotsuchi, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : 超音波検査で計側した各種脂肪組織厚と冠動脈硬化症との関連, 第86回日本超音波医学会学術集会, May 2013.
113.	幸田舞子, Takayuki Ise, 川端豊, 門田宗之, 原知也, 太田理絵, Mika Bando, 坂東左知子, 松浦朋美, Toshiyuki Niki, Junko Hotsuchi, Koji Yamaguchi, Shusuke Yagi, Takashi Iwase, Yoshio Taketani, Hirotsugu Yamada, Masashi Akaike, 林友鴻, 長谷川拓也 and Masataka Sata : 経皮的中隔心筋焼灼術が奏功した閉塞性肥大型心筋症の1例, 第102回日本循環器学会中国・四国合同地方会, May 2013.
114.	Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, 川端豊, 門田宗之, Toshiyuki Niki, Mika Bando, 坂東左知子, 松浦朋美, Koji Yamaguchi, Shusuke Yagi, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心病変の経過を観察し得たBecker型筋ジストロフィーによる心不全の1例, 第102回日本循環器学会中国・四国合同地方会, May 2013.
115.	Takayuki Ise, Shusuke Yagi, Takashi Iwase, 門田宗之, Toshiyuki Niki, Mika Bando, 坂東左知子, 松浦朋美, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 慢性心不全におけるAdaptive-Servo Ventilationの血行動態に対する効果, 第102回日本循環器学会中国・四国合同地方会, May 2013.
116.	Sumiko Yoshida, Ken-ichi Aihara, Yasumasa Ikeda, Matomo Sakari, Takahiro Matsumoto, Masashi Akaike, Masataka Sata and Toshio Matsumoto : アンドロゲン受容体は性差非依存的にVEGF受容体を介して虚血反応性血管新生を促進する, 第86回日本内分泌学会学術総会, Apr. 2013.
117.	Ken-ichi Aihara, Sumiko Yoshida, 上元良子, 石川カズ江, Masashi Akaike and Toshio Matsumoto : 重症下肢虚血壊死に対するピタバスタチンの組織保護効果に関する検討, 第86回日本内分泌学会学術総会, Apr. 2013.
118.	Takayuki Ise, Shusuke Yagi, Masashi Akaike, Takashi Iwase, M Kadota, R Ota, Y Kawabata, T Hara, K Ogasawara, Mika Bando, S Bando, T Matsuura, Toshiyuki Niki, J Hotchi, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Adaptive Servo-Ventilation Improves Symptoms and Hemodynamics in Both Patients with Systolic and Diastolic Heart Failure., 第77回日本循環器学会学術集会, Mar. 2013.
119.	Takayuki Ise, Takashi Iwase, Shoichiro Takao, M Kadota, Mika Bando, S Bando, T Matsuura, Toshiyuki Niki, J Hotchi, Shusuke Yagi, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masafumi Harada and Masataka Sata : Evaluation of Right Ventricular Hypertrophy by Cardiac Magnetic Resonance is Useful for Detecting Cardiac Amyloidosis., 第77回日本循環器学会学術集会, Mar. 2013.
120.	Shusuke Yagi, Takayuki Ise, Hirotsugu Yamada, S Nishio, Yuka Ueda, Takashi Iwase, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Ratio of Eicosapentaenoic Acid to Arachidonic Acid is a Predictive Factor of Albuminuria and Endothelial Function in Patients with Dyslipidemia., 第77回日本循環器学会学術集会, Mar. 2013.
121.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, Takayuki Ise, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Ken-ichi Aihara, Tetsuzo Wakatsuki, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata : Differentiation of Left Ventricular Systolic Dysfunction Related to Cardiac Sarcoidosis and Other Heart Diseases Using contrast-enhanced Cardiovascular Magnetic Resonance., 第77回日本循環器学会学術集会, Mar. 2013.
122.	M Kadota, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike, R Ota, Y Kawabata, T Hara, K Ogasawara, Mika Bando, S Bando, T Matsuura, Toshiyuki Niki, J Hotchi, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Effects of Tolvaptan are Predicted by Vasopressin/Aldosterone Ratio and Urine Osmolality in Patients with Chronic Heart Failure., 第77回日本循環器学会学術集会, Mar. 2013.
123.	S Sakamoto, M Kadota, Takayuki Ise, Takashi Iwase, S Bando, T Matsuura, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Shusuke Yagi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, Masashi Akaike and M Takeuchi : 再熱と寛解を繰り返す特発性心膜炎に対しイブプロフェンが有効であった1例, 第246回徳島医学会学術集会(平成24年度冬期), Feb. 2013.
124.	M Koda, Masataka Sata, Takayuki Ise, Y Kawabata, Takashi Iwase, M Kadota, T Hara, R Ota, Mika Bando, S Bando, T Matsuura, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Shusuke Yagi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, S Okazaki, 林友鴻 and T Hasegawa : 難治性の閉塞性肥大型心筋症に対して経皮的中隔心筋焼灼術が著効した1例, 第246回徳島医学会学術集会(平成24年度冬期), Feb. 2013.
125.	Yuka Ueda, Takayuki Ise, Takashi Iwase, K Maeda, K Nishikawa, M Kadota, T Hara, Y Kawabata, R Ota, Toshiyuki Niki, Koji Yamaguchi, Shusuke Yagi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinsuke Katoh, Natsuo Yasui and Masataka Sata : 心臓リハビリテーションにおける禁煙継続効果の検討, 第101回日本循環器学会四国地方会, Dec. 2012.
126.	Y Kawabata, Takayuki Ise, T Matsuura, S Bando, Takashi Iwase, K Ogasawara, Mika Bando, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Shusuke Yagi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 高度肥満を伴った拡張型心筋症の1例, 第101回日本循環器学会四国地方会, Dec. 2012.
127.	S Sakamoto, M Kadota, Takayuki Ise, Takashi Iwase, S Bando, T Matsuura, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Shusuke Yagi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 再燃と寛解を繰り返す特発性心膜炎に対しイブプロフェンが有効であった1例, 第101回日本循環器学会四国地方会, Dec. 2012.
128.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, 松本規子 and Masashi Akaike : システム，支援，フィードバックに注目した内視鏡下手術トレーニング, 第25回日本内視鏡外科学会総会, Dec. 2012. (Keyword) 国内学会
129.	M Kadota, Takayuki Ise, Takashi Iwase, Masashi Akaike, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Tetsuzo Wakatsuki, Takeshi Soeki and Masataka Sata : Prediction of Responder and Influence for Cardio-Renal Interaction by Tolvaptan in Patients with Chronic Heart Failure., 第16回日本心不全学会学術集会, Nov. 2012.
130.	Takayuki Ise, Shusuke Yagi, Masashi Akaike, Takashi Iwase, M Kadota, T Hara, Koji Yamaguchi, Yoshio Taketani, Tetsuzo Wakatsuki and Masataka Sata : Acute Hemodynamic Effects of Adaptive Servo-Ventilation in Patients with Chronic Heart Failure., 第16回日本心不全学会学術集会, Nov. 2012.
131.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Masashi Akaike : 最良の外科医の教育とは何か∼システム，支援，フィードバックに着眼した教育∼, 第74回日本臨床外科学会総会, Nov. 2012. (Keyword) 国内学会
132.	Takayuki Ise, Takashi Iwase, K Nanjo, Shoichiro Takao, R Ota, S Bando, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masafumi Harada and Masataka Sata : 心臓MRIを用いた左室肥大患者における右室壁厚の検討, 第60回日本心臓病学会学術集会, Sep. 2012.
133.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu, 松本規子 and Masashi Akaike : 腹腔鏡下胃切除術のトレーニングにおける開腹術からのフィードバックの有用性について, 第17回中国四国内視鏡外科研究会, Sep. 2012.
134.	Y Yokota, M Kadota, Takayuki Ise, Takashi Iwase, T Hara, R Ota, Y Kawabata, K Ogasawara, Mika Bando, S Bando, T Matsuura, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, Masashi Akaike, Mariko Egawa and Yoshinori Mitamura : 眼病変の経過中に心室中隔の肥厚および完全房室ブロックで発症した心サルコイドーシスの一例, 第245回徳島医学会学術集会(平成24年度夏期), Jul. 2012.
135.	Takashi Iwata, Mitsuo Shimada, Masami Nagamune and Masashi Akaike : 腹腔鏡下胃切除術の術者研修中における開腹術からのフィードバックの有用性について, 第44回日本医学教育学会大会, Jul. 2012.
136.	Hiroaki Mikasa, Masashi Akaike, Akiyoshi Nishimura and Yoshihiro Fukui : 共用試験OSCEによる臨床実習前教育の評価:項目特性曲線による評価方法, 第44回日本医学教育学会大会, Jul. 2012.
137.	Yuka Ueda, Takashi Iwase, Takayuki Ise, K Maeda, K Nishikawa, Mika Bando, K Ogasawara, S Bando, Toshiyuki Niki, J Hotchi, Koji Yamaguchi, N Tomita, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinsuke Katoh, Natsuo Yasui and Masataka Sata : 喫煙継続者における心臓リハビリテーションの効果の検討, 第18回心臓リハビリテーション学会, Jul. 2012.
138.	K Maeda, Yuka Ueda, Takayuki Ise, Takashi Iwase, K Nishikawa, Mika Bando, K Ogasawara, S Bando, Toshiyuki Niki, J Hotchi, Koji Yamaguchi, N Tomita, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinsuke Katoh, Natsuo Yasui and Masataka Sata : 患者の気持ちを汲んだ患者教育の実際, 第18回心臓リハビリテーション学会, Jul. 2012.
139.	A Takashima, Takayuki Ise, Yuka Ueda, K Maeda, K Nishikawa, K Ogasawara, Mika Bando, N Tomita, Toshiyuki Niki, J Hotchi, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Shinsuke Katoh, Masashi Akaike, Natsuo Yasui and Masataka Sata : 心臓リハビリテーションは酸化LDLを低下させる, 第18回心臓リハビリテーション学会, Jul. 2012.
140.	A Tachibana, Takayuki Ise, Takeshi Soeki, Takashi Iwase, R Ota, M Kadota, T Hara, Mika Bando, K Ogasawara, S Bando, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : CRT-Dが著効した重症拡張型心筋症の2症例, 第100回日本循環器学会中国・四国合同地方会, Jun. 2012.
141.	S Nagasaka, Takayuki Ise, Takashi Iwase, R Ota, M Kadota, T Hara, Mika Bando, K Ogasawara, S Bando, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : マルチモダリティを用いて鑑別し得た冠動脈病変合併たこつぼ型心筋症の1症例, 第100回日本循環器学会中国・四国合同地方会, Jun. 2012.
142.	Takayuki Ise, K Nanjo, Takashi Iwase, Shoichiro Takao, R Ota, M Kadota, T Hara, Mika Bando, K Ogasawara, S Bando, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masafumi Harada and Masataka Sata : 左室肥大患者における右室壁厚の検討, 第100回日本循環器学会中国・四国合同地方会, Jun. 2012.
143.	Takayuki Ise, Takashi Iwase, R Ota, M Kadota, T Hara, A Takashima, H Yamasaki, Mika Bando, K Ogasawara, S Bando, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Adaptive Servo-Ventilationが心不全治療に有効であった心アミロイドーシスの2症例, 第100回日本循環器学会中国・四国合同地方会, Jun. 2012.
144.	K Maeda, Yuka Ueda, Takayuki Ise, Takashi Iwase, K Nishikawa, Mika Bando, K Ogasawara, S Bando, Toshiyuki Niki, J Hotchi, Koji Yamaguchi, N Tomita, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinsuke Katoh, Natsuo Yasui and Masataka Sata : チーム医療で取り組む重症心不全に対する心臓リハビリテーション, 第100回日本循環器学会中国・四国合同地方会, Jun. 2012.
145.	S Taoka, Takayuki Ise, Takashi Iwase, R Ota, M Kadota, T Hara, K Ogasawara, Mika Bando, S Bando, Toshiyuki Niki, J Hotchi, N Tomita, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : テニスラケットによる打撲が誘引で深部静脈血栓・急性肺塞栓症を来した1症例, 第100回日本循環器学会中国・四国合同地方会, Jun. 2012.
146.	鶴尾美穂, 寺澤敏秀, 木戸里佳, Sumiko Yoshida, Tomoyuki Yuasa, Takeshi Kondo, 笠松哲司, 近藤絵里, Mizuho Kinouchi, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and Masashi Akaike : 粥状動脈硬化病変を呈した高Lp(a)血症合併糖尿病の姉妹例, 第55回日本糖尿病学会年次学術集会, May 2012.
147.	Sumiko Yoshida, Ken-ichi Aihara, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : エイコサペントエン酸は酸化ストレス抑制を介して心臓リモデリングを抑制する, 日本高血圧学会第1回臨床高血圧フォーラム, May 2012. (Keyword) Eicosapentaenoic Acid(薬理学,治療的利用) 疾患モデル(動物) 心臓血管疾患(超音波診断,病理学,予防) 酸化ストレス BALB Cマウス心室リモデリング(予防) ヒトマウス動物男女
148.	Ken-ichi Aihara, Sumiko Yoshida, Masashi Akaike and Toshio Matsumoto : 血管内皮機能制御における血圧関連指標の意義, 日本高血圧学会第1回臨床高血圧フォーラム, May 2012.
149.	Masashi Akaike : ステロイドによる血管内皮細胞障害と骨壊死の関係, 第56回日本リウマチ学会総会・学術集会, Apr. 2012.
150.	Munkbaatar Dagvasumberel, Michio Shimabukuro, Nishiuchi Takeshi, Hirata Yoichiro, Takeshi Soeki, Masashi Akaike, Takashi Iwase, Kenya Kusunose, Toshiyuki Niki, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Shusuke Yagi, Tomita Noriko, Hirotsugu Yamada, Tetsuzo Wakatsuki, Hirotsugu Kurobe, Tetsuya Kitagawa and Masataka Sata : Gender Disparities in Association of Epicardial Adipose Tissue Volume and Coronary Atherosclerosis., 第76回日本循環器学会学術集会, Mar. 2012.
151.	Kimura Sahika, Yuka Ueda, Takayuki Ise, Takashi Iwase, Takashima Akira, Yamazaki Hiromu, Ogasawara Kozue, Bando Sachiko, Hayashi Shuji, Takeuchi Hidekazu, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, Tomita Noriko, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Cardiac Rehabilitation decreases Urinary Albumin Excretion in Patients with Cardiovascular Disease., 第76回日本循環器学会学術集会, Mar. 2012.
152.	Takashima Akira, Takayuki Ise, Takashi Iwase, Yuka Ueda, Masashi Akaike, Yamazaki Hiromu, Mika Bando, Ogasawara Kozue, Bando Sachiko, Tomita Noriko, Takeuchi Hidekazu, Toshiyuki Niki, Hotchi Junko, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : Effect of Cardiac Rehabilitation on Level of Oxidized LDL., 第76回日本循環器学会学術集会, Mar. 2012.
153.	Takeshi Soeki, Toshiyuki Niki, Koji Yamaguchi, 坂東左知子, Yuka Ueda, 冨田紀子, Takayuki Ise, Kenya Kusunose, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Michio Shimabukuro and Masataka Sata : Inflammatory Biomarkers as Predictors of Vulnerable Coronary Plaques., 第76回日本循環器学会学術集会，Symposium 3, Mar. 2012.
154.	立花綾香, Yuka Ueda, Takayuki Ise, 高島啓, 山崎宙, 小笠原梢, 坂東左知子, Toshiyuki Niki, 發知淳子, 冨田紀子, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, Masashi Akaike and 廣野明 : CRT-Dが著効した重症慢性心不全の1例, 第244回徳島医学会学術集会 (平成23年度冬期), Feb. 2012.
155.	田岡志保, Yuka Ueda, Takayuki Ise, 高島啓, 山崎宙, 小笠原梢, 坂東左知子, Toshiyuki Niki, 發知淳子, 冨田紀子, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, Masashi Akaike and 井上洋行 : テニスラケットによる外傷が誘因で深部静脈血栓・急性肺塞栓症を来した一症例, 第244回徳島医学会学術集会 (平成23年度冬期), Feb. 2012.
156.	Mika Bando, Hirotsugu Yamada, 冨田紀子, 發知淳子, 小笠原梢, 高島啓, 山崎宙, 坂東左知子, Takayuki Ise, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, 西尾進, 林修司, 中川摩耶, 玉井利奈, 平田有紀奈 and 弘田大智 : 脂質低下療法による頸動脈プラーク安定化の評価:超音波integrated backscatterを用いたカラーマッピングシステムの臨床応用, 第244回徳島医学会学術集会 (平成23年度冬期), Feb. 2012.
157.	太田理絵, Tetsuzo Wakatsuki, Takashi Iwase, Shoichiro Takao, Hirotsugu Yamada, Masashi Akaike, 坂東左知子, Toshiyuki Niki, Hayato Nose, 冨田紀子, Koji Yamaguchi, Yoshio Taketani, Takeshi Soeki, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata : 肺，皮膚病変診断4年後に心病変が顕在化したサルコイドーシスの1例, 第22回日本心血管画像動態学会, Jan. 2012.
158.	前田香代子, Yuka Ueda, Takayuki Ise, Takashi Iwase, 西川幸治, 高島啓, 小笠原梢, 山崎宙, 坂東左知子, Toshiyuki Niki, 發知淳子, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinjiro Takata, Natsuo Yasui and Masataka Sata : 大学病院での心臓リハビリテーション立ち上げの問題点, 第99回日本循環器学会四国地方会, Dec. 2011.
159.	鶴尾美穂, 寺沢敏秀, 木戸里佳, Tomoyuki Yuasa, Sumiko Yoshida, 笠松哲司, Akio Kuroda, Munehide Matsuhisa, Toshio Matsumoto and Masashi Akaike : 粥状動脈硬化病変を呈した糖尿病合併高Lp(a)血症の姉妹例, 日本糖尿病学会中国四国地方会第49回総会, Nov. 2011.
160.	Takashi Iwata, Mitsuo Shimada, Nobuhiro Kurita, Horohiko Sato, Masanori Nishioka, Shinya Morimoto, Kouzou Yoshikawa, Tomohiko Miyatani, 柏原秀也, Chie Takasu and Masashi Akaike : スキルスラボのシミュレーターを駆使した医療トレーニングの有用性 (第49回日本癌治療学会学術集会), The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 727, Oct. 2011. (Keyword) 質問紙法 / 外科手術 / 腫瘍 / 医学生涯教育 / Homo sapiens
161.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, Hayato Nose, Takayuki Ise, 小笠原梢, 山崎宙, 髙島啓, 坂東左知子, Toshiyuki Niki, Kenya Kusunose, 發知淳子, 冨田紀子, Yuka Ueda, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata : 心臓MRIによるサルコイドーシス心病変検出の有用性, 第31回日本サルコイドーシス/肉芽腫性疾患学会総会, Oct. 2011.
162.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : エイコサペントエン酸の酸化ストレス抑制を介したアンジオテンシンII刺激による心血管リモデリング抑制効果の検討, 第34回日本高血圧学会総会, Oct. 2011.
163.	木谷光宏, Takeshi Soeki, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Tetsuzo Wakatsuki, Masashi Akaike, 山本浩史, 折野俊介, 角谷昭佳, 坂東重信 and Masataka Sata : 高血圧患者におけるシルニジピンの酸化ストレスに対する作用, 第34回日本高血圧学会総会, Oct. 2011.
164.	Takayuki Ise, Takashi Iwase, Kumiko Kagawa, Toshiyuki Niki, Kenya Kusunose, 冨田紀子, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masahiro Abe, Masashi Akaike and Masataka Sata : Successful Autologous Peripheral Blood Stem Cell Transplantation for Primary Cardiac Amyloidosis Patients with Heart Failure : three cases report., 第15回日本心不全学会学術集会, Oct. 2011.
165.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, Hayato Nose, 久岡白陽花, Takayuki Ise, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Yasuhiko Nishioka, Masafumi Harada and Masataka Sata : サルコイドーシス心病変検出における心臓MRI検査の有用性, 第59回日本心臓病学会学術集会, Sep. 2011.
166.	坂東左知子, Takeshi Soeki, Toshiyuki Niki, 久岡白陽花, 竹内秀和, 冨田紀子, Kenya Kusunose, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Kenji Kangawa and Masataka Sata : グレリンによる自律神経およびConnexin43発現調節を介した抗不整脈作用の検討, 第59回日本心臓病学会学術集会, Sep. 2011.
167.	Takeshi Soeki, 坂東左知子, Toshiyuki Niki, 久岡白陽花, 竹内秀和, Kenya Kusunose, Yuka Ueda, 冨田紀子, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心房細動における局所炎症反応に関する検討, 第59回日本心臓病学会学術集会, Sep. 2011.
168.	Ken-ichi Aihara, Sumiko Yoshida, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, 久岡白陽花, 平田陽一郎, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Eicosapentaenoic acid-to-arachidonic acid ratio is inversely associated with albuminuria in individuals with cardiovascular risk factors, 第75回日本循環器学会総会・学術集会パシフィコ横浜, Aug. 2011.
169.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Eicosapentaenoic acid protects against angiotensin II-induced cardiovascular remodeling via attenuation of oxidative stress., 第75回日本循環器学会総会・学術集会パシフィコ横浜, Aug. 2011.
170.	C. Nishio, M. Higashida, Y. Hirata, Hirotsugu Kurobe, Masashi Akaike, Yutaka Nakaya, Tetsuya Kitagawa and Masataka Sata : GLP-1 Receptor Agonist Attenuates Vascular Remodeling after Endovascular Injury., 第75回日本循環器学会総会・学術集会, Aug. 2011.
171.	M. Higashida, C. Nishio, Y. Hirata, Hirotsugu Kurobe, Masashi Akaike, Yutaka Nakaya, Tetsuya Kitagawa and Masataka Sata : HMGB1 Plays a Critical Role in Chronic Inflammation and Vascular Remodeling after Endovascular Injury., 第75回日本循環器学会総会・学術集会, Aug. 2011.
172.	Masashi Akaike, Koichiro Tsuchiya, Yoshiki Kashiwada, Yoshihisa Takaishi, Toshiaki Tamaki, Takashi Iwase, Masataka Sata, Ken-ichi Aihara, Sumiko Yoshida, Toshio Matsumoto, 佐藤千穂, 西条伴香 and Hiroaki Yanagawa : 生活習慣病関連リスクファクターに及ぼすスダチ果皮加工品の効果 ∼探索的臨床試験による検討∼, 第243回徳島医学会学術集会公開シンポジウム, Jul. 2011.
173.	Masashi Akaike, Koichiro Tsuchiya, Yoshiki Kashiwada, Yoshihisa Takaishi, Toshiaki Tamaki, Takashi Iwase, Masataka Sata, Ken-ichi Aihara, 吉田守実子, Toshio Matsumoto, 佐藤千穂, 西条伴香 and Hiroaki Yanagawa : 生活習慣病関連リスクファクターに及ぼすスダチ果皮加工品の効果-探索的臨床試験による検討-, 第243回徳島医学会学術集会, Jul. 2011.
174.	高木恵理, 高島啓, Koji Yamaguchi, Yoshio Taketani, 坂東左知子, 冨田紀子, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Yuka Ueda, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, Atsushi Morimoto, Ichiro Hashimoto, Hideki Nakanishi, 和田美智子, 石本武男 and 田蒔正治 : 重症下肢虚血病変に対して経皮的下肢動脈血管形成術が奏功し，予定されていた下肢切手術を回避できた一症例, 第243回徳島医学会学術集会, Jul. 2011.
175.	高島啓, Takeshi Soeki, Koji Yamaguchi, Yoshio Taketani, 坂東左知子, 林修司, 久岡白陽花, 冨田紀子, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Yuka Ueda, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 埋め込み型デバイスにより胸郭内インピーダンスの増悪と改善が観察できた拡張相肥大型心筋症の一例, 第243回徳島医学会学術集会, Jul. 2011.
176.	Masami Nagamune, Takashi Iwata and Masashi Akaike : 医療安全をめざした多職種間連携教育の取り組みー徳島大学のIPEモデルー, 第43回日本医学教育学会大会, Jul. 2011.
177.	Takashi Iwata, Masashi Akaike, Masami Nagamune, Mitsuo Shimada, Nobuhiro Kurita, Masanori Nishioka and Hiroshi Okitsu : 地域で研修する若手医師に対する大腸癌鏡下手術の教育における問題点と対策:地方からの提言, 第43回日本医学教育学会大会, Jul. 2011.
178.	Hiroaki Mikasa, Masashi Akaike and Yoshihiro Fukui : 看護学専攻学生に対する統計学教育改善の試み, Jul. 2011.
179.	西川幸治, Yuka Ueda, 久岡白陽花, 前田香代子, Takashi Iwase, 坂東左知子, 林修司, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinjiro Takata, Natsuo Yasui and Masataka Sata : 当院心臓リハビリテーション参加者の運動能力について, 第17回日本心臓リハビリテーション学会学術集会, Jul. 2011.
180.	前田香代子, Yuka Ueda, 久岡白陽花, Takashi Iwase, 西川幸治, 坂東左知子, 林修司, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinjiro Takata, Natsuo Yasui and Masataka Sata : 大学病院での心臓リハビリテーション立ち上げに携わって, 第17回日本心臓リハビリテーション学会学術集会, Jul. 2011.
181.	久岡白陽花, Yuka Ueda, Takashi Iwase, 前田香代子, 西川幸治, 坂東左知子, 林修司, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinjiro Takata, Natsuo Yasui and Masataka Sata : 尿中アルブミン排泄量に及ぼす心臓リハビリテーションの効果, 第17回日本心臓リハビリテーション学会学術集会, Jul. 2011.
182.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 林修司, 玉井利奈, Takeshi Soeki, Masashi Akaike and Masataka Sata : TE-e'は左室拡張末期圧を反映する―下肢腸圧および硝酸薬負荷を用いた検討―, 第84回日本超音波医学会学術集会, May 2011.
183.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 玉井利奈, 佐藤光代, 冨田紀子, 林修司, Takeshi Soeki, Masashi Akaike and Masataka Sata : 冠動脈硬化症を最も反映する非侵襲的血管検査指標は何か?, 第84回日本超音波医学会学術集会, May 2011.
184.	前田香代子, Yuka Ueda, 久岡白陽花, Takashi Iwase, 西川幸治, 坂東左知子, 林修司, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinjiro Takata, Natsuo Yasui and Masataka Sata : 通院型心臓リハビリテーションの継続における開始3カ月目の重要性, 第98回日本循環器学会中国・四国合同地方会, May 2011.
185.	西川幸治, Yuka Ueda, 久岡白陽花, 前田香代子, Takashi Iwase, 坂東左知子, 林修司, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinjiro Takata, Natsuo Yasui and Masataka Sata : 心臓リハビリによる運動能力改善を阻害する因子の検討, 第98回日本循環器学会中国・四国合同地方会, May 2011.
186.	太田理絵, Takashi Iwase, 久岡白陽花, Hirotsugu Yamada, Yasuhiko Nishioka, Shoichiro Takao, 坂東左知子, Hayato Nose, Kenya Kusunose, Toshiyuki Niki, 冨田紀子, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Saburo Sone and Masataka Sata : 心室固有調律が心病変診断のきっかけとなったサルコイドーシスの1例, 第98回日本循環器学会中国・四国合同地方会, May 2011.
187.	原知也, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 林修司, 玉井利奈, 坂東左知子, 久岡白陽花, Toshiyuki Niki, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心サルコイドーシスにおける左室形態異常の多様性, 第98回日本循環器学会中国・四国合同地方会, May 2011.
188.	本田壮一, 川井尚臣, 白川光雄, 小原聡彦, Masashi Akaike and Masataka Sata : 急性冠症候群の医療連携―「海部プロジェクト」自験症例より―, 第98回日本循環器学会中国・四国合同地方会, May 2011.
189.	久岡白陽花, Yuka Ueda, Takashi Iwase, 前田香代子, 西川幸治, 坂東左知子, 林修司, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Shinjiro Takata, Natsuo Yasui and Masataka Sata : 尿中アルブミン排出量に及ぼす通院心臓リハビリテーションの効果, 第98回日本循環器学会中国・四国合同地方会, May 2011.
190.	坂東左知子, Takeshi Soeki, 久岡白陽花, 冨田紀子, 竹内秀和, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 房室結節三重伝道路の存在が示唆された房室結節リエントリー性頻拍の1例, 第98回日本循環器学会中国・四国合同地方会, May 2011.
191.	外磯千智, Takashi Iwase, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, Masashi Akaike, Shoichiro Takao and Masafumi Harada : 心臓MRI検査で左室に広範なガドリニウム異常集積を認めたNoonan syndromeの1例, 第104回日本内科学会四国地方会, May 2011.
192.	安積麻衣, Takashi Iwase, Toshiyuki Niki, Tetsuzo Wakatsuki, Masataka Sata, Masashi Akaike, Shoichiro Takao, Masafumi Harada, Yasuhiko Nishioka and Saburo Sone : 眼，肺，筋病変に続いて経過中に新病変の顕在化を認めたサルコイドーシスの一例, 第104回日本内科学会四国地方会, May 2011.
193.	Ken-ichi Aihara, Sumiko Yoshida, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : フェノフィブラートはアンジオテンシンⅡ負荷による高血圧と心筋リモデリングを抑制する, 第84回日本内分泌学会学術総会, Apr. 2011.
194.	Hirotsugu Kurobe, 平田陽一郎, 西雄千佳, 東田真由子, 松岡祐貴, Masashi Akaike, Yutaka Nakaya, Tetsuya Kitagawa and Masataka Sata : GLP-1 receptor agonist が血管リモデリングに与える影響の検討, 第84回日本内分泌学会学術総会, Apr. 2011.
195.	Yasumasa Ikeda, Ken-ichi Aihara, Sumiko Yoshida, 佐藤隆史, Masashi Akaike, Toshiaki Tamaki, 加藤茂明 and Toshio Matsumoto : 心血管リモデリングにおける男性ホルモンの作用, 第84回日本内分泌学会学術集会シンポジウム「心血管病を内分泌・代謝面から考察する」, Apr. 2011.
196.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, 石川カズ江, Sumiko Yoshida, Yuka Ueda, Takashi Iwase, Masataka Sata and Toshio Matsumoto : グルココルチコイド誘発性血管内皮細胞障害に対するアルドステロン受容体拮抗薬の効果, 第84回日本内分泌学会学術総会, Apr. 2011.
197.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : エイコサペントエン酸は酸化ストレス抑制を介してアンジオテンシンⅡ刺激による心血管リモデリングを抑制する, 第84回日本内分泌学会学術総会, Apr. 2011.
198.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : 虚血ストレスによる骨格筋アポトーシスおよび血管新生におけるアンドロゲン受容体の意義, 第84回日本内分泌学会学術総会, Apr. 2011.
199.	Hirotsugu Kurobe, Ken-ichi Aihara, 平田陽一郎, 西矢昌子, 中山泰介, Tatsuo Motoki, Mikio Sugano, Tamotsu Kanbara, Takashi Kitaichi, Masashi Akaike, Masataka Sata, Tetsuya Kitagawa and Toshio Matsumoto : エゼチミブ投与による脂質代謝および血管機能改善効果の検討, 第84回日本内分泌学会学術総会, Apr. 2011.
200.	Yasumasa Ikeda, Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida, Takashi Iwase, Yoshitaka Kihira, Keisuke Ishizawa, Shuhei Tomita, Masataka Sata, Toshio Matsumoto and Toshiaki Tamaki : Heparin cofactor II enhances vascular endothelial cells function and angiogenesis, 第75回日本循環器学会総会・学術集会, Mar. 2011.
201.	S. Bando, Takeshi Soeki, Toshiyuki Niki, Y. Hirata, N. Tomita, H. Takeuchi, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Plasma Brain Natriuretic Peptide (BNP) Level is Elevated in Patients with Cancer., 第75回日本循環器学会総会・学術集会, Mar. 2011.
202.	Takeshi Soeki, Toshiyuki Niki, Koji Yamaguchi, S. Bando, Yuka Ueda, N. Tomita, Takayuki Ise, Kenya Kusunose, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Michio Shimabukuro and Masataka Sata : Inflammatory Biomarkers as Predictors of Vulnerable Coronary Plaques., 第76回日本循環器学会学術集会，Symposium 3, Mar. 2011.
203.	C. Nishio, M. Higashida, Y. Hirata, Hirotsugu Kurobe, Masashi Akaike, Yutaka Nakaya, Tetsuya Kitagawa and Masataka Sata : GLP-1 Receptor Agonist Attenuates Vascular Remodeling after Endovascular Injury., 第75回日本循環器学会総会・学術集会, Mar. 2011.
204.	M. Higashida, C. Nishio, Y. Hirata, Hirotsugu Kurobe, Masashi Akaike, Yutaka Nakaya, Tetsuya Kitagawa and Masataka Sata : HMGB1 Plays a Critical Role in Chronic Inflammation and Vascular Remodeling after Endovascular Injury., 第75回日本循環器学会総会・学術集会, Mar. 2011.
205.	S. Nishio, Hirotsugu Yamada, Kenya Kusunose, N. Tomita, S. Hayashi, K. Endo, R. Tamai, J. Miki, S. Bando, Toshiyuki Niki, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Which Noninvasive Vascular Index is the Best Predictor of the Severity of Coronary Atherosclerosis?, 第75回日本循環器学会総会・学術集会, Mar. 2011.
206.	S. Hayashi, Hirotsugu Yamada, S. Nishio, N. Tomita, Kenya Kusunose, K. Endo, R. Tamai, S. Bando, S. Hisaoka, H. Takeuchi, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Tricuspid Annular Motion Velocity in Left Ventricular Hypertrophy: Comparison between Hypertensive Heart Disease and Hypertrophic Cardiomyopathy., 第75回日本循環器学会総会・学術集会, Mar. 2011.
207.	Toshiyuki Niki, Takeshi Soeki, S. Bando, Kenya Kusunose, S. Hisaoka, S. Hayashi, Yuka Ueda, S. Tomita, H. Takeuchi, Takashi Iwase, Yoshio Taketani, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Role of Circulating High-Mobility Group Box-1 (HMGB1) in Patients with Coronary Artery Disease., 第75回日本循環器学会総会・学術集会, Mar. 2011.
208.	Kenya Kusunose, Hirotsugu Yamada, N. Tomita, S. Nishio, S. Bando, S. Hisaoka, S. Hayashi, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Clinical Efficacy of Beat-to-beat Variability of Diastolic Filling in Atrial Fibrillation., 第75回日本循環器学会総会・学術集会, Mar. 2011.
209.	Koji Yamaguchi, Tetsuzo Wakatsuki, Toshiyuki Niki, Koji Yamaguchi, S. Bando, S. Hisaoka, S. Hayashi, Yuka Ueda, N. Tomita, H. Takeuchi, Kenya Kusunose, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Masashi Akaike and Masataka Sata : Local Persistent Coagulative Response to Zotarolimus-eluting, Sirolimus-eluting and Bare-metal Stents Implanted in Patients with Stable Angina., 第75回日本循環器学会総会・学術集会, Mar. 2011.
210.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, S. Bando, S. Hisaoka, Toshiyuki Niki, Kenya Kusunose, N Tomita, Y. Hirata, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, M. Harada and Masataka Sata : Diagnostic Utility of Cardiac Magnetic Resonance for Prediction of Cardiac Events in Patients with Hypertrophic Cardiomyopathy., 第75回日本循環器学会総会・学術集会, Mar. 2011.
211.	Tetsuzo Wakatsuki, Koji Yamaguchi, Yoshio Taketani, Toshiyuki Niki, Kenya Kusunose, N. Tomita, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : Analysis of Tissue Characteristics of In-Stent Restenotic Lesion 5-Years after Coronary Stenting with Drug-Eluting Stent Using Integrated Backscatter Intravascular Ultrasound., 第75回日本循環器学会総会・学術集会, Mar. 2011.
212.	高柳友貴, Toshiyuki Niki, 坂東左知子, 久岡白陽花, 林修司, Yuka Ueda, 冨田紀子, 竹内秀和, Kenya Kusunose, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, 中山泰介, Tetsuya Kitagawa and 村野栄一 : ペースメーカーリードの弁尖穿通による重症三尖弁逆流症の一例, 第242回徳島医学会学術集会，平成22年度冬期, Feb. 2011.
213.	坂東美佳, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 竹内秀和, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, Hayato Nose, Hideki Otsuka and Masafumi Harada : 拡張型心筋症として診断・加療されていた心サルコイドーシスの一例, 第242回徳島医学会学術集会，平成22年度冬期, Feb. 2011.
214.	末広英也, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 坂東左知子, 久岡白陽花, 林修司, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, Hayato Nose, Hideki Otsuka, Shoichiro Takao and Masafumi Harada : 心サルコイドーシスにおける左室形態異常の多様性, 第242回徳島医学会学術集会，平成22年度冬期, Feb. 2011.
215.	太田理絵, 冨田紀子, Kenya Kusunose, 坂東左知子, 久岡白陽花, 林修司, 竹内秀和, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, 木村建彦, 西内健, Hirotsugu Kurobe and Tetsuya Kitagawa : 出産後の甲状腺機能亢進症が発見の契機となったLeft Main Coronary Trunk Compression Syndromeの一例, 第242回徳島医学会学術集会，平成22年度冬期, Feb. 2011.
216.	Takashi Iwata, Masami Nagamune, Akiko Tsuji, 福富美紀, 射場智美 and Masashi Akaike : 医療安全の学習基盤形成を目指した早期職種間連携教育の取り組み., 第242回徳島医学会学術集会, Feb. 2011.
217.	髙島啓, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 坂東左知子, 久岡白陽花, 林修司, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, 竹崎彰夫, Hiroya Tada and Saburo Sone : コントラスト心エコー法で診断できたHepatopulmonary Syndromeの1例, 第242回徳島医学会学術集会，平成22年度冬期, Feb. 2011.
218.	清水拓, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 玉井利奈, 遠藤桂輔, 佐藤光代, 河野裕美, Masashi Akaike and Masataka Sata : 運動負荷心エコー法を用いた膠原病例における潜在性肺動脈性高血圧症の検出, 第242回徳島医学会学術集会，平成22年度冬期, Feb. 2011.
219.	竹内秀和, 久岡白陽花, Toshiyuki Niki, Koji Yamaguchi, Takashi Iwase, Takeshi Soeki, Masashi Akaike and Masataka Sata : Fibrinogen relates to free triiodothyronin (FT3) negatively, which might be regulated via Hdac3., 第97回日本循環器学会四国地方会, Feb. 2011.
220.	平田陽一郎, Tatsuo Motoki, Hirotsugu Kurobe, Masashi Akaike, 田端実, 高梨秀一郎, Tetsuya Kitagawa and Masataka Sata : 心臓周囲脂肪組織における炎症性サイトカインの発見と冠動脈病変の関連, 第40回日本心脈管作動物質学会, Feb. 2011.
221.	Hirotsugu Yamada, 玉井利奈, 清水拓, 西尾進, Takashi Iwase, Kenya Kusunose, 遠藤桂輔, Masashi Akaike, Masataka Sata and Shusuke Yagi : 膠原病と肺高血圧, 肺高血圧症とエンドセリン学術講演会, Dec. 2010.
222.	小笠原梢, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, 竹崎彰夫, 多田浩也, Saburo Sone and Masataka Sata : コントラスト心エコー法で診断できたHepatopulmonary Syndromeの1例, 第97回日本循環器学会四国地方会, Dec. 2010.
223.	坂東左知子, Takeshi Soeki, Toshiyuki Niki, 久岡白陽花, 平田陽一郎, 冨田紀子, 竹内秀和, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takashi Iwase, Masashi Akaike and Masataka Sata : 二種類の上室性頻拍出が認められた例, 第97回日本循環器学会四国地方会, Dec. 2010.
224.	高柳友貴, Toshiyuki Niki, Hirotsugu Yamada, Kenya Kusunose, Koji Yamaguchi, Takashi Iwase, 冨田紀子, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : ペースメーカーリードの弁尖穿通による重症三尖弁逆流症の1例, 第97回日本循環器学会四国地方会, Dec. 2010.
225.	竹内秀和, 平田陽一郎, 冨田紀子, Kenya Kusunose, Yoshio Taketani, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : HDL-C interacts to EPA positively,which might mean HDL-C regulates EPA via SREBP., 第97回日本循環器学会四国地方会, Dec. 2010.
226.	坂東美佳, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, 竹内秀和, 竹谷義雄, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心サルコイドーシスの1例, 第97回日本循環器学会四国地方会, Dec. 2010.
227.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : アンドロゲン受容体は虚血後骨格筋細胞のアポトーシスと血管新生を制御する, 第18回日本血管生物医学会学術集会, Dec. 2010.
228.	平田陽一郎, Tatsuo Motoki, Hirotsugu Kurobe, Masashi Akaike, 田端実, 高梨秀一郎 and Masataka Sata : Macrophages shift toward inflammatory state in epicardial fat of patients with coronary artery disease., 第18回日本血管生物医学会学術集会, Dec. 2010.
229.	平田陽一郎, Tatsuo Motoki, Hirotsugu Kurobe, Masashi Akaike, 田端実, 高梨秀一郎 and 佐田政隆 : Macrophages shift toward inflammatory state in epicardial fat of patients with coronary artery disease., Dec. 2010.
230.	Masashi Akaike : 虚血性心疾患と喫煙 ∼職場における喫煙対策を含めて∼, 第5回日本禁煙科学会学術総会, Nov. 2010.
231.	末広英也, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心室中隔肥厚を認めた心サルコイドーシスの1例, 第103回日本内科学会四国地方会, Nov. 2010.
232.	山崎宙, Koji Yamaguchi, Kenya Kusunose, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 趾間部のマダニ咬傷後に足趾血行不良から壊死に陥った1例, 第103回日本内科学会四国地方会, Nov. 2010.
233.	Masashi Akaike : 後期専門研修医の教育のあり方, 日本臨床麻酔学会第30回大会, Nov. 2010.
234.	遠藤桂輔, 斉藤憲, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 西尾進, 林修司, Takeshi Soeki, Masashi Akaike and Masataka Sata : 高度僧帽弁輪石灰化による多発性脳梗塞の1例, 第20回日本超音波医学会四国地方会学術集会, Oct. 2010.
235.	太田理恵, 冨田紀子, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 遠藤桂輔, 佐藤光代, Takeshi Soeki, Masashi Akaike and Masataka Sata : 産後の甲状腺機能亢進が診断の契機となったLeft Main Coronary Trunk Compression Syndromeの一例, 第20回日本超音波医学会四国地方会学術集会, Oct. 2010.
236.	河野裕美, Hirotsugu Yamada, 佐藤光代, 西尾進, 冨田紀子, 遠藤桂輔, Kenya Kusunose, Takeshi Soeki, Masashi Akaike and Masataka Sata : Intramural hematoma(IMH)を呈したStanford B型大動脈解離の二例, 第20回日本超音波医学会四国地方会学術集会, Oct. 2010.
237.	玉井利奈, Hirotsugu Yamada, 西尾進, 遠藤桂輔, Toshiyuki Niki, Kenya Kusunose, 冨田紀子, Takeshi Soeki, Masashi Akaike and Masataka Sata : 三次元心エコー法により術前診断ができたペースメーカーリードの弁尖穿通による重症三尖弁逆流の一例, 第20回日本超音波医学会四国地方会学術集会, Oct. 2010.
238.	林修司, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 冨田紀子, 遠藤桂輔, 玉井利奈, Takeshi Soeki, Masashi Akaike and Masataka Sata : 徐脈の高齢者において僧帽弁口血流波形がE>Aを呈するメカニズムについての検討, 第20回日本超音波医学会四国地方会学術集会, Oct. 2010.
239.	清水拓, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 玉井利奈, 遠藤桂輔, 佐藤光代, 河野裕美, Masashi Akaike and Masataka Sata : 運動負荷心エコー法を用いた膠原病例における潜在性肺動脈性肺高血圧症の検出, 第20回日本超音波医学会四国地方会学術集会, Oct. 2010.
240.	末広英也, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 佐藤光代, 冨田紀子, 玉井利奈, 遠藤桂輔, Masashi Akaike and Masataka Sata : 心室中隔肥厚を認めた心サルコイドーシスの1例, 第20回日本超音波医学会四国地方会学術集会, Oct. 2010.
241.	Masashi Akaike, Shusuke Yagi, Ken-ichi Aihara, 石川カズ江, Yasumasa Ikeda, Sumiko Yoshida, Yuka Ueda, Takashi Iwase, Toshio Matsumoto and Masataka Sata : ピタバスタチンによる血管内皮細胞での一酸化窒素合成酵素の発現亢進作用とその機序の検討, 第33回日本高血圧学会総会, 390, Oct. 2010. (Keyword) 血管内皮高血圧(薬物療法) Pitavastatin(治療的利用,薬理学) 内皮細胞 *Nitric Oxide Synthase Type III ヒト
242.	Hirotsugu Yamada, 三代裕一郎, Kenya Kusunose, Toshiyuki Niki, 林修司, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 高齢者および壮年者における高圧利尿薬インダパミドの少量追加投与の有効性と安全性-連日投与と隔日投与の比較-, 第33回日本高血圧学会総会, Oct. 2010.
243.	Koji Yamaguchi, Tetsuzo Wakatsuki, 坂東左知子, 久岡白陽花, Toshiyuki Niki, Kenya Kusunose, 冨田紀子, 竹内秀和, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike, Masataka Sata and 麻植塚浩康 : 冠動脈プラークに対する薬剤多面的効果の検討-Integrated backscatter IVUS観察による観点から-, 第58回日本心臓病学会学術集会, Sep. 2010.
244.	Tetsuzo Wakatsuki, Toshiyuki Niki, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : 薬剤溶出ステントによる冠動脈内皮機能障害の経年変化に関する検討, 第58回日本心臓病学会学術集会, Sep. 2010.
245.	冨田紀子, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 林修司, 遠藤桂輔, 河野裕美, 平岡葉月, 佐藤光代, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : S字状中隔を呈する例の心エコー・ドプラ所見についての検討, 第58回日本心臓病学会学術集会, Sep. 2010.
246.	坂東左知子, Takeshi Soeki, Toshiyuki Niki, 久岡白陽花, 竹内秀和, 平田陽一郎, 冨田紀子, Kenya Kusunose, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 脳性ナトリウム利尿ペプチド(BNP)と癌との関係について, 第58回日本心臓病学会学術集会, Sep. 2010.
247.	Takeshi Soeki, Toshiyuki Niki, 坂東左知子, 久岡白陽花, 竹内秀和, Kenya Kusunose, 冨田紀子, 平田陽一郎, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Kenji Kangawa and Masataka Sata : グレリンの心臓自律神経への作用と心血管系における意義, 第58回日本心臓病学会学術集会, Sep. 2010.
248.	林修司, Hirotsugu Yamada, 中田拓史, Kenya Kusunose, 西尾進, 冨田紀子, 玉井利奈, 遠藤桂輔, 河野裕美, 平岡葉月, 佐藤光代, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 僧帽弁口血流速波形用いた左室拡張能評価の限界:E>Aパターンを呈する高齢者での検討, 第58回日本心臓病学会学術集会, Sep. 2010.
249.	遠藤桂輔, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 冨田紀子, 三木淳子, 林修司, 玉井利奈, 河野裕美, 平岡葉月, 佐藤光代, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Ken Saito and Masataka Sata : EPA/AA比は冠動脈疾患の重症度に相関する:徳島大学病院循環器内科データベースを用いた検討, 第58回日本心臓病学会学術集会, Sep. 2010.
250.	Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Kenya Kusunose, Yoshio Taketani, Takashi Iwase, 冨田紀子, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : 薬剤溶出ステント植え込み慢性期における冠動脈局所凝固異常に対するスタチンの効果, 第58回日本心臓病学会学術集会, Sep. 2010.
251.	冨田紀子, Kenya Kusunose, 玉井利奈, 遠藤桂輔, 西尾進, 三木淳子, 林修司, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, 若槻哲三, Masashi Akaike and Masataka Sata : 出産後の甲状腺機能亢進症が発見の契機となったLeft Main Coronary Trunk Compression Syndromeの一例, 第58回日本心臓病学会学術集会, Sep. 2010.
252.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 玉井利奈, 遠藤桂輔, 三木淳子, 坂東左知子, Toshiyuki Niki, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 拡張型心筋症の左室内同期不全に対する前負荷増大の影響:3次元心エコー法を用いた検討, 第58回日本心臓病学会学術集会, Sep. 2010.
253.	玉井利奈, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 冨田紀子, 三木淳子, 林修司, 遠藤桂輔, 河野裕美, 平岡葉月, 佐藤光代, Takashi Iwase, 添木武, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 下肢陽圧負荷心エコー法が臨床的に有用であった肥大型心筋症の2例, 第58回日本心臓病学会学術集会, Sep. 2010.
254.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 林修司, 玉井利奈, 遠藤桂輔, 三木淳子, 竹崎彰夫, Hiroya Tada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Saburo Sone and Masataka Sata : コントラスト心エコー法で診断できたHepatopulmonary Syndoromeの1例, 第58回日本心臓病学会学術集会, Sep. 2010.
255.	Hirata Yoichiro, Tatsuo Motoki, Hirotsugu Kurobe, Masashi Akaike, Tabata Minoru, Takanashi Shuichiro, Igarashi Takashi, Tetsuya Kitagawa and Masataka Sata : Macrophage Polarization in Epicardial Adipose Tissue Enhances Atherosclerosis of Human Coronary Arteries., The58th Annual Scientific Session of the Japanese College of Cardiology, Sep. 2010.
256.	Masashi Akaike, Yoshiyasu Terashima, Hiroaki Mikasa, Toshio Doi and Yoshihiro Fukui : 共用試験医学系OSCE医療面接ステーションに並施した臨床推論筆記試験の試み, 第42回日本医学教育学会, Jul. 2010.
257.	Masashi Akaike, Hiroaki Mikasa, Tatsuya Okada, Tomiaki Morikawa, Yoshiyasu Terashima, Keisuke Izumi and Yoshihiro Fukui : WEB講義日程表による講義データベースの構築とその活用, 第42回日本医学教育学会, Jul. 2010.
258.	Masashi Akaike : 第42回日本医学教育学会ランチョンセミナー「専門医研修のブースター」 ―高度医療人養成推進事業とシミュレーション教育―人工心肺補助訓練および豚を用いた技能講習会, 第42回日本医学教育学会, Jul. 2010.
259.	Hiroaki Mikasa, Masashi Akaike, Yoshiyasu Terashima, Tetsuro Ohmori and Yoshihiro Fukui : 医学科卒業試験問題の難易度・識別力判定のための項目特性分析, 第42回日本医学教育学会大会, Jul. 2010.
260.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : A role of androgen receptor in ischemia-induced tissue damage and angiogenesis in male, 第42回日本動脈硬化学会総会・学術集会長良川国際会議場, Jul. 2010.
261.	Y. Sumiko, Ken-ichi Aihara, T. Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : A role of androgen receptor in iscchemia-induced tissue damage and angiogenesis in male., 第42回日本動脈硬化学会総会・学術集会, Jul. 2010.
262.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : アンドロゲンーアンドロゲン受容体系は下肢虚血における組織傷害防御と血管新生に必須である, 2010 年度(第 52 回)日本老年医学会学術集会神戸国際会議場・神戸商工会議所・神戸ポートピアホテル, Jun. 2010.
263.	小笠原梢, 仁木敏之, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, 冨田紀子, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Takeshi Soeki, Masashi Akaike, Masataka Sata and Tetsuya Kitagawa : IgA腎症ともやもや病を合併した若年発症の感染性心内膜炎の一例, 第96回日本循環器学会中国・四国合同地方会, Jun. 2010.
264.	岩河早保, Kenya Kusunose, Takashi Iwase, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, 冨田紀子, Yoshio Taketani, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, 橋詰俊二, 木村建彦 and 西内健 : 出産後left main compression syndromeによる狭心症を発症した心内膜床欠損(不完全型)の1例, 第96回日本循環器学会中国・四国合同地方会, Jun. 2010.
265.	坂東美佳, Koji Yamaguchi, Takashi Iwase, Kenya Kusunose, 仁木敏之, 冨田紀子, Kunihiko Koshiba, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 高度拡張不全による心不全症状の再燃を認めた心尖部肥大型心筋症の1例, 第96回日本循環器学会中国・四国合同地方会, Jun. 2010.
266.	阿部容子, Takeshi Soeki, 仁木敏之, Kenya Kusunose, 平田陽一郎, 冨田紀子, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, 坂東正章, 清水渉 and Masataka Sata : KCNH2遺伝子にダブル変異を認めた先天性QT延長症候群の1例, 第96回日本循環器学会中国・四国合同地方会, Jun. 2010.
267.	Kenya Kusunose, Yoshio Taketani, 西尾進, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Takashi Iwase, 冨田紀子, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 右腎癌摘出後に心不全を繰り返した腎動脈狭窄症の一例, 第96回日本循環器学会中国・四国合同地方会, Jun. 2010.
268.	仁木敏之, Takeshi Soeki, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takashi Iwase, 冨田紀子, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心電図異常が乏しいBrugada症候群の1例, 第96回日本循環器学会中国・四国合同地方会, Jun. 2010.
269.	鹿草宏, 仁木敏之, Kenya Kusunose, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 急性大動脈解離の1例, 日本内科学会第102回四国地方会, May 2010.
270.	原知也, 仁木敏之, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata and 関啓 : 大動脈二尖弁における感染性心内膜炎に合併した大動脈弁輪周囲膿瘍の1例, 日本内科学会第102回四国地方会, May 2010.
271.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 林修司, 河野裕美, 佐藤光代, Takeshi Soeki, Masashi Akaike and Masataka Sata : 虚血の診断に有用な指標は何か?, 日本超音波医学会第83回学術集会, May 2010.
272.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 林修司, 河野裕美, 佐藤光代, Takeshi Soeki, Masashi Akaike and Masataka Sata : 卵円孔開存の診断におけるコントラストリアルタイム3次元経食道心エコー法の有用性, 日本超音波医学会第83回学術集会, May 2010.
273.	高島弘光, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 冨田紀子, 三村千尋, 佐藤光代, Takeshi Soeki, Masashi Akaike and Masataka Sata : 大動脈弁硬化における頸動脈の動脈硬化所見の検討, 日本超音波医学会第83回学術集会, May 2010.
274.	Hirotsugu Yamada, Kenya Kusunose, 西尾進, 河野裕美, 佐藤光代, 冨田紀子, 林修司, Takeshi Soeki, Masashi Akaike and Masataka Sata : 下肢陽圧負荷時の僧帽弁口血流速波形の反応性を用いた軽症心不全患者の予後予測:''前負荷ストレス心エコー法''の臨床応用, 日本超音波医学会第83回学術集会, May 2010.
275.	Yoshio Taketani, Tetsuzo Wakatsuki, Hirotsugu Yamada, Koji Yamaguchi, 西尾進, Kenya Kusunose, 冨田紀子, 林修司, 仁木敏之, Kunihiko Koshiba, Takashi Iwase, Takeshi Soeki, Masashi Akaike and Masataka Sata : スタチンによる冠動脈プラーク性状の短期変化についてのIB-IVUSを用いた検討, 第21回日本心エコー図学会学術集会, May 2010.
276.	林修司, Hirotsugu Yamada, 西尾進, Kenya Kusunose, 冨田紀子, 河野裕美, 平岡葉月, 佐藤光代, 三木淳子, 仁木敏之, Koji Yamaguchi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 3次元経食道心エコー(3D-TEE)法にて経過が観察できた巨大左心耳血栓の1例, 第21回日本心エコー図学会学術集会, May 2010.
277.	遠藤桂輔, Hirotsugu Yamada, 西尾進, 冨田紀子, Kenya Kusunose, 林修司, 佐藤光代, 平岡葉月, 河野裕美, 三木淳子, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata and Ken Saito : リアルタイム3次元経食道エコー法により観察しえた孤立性僧帽弁クレフトの1例, 第21回日本心エコー図学会学術集会, May 2010.
278.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, Takashi Iwase, 冨田紀子, 林修司, 三木淳子, 遠藤桂輔, 河野裕美, 平岡葉月, 佐藤光代, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心房のみの心アミロイドーシスにおける心筋局所ストレインとMRIガドリニウム遅延造影所見の比較, 第21回日本心エコー図学会学術集会, May 2010.
279.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 林修司, 遠藤桂輔, 河野裕美, 平岡葉月, 佐藤光代, 三木淳子, Yoshio Taketani, Takeshi Soeki, Masashi Akaike and Masataka Sata : コントラスト心エコー法で診断した肝肺症候群の1例, 第21回日本心エコー図学会学術集会, May 2010.
280.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 林修司, 三木淳子, 遠藤桂輔, 河野裕美, 平岡葉月, 佐藤光代, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心房のみの心病変を認めた多発性筋炎の一例, 第21回日本心エコー図学会学術集会, May 2010.
281.	中田拓史, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 冨田紀子, 林修司, 遠藤桂輔, 河野裕美, 平岡葉月, 佐藤光代, 三木淳子, Yoshio Taketani, Takeshi Soeki, Masashi Akaike and Masataka Sata : 僧帽弁口血流速波形がE>Aパターンを呈する高齢者の内訳, 第21回日本心エコー図学会学術集会, May 2010.
282.	Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Toshio Matsumoto, Takashi Iwase, Masashi Akaike and Masataka Sata : ロスバスタチンによる心筋リモデリング抑制効果の検討, 第83回日本内分泌学会学術総会, Mar. 2010.
283.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Accelerated cellular apoptosis and impaired angiogenesis after hindlimb ischemia in male mice lacking androgen receptor, 第74回日本循環器学会総会・学術集会国立京都国際会館, Mar. 2010.
284.	Hirotsugu Kurobe, 浦田将久, Yayoi Fukuhara, Tamotsu Kanbara, Ken-ichi Aihara, Masashi Akaike, Yousuke Takahama, Toshiaki Tamaki, Toshio Matsumoto, Shuhei Tomita and Tetsuya Kitagawa : 血管リモデリング時の転写因子HIF-1αの役割 (第110回日本外科学会定期学術集会), Journal of Japan Surgical Society, Vol.111, No.2, 701, Mar. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543027394884480 (CiNii: 1572543027394884480)
285.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 遠藤桂輔, 河野裕美, 佐藤光代, Takeshi Soeki, Masashi Akaike, Masataka Sata and 平岡葉月 : 心エコー・ドプラ指標により前負荷軽減に対する心反応性は予測できるか, 日本超音波医学会四国地方会, Dec. 2009.
286.	Tatsuya Okada, Tomiaki Morikawa, Yuu Tamaki, Masato Tagi, Hiroki Moriguchi, Yoshiyasu Terashima, Hiroaki Mikasa, Masashi Akaike and Yoneo Yano : PBLにおけるシナリオ作成支援, 医療情報学連合大会論文集29回, 913-914, Nov. 2009.
287.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, 住友由佳, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Hirotsugu Yamada, Masataka Sata and 西尾進 : 副腎アンドロゲンDHEASの抗動脈硬化作用における性差の検討, 第32回日本高血圧学会学術集会, Oct. 2009.
288.	Ken-ichi Aihara, Yuichi Fujinaka, Mizuho Kinouchi, Sumiko Yoshida, 鈴木麗子, 倉橋清衛, Itsuro Endo, Shusuke Yagi, Takashi Iwase, 平田陽一郎, Masashi Akaike, Masataka Sata and Toshio Matsumoto : 内臓脂肪蓄積制御に関わる因子の臨床的検討, 第32回日本高血圧学会総会, 196, Oct. 2009. (Keyword) LDL Cholesterol 危険因子 *腹腔内脂肪(X線診断) ヒト中年(45~64) 高齢者(65~79) 男女
289.	Sumiko Yoshida, Ken-ichi Aihara, 伊勢孝之, 上田由佳, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Masashi Akaike, Masataka Sata and Toshio Matsumoto : 副腎アンドロゲンDHEASの抗動脈硬化作用における性差の検討, 第32回日本高血圧学会総会, Oct. 2009.
290.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, 石川カズ江, Sumiko Yoshida, Yuka Ueda, Shusuke Yagi, Takashi Iwase, Toshio Matsumoto and Masataka Sata : ミネラルコルチコイド受容体を介したグルココルチコイド過剰による血管内皮細胞障害作用, 第32回日本高血圧学会総会, 244, Oct. 2009. (Keyword) Glucocorticoids 血管内皮細胞系 Mineralocorticoid Receptors 内皮細胞ヒト
291.	Koji Yamaguchi, Tetsuzo Wakatsuki, 仁木敏之, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, 冨田紀子, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : シロリムス溶出性ステント留置後における局所凝固反応とステント長の関連性, 第57回日本心臓病学会学術集会, Sep. 2009.
292.	Takashi Iwase, Shoichiro Takao, Masashi Akaike, 足立克仁, Shusuke Yagi, 仁木敏之, Kenya Kusunose, Koji Yamaguchi, Kunihiko Koshiba, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masafumi Harada, Hiromu Nishitani and Masataka Sata : Duchenne型筋ジストロフィー女性キャリアにおける心病変早期検出の試み-心臓MRIによる検討-, 第57回日本心臓病学会学術集会, Sep. 2009.
293.	冨田紀子, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 遠藤桂輔, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 大動脈弁硬化の進行に関連する因子, 第57回日本心臓病学会学術集会, Sep. 2009.
294.	Kunihiko Koshiba, Takeshi Soeki, 仁木敏之, Kenya Kusunose, 平田陽一郎, Koji Yamaguchi, 冨田紀子, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Th1/Th2バランスの改善を介したPravastatinの実験的自己免疫性心筋炎抑制効果, 第57回日本心臓病学会学術集会, Sep. 2009.
295.	Tetsuzo Wakatsuki, Koji Yamaguchi, 仁木敏之, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Yoshio Taketani, 冨田紀子, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : 薬剤溶出ステント植え込み後慢性期の冠動脈局所炎症と凝固異常遷延の関連性, 第57回日本心臓病学会学術集会, Sep. 2009.
296.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 遠藤桂輔, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心房細動におけるE/e'の計測法:dual Doppler法を用いた検討, 第57回日本心臓病学会学術集会, Sep. 2009.
297.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 佐藤光代, 平岡葉月, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : ASD，PSに合併した右室転移性腫瘤の1例, 第57回日本心臓病学会学術集会, Sep. 2009.
298.	Takeshi Soeki, 仁木敏之, Kunihiko Koshiba, Kenya Kusunose, 平田陽一郎, Koji Yamaguchi, Shusuke Yagi, 冨田紀子, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 血漿pentraxin3 (PTX3)濃度は冠動脈不安定プラークの指標となり得るか?, 第57回日本心臓病学会学術集会, Sep. 2009.
299.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 遠藤桂輔, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 僧帽弁口血流と僧帽弁輪運動の開始時間の差は左室拡張末期圧を反映する:下肢陽圧負荷を用いた検討, 第57回日本心臓病学会学術集会, Sep. 2009.
300.	近藤可菜, Shusuke Yagi, Masashi Akaike, Takashi Iwase, Kenya Kusunose, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, 冨田紀子, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 重症心不全患者に対するAdaptive-servo ventilator療法の効果, 第239回徳島医学会学術集会, Aug. 2009.
301.	平田陽一郎, 仁木敏之, Koji Yamaguchi, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata, Hirotsugu Kurobe, Tamotsu Kanbara, 筑後文雄, Tetsuya Kitagawa and 堀貴樹 : 冠動脈周囲脂肪組織におけるマクロファージ浸潤の動脈硬化病変形成に与える影響, 第239回徳島医学会学術集会, Aug. 2009.
302.	Ken-ichi Aihara, Yuichi Fujinaka, Mizuho Kinouchi, Sumiko Yoshida, 倉橋清衛, Itsuro Endo, Yuka Ueda, 平田陽一郎, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Influence of lipid profile on endothelial function in subjects with cardiovascular risk factors, 第41回日本動脈硬化学会総会・学術集会, Jul. 2009.
303.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Regular use of rosuvastatin attenuates carotid atherosclerosis regardless of LDL cholesterol lowering effect, 第41回日本動脈硬化学会総会・学術集会, Jul. 2009.
304.	平岡葉月, Hirotsugu Yamada, 西尾進, 佐藤光代, Kenya Kusunose, 冨田紀子, Masashi Akaike, Takashi Kitaichi, Tetsuya Kitagawa and Masataka Sata : 3D経食道心エコー法で診断できた僧帽弁位人工弁機能不全の一例, 第34回日本超音波検査学会, Jun. 2009.
305.	仁木敏之, Tetsuzo Wakatsuki, Koji Yamaguchi, Kenya Kusunose, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, 冨田紀子, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : たこつぼ型心筋障害の亜型と考えられた左室mid-portion ballooningの二例, 第94回日本循環器学会中国・四国合同地方会, Jun. 2009.
306.	Kenya Kusunose, Hirotsugu Yamada, 冨田紀子, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心エコーによる心病変の経過観察が可能であった続発性(AA)アミロイドーシスの一例, 第94回日本循環器学会中国・四国合同地方会, Jun. 2009.
307.	Kunihiko Koshiba, 仁木敏之, Kenya Kusunose, 平田陽一郎, Koji Yamaguchi, 冨田紀子, Yoshio Taketani, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Takeshi Soeki, Masashi Akaike and Masataka Sata : 多発性筋炎に伴う心障害の一例, 第94回日本循環器学会中国・四国合同地方会, Jun. 2009.
308.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 平岡葉月, 佐藤光代, 多田津陽子, 冨田紀子, Takeshi Soeki, Masashi Akaike and Masataka Sata : 安静時post systolic shortening による虚血心筋の検出, 日本超音波医学会第82回学術集会, May 2009.
309.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 平岡葉月, 佐藤光代, 多田津陽子, 冨田紀子, Takeshi Soeki, Masashi Akaike and Masataka Sata : 下肢静脈血栓スクリーニング検査で発見されたベーカー嚢胞破裂の2症例, 日本超音波医学会第82回学術集会, May 2009.
310.	鶴尾美穂, 寺澤敏秀, 三原正明, Tomoyuki Yuasa, 江尻純子, 笠松哲司, 瀬尾浩二, Mizuho Kinouchi, 工藤美千代, Sumiko Yoshida and Masashi Akaike : 著名な高Lp(a)血症を合併した糖尿病患者における血管障害の検討, 第52回日本糖尿病学会年次学術集会, May 2009.
311.	倉橋清衛, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Yuichi Fujinaka, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : 一酸化炭素中毒にて急性心筋梗塞を発症した2型糖尿病の1例, 第100回日本内科学会四国地方会, May 2009.
312.	Shusuke Yagi, Takashi Iwase, Masashi Akaike, Koji Yamaguchi, Kunihiko Koshiba, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki and Masataka Sata : 重症心不全患者における酸素療法とAdaptive-servo ventilator療法の効果の比較検討, 日本内科学会第100回四国地方会, May 2009.
313.	Itsuro Endo, 藤村光則, Sumiko Yoshida, 栗若里佳, Shinsuke Kido, Takashi Iwase, Daisuke Inoue, Ken-ichi Aihara, Yuichi Fujinaka, Masashi Akaike and Toshio Matsumoto : 冠動脈不安定プラーク予測因子としてのICTP, 第82回日本内分泌学会学術総会, Vol.85, No.1, 283, Apr. 2009. (Keyword) 生物学的マーカー Peptide Fragments(血液) 冠状動脈硬化症(診断) 動脈硬化症-アテローム性(診断) Collagen Type I(血液) *ICTP (Collagen Type I C-Terminal Telopeptides)(血液) ヒト男女
314.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, 石川カズ江, 住友由佳, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Toshio Matsumoto and Masataka Sata : グルココルチコイド誘発性血管内皮細胞障害におけるミネラルコルチコイド受容体の関与, 第82回日本内分泌学会学術総会, Vol.85, No.1, 373, Apr. 2009. (Keyword) Glucocorticoids(毒性・副作用) 血管内皮培養細胞 Mineralocorticoid Receptors(薬理学) 内皮細胞ヒト
315.	Sumiko Yoshida, Ken-ichi Aihara, 西尾進, 倉橋清衛, Itsuro Endo, Yuichi Fujinaka, Takayuki Ise, 住友由佳, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Masashi Akaike, Masataka Sata and Toshio Matsumoto : 副腎アンドロゲンDHEASは血管内皮機能非依存的に頸動脈硬化を抑制する, 第82回日本内分泌学会学術総会, Vol.85, No.1, 366, Apr. 2009. (Keyword) 頸動脈疾患血管内皮動脈硬化症 Dehydroepiandrosterone Sulfate(薬理学) ヒト男女
316.	佐藤光代, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 平岡葉月, 冨田紀子, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 経食道心エコー検査により治療経過が観察できた高安動脈炎に伴う肺動脈狭窄症の一例, 第20回日本心エコー図学会学術集会, Apr. 2009.
317.	平岡葉月, Hirotsugu Yamada, 西尾進, 佐藤光代, 高松直子, Kenya Kusunose, 冨田紀子, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心エコーによる心病変の経過観察が可能であった続発性(AA)アミロイドーシスの一例, 第20回日本心エコー図学会学術集会, Apr. 2009.
318.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 平岡葉月, 佐藤光代, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 三尖弁輪運動速波形を用いた二次性肺高血圧の評価, 第20回日本心エコー図学会学術集会, Apr. 2009.
319.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 平岡葉月, 佐藤光代, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : Post systolic shortening(PSS)による心筋虚血の検出, 第20回日本心エコー図学会学術集会, Apr. 2009.
320.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 平岡葉月, 佐藤光代, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 僧帽弁口血流と僧帽弁輪運動の不整合は左室拡張能の評価に有用か:dual Doppler systemを用いた検討, 第20回日本心エコー図学会学術集会, Apr. 2009.
321.	Sumiko Yoshida, Ken-ichi Aihara, 倉橋清衛, Itsuro Endo, Yuichi Fujinaka, 住友由佳, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase and Masashi Akaike : DHEASは血管内皮機能に依存せず動脈硬化を抑制する(頸動脈エコーを用いた臨床的検討), 第106回日本内科学会総会・講演会, Vol.98, No.Suppl., 139, Apr. 2009. (Keyword) 頸動脈(超音波診断) 超音波診断動脈硬化症(超音波診断) Dehydroepiandrosterone Sulfate(薬理学,血液) ヒト男女
322.	Ken-ichi Aihara, Sumiko Yoshida, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Toshio Matsumoto, Takashi Iwase, Masashi Akaike and Masataka Sata : ロスバスタチンによる心筋リモデリング抑制効果の検討, 第83回日本内分泌学会学術総会国立京都国際会館, Mar. 2009.
323.	Ken-ichi Aihara, Sumiko Yoshida, Takayuki Ise, Sumitomo Yuka, Shusuke Yagi, Takashi Iwase, Kurahashi Kiyoe, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Increased serum triglyceride but not LDL cholesterol is associated with left ventricular diastolic dysfunction., 第73回日本循環器学会総会・学術集会, Mar. 2009.
324.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, 住友由佳, Shusuke Yagi, Takashi Iwase, 倉橋清衛, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Dehydroepiandrosterone sulfate is an antivascular remodeling factor, 第73回日本循環器学会総会・学術集会, Mar. 2009.
325.	住友由佳, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : Heparin Cofactor II-deficient Mice Exert Exacerbation of Angiotensin II-induced Cardiac Remodeling through Enhancement of NADPH oxidase - TGF- 1 Pathway, 第73回日本循環器学会総会・学術集会, Mar. 2009.
326.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, 石川カズ江, Sumiko Yoshida, 住友由佳, Shusuke Yagi, Takashi Iwase, Toshio Matsumoto and Masataka Sata : Glucocorticoid Excess Causes Vascular Endothelial Cell Dysfunction through Activation of Mineral Corticoid Receptor, 第73回日本循環器学会総会・学術集会, Mar. 2009.
327.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 仁木敏之, 冨田紀子, 山口浩司, 小柴邦彦, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, 河野智彦 and Masataka Sata : 右心不全を契機に診断された肺動脈狭窄症の一例, 第93回日本循環器学会四国地方会, Dec. 2008.
328.	Shusuke Yagi, Takashi Iwase, Kenya Kusunose, 仁木敏之, 山口浩司, 小柴邦彦, 冨田紀子, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 強皮症に伴う難治性末梢循環不全に対するエンドセリン受容体拮抗薬の有用性, 第93回日本循環器学会四国地方会, Dec. 2008.
329.	小柴邦彦, Takeshi Soeki, 仁木敏之, Kenya Kusunose, 山口浩司, 冨田紀子, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 両側肺血栓症と多発性体循環系塞栓症を合併した1例, 第93回日本循環器学会四国地方会, Dec. 2008.
330.	山口浩司, Tetsuzo Wakatsuki, 仁木敏之, Kenya Kusunose, 小柴邦彦, 冨田紀子, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : 冠動脈ステント3種(CYPHER, TAXUS, DRIVER)の慢性期病理組織所見の比較と局所凝固反応の関連性, 第93回日本循環器学会四国地方会, Dec. 2008.
331.	Itsuro Endo, 藤村光則, Sumiko Yoshida, 栗若里佳, Shinsuke Kido, Takashi Iwase, Daisuke Inoue, Ken-ichi Aihara, Yuichi Fujinaka, Masashi Akaike and Toshio Matsumoto : 冠動脈不安定プラーク予測因子としてのICTP, 第26回日本骨代謝学会学術集会, 194, Oct. 2008. (Keyword) Peptide Fragments(血液) 冠状動脈硬化症 Collagen Type I(血液) ICTP (Collagen Type I C-Terminal Telopeptides)(血液) ヒト男女
332.	Ken-ichi Aihara, Sumiko Yoshida, Takayuki Ise, 住友由佳, 倉橋清衛, Itsuro Endo, Yuichi Fujinaka, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : 左室拡張能に対する脂質代謝異常の意義, 第31回日本高血圧学会総会, Oct. 2008.
333.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, 住友由佳, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : 副腎アンドロゲンDHEASは頚動脈血流の制御因子である, 第31回日本高血圧学会学術集会, Oct. 2008.
334.	住友由佳, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Masashi Akaike and Masataka Sata : ヘパリンコファクターⅡは抗酸化ストレス作用を介してアンジオテンシンIIによる心房および心室のリモデリングを抑制する, 第31回日本高血圧学会総会, Oct. 2008.
335.	Masashi Akaike, Shusuke Yagi, Ken-ichi Aihara, 石川カズ江, Yasumasa Ikeda, Sumiko Yoshida, 住友由佳, Takashi Iwase, 阿部純一, Toshio Matsumoto and Masataka Sata : ピタバスタチンはERK5-KLF2経路の活性化を介して血管内皮細胞での一酸化窒素合成酵素の発現を亢進する, 第31回日本高血圧学会総会, Oct. 2008.
336.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, 住友由佳, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : 副腎アンドロゲンDHEASの血管への作用(頚動脈エコーを用いた臨床的検討), 第13回武田高血圧シンポジウム, Oct. 2008.
337.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 佐藤光代, 高松直子, Takeshi Soeki, Masashi Akaike and Masataka Sata : 頸動脈狭窄性病変におけるB-Flowの有用性, 第18回日本超音波医学会四国地方会学術集会, Oct. 2008.
338.	山中森晶, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 佐藤光代, Takeshi Soeki, Masashi Akaike and Masataka Sata : 壁運動正常例におけるpost systolic shortening (PSS) についての検討, 第18回日本超音波医学会四国地方会学術集会, Oct. 2008.
339.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 佐藤光代, Takeshi Soeki, Masashi Akaike, 阿部美保, 河野和弘, 角谷昭佳 and Masataka Sata : リアルタイム3次元経食道心エコー図で診断しえた肺動脈狭窄症の一例, 第18回日本超音波医学会四国地方会学術集会, Oct. 2008.
340.	西尾進, Hirotsugu Yamada, Kenya Kusunose, 仁木敏之, 山口浩司, Shusuke Yagi, 小柴邦彦, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Yasunori Nagamine and Masataka Sata : Automated Function Imaging法による左室局所壁運動異常評価:心エコー初心者による肉眼的評価との比較, 第56回日本心臓病学会学術集会, Sep. 2008.
341.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 仁木敏之, 山口浩司, Shusuke Yagi, 小柴邦彦, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 高血圧性心疾患における左房ポンプ機能の評価:Left Atrial Ejection Forceを用いた検討, 第56回日本心臓病学会学術集会, Sep. 2008.
342.	Tetsuzo Wakatsuki, 山口浩司, 仁木敏之, Kenya Kusunose, 小柴邦彦, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Masashi Akaike and Masataka Sata : 薬剤溶出ステント植え込み後の冠動脈内皮機能障害と局所炎症遷延の関連性, 第56回日本心臓病学会学術集会, Sep. 2008.
343.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 仁木敏之, 山口浩司, Shusuke Yagi, 小柴邦彦, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心房細動におけるTEI indexの有用性:Dual Doppler法を用いた検討, 第56回日本心臓病学会学術集会, Sep. 2008.
344.	仁木敏之, Takeshi Soeki, 小柴邦彦, Kenya Kusunose, 山口浩司, Shusuke Yagi, Takashi Iwase, Hirotsugu Yamada, Tetsuzo Wakatsuki, Masashi Akaike, 福田大和, 篠原尚典, 福田信夫, 田村禎通 and Masataka Sata : 虚血性心疾患におけるHMGBI (high mobility group box 1) の診断的意義, 第56回日本心臓病学会学術集会, Sep. 2008.
345.	Ken-ichi Aihara, Sumiko Yoshida, Takayuki Ise, 住友由佳, Shusuke Yagi, Takashi Iwase, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike and Toshio Matsumoto : 脂質代謝異常による左室拡張障害の臨床的検討, 第40回日本動脈硬化学会総会, 249, Jul. 2008. (Keyword) 脂質異常症(合併症) / 左心室機能障害(病因) / Homo sapiens / male / female
346.	Sumiko Yoshida, Ken-ichi Aihara, Takayuki Ise, 住友由佳, Shusuke Yagi, Takashi Iwase, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike and Toshio Matsumoto : 副腎アンドロゲンの頸動脈硬化抑制作用に関する検討, 第40回日本動脈硬化学会総会, 253, Jul. 2008. (Keyword) Androgens(治療的利用) / 頸動脈疾患(予防) / 頸動脈疾患(予防) / 動脈硬化症(予防) / 副腎 / Homo sapiens / male / female
347.	Shusuke Yagi, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, 住友由佳, Yasumasa Ikeda, 岩瀬俊, Takeshi Soeki, Masashi Akaike and Toshio Matsumoto : ピタバスタチンはRac-1を介した酸化ストレス制御によりeNOS非依存的にアンジオテンシンIIによる心房リモデリングを抑制する, 第40回日本動脈硬化学会総会, 203, Jul. 2008. (Keyword) Angiotensin II 抗酸化剤(治療的利用) 心房動脈硬化症(薬物療法) 酸化ストレス rac GTP-Binding Proteins 心室リモデリング *Pitavastatin(治療的利用) マウス動物
348.	Sumiko Yoshida, Ken-ichi Aihara, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Takayuki Ise, 住友由佳, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : 頸動脈血行動態における副腎アンドロゲンの臨床的意義, 第81回日本内分泌学会学術総会, Vol.84, No.1, 202, May 2008. (Keyword) Androgens(血液) 頸動脈 *副腎血行力学ヒト成人(19~44) 男女
349.	Ken-ichi Aihara, Sumiko Yoshida, Takayuki Ise, 住友由佳, Shusuke Yagi, Takashi Iwase, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike and Toshio Matsumoto : 左室拡張能における脂質代謝異常の影響に関する検討, 第81回日本内分泌学会学術総会, Vol.84, No.1, 222, May 2008. (Keyword) 脂質異常症左心室機能ヒト成人(19~44) 男女
350.	三原正朋, Ken-ichi Aihara, Yuichi Fujinaka, Chisato Kosugi, Mizuho Kinouchi, Masashi Akaike and Toshio Matsumoto : トロンビンによるインスリン抵抗性制御機構の解析, 第52回日本糖尿病学会年次学術集会, Vol.51, No.Suppl.1, S-126, May 2008. (Keyword) Thrombin(治療的利用) インスリン抵抗性(薬物療法) 3T3-L1細胞マウス動物
351.	岡田早未, Hirotsugu Yamada, Kenya Kusunose, 佐藤光代, 平岡葉月, 西尾進, 河野裕美, 多田津陽子, Takeshi Soeki and Masashi Akaike : 高血圧性心疾患における左室リモデリングと左室拡張能の関連, 第81回日本超音波医学会学術集会, May 2008.
352.	佐藤光代, Hirotsugu Yamada, Kenya Kusunose, 平岡葉月, 西尾進, 河野裕美, 多田津陽子, Takeshi Soeki and Masashi Akaike : 高血圧患者における心電図の左房負荷は何を表しているか?-心エコー・ドプラ法による再検討-, 第81回日本超音波医学会学術集会, May 2008.
353.	Kenya Kusunose, Hirotsugu Yamada, 河野裕美, 西尾進, 平岡葉月, 佐藤光代, 多田津陽子, Takeshi Soeki and Masashi Akaike : 心房細動症例におけるTEI indexの有用性:Dual Doppler法を用いた検討, 第81回日本超音波医学会学術集会, May 2008.
354.	Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, 住友由佳, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : 1α 25 dihydroxyvitamin D3 is a protective factor against vascular remodeling and glucose tolerance in elderly individuals, 第72回日本循環器学会学術集会, Mar. 2008.
355.	住友由佳, Ken-ichi Aihara, Takayuki Ise, Sumiko Yoshida, Shusuke Yagi, Takashi Iwase, 石川カズ江, Masashi Akaike and Toshio Matsumoto : Angiotensin II-induced cardiac remodeling is exacerbated with increased oxidative stress in heparin cofactor II-deficient mice., 第72回日本循環器学会総会・学術集会, Mar. 2008.
356.	Masashi Akaike, Shusuke Yagi, Ken-ichi Aihara, Yasumasa Ikeda, 石川カズ江, Takayuki Ise, Sumiko Yoshida, 住友由佳, Takashi Iwase, Abe Jun-ichi and Toshio Matsumoto : HMG-CoA Reductase Inhibitor Pitavastatin Increases the Expression of Endothelial NOS through Activation of ERK5-KLF2 Pathway in Vascular Endothelial Cells, 第72回日本循環器学会学術集会, Mar. 2008.
357.	Kenya Kusunose, Hirotsugu Yamada, 仁木敏之, 山口浩司, 小柴邦彦, Takeshi Soeki, Tetsuzo Wakatsuki, Shusuke Yagi, Takashi Iwase, Masashi Akaike, 阿部美保 and Tetsuya Kitagawa : 両心房腫瘤の一例, 第102回UCG談話会, Feb. 2008.
358.	Kenya Kusunose, Takeshi Soeki, 仁木敏之, 山口浩司, 小柴邦彦, Hirotsugu Yamada, Tetsuzo Wakatsuki, Shusuke Yagi, Takashi Iwase and Masashi Akaike : 心エコーで心室中隔瘤の診断に苦慮した心サルコイドーシスの一例, 第91回日本循環器学会四国地方会学術集会, Nov. 2007.
359.	住友由佳, Ken-ichi Aihara, Takayuki Ise, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : レニン・アンジオテンシン活性下におけるヘパリンコファクターIIの心筋リモデリングへの影響, 第30回日本高血圧学会総会, 170, Oct. 2007. (Keyword) Angiotensins Heparin Cofactor II Renin 心室リモデリングマウス動物
360.	Shusuke Yagi, Ken-ichi Aihara, Yasumasa Ikeda, Takayuki Ise, 住友由佳, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : Pitavastatinはangiotensin IIによる心腎障害をeNOS非依存性にrac1抑制による酸化ストレス抑制を介して改善する, 第30回日本高血圧学会総会, 205, Oct. 2007. (Keyword) Angiotensin II 心臓疾患(実験的) 腎臓疾患(実験的) 酸化ストレスノックアウトマウス rac GTP-Binding Proteins Pitavastatin(薬理学) マウス動物
361.	Masashi Akaike, Ken-ichi Aihara, Shusuke Yagi, Yasumasa Ikeda, 石川カズ江, 住友由佳, Takashi Iwase and Toshio Matsumoto : グルココルチコイド誘発性高血圧に対するピタバスタチンの効果とその機序の検討, 第30回日本高血圧学会総会プログラム, 210, Oct. 2007. (Keyword) Glucocorticoids 高血圧(薬物療法,実験的) C57BLマウス Pitavastatin(治療的利用,薬理学) マウス動物オス
362.	Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, Takayuki Ise, 住友由佳, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : 血管リモデリング制御因子としての活性化ビタミンD, 第30回日本高血圧学会総会, 260, Oct. 2007. (Keyword) Vitamin D(治療的利用) 動脈硬化症(薬物療法,診断) *血管リモデリングヒト男女
363.	Ken-ichi Aihara, Sumiko Yoshida, Takeshi Kondo, 栗若里佳, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Shusuke Yagi, 住友由佳, Masashi Akaike and Toshio Matsumoto : 活性型ビタミンDは血漿アンチトロンビン活性の制御に関与する, 日本内分泌学会第7回四国支部学術集会, Vol.83, No.4, 834, Sep. 2007. (Keyword) Antithrombins(血液) Calcitriol(治療的利用,薬理学) ヒト中年(45~64) 高齢者(65~79) 男女
364.	Kenya Kusunose, Hirotsugu Yamada, 仁木敏之, 山口浩司, 小柴邦彦, Tomohito Kawano, Takeshi Soeki, Tetsuzo Wakatsuki, Shusuke Yagi, Takashi Iwase, Masashi Akaike, 谷口哲三 and Shoichiro Takao : 不可解な心電図異常を呈し，肥大型心筋症を疑う1例, 第12回中国四国心筋症研究会, Sep. 2007.
365.	Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, 住友由佳, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : 活性化ビタミンDは臨床的動脈硬化抑制因子である, 第39回日本動脈硬化学会総会・学術集会, 250, Jul. 2007. (Keyword) Calcitriol(血液) 断面研究動脈硬化症(予防) ヒト中年(45~64) 高齢者(65~79) 男女
366.	Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, 住友由佳, Takashi Iwase, Takeshi Kondo, 重清友理, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Masashi Akaike and Toshio Matsumoto : 活性化ビタミンDの抗動脈硬化作用に関する臨床的検討, 第80回日本内分泌学会学術総会, Vol.83, No.1, 159, Jun. 2007. (Keyword) Calcitriol(治療的利用,薬理学) 動脈硬化症(薬物療法,診断) Maxacalcitol(血液) ヒト中年(45~64) 高齢者(65~79) 男女
367.	Takashi Iwase, 住友由佳, Shusuke Yagi, Yasumasa Ikeda, Ken-ichi Aihara, Shuji Ozaki, Masashi Akaike, Masahiro Abe, Toshio Matsumoto and Tetsuya Kitagawa : エリスロポイエチンを用いた新たな血管新生療法の試み, 第104回日本内科学会総会・講演会, Vol.96, No.Suppl., 133, Apr. 2007. (Keyword) Erythropoietin(治療的利用) 血液成分除去法動脈閉塞性疾患(治療) *末梢血幹細胞移植ヒト
368.	Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Shusuke Yagi, 住友由佳, Takashi Iwase, Hiroyuki Azuma and Toshio Matsumoto : 活性化ビタミンDによる血管リモデリング制御作用, 第104回日本内科学会総会・講演会, Vol.96, No.Suppl., 194, Apr. 2007. (Keyword) Vitamin D(治療的利用) 動脈閉塞性疾患(診断,薬物療法) 末梢血管疾患(診断,薬物療法) 血管リモデリングヒト中年(45~64) 高齢者(65~79) 男女
369.	Shusuke Yagi, Ken-ichi Aihara, Yasumasa Ikeda, 住友由佳, Takashi Iwase, Masashi Akaike and Toshio Matsumoto : PitavastatinはAngiotensin IIによる心血管リモデリングと腎障害をeNOS非依存性に抑制する, 第36回日本心脈管作動物質学会, Vol.30, No.1, 24, Feb. 2007. (Keyword) Angiotensin II(毒性・副作用) 腎臓疾患(実験的,化学的誘発) 経口投与酸化ストレス心室リモデリング Pitavastatin(薬理学) 血管リモデリング *Nitric Oxide Synthase Type III マウス動物
370.	Yasumasa Ikeda, Ken-ichi Aihara, Masashi Akaike, 住友由佳, Shusuke Yagi, Takashi Iwase, Hiroyuki Azuma, 加藤茂明 and Toshio Matsumoto : アンドロゲン-アンドロゲン受容体システムによる血管リモデリング制御機構の解析, 第36回日本心脈管作動物質学会, Vol.30, No.1, 35, Feb. 2007. (Keyword) Androgens Angiotensin II Androgen Receptors 酸化ストレス一酸化窒素 *血管リモデリングマウス動物オス
371.	Masashi Akaike, Ken-ichi Aihara, Yasumasa Ikeda, 石川カズ江, Shusuke Yagi, 住友由佳, Takashi Iwase and Toshio Matsumoto : ピタバスタチンは血管内皮機能の改善を介してグルココルチコイド過剰による高血圧を予防する, 第36回日本心脈管作動物質学会, Vol.30, No.1, 39, Feb. 2007. (Keyword) Dexamethasone(毒性・副作用) Glucocorticoids(毒性・副作用) 血管内皮高血圧(予防,化学的誘発,実験的) Pitavastatin(治療的利用,薬理学) マウス動物オス
372.	Ken-ichi Aihara, Yasumasa Ikeda, Shusuke Yagi, 住友由佳, Takashi Iwase, Hiroyuki Azuma, 加藤茂明, Masashi Akaike and Toshio Matsumoto : ApoE欠損マウスにおける血漿ヘパリンコファクターII活性の低下は酸化ストレスを増大させ粥状動脈硬化を促進させる, 第36回日本心脈管作動物質学会, Vol.30, No.1, 41, Feb. 2007. (Keyword) Apolipoproteins E Heparin Cofactor II 動脈硬化症-アテローム性(実験的) 免疫組織化学酸化ストレスノックアウトマウスマウス動物
373.	多田真理枝, 住友由佳, Takashi Iwase, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma, Toshio Matsumoto and Hirotsugu Yamada : 心不全症状を繰り返した心尖部肥大型心筋症の一例, 第89回日本循環器学会四国地方会, Dec. 2006.
374.	Hirotsugu Kurobe, Yuki Izawa, Yayoi Fukumura, Tamotsu Kanbara, Atsushi Kurushima, Ken-ichi Aihara, Masashi Akaike, Masashi Kano, Takashi Kitaichi, Yutaka Masuda, Hiroyuki Azuma, Toshiaki Tamaki, Toshio Matsumoto, Tetsuya Kitagawa, Shuhei Tomita and Masanori Yoshizumi : HIF-ARNT transcriptional system in T cells has a pivotal role in vascular in flammation and remodeling., 第70回日本循環器学会学術総会, Mar. 2006.
375.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, Mitsunori Fujimura, Syusuke Yagi, Syunji Hashizume, Yasumasa Ikeda, Takashi Iwase, Nobuyuki Takamori, Tetsuya Kitagawa and Toshio Matsumoto : Plasma Heparin Cofactor II Activity is Inversely Associated with Prevalence of Peripheral Arterial Disease in Elderly individuals., 第70回日本循環器学会学術総会, Mar. 2006.
376.	Ken-ichi Aihara, Mihara Masatomo, Azuma Hiroyuki, Masashi Akaike, Takaya Matsushita, Yasumasa Ikeda, Shusuke Yagi, Takashi Iwase, Hashizume Shunji, Fujimura Mitsunori and Toshio Matsumoto : Thrombin inactivation by synthetic thrombin antagonist argatroban ameliorates insulin resistance in type 2 diabetic db/db mice, The 70th Anniversary Annual Scientific Meetings of the Japanese Circulation Society, Mar. 2006.
377.	Hirotsugu Kurobe, Shuhei Tomita, Yuki Izawa, 福原弥生, Tamotsu Kanbara, Ken-ichi Aihara, Masashi Akaike, Tetsuya Kitagawa, Toshio Matsumoto, Masanori Yoshizumi and Toshiaki Tamaki : T細胞特異的HIF1αKOマイスではカフモデルにて血管リモデリングが促進される, 第15回日本循環薬理学会, Nov. 2005.
378.	山口浩司, Tetsuzo Wakatsuki, 福田大和, 小柴邦彦, Tomohito Kawano, Hirotsugu Yamada, Takeshi Soeki, 岩瀬俊, 藤村光則, Masashi Akaike and Hiroyuki Azuma : たこつぼ型心筋障害の亜型と考えられた左室mid-portion ballooningの一例, 第87回日本循環器学会中国・四国合同地方会, Nov. 2005.
379.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, 藤村光則, Shusuke Yagi, 橋詰俊二, Yasumasa Ikeda, Takashi Iwase, Tetsuya Kitagawa and Toshio Matsumoto : ヘパリンコファクターIIは末梢動脈閉塞症に対する独立した防御因子である, 第28回日本血栓止血学会学術集会, Nov. 2005.
380.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, Masataka Sata, Yasumasa Ikeda, 藤村光則, 橋詰俊二, Takashi Iwase, Shusuke Yagi, 大水章正, 塚田稔, Tetsuya Kitagawa, 加藤茂明 and Toshio Matsumoto : 新規血管リモデリング抑制因子ヘパリンコファクターIIの臨床および分子生物学的解析, 第13回日本血管生物医学会, Oct. 2005.
381.	Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, 藤村光則, Yasumasa Ikeda, 橋詰俊二, Hiroyuki Azuma and Toshio Matsumoto : Pitavastatinは,Angiotensin IIによるマウス冠動脈リモデリングを抑制する, 第37回日本動脈硬化学会総会, 232, Jul. 2005. (Keyword) Angiotensin II 心臓血管疾患(診断,外科的療法,実験的) *Pitavastatin(薬理学) 血管リモデリング頸動脈内膜中膜肥厚度マウス動物
382.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, 藤村光則, 橋詰俊二, 大水正章, 塚田稔, 加藤茂明 and Toshio Matsumoto : 新規血管リモデリング抑制因子ヘパリンコファクターIIの分子生物学的解析, 第37回日本動脈硬化学会総会, 233, Jul. 2005. (Keyword) *Heparin Cofactor II 遺伝子発現血管疾患(病理学,実験的) 分子生物学血管リモデリングマウス動物
383.	Ken-ichi Aihara, 三原正朋, Yasumasa Ikeda, Shusuke Yagi, 藤村光則, 橋詰俊二, Takaya Matsushita, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : トロンビン作用の阻害は2型糖尿病モデルdb/dbマウスのインスリン抵抗性を改善する, 第78回日本内分泌学会総会学術集会, Vol.81, No.1, 190, Jul. 2005. (Keyword) Thrombin(拮抗物質・阻害物質) *インスリン抵抗性糖尿病-2型(診断,実験的) Argatroban(薬理学) メタボリックシンドローム(病因) マウス動物
384.	Yasumasa Ikeda, Ken-ichi Aihara, Masashi Akaike, Shusuke Yagi, Takashi Iwase, 橋詰俊二, 藤村光則, Hiroyuki Azuma, 加藤茂明 and Toshio Matsumoto : アンドロゲン-アンドロゲン受容体システムはドキソルビシンによる心筋酸化ストレスに対して防御的に作用する, 第78回日本内分泌学会総会学術集会, Vol.81, No.2, 548, Jul. 2005. (Keyword) Androgens(薬理学) Doxorubicin(毒性・副作用) Androgen Receptors(薬理学) 心筋疾患(実験的,化学的誘発) 心臓ミトコンドリア酸化ストレスノックアウトマウスマウス動物オス
385.	Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Takashi Iwase, 橋詰俊二, 藤村光則, Hiroyuki Azuma and Toshio Matsumoto : Pitavastatinは,Angiotensin IIによるマウス冠動脈および心筋リモデリングを抑制する, 第78回日本内分泌学会総会学術集会, Vol.81, No.2, 564, Jul. 2005. (Keyword) Angiotensin II 冠血管 C57BLマウス心室リモデリング *Pitavastatin(薬理学) 冠状動脈マウス動物
386.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Masataka Sata, Fujimura MItsunori, Hashizume Shunji, Yasumasa Ikeda, Shusuke Yagi, Kawano Hirotaka, Yamada Takashi, Fukuda Tohru, Sekine Keisuke, Sato Takashi, Nakamichi Yuko, Yamamoto Yoko, Yoshimura Kimihiro, Watanabe Tomoyuki, Nakamura Takashi, Ohmizu Akira, Tsukada Minoru, Shigeaki Kato and Toshio Matsumoto : Heparin cofactor II is required for fetal development and attenuates cuff-injured vascular remodeling in mice, The 37th Japan Atherosclerosis Society Annual Meeting, Jul. 2005.
387.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Hirotsugu Kurobe, 藤村光則, Shusuke Yagi, 橋詰俊二, Yasumasa Ikeda, Tetsuya Kitagawa and Toshio Matsumoto : ヘパリンコファクターIIは末梢動脈閉塞性病変進展に対する新規抑制因子である, 第102回日本内科学会総会・講演会, Vol.94, No.Suppl., 228, Apr. 2005. (Keyword) Heparin Cofactor II 血圧測定動脈閉塞性疾患(診断) 足関節上腕血圧比ヒト中年(45~64) 高齢者(65~79)
388.	Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Kato Midori, Fujimura Mitsunori, Hashizume Shunji, Shusuke Yagi, Hiroyuki Azuma and Toshio Matsumoto : Angiotensin II Antagonist Valsartan Ameliorates Nitric Oxide Bioavailability and Arterial Stiffness Accompanied with The Reduction of Blood Pressure and Pulse Pressure in Elderly Hypertensives, 第69回日本循環器学会総会・学術集会, Mar. 2005.
389.	Ken-ichi Aihara, Masashi Akaike, Yasumasa Ikeda, Shusuke Yagi and Toshio Matsumoto : Arterial Cuff Injury Causes Enhanced Neointimal Formation and Increased Adventitial Area in Heterozygous Heparin Cofactor II Deficient Mice, 第69回日本循環器学会総会・学術集会, Mar. 2005.
390.	Yasumasa Ikeda, Ken-ichi Aihara, Masashi Akaike, 藤村光則, Shusuke Yagi, 橋詰俊二, Hiroyuki Azuma, 加藤茂明 and Toshio Matsumoto : アンドロゲン-アンドロゲン受容体系は生体の心筋防御機構である, 第42回日本臨床分子医学会学術総会, 78, 2005. (Keyword) Androgens Angiotensin II Androgen Receptors 心筋心室リモデリングマウス動物オス
391.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, 藤村光則, 橋詰俊二, Shusuke Yagi, 加藤茂明 and Toshio Matsumoto : ヘパリンコファクターII欠乏マウスにおける血管リモデリング異常の解析, 第27回日本血栓止血学会学術集会, Nov. 2004.
392.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, 藤村光則, 吉田智則, 橋詰俊二, 加藤みどり, Yasumasa Ikeda, 周藤俊樹, 加藤茂明 and Toshio Matsumoto : ビタミンD-ビタミンD受容体システムによる血液凝固調節作用の解析, 第77回日本内分泌学会学術総会, Vol.80, No.1, 138, Jun. 2004. (Keyword) Thromboplastin *Vitamin D(薬理学) 遺伝子発現血液凝固血小板凝集 Calcitriol Receptors マウス動物
393.	Yasumasa Ikeda, Ken-ichi Aihara, Masashi Akaike, 森岡将臣, 加藤みどり, 橋詰俊二, 山口普史, 藤村光則, 吉田智則, Hiroyuki Azuma, 加藤茂明 and Toshio Matsumoto : アンドロゲン-アンドロゲン受容体システムは生体における心筋肥大及び心筋線維化の調節因子である, 第77回日本内分泌学会学術総会, Vol.80, No.1, 96, Jun. 2004. (Keyword) Androgens Androgen Receptors 心筋疾患 *心筋症-肥大性(診断,病理学,実験的) 線維症ノックアウトマウス心筋線維症(診断,病理学,実験的) マウス動物
394.	山口普史, 七條加奈, Takaya Matsushita, Yasumasa Ikeda, 森岡将臣, 加藤みどり, 橋詰俊二, 藤村光則, 吉田智則, Ken-ichi Aihara, Daisuke Inoue, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : 拡張型心筋症様病態を呈したCushing病の一例, Circulation journal : official journal of the Japanese Circulation Society, Vol.68, No.0, 828, Apr. 2004. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1573387451866119936 (CiNii: 1573387451866119936)
395.	Yasumasa Ikeda, 山口普史, 七條加奈, 森岡将臣, 加藤みどり, 橋詰俊二, 吉田智則, 藤村光則, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma, Toshio Matsumoto, 木村建彦 and 西内健 : Torsade de pointesを合併した汎下垂体機能低下症の一例, Circulation journal : official journal of the Japanese Circulation Society, Vol.68, No.0, 828, Apr. 2004. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571135652052441728 (CiNii: 1571135652052441728)
396.	橋詰俊二, Yasumasa Ikeda, 加藤みどり, 山口普史, 吉田智則, 藤村光則, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : 核内受容体PPARαの活性化は巨核球/血小板内PDGF-BBの産生を抑制する, 第36回日本動脈硬化学会総会, 196, 2004. (Keyword) 血小板由来増殖因子巨核球血小板培養腫瘍細胞白血病-急性赤芽球性細胞質受容体と核内受容体ペルオキシソーム増殖因子活性化受容体ヒト in vitro
397.	Ken-ichi Aihara, 高森信行, Yasuhiko Kanagawa, 藤村光則, 加藤みどり, 橋詰俊二, Yasumasa Ikeda, 田村克也, 近藤彰, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : ヘパリンコファクターIIの動脈硬化抑制作用に関する臨床的検討, 第41回日本臨床分子医学会学術総会, 55, 2004. (Keyword) Heparin Cofactor II Serine Proteinase Inhibitors(血液) ステント動脈硬化症血管平滑筋細胞増殖 Cofactor ヒト
398.	山口普史, Yasumasa Ikeda, 橋詰俊二, 加藤みどり, 吉田智則, 藤村光則, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : 遺伝性出血性末梢血管拡張症9家系における臨床病型と遺伝子変異に関する解析, 第25回日本血栓止血学会学術集会, Vol.14, No.5, 456, Nov. 2003. (Keyword) 遺伝性疾患出血変異 *毛細血管拡張症-遺伝性出血性(診断,遺伝学) 遺伝学的検査骨形成因子受容体I型ヒト
399.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, 高森信行, Yasuhiko Kanagawa, 藤村光則, 吉田智則, 橋詰俊二, 加藤みどり, 山口普史, Yasumasa Ikeda, 加藤修司, 荒瀬友子, 近藤彰 and Toshio Matsumoto : ヘパリンコファクターIIは高齢者における新規動脈硬化抑制因子である, 第25回日本血栓止血学会学術集会, Vol.14, No.5, 439, Nov. 2003. (Keyword) Antithrombins *Heparin Cofactor II(薬理学) HDL Cholesterol 動脈硬化症(診断,予防) 高齢者 Lipoprotein(a) ヒト中年(45~64) 高齢者(65~79) 高齢者(80~) 男女
400.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, Fujimura Mitsunori, Sudo Toshiki, Hayashi Hideki, Yamada Yoshihisa, Yoshida Tomonori, Yamaguchi Hiroshi, Hashizume Shunji, Kato Midori and Toshio Matsumoto : Vitamin D/Vitamin D Receptor System Regulates Antithrombogenicity in vivo, 第68回日本循環器学会総会学術集会, Mar. 2003.
401.	Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma, Toshio Matsumoto, Michiko Yamashita, Yoshimura Kimihiro and Imagawa Jun-ichi : Elevated blood pressure with a cardiovascular remodeling in mice lacking vitamin D receptor, 第66回日本循環器学会総会・学術集会, Apr. 2002.
402.	高森信行, 橋詰俊二, 加藤みどり, 吉田智則, Ken-ichi Aihara, 松山まどか, 石川カズ江, 藤村光則, Yasuhiko Kanagawa and Masashi Akaike : ヘパリンコファクターIIと動脈硬化発症との関連性甲状腺機能異常症患者での解析, 第22回日本血栓止血学会学術集会, Vol.11, No.5, 485, Nov. 2000. (Keyword) Heparin Cofactor II 動脈硬化症甲状腺機能正常患者症候群ヒト
403.	Masashi Akaike, Hiroyuki Azuma, 香川礼香, 井内貴彦, 藤村光則, 橋詰俊二, 高森信行, 吉田智則, Ken-ichi Aihara, Yasuhiko Kanagawa, Toshio Matsumoto, Kazuya Matsumoto, 林郁郎, 田村克也 and 西内健 : 血中リポ蛋白(a)濃度に及ぼすアスピリンの影響 : アポリポ蛋白(a)アイソフォーム解析を用いた検討, 第64回日本循環器学会学術集会, Vol.64, No.0, 427, Mar. 2000. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570291227165355136 (CiNii: 1570291227165355136)
404.	高森信行, 橋詰俊二, Yasuhiko Kanagawa, Ken-ichi Aihara, 吉田智則, 井内貴彦, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : ヘパリンコファクターIIと動脈硬化発症の関連性, 第21回日本血栓止血学会学術集会, Vol.10, No.5, 393, Nov. 1999. (Keyword) Heparin Heparin Cofactor II(生理学) 動脈硬化症 Cofactor ヒト中年(45~64) 高齢者(65~) 男女
405.	Yasuhiko Kanagawa, Ken-ichi Aihara, 高森信行, 吉田智則, 井内貴彦, Masashi Akaike, 重清俊雄, Hiroyuki Azuma and Toshio Matsumoto : Pro443からLeuへの変異を有する先天性ヘパリンコファクター(HC)II欠乏症の分子機構の解明, 第21回日本血栓止血学会学術集会, Vol.10, No.5, 355, Nov. 1999. (Keyword) Heparin(欠損・欠乏) 血液蛋白質障害(発生学・遺伝学) 変異 Cofactor ヒト
406.	Masashi Akaike, 井内貴彦, 高森信行, Ken-ichi Aihara, 吉田智則, Yasuhiko Kanagawa, Itsuro Endo, Takao Mitsui, Hiroyuki Azuma, 重清俊雄 and Toshio Matsumoto : 先天性ヘパリンコファクターII(HC II)欠乏症でみられた多発性動脈病変 : 動脈硬化症の進展におけるHCIIの臨床的意義の検討, 第63回日本循環器学会学術集会, Vol.63, No.1, 645, Mar. 1999. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1574231876839482624 (CiNii: 1574231876839482624)
407.	Masashi Akaike, Hiroyuki Azuma, 高森信行, Kazuya Matsumoto, 林郁郎, 田村克也, 西内健, Ken-ichi Aihara, Yasuhiko Kanagawa and 井内貴彦 : 高リポ蛋白(a)血症に及ぼすアスピリンの影響アポリポ蛋白(a)アイソフォームとの関連, The Journal of Japan Atherosclerosis Society, Vol.26, No.8, 137, 1999. (Keyword) Aspirin 高リポ蛋白質血症(生化学) Lipoprotein(a) 蛋白質アイソフォームヒト
408.	Masashi Akaike, 井内貴彦, 高森信行, Ken-ichi Aihara, 吉田智則, Yasuhiko Kanagawa, Itsuro Endo, Takao Mitsui, Hiroyuki Azuma and 重清俊雄 : 先天性ヘパリンコファクターII(HC II)欠乏症でみられた多発性動脈病変動脈硬化症の進展におけるHCIIの臨床的意義の検討, Japanese Circulation Journal, Vol.63, No.Suppl.I, 645, 1999. (Keyword) Heparin Cofactor II(欠損・欠乏) 動脈硬化症(先天性) ヒト
409.	Masashi Akaike, Hiroyuki Azuma, 香川礼香, Yasuhiko Kanagawa, Ken-ichi Aihara, 井内貴彦, 高森信行, 吉田智則, Toshio Matsumoto and Kazuya Matsumoto : 高リポ蛋白(a)血症に及ぼすaspirinの影響アポリポ蛋白(a)アイソフォームとの関連, Shikoku Acta Medica, Vol.55, No.2, 82, 1999. (Keyword) Apolipoproteins A Aspirin 高リポ蛋白質血症蛋白質アイソフォームヒト (Tokushima University Institutional Repository) ● Metadata: 112136 (Tokushima University Institutional Repository: 112136)
410.	Masashi Akaike, Hiroyuki Azuma, Kazuya Matsumoto, 林郁郎, 田村克也, 西内健, 香川礼香, Yasuhiko Kanagawa, Ken-ichi Aihara and 井内貴彦 : 血中リポ蛋白(a)濃度に及ぼすアスピリンの影響アポ蛋白(a)アイソフォームとの関連, Folia endocrinologica Japonica, Vol.75, No.1, 175, 1999. (Keyword) Aspirin Lipoprotein(a)(血液,薬物影響) Apoprotein(a) ヒト in vitro
411.	Masashi Akaike, Yasuhiko Kanagawa, 香川礼香, 吉田智則, Ken-ichi Aihara, Hiroyuki Azuma, Toshio Matsumoto and Kazuya Matsumoto : 高Lp(a)血症に及ぼすaspirinの影響 Lp(a)アイソフォーム解析を用いた検討, The Journal of the Japanese Society of Internal Medicine, Vol.88, 139, 1999. (Keyword) Aspirin(薬理学) Lipoprotein(a)(血液,薬物影響,代謝性障害) ヒト
412.	Yasuhiko Kanagawa, 重清俊雄, Ken-ichi Aihara, 松山まどか, 香川礼香, 宮本和正, 井内貴彦, Masashi Akaike, Hiroyuki Azuma and Toshio Matsumoto : 先天性ヘパリンコファクターII(HCII)欠乏症1家系の遺伝子解析, 第20回日本血栓止血学会学術集会, Vol.9, No.4, 315, Nov. 1998. (Keyword) Heparin Cofactor II(欠損・欠乏) 血液蛋白質障害配列分析ヒト
413.	柴田泰伸, 若槻真紀, 加部一行, Masashi Akaike, 新谷保実, Shiro Saito, Katsuhiko Yoshimoto, 川人智久, 筑後文雄, Takaki Hori and Tetsuya Kitagawa : 僧帽弁に粘液腫様変性が認められた先端巨大症合併MEN 1型の1例, 第208回徳島医学会(平成5年度冬期総会), Jan. 1994.
414.	新谷保実, Katsuhiko Yoshimoto, 金崎淑子, Masashi Akaike, 堀江秀茂, 細井恵美子, 横越浩, Hiroshi Bandou, 山崎柳一, 依田啓司, 松本圭蔵, Toshiaki Sano and Shiro Saito : MEN I型のGHRH産生膵腫瘍に見い出されたGH分泌下垂体腫瘍, 第66回日本内分泌学会学術総会(金沢), Jun. 1993.

Et cetera, Workshop:

1.	Sumiko Yoshida, Ken-ichi Aihara, Masashi Akaike and Toshio Matsumoto : ステロイド性大腿骨頭壊死症予防に向けた，大量グルココルチコイドによる酸化ストレスおよび血管内皮機能の変化と，ピタバスタチンの臨床的有効性の検討, 特発性大腿骨頭壊死症の治療法確立と革新的予防法開発にむけた全国学術研究, Aug. 2016.
2.	村上貴寛, Shusuke Yagi, 原知也, Takayuki Ise, Kenya Kusunose, Tomomi Matsuura, Takeshi Tobiume, Koji Yamaguchi, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Masashi Akaike, 春藤譲治 and Masataka Sata : 原発性アルドステロン症の診断に有用な臨床所見の検討, 第253回徳島医学会学術集会(平成28年度夏期), Jul. 2016.
3.	Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida and Toshio Matsumoto : グルココルコイド過剰誘導酸化ストレスの臨床的評価とeNOSの有無におけるピタバスタチンの虚血臓器保護効果機構の差異, 厚生労働科学研究費補助金平成27年度第1回班会議, Aug. 2015.
4.	Ken-ichi Aihara, Sumiko Yoshida, Yasumasa Ikeda, Masashi Akaike, 加藤茂明 and Toshio Matsumoto : 虚血耐性における性差非依存性のアンドロゲン受容体作用, 第5回核内受容体・ホルモン研究会, Mar. 2013.
5.	Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida and Toshio Matsumoto : Pitavastatinは血管内皮機能障害を背景にした重症虚血誘導組織壊死を抑制する, 厚生労働科学研究費補助金難治性疾患克服研究事業特発性大腿骨頭壊死症調査研究班平成24 年度第2回班会議, Jan. 2013.
6.	Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida and Toshio Matsumoto : 血管内皮機能障害を背景にした重症虚血誘導組織壊死に対するpitavastatinの効果, 厚生労働科学研究費補助金難治性疾患克服研究事業特発性大腿骨頭壊死症調査研究班平成24 年度第1回班会議, Aug. 2012.
7.	Sumiko Yoshida, Ken-ichi Aihara, Yasumasa Ikeda, Masashi Akaike, 加藤茂明 and Toshio Matsumoto : アンドロゲン受容体は，虚血ストレスに対する骨格筋アポトーシス防御および血管新生に必須である, 第4回核内受容体研究会, Apr. 2012.
8.	Mika Bando, Hirotsugu Yamada, 西尾進, 冨田紀子, 發知淳子, 林修司, 中川摩耶, 玉井利奈, 平田有紀奈, 弘田大智, 小笠原梢, 髙島啓, 山崎宙, 坂東左知子, Takayuki Ise, Toshiyuki Niki, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 質低下療法による頸動脈プラーク安定化の評価, 第5回T0kushima Young Investigators Conference, Mar. 2012.
9.	Ken-ichi Aihara, Masashi Akaike, Sumiko Yoshida and Toshio Matsumoto : 酸化ストレス抑制作用を介したグルココルチコイド誘発性血管内皮細胞障害治療, 厚生労働科学研究費補助金難治性疾患克服研究事業特発性大腿骨頭壊死症調査研究班平成23 年度第2回班会議, Dec. 2011.
10.	Takashi Iwase, Takayuki Ise, 小笠原梢, 山崎宙, 高島啓, 坂東左知子, Toshiyuki Niki, Kenya Kusunose, 發知淳子, 冨田紀子, Yuka Ueda, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, Shoichiro Takao, Hayato Nose, Masafumi Harada, Masashi Akaike and 足立克仁 : Duchenne型筋ジストロフィー女性キャリアの心病変検出における心臓MRI検査の有用性, 第16回中四国心筋症・心不全研究会, Sep. 2011.
11.	原知也, Takashi Iwase, 高島啓, 山崎宙, 小笠原梢, 坂東左知子, Takayuki Ise, Toshiyuki Niki, Kenya Kusunose, Yuka Ueda, 冨田紀子, Koji Yamaguchi, Yoshio Taketani, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata, Masashi Akaike, Hayato Nose, Shoichiro Takao, Hideki Otsuka, Masafumi Harada and Yasuhiko Nishioka : 心サルコイドーシス診断の手引きにおける各種診断モダリティーの検討, 第16回中四国心筋症・心不全研究会, Sep. 2011.
12.	Masashi Akaike, Ken-ichi Aihara, Sumiko Yoshida and Toshio Matsumoto : グルココルチコイド誘発性血管内皮細胞障害に対する酸化ストレス抑制の意義, 厚生労働科学研究費補助金難治性疾患克服研究事業特発性大腿骨頭壊死症調査研究班平成23 年度第1回班会議, Aug. 2011.
13.	清水拓, Kenya Kusunose, Hirotsugu Yamada, 西尾進, 玉井利奈, 遠藤桂輔, 佐藤光代, 河野裕美, Masashi Akaike and Masataka Sata : 運動負荷心エコー法を用いた膠原病例における潜在性肺動脈性高血圧症の検出, 第2回徳島肺高血圧研究会, Apr. 2011.
14.	Sumiko Yoshida, Ken-ichi Aihara, Yasumasa Ikeda, Masashi Akaike, 加藤茂明 and Toshio Matsumoto : アンドロゲン受容体は，虚血ストレスに対する骨格筋アポトーシス防御および血管新生に必須である, 第3回核内受容体研究会帝人ファーマ株式会社, Mar. 2011.
15.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : エイコサペンタエン酸の心血管リモデリング抑制効果の検討, 第3回Tokushima Young Investigators Conference, Mar. 2011.
16.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : EPAによる心血管リモデリング抑制効果の検討, 第30回心血管セミナー, Jan. 2011.
17.	遠藤桂輔, Hirotsugu Yamada, Kenya Kusunose, 西尾進, 冨田紀子, 三木淳子, 林修司, 玉井利奈, 河野裕美, 平岡葉月, 佐藤光代, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Ken Saito and Masataka Sata : 陳旧性心筋梗塞症における心電図左房負荷所見の意義:心エコー・ドプラ法を用いた検討, 心・血管クラスターミニリトリート, Jan. 2011.
18.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 林修司, 三木淳子, Toshiyuki Niki, Koji Yamaguchi, Takashi Iwase, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 左室内同期不全に対する前負荷の影響拡張型心筋症における下肢陽圧負荷3次元心エコー法を用いた検討, 先進血管エコー研究会, Aug. 2010.
19.	遠藤桂輔, Hirotsugu Yamada, 西尾進, 冨田紀子, Kenya Kusunose, 林修司, 佐藤光代, 平岡葉月, 河野裕美, 三木淳子, 玉井利奈, Koji Yamaguchi, Yoshio Taketani, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata and Ken Saito : 心電図異常を指摘され，心エコー検査で発見された左室緻密化障害の1例, 第3回蔵本エコーカンファレンス, Jul. 2010.
20.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : 虚血および血管新生におけるアンドロゲン作用の検討, 興和学術講演会, May 2010.
21.	Ken-ichi Aihara, Sumiko Yoshida, Yasumasa Ikeda, Masashi Akaike, 加藤茂明 and Toshio Matsumoto : 心血管ストレスに対するandrogen-androgen 受容体系の役割, 第2回核内受容体研究会, Mar. 2010.
22.	Sumiko Yoshida, Ken-ichi Aihara, Yuka Ueda, Yasumasa Ikeda, 倉橋清衛, Mizuho Kinouchi, Itsuro Endo, Yuichi Fujinaka, Takashi Iwase, Masashi Akaike, Masataka Sata and Toshio Matsumoto : 下肢虚血モデルを用いたアンドロゲン受容体による虚血臓器保護効果の検討, 第15回徳島内分泌研究会, Nov. 2009.
23.	Kenya Kusunose, Hirotsugu Yamada, 西尾進, 冨田紀子, 遠藤桂輔, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Yoshio Taketani, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike and Masataka Sata : 心房細動におけるE/e'の計測法:dual Doppler法を用いた検討, 第8回先進血管エコー研究会, Aug. 2009.
24.	倉橋清衛, Shingen Nakamura, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Yuichi Fujinaka, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata : 一酸化炭素中毒を契機に発見された急性心筋梗塞の一例, 第9回徳島総合診療研究会, Jul. 2009.
25.	山中森晶, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata and 西尾進 : 脳卒中患者における心エコー検査の現状:徳島大学病院SCU搬送例における検討, 第11回徳島脳卒中研究会, Feb. 2009.
26.	山中森晶, Hirotsugu Yamada, Kenya Kusunose, 冨田紀子, 仁木敏之, Koji Yamaguchi, Kunihiko Koshiba, Shusuke Yagi, Takashi Iwase, Takeshi Soeki, Tetsuzo Wakatsuki, Masashi Akaike, Masataka Sata and 西尾進 : 脳卒中患者における心エコー検査の現状:徳島大学病院SCU搬送例における検討, 脳卒中研究会, Feb. 2009.
27.	Ken-ichi Aihara, Hiroyuki Azuma, Masashi Akaike, Yasumasa Ikeda, Shusuke Yagi, 住友由佳, Sumiko Yoshida, Takayuki Ise, Takashi Iwase and Toshio Matsumoto : 新規血管リモデリング抑制因子ヘパリンコファクターIIの分子生物学的解析, 第9回四国循環器研究会, Sep. 2007.

Report:

1.	Masashi Akaike, Takuji Kawano, Masanori Miyata, Hiroshi Yoshida, Masayoshi Shinhara, Hayato Ueda and Maiko Kamioka : 2017 Annual Report on Faculty Development Programs at Tokushima University, Journal of University Education Research, No.15, 77-99, Mar. 2018. (Tokushima University Institutional Repository) ● Metadata: 110954 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050583647830409856 (Tokushima University Institutional Repository: 110954, CiNii: 1050583647830409856)
2.	Masashi Akaike, Takuji Kawano, Masanori Miyata, Hiroshi Yoshida, Masayoshi Shinhara, Maiko Kamioka and Yuka Kubota : 2016 Annual Report on Faculty Development Programs at Tokushima University, Journal of University Education Research, No.14, 99-119, Mar. 2017. (Summary) 全学FD 推進プログラムは2002 年度から開始され，FD の体系化，組織化，日常化等を推進してきた．2016 年度は，例年開催している，「授業設計ワークショップ」，「授業参観・授業研究会」，「大学教育カンファレンスin 徳島」，「ティーチング・ポートフォリオ作成ワークショップ」の他に，各学部等におけるFD の実態を把握し，成果や課題を明らかにした上で，ニーズの明確化，今後の学部等FD と総合教育センターの支援の在り方について検討するために，「質保証のための分野別ワークショップ」を開催した．また，大学教育再生加速プログラムに関連するSIH 道場FD・説明会の実施や学内でアクティブ・ラーニングを推進するためにLED カフェ等を実施した．各プログラムについて概要を記載し，アンケート結果等から成果と今後の課題について考察する． (Keyword) Quality Assurance / Disciplinary Workshop / Acceleration Program for University Education / Classroom Observation & Discussion Meeting / University Education Conference (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050302172853907072 (CiNii: 1050302172853907072)

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

AIを用いた対話型医療面接トレーニングシステムの開発 (Project/Area Number: 22K10363 )
Research on generic abilities and skills required for clinical clerkship (Project/Area Number: 21K10351 )
Study of the educational effect by new methods of workplace-based teaching and assessment in clinical clerkship (Project/Area Number: 18K10004 )
A study of an educational program using unidentified fresh cadaver and simulators to improve medical safety skills. (Project/Area Number: 17K08918 )
Development of training program introducing clinical clerkship to acquire 360 degree communication skills and abilities (Project/Area Number: 15K08554 )
Study on international sense upbringing of overseas interchange program in Clinical Skills Laboratory. (Project/Area Number: 26460603 )
Pathophysiological roles of heparin cofactor II in cardiac remodeling and insulin resistance (Project/Area Number: 21591140 )
Glucocorticoid-induced vascular endothelial dysfunction through activation of mineralcorticoid receptor (Project/Area Number: 21590955 )
A novel therapeutic strategy for glucocorticoid-induced vascula endothelial dysfundtion (Project/Area Number: 19590866 )
Translational Research of-Heparin Cofactor II for Athemsderosis Prevention (Project/Area Number: 18590816 )
Novel regulatory mechanism of vascular endothelial function mediated by BMK1/ERK5 and its application for anti-atherosclerosis therapy (Project/Area Number: 17590740 )
Molecular mechanic sum of the regulation and dies regulation of bone homeostasis and Development of therapeutic approaches (Project/Area Number: 17209035 )
Novel anti-atherosclerotic and anti-thrombotic action of plasma heparin cofactor II (Project/Area Number: 16590692 )
Mitochondrial dysfunction mediated by the activation of glucocorticoid receptor (Project/Area Number: 14570601 )
Thrombin-induoed vascular injury through the overproduction of reactive oxygen species (Project/Area Number: 12670674 )
Mitochondrial damage mediated by reactive oxygen species : A study in corticosteroid myopathy and mitochondrial encephalomyopathies (Project/Area Number: 12670606 )
Analysis of cardiovascular complications by the production of reactive oxygen species from mitochondria in patients with glucocrticoid excess (Project/Area Number: 10670663 )
Development of novel agents using the method of modulating the transcriptional activity of apo (a) gene (Project/Area Number: 10557105 )
Elucidation of genetic abnormality and molecular pathogenesis of hereditary hemorrhagic telangiectasia (Project/Area Number: 09671117 )
高リポ蛋白(a)血症に対する治療薬の作用機序の解明と新しい治療薬のスクリーニング (Project/Area Number: 07807072 )
脳性ナトリウム利尿ペプチドによる筋ジストロフィー患者の心機能評価 (Project/Area Number: 07770510 )
Search by Researcher Number (90271080)

Professor : Akaike, Masashi

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Academic Letter:

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Report:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)